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Abstract 
Background and Aims: 
Primary endocrine therapy (PET) is a common alternative to surgery for frailer older women with 
operable, oestrogen sensitive breast cancer but may result in treatment failure, contributing to the 
poor outcomes seen in this age group. Criteria for patient selection for such treatment are lacking 
with no clear guidance and wide variance in clinician opinion about the appropriate use of the non-
surgical option.  There is debate about whether cancer specific and overall survival outcomes vary 
between treatment types with little high quality research published in the field.  This mixed-methods 
study aimed to identify whether outcomes vary by treatment type and whether clinician preference 
contributes to the variation in treatment of older breast cancer patients in the UK and to explore 
some of the factors influencing clinician decision making. 
Methods and Results: 
This thesis used a range of methods to explore this issue including literature review and meta-
analysis to assess published evidence of variance and its clinical impact, registry data analysis to 
assess the extent of the variance in current UK practice and whether this was significant when 
adjusted for case mix and then to explore the underlying  reasons behind the variance using a 
combination of qualitative and questionnaire study of UK HCP in the field of breast care to 
determine why the variance exists. 
Each of these components is summarised below: 
A meta-analysis of data from six randomised controlled trials and 31 non-randomised studies 
demonstrated superior disease control and a likely survival benefit for surgery over PET in patients 
with predicted life expectancies of five years or more. 
Analysis of cancer registry data on 17154 women over 70 with ER+ operable breast cancer between 
2002 and 2010 demonstrated considerable variation in surgery rates at hospital level which 
persisted despite case mix adjustment. 
Semi-structured qualitative interviews with 34 specialist healthcare professionals (HCPs) from 14 UK 
sites demonstrated a variety of factors HCPs consider when determining treatment. Opinion was 
divided regarding the best way to treat dementia patients and whether PET should be offered as a 
treatment option.  
A questionnaire survey of Association of Breast Surgery members demonstrated that comorbidities 
were most important in determining treatment of older breast cancer patients. Opinion was divided 
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over the treatment of dementia patients. Only a quarter felt PET should be offered to all patients 
over 70 years. 
A Discrete Choice Experiment contained within the questionnaire demonstrated five variables (age, 
co-morbidity, cognition, functional status and cancer size) were independently associated with 
treatment preference (p<0.05) for surgery or PET.  
Conclusions: 
Meta-analysis of the published literature and registry data analysis corrected for case mix suggests 
that PET may result in inferior cancer specific and overall survival in older women.  PET is however a 
valuable option in those with a short predicted life expectancy and case selection is therefore of 
critical importance in outcome optimisation.  Analysis of registry data suggests that case mix does 
not fully explain treatment variation in older women with operable breast cancer which indicates 
that thresholds for selection vary widely and evidence based guidelines would be of value in 
standardising best practice. Clinicians vary in the factors they consider important in the decision 
making process and whether patients should be offered a choice of treatment themselves.  This 
practice variance, coupled with the inferior outcomes associated with PET in poorly selected women 
could be a significant contributing factor to globally inferior breast cancer outcomes in older women.  
Clinical guidelines are urgently needed to address this variability. 
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Chapter 1: Introduction 
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1.1. Overview of breast cancer 
1.1.1. Epidemiology 
Breast cancer is the most common cancer in the UK [1], accounting for nearly a third of all new 
cancer diagnoses in women in England [2], with 42 489 new cases diagnosed in the UK in 2012 [1, 3]. 
The incidence of breast cancer is rising, and has increased by 90% between 1971 and 2010 [2], so 
that a woman now has a 1 in 8 chance of developing the disease over their lifetime [4]. Despite this 
rising incidence, mortality rates from breast cancer in England and Wales have fallen by 37% since 
1971, with just over 10 144 deaths in 2013 [2, 5] (see figure 1.1, reproduced with data from the 
Cancer Research UK website [1]).  
 
Figure 1.1: Age standardised breast cancer incidence and mortality rates in the UK 1975-2008 
(reproduced from the Cancer Research UK website [1]). 
 
1.1.2. Clinical presentation of breast cancer 
1.1.2.1. Clinical features 
Breast cancer may be symptomatic or asymptomatic at presentation. Around two thirds of patients 
are symptomatic at diagnosis, with the most common symptom being a painless breast lump in 
more than 80% of cases [6]. Other symptomatic presentations include: 
 A palpable axillary mass (from involved lymph nodes); 
 A change in size or shape of the breast; 
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 A change in nipple position, shape or becoming inverted; 
 Skin changes with puckering, dimpling or peau d’orange; 
 Nipple discharge; 
 A rash or crusting over the nipple; 
 Pain in the breast or axilla; 
 Symptoms of metastatic disease which will vary depending on the site of spread, with 
common sites including the liver, bone and lungs. Around 4% of breast cancers will have 
signs or symptoms of metastases at the time of presentation [7]. 
The remaining one third of breast cancers in the UK are diagnosed among asymptomatic patients via 
the NHS breast screening programme. 
  
1.1.2.2. Diagnosis 
Symptomatic patients in the UK are referred from primary care into designated breast clinics within 
local hospitals [8]. Asymptomatic patients are referred from the NHS Breast Screening Programme 
into these same one-stop breast clinics. Diagnosis within these clinics are accomplished utilising a 
method of triple assessment [9]; that is: 
 Clinical examination; 
 Imaging (with mammography and/or ultrasound); 
 Core biopsy and/or fine needle aspiration cytology. 
Ultrasound assessment is particularly useful in women below the age of 35 years as they have 
denser breast tissue which makes mammography less sensitive [10]. 
During the initial assessment, patients with suspicious breast lesions will also undergo clinical and 
ultrasound assessment of the ipsilateral axilla to identify any abnormal lymph nodes – if found, these 
are subjected to image-guided core biopsy. 
  
1.1.2.3. Staging 
Breast cancer is staged according to three factors, the size of the tumour, the presence or absence of 
tumour cells within the local lymph nodes, and the spread of tumour cells to other parts of the body 
(metastases). 
Staging provides information about the disease extent, prognosis and can guide clinicians on 
appropriate treatment. 
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Several staging systems are in operation, with the most common in the UK being the TNM (tumour, 
node, metastases) staging system [11] (see table 1.1). 
Primary Tumour (T) Lymph node status (L) Metastases (M) 
Tx Primary tumour cannot 
be assessed 
Nx Unable to assess lymph 
node status. 
Mx Unable to assess for 
metastases. 
T0 No evidence of primary 
tumour 
N0 No evidence of lymph 
node spread. 
M0 No evidence of 
metastasis. 
Tis Carcinoma in situ N1 Metastasis in moveable 
axillary lymph nodes. 
M1 Metastatic spread. 
T1 Tumour ≤2cm in greatest 
dimension 
N2 Metastasis in fixed 
axillary lymph nodes +/- 
internal mammary 
nodes. 
T2 Tumour ≥2cm, <5cm. N3 Metastasis in 
supraclavicular lymph 
nodes +/- 
axillary/internal 
mammary nodes. 
T3 Tumour >5cm. 
T4 Tumour of any size with 
direct invasion into chest 
wall (T4a) or skin (T4b) or 
inflammatory cancer (c) 
Table 1.1: Abridged TNM staging system for breast cancer, 7th Edition [11]. 
 
1.1.3. Treatment options for operable breast cancer 
Breast cancer management is complex and dependent on many factors. A detailed description of 
breast cancer management in its entirety is outside the scope of this thesis, however a brief 
overview of breast cancer management is presented below.  
 
1.1.3.1. Surgery 
Surgery is the cornerstone of treatment for women with early breast cancer and is usually the first 
line treatment option [9]. The primary aim of surgical management is local disease control (i.e. 
removal of the tumour) and secondarily to provide accurate assessment of disease stage to guide 
further therapies. 
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Surgery to the breast 
Surgery to the breast usually involves either breast conservation, e.g. wide local excision (WLE) or 
mastectomy. Breast conservation surgery (BCS) is accompanied by post-operative radiotherapy of 
the remaining breast tissue. A meta-analysis of the long-term results of six randomised controlled 
trials has demonstrated that patients treated with BCS and radiotherapy have equivalent survival to 
those treated with mastectomy, however the former is associated with slightly higher local 
recurrence rates [12]. The type of surgery undertaken may depend on several factors: 
 Tumour characteristics, particularly size relative to breast size, multi-centricity and the 
presence of inflammatory change. 
 Patient breast size and shape and the location of the tumour in the breast. 
 Patient preference. 
UK Clinical guidance also recommends that patients undergoing mastectomy should also be offered 
the choice of some form of reconstructive surgery [9, 13].  Some patients may be offered more 
complex conservation surgery options where breast reshaping is also performed to permit enhanced 
cosmesis whilst permitting larger volume resections (oncoplastic surgery/therapeutic mammoplasty 
techniques). 
 
Surgery to the axilla 
Surgery to the breast is usually accompanied by some form of axillary surgery. The axillary lymph 
nodes are usually the initial site of spread for breast cancer and contain metastatic deposits in 
around 40% of patients at diagnosis [14-16].The presence and extent of axillary lymph node 
involvement is the most powerful predictor of recurrence and survival [17]; and decreases a 
patient’s 5-year survival by approximately 28–40% [14, 18]. The secondary aim of axillary surgery is 
loco-regional control which has been shown to also improve survival [19-23]. 
If pre-operative imaging assessment confirms metastatic spread to the lymph nodes, the patient will 
be offered an axillary lymph node clearance at the same time as their initial breast surgery – this 
removes all the axillary contents, including all lymph nodes in this region. If there is no clinical or 
radiological evidence of lymph node involvement pre-operatively, the patient will undergo limited 
axillary sampling, usually via a sentinel lymph node biopsy technique, at time of initial surgery.  This 
is less extensive surgery than full clearance and is associated with a reduced incidence of 
complications (for example, arm lymphoedema [24]). Axillary SLNB attempts to identify the sentinel 
lymph node – i.e. the first node to receive lymph from the area containing the primary tumour. 
There are several methods that have been used to identify the sentinel node: 
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 Blue dye [25]. 
 Radioactive isotope injection with lymphoscintigraphy and intra-operative gamma-probe 
localisation [26-28]. 
 Iron oxide injection with an intra-operative magnetometer [29]. 
 A range of other localisation techniques are also available (iodine seeds [30], fluorescent 
dyes [31] etc) 
If SLNB identifies metastatic deposits in the nodes, the patient will usually undergo axillary clearance 
as a second procedure; if negative, no further axillary surgery is required.  This pathway has recently 
been called into question by the controversial but practice changing Z0011 trial which suggested 
that omission of clearance in low risk disease where the axilla will be irradiated as part of tangential 
RT fields is associated with equivalent survival and local control to standard care [32].  Protocols are 
currently undergoing review as further research is carried out to validate these findings. 
 
1.1.3.2. Adjuvant therapies 
Adjuvant therapies aim to reduce the risk of breast cancer recurrence in those patients with early 
breast cancer who undergo potentially curative surgery. 
There are four main types: 
 Radiotherapy; 
 Chemotherapy; 
 Endocrine Therapy; 
 Biological Therapy. 
Not every patient is suitable for or requires every type of adjuvant therapy and decisions are made 
on the basis of many factors, including: 
 The type of surgery undertaken; 
 The stage of the cancer; 
 The biology of the cancer, for example the hormone receptor and HER-2 status; 
 The calculated prognosis, for example, using the Nottingham Prognostic Index or more 
recently more sophisticated scoring algorithms such as PREDICT and Adjuvant OnLine; 
 More complex biological prognostic scores may also be of value in borderline cases where 
chemotherapy benefit may be less certain.  These include measuring the tumour 
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proliferation index (Ki67 score) or using a commercial multigene array such as Oncotye DX 
[33], Mammaprint [34], etc. 
 The age, fitness and wishes of the patient. 
 
Radiotherapy 
Radiotherapy to the breast is necessary following breast-conservation surgery [9, 35] as it 
significantly reduces the rate of local disease recurrence [36], making it as effective as mastectomy 
[36]. 
Patients who undergo mastectomy may be offered adjuvant radiotherapy to the chest wall and 
regional lymph nodes if they are at high risk of loco-regional recurrence. Tumour characteristics with 
an increased risk of loco-regional recurrence include [9]: 
 Large tumour size; 
 Axillary lymph node involvement; 
 Extensive lympho-vascular invasion; 
 Positive resection margins. 
Post-mastectomy radiotherapy reduces the risk of breast cancer recurrence by around two thirds 
and consequently reduces mortality [37-40]. The indications for post mastectomy radiotherapy may 
have slightly broadened recently since the publication of the latest overview from the EBCTCG which 
showed both overall survival, LR and DFS advantage in a wider range of scenarios [41]. 
 
Endocrine therapy 
Some breast cancers express the oestrogen receptor (ER) on the surface of their nuclear membrane. 
These cancers are stimulated to proliferate in the presence of oestrogen. ER positivity increases with 
age [42, 43].  
 A large American database of 50,828 patients with invasive breast cancer demonstrated 83% 
ER positivity in 55-64 year olds, compared to 91% positivity in those aged 85 years or older 
[44].  
 A Canadian cohort of 1174 women found 70.4% ER positivity in women age 50-69 years and 
79.4% in those aged 70 years or older [45].  
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 In the UK, of the 14,330 women diagnosed with breast cancer in 2006 with known ER status, 
patients younger than 50 years were ER positive in 77%, compared with 87% in those aged 
50-70 years [46]. 
Endocrine therapies are used in patients with ER positive breast cancer and work to reduce the 
effect of oestrogen on breast cancer cells. The type of endocrine therapy used depends on the 
menopausal status of the patient [47], examples include: 
 Tamoxifen, which is a selective oestrogen receptor modulator, prevents oestrogen from 
binding to the ER and can be used in both pre- and post-menopausal women. Tamoxifen has 
been shown to improve survival by 31% in women with ER positive breast cancer after 5 
years treatment [48] and longer durations of therapy (up to 10 years) may have even greater 
benefit [49].  
 Aromatase inhibitors (AIs), such as anastrazole, letrozole and exemestane, work by inhibiting 
the synthesis of oestrogen (via the enzyme aromatase) and are used in post-menopausal 
women. AIs have been shown to be more effective than tamoxifen at improving disease-free 
survival and time to recurrence in the adjuvant setting in post-menopausal women [50, 51]. 
 In pre-menopausal women, ovarian ablation (by surgery or irradiation) or ovarian 
suppression (e.g. using a luteinising-hormone-releasing-hormone inhibitor) has a similar 
effect as tamoxifen as the ovaries are the main source of oestrogen production in this group 
[48].  Adding ovarian suppression to tamoxifen has been shown to improve disease 
outcomes for premenopausal women who are at sufficient risk of recurrence to warrant 
chemotherapy [52]. 
 
Chemotherapy 
Chemotherapy reduces the risk of recurrence and death in women with early stage breast cancer 
[48]. A meta-analysis of randomised controlled trials by the Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) found that the survival benefit is highly dependent on age at diagnosis 
[48] and a Cochrane review [53] demonstrated both overall and disease-free survival with the use of 
taxanes. NICE therefore recommends that a docetaxel chemotherapy regimen should be offered to 
patients with lymph-node positive breast cancer [9]. 
Due to the aggressive nature of chemotherapy treatment, with side-effects including lethargy, 
nausea and vomiting, alopecia and infertility (in premenopausal women), it is reserved for treating 
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women with significant risk of recurrence or among those with oestrogen receptor (ER) negative 
tumours. 
Women over the age of 70 years have been under-represented in studies and clinical trials focusing 
on chemotherapy benefit; however there are data to suggest that fitter, less frail, older women 
should be offered the same treatment as younger women [54, 55]. 
 
Biological agents 
Human Epidermal Growth Factor Receptor 2 (HER-2), also known as Neu, ErbB-2, CD340 or p185, is a 
cell-surface protein that is over-expressed in approximately 20% of breast cancers [56]. Over-
expression, or amplification, of HER-2 is associated with increased recurrence and poorer prognosis 
[57]. 
Trastuzumab (Herceptin™) is a monoclonal antibody that is used to treat breast cancers that over-
express the HER-2 receptor and has been shown to significantly reduce the risk of recurrence by up 
to 50% in these women  [58].  The range of biologically targeted agents with evidence of benefit in 
breast cancer is rapidly evolving and well beyond the scope of this review but the most 
mechanistically interesting are agents such as TDM1 which is a HER-2 directed delivery mechanism 
(antibody) which permits precise targeting of the chemotherapy agent emtansine directly to HER-2 
positive breast cancer cells [59].  Whether state funded health care systems will be able to afford 
these agents may be a major factor in limiting their use. 
 
1.1.3.3. Neo-adjuvant therapies 
Neo-adjuvant therapy, also called primary or preoperative treatment, is used before surgery to 
down-stage large or locally-advanced tumours in order to allow surgical removal or enable breast 
conservation. Endocrine therapy, chemotherapy and trastuzumab are all used in the neo-adjuvant 
setting to shrink the primary tumour prior to definitive surgery [60].  
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1.2. Breast cancer in older women 
This thesis focusses on the treatment variation in older women with operable breast cancer. Within 
the literature various age cut-offs are used to define “older” or “elderly” women, including those 
aged 65, 70 and 80 years or over. For the purposes of this thesis, “older women” will be used to 
describe those aged 70 years or over, unless otherwise stated, as this was the most consistently used 
age cut-off.  
 
1.2.1. Rising incidence of breast cancer in older women 
Age has been shown to be the strongest risk factor for the development of breast cancer after 
female sex [61] and as such, the incidence of breast cancer, like most cancers [62, 63], has a strong 
positive correlation with increasing age [64] (see figure 1.2, reproduced with data from the Cancer 
Research UK website [1]). Worldwide, around one third of breast cancers occur in those women over 
65 years old, with this percentage increasing to over 40% in more developed countries [65, 66]. 
There has also been a rise in the number of older women attending breast screening, with a 
resultant increase in the diagnosis of small cancers in this group [67].  
 Figure 
1.2: Number of breast cancer cases by age at diagnosis (reproduced with data from the Cancer 
Research UK website [1]). 
There are three proposed mechanisms that are thought to increase the incidence of cancer in older 
patients [63]: 
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1. Older patients have an increased duration of exposure to carcinogenic factors. 
2. Ageing cells and tissues are thought to be more sucseptible to carcinogens than younger ones. 
3. Ageing produces changes in the body environment that favour tumour development  (such as 
chronic inflammation and reduced sensitivity to insulin). 
 
1.2.2. Variability in the treatment of older women with breast cancer 
In the UK, the use of PET to treat older women is common and non-surgical management increases 
with increasing age [68], with studies demonstrating that 40% of women over the age of 70 years 
[69, 70] and 55% of women over the age of 80 years [71] are treated in this way. Despite this, there 
is wide variation in practice in the UK, with some regions having up to 40% non-operative treatment 
rates for older women with breast cancer, compared to other areas where the rate is only 10% [72] 
– see figure 1.3. The result is that there may be some women in the low surgery rate regions who 
are inappropriately denied surgery, whereas in the high surgery areas women may undergo surgery 
for little or no benefit. 
 
Figure 1.3: Percentage of women over 70 treated non-operatively by UK region (reproduced with 
data taken from the BCCOM Audit Year 3 [73]). 
 
Outside of the UK, non-surgical treatment of older women with operable breast cancer is far less 
common: 
 A study from Eire found 26% of women over 70 years were treated with PET [74]. 
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 In France, Garbay and colleagues reported that only 9% of older women did not receive 
surgery [75]. 
 In Italy, the percentage of women who are treated non-surgically falls to 3% according to a 
study by Crivellari [76]. 
 Van Dalsen in the Netherlands showed that 16% of older women were treated without 
surgery [77]. 
 In Sweden, the Geneva Cancer registry recorded that 32% of women over the age of 80 
years were treated with tamoxifen only [78]. 
 A large audit across Australia and New Zealand demonstrated that 97% of women were 
treated with some form of surgery [79]. 
 A large population study from the US found that 99.5% of women aged 75-84 and 99.3%  of 
those over 85 were treated surgically [44]. 
 
1.2.3. Why variation in treatment of older breast cancer patients is an 
important issue 
1.2.3.1. An ageing population 
The developed countries of the world, including western Europe, the USA, Canada, Australia, New 
Zealand and Japan, have increased their populations’ life expectancy by around 30 years during the 
20th Century [80]. The greatest survival gains are in the older age groups, which represent the most 
rapidly increasing population groups in developed nations [81]. The result is an ageing population, 
and the overall health status of this group is also improving [80, 82]. Improved disease prevention 
with better control of chronic diseases, mean older people are living longer even in the presence of 
chronic health problems. Despite this, there is wide variation in the health status of this age group, 
with some 75 year olds who are fit, healthy and active, whilst others are frail, with multiple co-
morbidities, necessitating assisted living. 
 
1.2.3.2. Survival in older women with breast cancer 
Breast cancer outcomes have been shown to be inferior in older women compared to those in 
younger women [83-86]. In fact, recent reports demonstrate that patients over the age of 70 are the 
only group of cancer patients where the mortality from cancer is not falling and may even be rising 
[83].  
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In addition, evidence suggests that cancer outcomes in those aged over 75 are poorer in the UK 
compared to other comparable countries [87] and this inequality is a major priority for the NHS [87].  
Despite this, however, the clinical significance of breast cancer is proportionally less in older women 
as breast cancer specific mortality is overtaken by other-cause mortality; with breast cancer causing 
only approximately 23% of deaths in women with breast cancer in their mid-80s, compared to 73% 
of deaths in patients in their early 50s [44]. That being said, there is convincing evidence that women 
over the age of 80 have a higher risk of dying of their breast cancer than women in their 70s [84], a 
phenomenon that is thought may be due, in part, to sub-optimal treatment [88]. 
 
1.2.3.3. Evidence of “sub-optimal” treatment in older women with breast cancer 
Several studies have demonstrated the deviation from standard treatment protocols in the older 
breast cancer population compared to their younger counterparts: 
 In a UK population study that included 14048 patients, Ali and colleagues [89] showed that a 
lower percentage of older women (80+) received surgical treatment (42%), radiotherapy 
(26%) and chemotherapy (1%) than their younger counterparts (50-69 years old: 96%, 74% 
and 29% respectively). 
 Another UK registry study showed that women aged 80 or above with operable (stage 1-3a) 
breast cancer were 43 times less likely to receive primary surgery than patients aged 65-69 
years [68]. 
 Bastiaannet and colleagues [90] demonstrated similar findings in the Netherlands in their 
large population-based study including 127,805 patients. Surgical treatment was omitted 
significantly more in the older age groups (only 41.2% of 90+ year olds) that in the 65-69 
year old cohort (98.8%). Their use of hormone monotherapy, or PET, increased with 
increasing age, with only 2.0% of 65-69 year olds treated this way, compared with 47.3% of 
90+ year olds. The use of adjuvant systemic therapy also followed an age-related trend, with 
70.7% of 65-69 year olds receiving some form of systemic adjuvant therapy, compared to 
53.3% of 90+ year olds [90]. 
 A German cohort of 1922 patients again showed a discrepancy in treatment for older 
women; with less adherence to guidelines for radiotherapy and chemotherapy in the older 
age groups (omission of radiotherapy and chemotherapy respectively in the 80+ years: 60% 
and 98% vs. <70 years: 9% and 54%). The authors demonstrated a significant impact on both 
overall and disease-free survival as a consequence of under-treatment with radiotherapy 
[91]. 
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 A Canadian study including 1174 patients showed that women 70+ were much less likely to 
receive definitive loco-regional treatment than those aged 50-69 years (48.7% vs. 83.5%, 
p<0.0001) [45]. 
 These results were again confirmed by an analysis of patients with early stage breast cancer 
in the Netherlands [84], comparing those of 75 years or more with patients younger than 65 
years. Patients in the older group were more likely not to receive any surgical treatment 
(21.5 vs. 0.5%; p<0.001) or any axillary surgery (25.7 vs. 1.6%; p<0.001), and were less likely 
to receive radiotherapy (25.1 vs. 67.8%; p<0.001) or chemotherapy (49.0 vs. 0.4%; p<0.001). 
In addition, they demonstrated that under-treatment had a significantly worse impact on 5-
year survival. In the younger cohort, overall survival was significantly lower in those who 
received non-conventional guidelines (HR 1.68, 95% CI: 1.46-1.94, p<0.001) and this was 
even more pronounced in the older group (HR 2.56, 2.31-2.84, p<0.001). 
Some of this treatment variation may be explained by levels of co-morbidity and frailty, where older 
women are deemed “unfit” to undergo the more intensive therapies. However, some studies have 
shown that increased age is the strongest predictor of lesser treatment [92]. 
 
1.2.3.4. A healthcare inequality 
The NHS Constitution makes clear that a core duty of the NHS is to promote equality [93]:  
“The NHS provides a comprehensive service, 
available to all irrespective of gender, race, 
disability, age, sexual orientation, religion or 
belief. It has a duty to each and every individual 
that it serves and must respect their human rights. 
At the same time, it has a wider social duty to 
promote equality through the services it provides 
and to pay particular attention to groups or 
sections of society where improvements in health 
and life expectancy are not keeping pace with the 
rest of the population.” 
As such, the Department of Health has deemed the variation in outcomes and treatment of older 
cancer patients a “healthcare inequality” [94] and the National Cancer Equality Initiative (NCEI) and 
Cancer Reform Strategy were created with the aim of tackling the inequalities in cancer, including 
those due to age [94, 95]. 
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The Cancer Reform Strategy states that the only acceptable criteria for not giving clinically 
appropriate treatment should be poor patient health or patients themselves choosing not to receive 
a particular treatment [95]. The Department of Health stresses that whilst it may be appropriate for 
some older patients to receive less intensive cancer treatments due to increasing comorbidity and 
frailty, chronological age itself should not be a determining factor [87]. 
 
1.2.4. Breast cancer biology in older breast cancer patients 
The biology of breast cancer tends to differ in older women from that in young women, with older 
patients tending to develop tumours with more favourable  biology [90]. Older patients tend to have 
tumours with higher rates of ER positivity [44, 96, 97], lower rates of HER-2 receptor expression [44, 
96] and lower grades and proliferative indices [44, 96]. 
However, older women are more likely to be diagnosed with more advanced disease [88]; the size of 
the primary tumour is larger [44, 65, 70, 88, 98, 99] and there are higher rates of locally advanced 
[65, 86] and metastatic disease [69, 100]. Several factors may account for these negative features, 
including the discontinuation of routine breast screening, reduced breast cancer awareness [101, 
102] and lower rates of regular self examination [103] amongst the older female population. 
 
1.2.5. Physiological effects of ageing 
Senescence is the term for the physiological changes that occur due to the ageing process. These 
changes are substantial and affect all bodily systems. This has a significant impact on the way older 
women tolerate treatments for breast cancer and may influence treatment choice. These 
physiological changes are summarised in table 1.2. 
 
1.2.5.1. Association between co-morbidity and ageing 
Increasing age is associated with higher rates of comorbidity [105], which potentially reduce the 
survival advantage of more aggressive breast cancer therapies [106] as other cause mortality 
increases [107]. Of particular importance are the diseases that may render anaesthesia hazardous, 
such as cardiac, respiratory and cerebrovascular disorders – all of which are more common in older 
patients [108, 109]. Breast-cancer patients with three or more significant co-morbidities have a 20-
fold higher rate of non-breast cancer deaths [110] and so the presence of comorbidities in older 
women is associated with less extensive treatment and poorer prognosis [105]. 
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Organ/ 
System 
Overall Changes Pathophysiology Clinical Impact 
Cardiac Reduced cardiac 
reserve 
↓Number of myocytes. 
↓Number of pacemaker 
cells. 
↓Arterial compliance. 
↓Exercise levels. 
↓Maximal heart rate. 
↑Afterload. 
Stiffening of myocardium, 
reducing diastolic filling. 
↓Tolerance to cardiac 
stress. 
↓Tolerance to rhythm 
disturbance. 
↑Risk of anaesthesia. 
 
Respiratory Reduced 
respiratory 
reserve 
↓Vital capacity. 
↓Lung elasticity.  
↓Strength/endurance of 
respiratory muscles. 
↓Mucous production. 
↓Ciliary function. 
↓Oxygen diffusion 
capacity. 
↓Respiratory reserve 
during exertion. 
↑Risk chest infection. 
↑Risk of anaesthesia. 
Renal Reduced renal 
reserve 
↓Number of nephrons by 
50% by age 70. 
↓Renal blood flow by 
50%. 
↓Creatinine clearance by 
30%. 
↓Ability to conserve 
water. 
↓Sensitivity to thirst and 
therefore poor self-
regulation. 
↓Ability to conserve 
sodium and excrete 
hydrogen. 
↓Ability to maintain fluid 
and electrolyte balance 
under stress. 
↑Risk of dehydration and 
fluid overload. 
↑Risk of anaesthesia. 
 
Sensory-
motor and 
CNS 
Reduced 
cognitive and 
motor functions 
40% incidence significant 
cognitive impairment by 
age 90. 
Reduced balance and 
agility. 
Reduced muscle strength. 
Risk of poor convalescence 
from therapy, falls, 
worsening of global 
function caused by 
anaesthesia. 
 
Table 1.2: Physiological effects of Ageing (reproduced from [104]). 
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Comprehensive Geriatric Assessment (CGA) 
Several attempts have been made to quantify the impact of co-morbidities and frailty on expected 
life expectancy. These Comprehensive Geriatric Assessments [111-113] are detailed but time-
consuming assessments that require the clinician to undergo specialist training to administer. There 
is no standard method for CGA but is should include measures of functional status, comorbidity, 
nutritional status, drug therapy, socioeconomic issues and the presence of geriatric syndromes. 
Other less complex tools exist that may be used to assess patient in terms of their co-morbidity 
burden, functional status or levels of frailty: 
 There are number of scoring systems for comorbidity in existence, with the Charlson Index 
(CCI) being one of the most commonly used and widely validated [114-117]. Others include 
the Kaplan-Feinstein Index (KFI) [118] and the Adult Comorbidity Evaluation-27 (ACE-27) 
[119, 120]. 
 The Activities of Daily Living Score (ADL) [121] and Instrumental Activities of Daily Living 
Score (IADL) [122] are measures of functional status. 
 The Groningen Frailty Index (GFI) is an example of a specific measure of frailty, although 
other tools, such as the Timed Up and Go Test [123] are often used as surrogate markers for 
frailty. 
In addition, Adjuvant! On-Line is a web-based tool that is used to predict the prognosis of individual 
patients and how this is may be altered by different adjuvant therapies [124]. The Adjuvant! 
Software accounts for the impact of co-morbidity but the categories are broad and vague, and is 
only of use in patients who have already undergone their primary surgery [125]. However it is not 
age specific. 
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1.3. Primary endocrine therapy (PET) as a treatment option for older 
women with operable breast cancer 
Primary Endocrine Therapy (PET) is the use of “anti-oestrogens” as the sole therapy for early stage, 
operable breast cancer. It is an alternative to the standard treatment of operative intervention 
combined with adjuvant therapy, and was first proposed as an alternative to surgery in older 
patients in the 1980s [126]. 
Current guidelines from the National Institute for Health and Care Excellence (NICE) state that PET 
should only be used where there are “significant comorbidities that precludes surgery” [9] and 
recommendations from the International Society of Geriatric Oncology (SIOG) and the European 
Society of Breast Cancer Specialists (EUSOMA) suggest that PET should only be offered to patients 
with a “short estimated life expectancy (<2-3 years), who are considered unfit for surgery… or who 
refuse surgery” [127]. However, neither specify which comorbidities may preclude surgery or what 
constitutes being unfit for surgery. As such it is left to the treating clinician to decide which breast 
cancer treatments a patient should be offered. This may be a causative factor in the considerable 
variability in treatment practice of older women with breast cancer across the UK,  where rates of 
non-surgical management range from 12-40% depending on region [73]. Indeed, a questionnaire 
survey found that whilst the majority of UK surgeons use PET to treat older women who are unfit for 
surgery, the percentage of older patients they treat in this way still varies considerably (<10-70%) 
[128]. 
 
1.3.1. Biology of PET in breast cancer 
1.3.1.1. Oestrogens 
Oestrogens are steroid hormones and are the primary female sex hormones. There are three main, 
naturally occurring oestrogens: 
 Oestrone (E1). 
 Oestradiol (E2). 
 Oestriol (E3). 
Oestrogens are responsible for the development of secondary sexual characteristics, such as breast 
development and maturation, and regulation of the menstrual cycle. During adulthood, oestrogen is 
also responsible for cyclical epithelial proliferation within the breast, as well as epithelial growth and 
proliferation during pregnancy. 
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Oestrogen production 
In pre-menopausal women, oestrogen production is mainly by the ovaries, following stimulation by 
Follicular Stimulating Hormone (FSH). However, oestrogens are produced in smaller amounts by the 
liver, adrenal glands, breasts and adipose tissue, mainly by a process of aromatisation of 
androstenedione [129-132]. 
 
Oestrogen receptors (ER) 
The actions of oestrogens are mediated by oestrogen receptors (ER). These are a group of 
intracellular proteins that are activated by oestrodiol [133], and form part of the nuclear hormone 
receptor family. Oestrogen, as a steroid hormone, is lipophilic and so passes through the cellular and 
nuclear membranes by a process of diffusion [134]. Inside the nuclei, oestrogen binds with ERs with 
high affinity and high specificity [134].  
Once activated, ERs are able to bind to DNA, forming the oestrogen receptor response element 
(ERE), which regulates gene activity in a process called gene transcription (see figure 1.4). The 
resulting protein products act as growth factors, their receptors and signalling molecules which 
promote cellular proliferation [135, 136]. 
 
Figure 1.4: Intracellular Oestrogen Pathway (modified from [137]). 
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There is also evidence to suggest that ERs located at the cell membrane may provide another 
mechanism for the growth-promoting effects of oestrogen, by activating other growth factor 
receptors, such as epidermal growth factor receptor (EGFR) family, for example HER-2 [138, 139]. 
 
Oestrogen function in breast cancer 
ER expression by breast cancer cells is variable, but expression increases with age [42, 43]. Women 
aged less than 40, have ER positive tumours in approximately 60% of cases [140], compared to 
women aged 85 years or older where the percentage of ER positivity increases to around 90% [44]. 
Tumours that express the ER are stimulated to grow under the influence of oestrogen [141]. The 
mechanism behind this action has been examined in laboratory settings in terms of the cell; in ER 
positive cancers, oestrogens increase the number of G0/G1 cells entering into the cell cycle, hence 
promoting mitosis and, therefore, proliferation [142, 143].  
Antagonism of the ER inhibits cell proliferation and may cause cell death [144], by blocking them in 
the Gap phase (G0/G1) of the cell cycle. This forms the basis for the mechanism of action of primary 
endocrine therapy (PET). 
 
1.3.2. History of PET 
Endocrine therapies have been used as a treatment for breast cancer for over a century, with the 
first bilateral oophorectomies being performed in 1872 [145, 146]. However  it wasn’t until ten years 
later that the relationship between breast cancer and ovarian function was first recognised, when 
Thomas Nunn reported a case of breast cancer that regressed at the commencement of menopause 
[147]. Seven years later,  surgical oophorectomy was proposed as a treatment for breast cancer 
[148]. It was on June 15th 1895 when a Glaswegian surgeon, George Beatson, first performed a 
bilateral oophorectomy to treat a woman with breast cancer, successfully resulting in a complete 
remission, with the patient surviving for 4 years after surgery [149, 150]. 
The exact benefits of ovarian ablation remained unclear until several randomised controlled trials 
were performed in the 1960s and 70s and the Early Breast Cancer Trialists Collaborative Group 
(EBCTCG) published their meta-analysis demonstrating improved disease-free and overall survival in 
pre-menopausal women treated in this way [151, 152]. 
Further developments in the field of endocrine therapy for breast cancer included adrenalectomy, 
hypophysectomy [153] and the introduction of anti-oestrogens, most notably tamoxifen and the 
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Aromatase Inhibitors. These drugs are still widely used today for the treatment of breast cancer in 
the adjuvant, neo-adjuvant and primary settings. 
 
1.3.3. Anti-oestrogen Therapies 
1.3.3.1. Tamoxifen 
Mechanisms of action of tamoxifen 
Tamoxifen is a selective oestrogen receptor modulator (SERM). It has a “mixed organ” effect, 
meaning that in some sites in the body, such as the breast epithelium, it acts as an oestrogen 
receptor antagonist, but in others (e.g. bone and endometrium) it acts as an agonist. Some of these 
effects are beneficial, such as its anti-breast cancer and anti-osteoporotic effects; however some are 
detrimental, leading to increased risks of endometrial cancer [154] and thromboembolism [155]. 
Tamoxifen is metabolised in the liver into its active metabolites, including 4-hydroxytamoxifen, 
which have a high affinity for binding with the ER. In the breast, 4-hydroxytamoxifen binds 
competitively to the ER and alters, or modulates, its formation – preventing the cellular events 
which occur as a result of the ERE complex. The resulting effect is inhibition of cellular proliferation 
(see figure 1.5), as the cell cycle is blocked in the early to mid G1 phase [156]. 
Discovery of tamoxifen 
Tamoxifen was discovered in the early 1960s by scientists searching for a new contraceptive at ICI 
Pharmaceuticals Division in the UK [157] and the academic community worked to develop the drug 
as a new targeted breast cancer treatment during the 1970s [158]. 
 
Clinical evidence for tamoxifen 
The first UK clinical study took place in 1971, with promising results in patients with advanced breast 
cancer [159]. A second clinical study led to further interest in the drug following a more definitive 
response [160].  
The first trial to demonstrate any survival advantage for tamoxifen was published in 1983 [161], and 
this looked at patients with early breast cancer who were given tamoxifen in addition to 
chemotherapy.  The problem with most of the early tamoxifen trials was that they didn’t select 
patients according to ER status and as such, didn’t show such a large or consistent benefit [162]. It 
wasn’t until the late 1990s, when the Early Breast Cancer Trialists’ Collaborative Group finally 
demonstrated that tamoxifen resulted in a definite increase in survival with their large meta-analysis 
[163].  
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Figure 1.5: Mechanism of action of tamoxifen. 
 
1.3.3.2. Aromatase Inhibitors (AIs) 
Mechanism of action of AIs 
In post-menopausal women, because of cessation of ovarian function, the main source of 
oestrogens is synthesis from adrenal androgens via the process of aromatisation in the skin, fat and 
muscle [153]. This process is catalysed by the enzyme aromatase which is the target molecule for 
aromatase inhibitors (AIs) – see figure 1.6. The result is suppression of oestrogen synthesis and as 
such, these drugs have none of the agonist activities of tamoxifen. 
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Figure 1.6: Mechanism of Action of Aromatase Inhibitors. 
Type I AIs 
Type I AIs are also known as aromatase inactivators – they have a steroidal structure and work by 
forming an irreversible bond with aromatase, thus permanently deactivating it [164]. Formestane 
and exemestane are both examples of type I AIs. 
 
Type II AIs 
Type II AIs are non-steroidal inhibitors and bind reversibly to a haem group in the activation site of 
the aromatase enzyme [153]. Anastrazole is an example of a type II AI. 
 
Discovery of Aromatase 
The isolation of both androgens and oestrogens in the 1930s allowed identification of the similarities 
between their biochemical structure and subsequent speculation that androgens might be 
converted into oestrogens [165-167]. However, the purification of aromatase did not occur until the 
1980s [168-170].  
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Aminoglutethamide 
Aminoglutethamine belongs to a group of drugs called adrenal steroid inhibitors and is also known 
as the first generation, non-selective aromatase inhibitor. It inhibits the conversion of cholesterol to 
20-α-hydroxycholesterol and blocks the synthesis of steroid hormones, including cortisol, 
aldosterone and oestrogens [171]. Aminoglutethamide was used as an alternative to surgical 
adrenalectomy for the treatment of breast cancer in post-menopausal women [172]. During  the 
1970s, scientists began  investigating the use of aminoglutethamide as a breast cancer treatment in 
clinical trials [173, 174]. Aminoglutethamine has since been used as a treatment for breast cancer 
among women who relapse following tamoxifen treatment [175]. Due to common side-effects, 
including inhibition of cortisol synthesis, drowsiness and skin rashes [176], this treatment  is no 
longer commonly used and it has been replaced by newer generation AIs. 
 
Formestane 
Formestane is a second-generation, type I AI that was discovered in the 1970s and was shown to 
reduce oestrogen levels in rats [177]. The first clinical trial of Formestane for the treatment of 
women with breast cancer was undertaken during the 1980s [178]. Again, Formestane is no longer 
in clinical use as it has been replaced by newer generation AIs. 
 
Third generation AIs 
The third generation AIs were developed in the early 1990s and block oestrogen production without 
exerting effects on other steroid pathways. The three AIs commonly used today include: 
 Anastrazole (Arimidex), a selective type II AI. 
 Letrozole (Femara), also a selective type II AI. 
 Exemestane (Aromasin), a selective type I AI. 
 
1.3.4. Relative efficacy of anti-oestrogens 
1.3.4.1. Metastatic setting 
Several trials have evaluated the efficacy of the third generation AIs compared to tamoxifen for the 
treatment of metastatic breast cancer [179-185]. The European TARGET study showed no significant 
difference between overall response rate (ORR) and time to progression (TTP) [184]. However the 
American TARGET study did show a significantly improved clinical benefit rate and longer TTP using 
anastrazole [183]. Anastrozole was subsequently approved as the first-line therapy for metastatic 
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breast cancer [179]. The International Letrozole Breast Cancer Group demonstrated superior efficacy 
with letrozole over tamoxifen with respect to several outcomes including: TTP, time to treatment 
failure, ORR, clinical benefit and overall survival (OS) rates [180]. Additionally, the European 
Organization for Research and Treatment of Cancer compared exemestane with tamoxifen for 
metastatic breast cancer and favoured exemestane for ORR and progression-free survival (PFS) 
[181]. 
 
1.3.4.2. Adjuvant setting 
Specific to the adjuvant setting, the third generation AIs have also been shown to be superior to 
tamoxifen. The first of these trials, the ATAC trial, comparing anastrazole, tamoxifen alone or in 
combination and that presented preliminary results at the San Antonio Breast Cancer Symposium in 
2001, demonstrated superior activity of anastrazole over tamoxifen in  terms of disease free survival 
but little significant benefit in terms of overall survival [186]. These results were confirmed in the 5 
and 10-year follow-up reports [51, 187] and by others since including the Italian Tamoxifen and 
Anastrazole Trial [188] and the Austrian Breast Cancer Study Group and Arimidex-Nolvadex Trials 
(Pooled Analysis) [189], both of which compared anastrazole to tamoxifen; the Breast International 
Group 1-98 Trial assessed letrozole versus tamoxifen monotherapy and also sequenced treatment 
[190]; and the Intergroup Exemestane Study compared tamoxifen alone for five years versus 
switching to exemestane after 2-3 years on tamoxifen [191]. All showed DFS advantage to the AI 
containing regimes over tamoxifen alone. 
There is also now good quality evidence that 10 years of adjuvant tamoxifen has superior efficacy to 
5 years of therapy [49]. 
 
1.3.4.3. Neo-adjuvant setting 
Studies investigating the use of third-generation AIs in the neo-adjuvant setting have, again shown 
them to be clinically effective, which is most relevant in terms of considering therapies for PET [192-
195]. Similarly, all three have been compared with tamoxifen within this setting: 
 Anastrazole, when compared to tamoxifen, has been shown to be equal in terms of 
objective tumour response rates in the neo-adjuvant setting, and superior in terms of breast 
conservation rates [196, 197]. However, both trials only used three months of neo-adjuvant 
therapy, which is not considered an adequate length of time to see a full response. 
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 Neo-adjuvant letrozole compared to tamoxifen for four months demonstrated significantly 
better tumour response rates and breast-conservation surgery rates in another randomised 
controlled trial [198]. 
 A randomised trial comparing exemestane with tamoxifen in this setting also demonstrated 
better results with the AI [199]. 
 Ellis and colleagues compared all three third-generation AIs in the neo-adjuvant setting for a 
period of up to 18 weeks in an randomised trial and found that treatment with letrozole 
resulted in the best clinical response rates [200]. 
 There is therefore compelling high level evidence in all treatment settings (adjuvant, 
palliative and neoadjuvant) that AIs are superior to tamoxifen in the treatment of ER positive 
breast cancer.  In the PET setting (most analogous to neo-adjuvant) there is no RCT evidence 
but numerous cohort studies have reported on both treatments suggesting that AIs may be 
the superior treatment.  These studies are reviewed formally in Chapter 3. 
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1.4. Surgery as a treatment for older women with operable breast 
cancer 
As discussed above (Section 1.1.3), surgery to fully excise the primary and any nodal disease is the 
mainstay of treatment for women of any age with early breast cancer [9]. Despite this, older patients 
are less likely to undergo surgery of any type and for those that do have surgery to the primary 
tumour, they are less likely to have axillary surgery compared to younger women [68, 84, 90]. There 
is also good evidence that they are also less likely to received other standard therapies such as post-
operative adjuvant radiotherapy [68, 84, 89-91, 201] or chemotherapy [84, 89, 91].  
There are good theoretical reasons why omission of what may otherwise be standard treatment may 
be adequate for older women.  Breast cancer may be an indolent disease and be controlled well by 
antioestrogens for many years; this time span may exceed the naturally predicted life expectancy of 
the women if she is frail or unfit and so be unnecessary.   
Older patients are likely to have increased levels of co-morbidity, decreased functional capacity and 
reduced physiological reserve seen in the older population [109, 202], making general anaesthesia 
more hazardous and reducing tolerance to the toxicity of adjuvant therapies. In addition, older 
patients’ cognitive and functional ability may worsen following general anaesthesia [203] and some 
post-operative complications are more common in older patients [204-207]. Having said this, surgery 
for breast cancer is generally well-tolerated in older women, with both low morbidity and very low 
mortality rates [65, 208, 209]. There are also several anaesthetic techniques which may permit 
surgery without general anaesthetic, including: 
 High thoracic epidural [210]. 
 Paravertebral block [211]. 
 Intercostal nerve block (not axillary surgery) [212]. 
 Local anaesthetic (limited axillary surgery only and challenging in women with larger breasts 
requiring mastectomy) [213]. 
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1.5. Comparison of PET vs surgery 
1.5.1. Advantages and disadvantages of PET and surgery 
1.5.1.1. Advantages of PET 
There are several clear advantages of PET as a treatment for older women with breast cancer. Some 
of these are discussed below. 
 
Efficacy 
Clinical benefit rates for PET in older women with ER positive breast cancers are generally high; a 
Cochrane review of seven randomised controlled trials reported that overall the cancer shrinks or 
fails to progress in 75% of cases [214, 215]. However, six out of the seven of these RCTs recruited 
patients without knowledge of the ER status of their cancer. A good clinical response can be 
expected in 79-90% of women with moderately or strongly ER positive tumours [216] compared to 
up to 100% progression rate in patients with ER negative tumours [217-221]. 
The overall survival with PET has also been shown to be equivalent to that of surgery on meta-
analysis of the available historic randomised controlled trials [214, 215]. However it must be noted 
that the trials are flawed in several ways which may have biased their outcomes.  These flaws 
include the fact that all of the women were fit for surgery under GA and the median age was 
relatively young compared to the more standard age for consideration of PET in current UK practice 
and most of the studies did not test for the ER status of the cancer so over 10% of the cases in the 
PET arms will have been effectively receiving no active treatment. 
 
Tolerability 
PET is well tolerated by older women [222-224] and has low toxicity [225]. 
Studies have demonstrated the older women express a high degree of satisfaction with this 
treatment [226]. 
 
Reassurance 
In addition to finding the treatment acceptable, some women report being reassured by the clinical 
response to PET, and have confidence that the treatment is working because they can feel the lump 
regressing [226]. 
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Avoidance of surgery 
For older women with a short life expectancy, either due to co-morbidity or extremes of age, PET 
may allow the avoidance of surgery altogether [225]. This is a particular advantage for those women 
who either refuse surgery, or are unfit to undergo a surgical procedure due to significant co-morbid 
conditions or extreme frailty. 
By avoiding surgery, patients also avoid the associated physical and psychological morbidity of an 
operation [216]. For more detail on these risks, see section 1.5.1.4. 
 
Avoidance of anaesthesia 
By not having surgery, these patients also remove the need for an anaesthetic, with all the 
associated risks (see section 1.5.1.4.). One of the main reasons patients do not wish to have an 
operation  is due to their fear of anaesthesia [226], and this is negated by using PET. 
 
Avoidance of hospitalisation 
Older patients who are treated with PET do not need to be admitted to hospital for their treatment, 
allowing them to maintain their independence and providing minimal disruption to their daily  life – 
these have all been shown to be important issues to this cohort of patients when choosing a 
treatment for operable breast cancer [226]. 
 
1.5.1.2. Disadvantages of PET 
Palpable lump 
Whilst the majority of patients with ER positive tumours will exhibit some regression of their clinical 
disease, a small but significant proportion will experience “static disease” – this is where, although 
the tumour is not progressing, there is no regression or shrinking of the palpable lump. This may be 
a source of anxiety in some women although in most studies, the reverse was reported, patients 
being reassured by the fact that they could feel the lump and it did not seem to be  getting any 
bigger [226]. 
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Relapse and progression 
The major drawback of PET is the relatively short and variable duration of response [216]. Up to half 
of all patients will suffer a relapse [227] on longer term follow-up with recurrence or progression of 
their disease after a mean duration of 18-24 months [216]. The duration of response is generally 
shorter in women who have only exhibited a partial or static response to PET, compared to those 
with a complete response [217, 220]. Looking at long-term data, one study showed that at 12 years, 
81% of older women treated with primary tamoxifen had developed progressive disease – this was 
compared with 38% after mastectomy alone [227]. The implication being that these women may 
require a change of management – either in the form of second-line hormone therapy, or with 
surgery or radiotherapy. It is probably worth noting that this study must have recruited a very fit 
cohort of women for this type of treatment considering that a significant number were still alive at 
12 years of follow up and most current clinical practice would not consider a woman with a 12 year 
predicted life expectancy to be suitable for this type of treatment. 
However, another study [219] found that 37% of women treated with PET had disease control for 
more than 5 years, and 16% had control for up to 10 years. 
 
Delay in surgical management 
Women who require an operation following progression on PET have the additional risks associated 
with being older at the time of surgery compared to when they were first diagnosed and Bergman 
and colleagues [228] found that up to 59% of women who needed a change in management were 
unfit for an operation at the time of progression. 
Several studies have reported that some clinicians feel that PET only “delays” the definitive surgical 
management [227] and that patients may not be fit for surgery or the tumour may be inoperable at 
that time of progression [229]. However, if case selection is appropriately limited to women with a 
substantially reduced life expectancy, surgery may be avoided altogether in many women. 
 
Disease-free survival 
A Cochrane review of the available randomised controlled trials found that PET was associated with 
a lower disease-free survival when compared to surgery [214, 215]. This is understandable, 
considering the high rate of progression associated with PET [227]. 
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Side effects of PET 
General effects 
Reported side-effects of tamoxifen include: hot flushes, nausea and sickness, fatigue and tiredness, 
mood disturbances, musculoskeletal disorders, vaginal bleeding and discharge, endometrial cancer, 
ischaemic cardiovascular events, ischaemic cerebrovascular events and venous thromboembolic 
events [230]. 
Reported side-effects of Aromatase Inhibitors are similar to those reported with tamoxifen but with 
a few key differences [230]. The ATAC (Arimidex, Tamoxifen Alone or in Combination) trial compared 
the frequency of complications in groups and the results are shown below table 1.3. 
 Anastrazole (n=3092) Tamoxifen (n=3092) p-value 
 n % n %  
Hot flushes 1082 35.0 1246 40.3 0.001 
Nausea and vomiting 346 11.2 339 11.0 0.777 
Fatigue and tiredness 512 16.6 491 15.9 0.469 
Mood disturbances 519 16.8 508 16.4 0.707 
Musculoskeletal disorders 936 30.3 732 23.7 <0.001 
Vaginal bleeding 147 4.8 270 8.7 <0.001 
Vaginal discharge 94 3.0 378 12.2 <0.001 
Endometrial malignancies 3 0.1 15 0.7 0.007 
Fractures 219 7.1 137 4.4 <0.001 
Ischaemic cardiovascular 
disease 
86 2.8 67 2.2 0.121 
Ischaemic cerebrovascular 
events 
68 2.2 116 3.8 <0.001 
Venous thromboembolic 
events 
68 2.2 116 3.8 <0.001 
Table 1.3: Incidences of side-effects of anti-oestrogen therapy [230] . 
 
Endometrial cancer 
There is a documented higher incidence of endometrial carcinoma in patients treated with adjuvant 
tamoxifen [230, 231], however this has been shown to have little effect on survival [232]. 
 
Bone health 
Aromatase inhibitors are associated with an increased incidence of osteoporosis [233]. Oestrogen 
inhibits bone resorption by affecting osteoclastogenesis and osteoclast function through its effects 
on local cytokines and growth factors [234]. The pathogenesis of osteoporosis in patients treated 
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with AIs results from a deficiency in oestrogen and subsequent increase in bone resorption, coupled 
with a decrease in the deposition of new bone in weight-bearing bones. In contrast, treatment with 
tamoxifen is protective against osteoporosis by acting as an oestrogen receptor agonist, thereby 
inhibiting osteoclast activity [235, 236]. 
In practice as most women in the over 70 age group have some degree of osteoporosis or 
osteopenia, steps should be taken when using these agents to monitor bone density and use 
prophylactic medication to offset this risk.  UK guidelines recommend that use of AIs in this age 
group be accompanied by bone protection therapies [237].  This may add to the cost of AI use 
relative to tamoxifen where such measures are not necessary. 
 
Follow-up 
In view of the high rate of disease progression on PET [227] and the variability in the length of time 
taken to progress [219], patients treated with PET alone require close follow-up in order to detect 
recurrence at an early stage, necessitating more frequent hospital visits which may be associated 
with disruption to their daily lives, anxiety and stress.  
 
1.5.1.3. Advantages of surgery 
Local control 
The Early Breast Cancer Trialists’ Collaborative Group have emphasised the importance of adequate 
local control [238] and in a Cochrane review comparing surgery with PET, local control in the surgical 
group was superior to that of the PET group [214, 215]. 
 
Better survival? 
Despite a Cochrane review reporting that there was no difference in overall survival when 
comparing PET to surgery [214, 215] – several of these trials were flawed by modern standards, 
particularly with regards to the treatment given; four out of the seven trials used a comparison of 
surgery only – when nowadays, all patients undergoing operative intervention would be treated with 
adjuvant endocrine therapy were appropriate. This is without taking into account modern surgical 
techniques, with adequate margins and the routine addition of radiotherapy to patients who 
undergo wide-local excision. 
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Additionally, there have been several studies demonstrating that survival is in fact superior in those 
older women who undergo surgical treatment: 
 Of the RCTs, a long-term report, with follow-up of 12 years, demonstrated a significantly 
higher overall and breast cancer-specific mortality in the group of women treated with 
tamoxifen only, when compared to those who underwent surgical intervention with 
adjuvant tamoxifen (HR = 1.3; 95%CI = 1.05-1.61 and HR = 1.75; 95%CI = 1.18-2.59 
respectively) [239]. However the comments above about poor selection criteria for PET such 
that any of these women would survive to have 12 year survival, make it almost inevitable 
that PET would fail. 
 Bouchardy and colleagues [78] reviewed the outcomes of 407 breast cancer patients aged 
80 years or over, treated between 1989 and 1999 in a retrospective cohort study. They 
found that adjusting for age, 5-years breast cancer-specific survival was low among women 
who were treated with tamoxifen only (51%) when compared to those women treated with 
breast-conserving surgery and adjuvant treatment (90%) [78]. 
 More recently, Ali and colleagues [89] reviewed the outcomes of 14048 women with breast 
cancer, who aged 50 years or older and treated in the East of England between 1999 and 
2007. The found that taking account of age, tumour stage, grade, deprivation level and type 
of hospital, surgery was associated with the greatest increase in relative survival on 
multivariate analysis [89].  
 
Well tolerated 
Surgery for breast cancer is generally well-tolerated, even in older women and evidence suggests 
that even mastectomy with axillary clearance in older women has both low morbidity and mortality 
rates [65, 208]. A study looking at older women’s views about treatment found that surgery was well 
tolerated in this group and patients reported being satisfied with how little their lives changed as a 
result of surgery [226]. However little is known about the long term impact and quality of life has 
never been formally assessed between these 2 groups. One study has used the General Health 
Questionnaire (GHQ; 28 items) to assess anxiety and depression in a randomised controlled setting 
comparing PET and surgery and found no long term difference in outcomes [240]. 
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1.5.1.4. Disadvantages of surgery 
Mortality 
Mortality rates from breast cancer surgery are very low, even in very elderly, frail women [104, 241]. 
Mortality rates for women over 65 years who undergo mastectomy under general anaesthesia was 
reported to be 1% in studies published over 30 years ago [208, 209]. A more recent study that 
analysed the outcomes of patients over 70 who had undergone wide local excision, either under 
local or general anaesthesia, reported a mortality rate of only 0.3% (two deaths in 658 patients) [69]. 
 
Other surgical complications 
Mortality is not the only potential complication of surgery and morbidity may be substantial. 
Complications may be physical or psychological [242]. 
Physical complication after breast surgery include: bleeding (including haematoma and the need for 
blood transfusion), infection, scarring, acute and chronic wound pain, seroma formation and skin 
necrosis after mastectomy (see table 1.4). 
 Incidence Affected by age Reference 
Seroma Variable, 10-30% 
depending on 
procedure. 
Women >70 years 
have 2.4 times higher 
risk than those <70. 
[204-207] 
Haematoma and 
wound infection 
8-10% No difference with 
age 
[69] 
Skin flap necrosis 1-6% No difference with 
age 
[245-247] 
Axillary paraesthesia 5-13% Decreased incidence 
in older women 
[207, 248]  
Lymphoedema Variable, up to 38%, 
depending on 
procedure 
Decrease incidence in 
older women 
[207, 249] 
Arm symptoms (pain, 
stiffness, numbness, 
weakness) after 
axillary surgery 
Variable, up to 73%, 
depending on 
procedure 
Decreased in the 
older women. 
[250, 251] 
Ability to self-care 
after axillary lymph 
node dissection 
25-35% Older women more 
likely to have 
difficulty with 
household chores. 
[248] 
Table 1.4: Incidence of surgical complications and their association with increasing age. 
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Physical complications after axillary surgery include: bleeding (including haematoma and need for 
blood transfusion), seroma formation, paraesthesia, shoulder stiffness, damage to the long thoracic 
nerve (leading to “winging” of the scapula), chronic neuropathic pain, lymphoedema and breast 
oedema [243, 244]. 
The overall the morbidity rate is approximately 19%, with the incidence of serious complications, 
such as chest infection, cardiac arrhythmia and myocardial infarction being quoted as 11% in one 
study [209]. 
It is also important to consider the psychological effects of breast surgery, in terms of a woman’s 
body image, sexuality and relationships and both breast-conserving surgery and mastectomy are 
associated with psychological morbidity [252, 253]. A randomised controlled trial looking at 
psychological distress in older women treated with either surgery or PET showed short-term 
impairment in psychological wellbeing at 3 months in the surgical group, however this difference 
had disappeared by 2 years [240]. 
 
Risks of anaesthesia 
General anaesthetic carries a small, but significant risk. Older patients in general have increased 
levels of co-morbidity, decreased functional capacity and reduced physiological reserve [109, 202], 
making general anaesthetic more hazardous. 
 
Reduction in quality of life 
There is evidence that surgery results in a reduction in quality of life for all patients [242, 254]. 
However in a comparison between surgery and PET, one study used the General Health 
Questionnaire (GHQ) to assess quality of life and showed that despite the initial reduction in scores 
with surgery, the long-term quality of life is equivalent between these two treatment types [240]. 
Quality of life using a robust, validated tool has not been assessed in patients treated with PET. 
Despite this, loss of independence and hospitalisation are among the reasons older women have 
stated for wishing to avoid surgical treatment [226, 255]. 
 
Body image perception 
Surgery, in particular mastectomy, results in obvious deformity and consequent psychological 
morbidity. Husain and colleagues [226] found that some older women feel “less of a woman” 
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because of loss of their breast and expressed that this was the worst part of the experience of 
undergoing breast cancer surgery. 
 
Lack of benefit 
A significant proportion of older breast cancer patients will die from co-morbid conditions, hence 
reducing the relative survival advantages associated with surgical treatment [106]. 
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1.6. The impact of clinician preference on the treatment of older 
women with breast cancer 
1.6.1. A trend towards shared decision-making  
Recent times have seen a change within the UK National Health Service, with a shift in the clinician-
patient relationship away from the paternalistic approach towards consultations [256] (with 
clinicians as primary decision makers and patients as passive recipients) toward a more shared 
decision-making (SDM) approach, which involves more active participation of patients in medical 
decision-making [257-265]. The SDM model was developed in the 1980s and is characterised by 
equal participation of both the patient and clinician in all components of decision-making with a 
mutual exchange of information [256]. The role of the clinician in SDM involves eliciting the patients’ 
desires [266] and providing an appraisal of the current best evidence to allow the patient to make an 
informed choice [267]. 
The General Medical Council, the UK’s regulatory body for doctors, states that clinicians should elicit 
a patient’s individual needs and priorities when discussing treatment options and should provide 
patients with adequate information regarding the risks and benefits of each treatment [268]. The 
Royal College of Surgeons also support this ethos, stating that clinicians should allow sufficient time 
to explain the pros and cons of a potential treatment, including available alternatives, and they 
should ascertain and respect the patients’ wishes [269]. 
SDM is particularly promoted in preference-sensitive decisions where there is more than one 
feasible treatment option and the optimal choice can only be determined by an individual patient’s 
characteristics, values and preferences [270-273]. SDM is associated with an increase in patient 
satisfaction with both the decision and the process of making it [274-276]. 
 
1.6.2. Variation in shared decision-making preferences in older women 
In order for patients to express a preference for a particular treatment, they must first be informed 
of the different treatment options as advocated in SDM [277], which means that for some older 
women it may be appropriate to offer PET as an alternative to ‘standard’ surgical treatment and 
allow the patient to decide what is best for them. In addition, not all older patients want to engage 
in SDM, with many preferring a more passive role [88, 278-280] which may account for as many as 
50% of older patients [281-283]. Several studies have shown that older patients tend to prefer a 
more clinician-directed style of decision-making [281, 284-292], suggesting that older patients prefer 
to be informed, but not involved in the decision-making [283, 293], and that some may even 
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perceive decision-making to be a burden [294]. Indeed, encouraging an active role in DM when 
patients prefer a more passive role may increase anxiety and cause distress [295, 296]. 
Unfortunately, clinicians are poor at judging a patient’s preferred level of decision-making control 
[281, 287, 297, 298]. 
A preference for a more passive decision-making style may result from patients being unfamiliar 
with SDM within medical decision-making [289, 299], or feeling that they do not have sufficient 
understanding, information or support to make informed decisions [299, 300]. Decision-making 
stress may be especially compounded by fear of a cancer diagnosis, connotations of dying and worry 
about choosing the “right” treatment [301, 302], particularly older patients who may face more 
complex decisions and greater risks from treatments [303].  
 
1.6.3. The impact of clinician preference on treatment 
Despite the trend towards SDM in today’s clinical practice, clinicians vary in their decision-making 
styles. For example some clinicians believe it is not necessary to present all treatment options to a 
patient [304-307], and the opportunity for patients to participate in decision-making may be 
dependent on their clinician’s consultation style [308]. Even those clinicians who do participate in 
SDM, may have a personal preference for one or the other treatment option, which they may impart 
to the patient, either intentionally or unintentionally.  
Clinician recommendation is the most influential factor affecting older womens’ breast cancer 
treatment decisions [88]. Indeed, patients rank a clinician’s recommendation higher than their own 
preference, implying that many patients are not willing to contradict their clinician’s 
recommendation even in pure preference-sensitive decisions [309].  
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1.7. The gap in knowledge 
It is clear that the treatment of older women with operable breast cancer may be considered a 
preference-sensitive decision, that there is variation in practice across the UK and that clinician 
preference may influence patient choice in SDM. However it is not known whether clinician 
preference is one of the causes of the observed variation in treatment of older women with 
operable breast cancer across the UK. 
This thesis aims to address this gap by identifying the extent of treatment variation in older women 
with operable breast cancer, how much of this variation can be accounted for by case-mix and how 
variability in clinician preference may contribute to the unexplained treatment variation:  
 Chapter 1 outlines the background to the study, underpinning why it is important to 
investigate this problem.  
 Chapter 2 presents the research question with the aims and objectives of this thesis before 
going on to describe the methodological and philosophical approaches used to address 
these.  
 Chapter 3 examines the current use of PET and surgery in the treatment of older women 
with operable breast cancer by means of a systematic review of the literature and meta-
analysis.  
 Chapter 4 reports on the variation in treatment practice and whether this can be accounted 
for by case mix.  
 Chapter 5 explores the factors that HCPs consider important in the treatment decision-
making process and identifies areas of variability in HCP opinions relating to the treatment 
of older breast cancer patients. 
 Chapter 6 uses the themes identified in Chapter 5 to investigate the important factors and 
variability in opinion regarding treatment of older breast cancer patients on the wider UK 
breast HCP population.  
 Chapter 7 assesses how the factors identified as important to HCPs affect treatment 
decision-making in experimental conditions to identify whether they account for variation. 
 Chapter 8 summarises the main findings from the study in relation to the aims and 
objectives. 
 Chapter 9 discusses study findings in the wider context of the problem being addressed. 
 Chapter 10 concludes the thesis by summation of the work presented and the conclusions 
that can be drawn. 
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Chapter 2: Study Overview  
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2.1. Research question 
“Is clinician preference a variable in the management of older women with operable breast cancer?” 
2.2. Study aim 
To examine the variability in the treatment of older women with operable breast cancer, after 
controlling for case mix, in relation to the views of specialist healthcare professionals (HCPs). 
 
2.3. Study objectives 
 To determine the level of variance in the treatment of older women with operable breast 
cancer. 
 To explore the views of specialist healthcare professionals towards the management of older 
women (>70yrs) with operable breast cancer, particularly in terms of PET versus surgery. 
 To identify the factors underlying treatment decision-making by HCPs relating to older 
women with breast cancer. 
 To quantitatively assess the above factors on a wide group of HCPs to determine whether 
they account for variation in treatment. 
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2.4. Study components 
This is a mixed methods study, comprising of both qualitative (QUAL) and quantitative (QUAN) 
methods, including: 
 Systematic review and meta-analysis: QUAN (Chapter 3) 
 Retrospective registry data analysis, using case-mix adjustment: QUAN (Chapter 4) 
 Semi-structured qualitative interviews: QUAL (Chapter 5) 
 HCP questionnaire survey: QUAN (Chapter 6) 
 Discrete choice experiment: QUAN (DCE; Chapter 7). 
The first two strands (systematic review, meta-analysis and registry data analysis; Chapters 3 & 4) 
examine the current use of PET and surgery for older women with operable breast cancer in the UK 
and whether the observed variation can be accounted for by case mix. The third strand (qualitative 
interviews; Chapter 5) explores which factors HCPs consider important in the treatment decision-
making process and the variability in HCP opinions relating to this. The fourth strand (questionnaire 
survey; Chapter 6) investigates these factors and the variability in opinion on the wider population of 
UK breast HCPs. The fifth strand (DCE; Chapter 7) assesses the factors identified in earlier strands on 
HCP decision-making in experimental conditions to identify whether they account for the observed 
variation.  
Figure 2.1 shows how the individual study components of the project fit together and are presented 
within this thesis. 
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Figure 2.1: Schema of PhD. 
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2.5. Methodological approach 
2.5.1. Philosophical underpinning of the study 
The philosophical world view point, or research paradigm, of a researcher has an important 
influence on the way research will be undertaken: Burrell and Morgan argue that scientific research 
involves either a subjective or objective approach. These approaches have their own research 
paradigms; positivism and constructivism respectively (see table 2.1). In terms of methodology, 
positivism is commonly associated with quantitative (QUAN) approaches and constructivism with 
qualitative (QUAL) approaches [310]. Objectivism and subjectivism can be described as two polar 
ends of a spectrum or continuum with varying philosophical positions aligned between them. These 
two opposing philosophical approaches are  delineated by several core assumptions concerning 
ontology, epistemology and methodology – each of these assumptions consequently affecting each 
other [311]. Knowledge of these assumptions is important in order to identify them within a project, 
and since mixed methods (MM) projects, combining both QUAN and QUAL methodologies do not fit 
neatly into either paradigm, it has been suggested that all MM researchers clearly articulate their 
philosophical assumptions in their research [310]. Table 2.1 describes the basic characteristics of 
four world viewpoints that are commonly used in research. 
For the purposes of this study, a pragmatic world viewpoint is adopted. Pragmatism is often 
considered as occupying a “middle ground” between the polar extremes of positivism and 
constructivism and is one of the commonly embraced paradigms for researchers conducting MM 
projects [312]. This pragmatic perspective allows the researcher to occupy different positions on the 
paradigm continuum [310], employing a “what works” approach, thereby giving primacy to the 
importance of the research question and valuing both objective and subjective knowledge [313]. 
This is in contrast to critical realism, which focusses only on the ability to point out the limitations of 
the polar opposite paradigms, and as such offering a platform for the use of a variety of methods to 
overcome these in a process of triangulation [314, 315]. 
As a surgical trainee with an interest in breast cancer treatment, I have worked alongside a variety of 
HCPs in different units who have differing standpoints and ways of working. As such I am used to 
trying out different clinical methods and adopting those that work within my own practice, for 
example practical techniques within the operating theatre, as well as investigating diagnostic 
problems using a combination of different techniques. Hence, on a personal level it seemed 
appropriate for me as a researcher to use the combination of methods in order to meet the overall 
aims and objectives of the study. 
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 Positivism Constructivism Pragmatism Critical Realism 
Ontology: 
The philosophy of 
existence, 
concerned with 
explaining the 
fundamental 
nature of being – 
what exists? 
There is a real 
world (or a 
single reality) 
which can be 
seen, 
understood and 
directly 
observed. 
All we know is 
interpreted 
through human 
senses and so 
there are multiple 
constructed 
realities which are 
products of human 
intellects. We 
therefore cannot 
know the real 
world. 
There is a real 
world 
independent of 
our thinking but 
that single reality 
cannot be 
determined. 
Concerned not 
with an account 
of how things 
are, but only 
solutions to 
problems and 
applications. 
There is a real 
world 
independent of 
our thinking and 
science can study 
this single reality 
but only 
imperfectly and 
not with 
certainty. 
Epistemology: 
The philosophy of 
knowledge, 
concerned with 
explaining how we 
come to know the 
world – what is 
the relationship 
between the 
knower and the 
known? 
Cause probably 
determines 
effect, the 
results of which 
can be 
objectively 
perceived by the 
researcher. 
Being objective 
is paramount. 
Use checks to 
eliminate bias. 
Results are 
subjective and 
based on the 
individuals studied 
as they develop 
differing meanings 
of their 
experience, and it 
is these views 
which are studied. 
Subjectivity results 
in bias which is 
openly reviewed 
and results are 
interpreted in light 
of these biases. 
There is a 
continuum of 
objectivity-
subjectivity and 
the researcher 
will be at 
differing points 
on this 
continuum in 
different stages 
in the research 
process. Inclusion 
of both unbiased 
and biased 
perspectives. 
Scientists are 
inherently biased 
by their culture 
experience and 
world views. All 
observation and 
measurement is 
fallible and 
possess error (or 
bias) and that all 
theory is 
revisable. Use 
triangulation to 
reduce error. 
Methodology: 
The actual ways, 
or methods, used 
to try and 
understand the 
world – the 
process of 
research. 
Deductive 
methods 
(theory-driven) – 
quantitative in 
nature. 
Inductive methods 
(theories are built 
from the views of 
the participants) – 
qualitative in 
nature. 
Uses whichever 
methodology 
works in the 
context of the 
problem and may 
combine both 
quantitative and 
qualitative 
methods to gain 
the best answers. 
Emphasises the 
importance of 
multiple 
measures and 
observations, 
each of which 
may possess 
different types of 
error and the 
need to use 
triangulation. 
Table 2.1: Summary of characteristics of four research paradigms (adapted from [310]). 
As such, at different points within the study, as a researcher I am occupying different points on the 
research paradigm continuum: 
 Subjectively utilising my “insider’s perspective” to more fully understand the research 
problem. 
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 Ensuring different views and voices are integrated into the study, giving the maximum 
diversity of viewpoints. 
 Being sensitive to the process of reflexivity and the influence that my personal experiences 
and position may exert on the research. 
 Viewing the overall problem of variation from an objective stance by statistically analysing 
data using a case-mix adjustment. 
 Objectively testing generated theory with experimental methods. 
In summary, a MM approach from a pragmatist’s perspective was viewed as being an effective 
methodological approach in order to develop a more comprehensive understanding of this research 
project, whilst at the same time being consistent with my pragmatic stance within my career and 
generally within my personal viewpoint. 
 
2.5.2. Quantitative, Qualitative and Mixed Methods approaches 
At its very simplest, quantitative and qualitative research methods can be described as gathering 
and analysing numbers and stories, respectively. Both have advantages and disadvantages [310, 316, 
317], as are summarised in table 2.2. 
Mixed methods research uses and integrate both QUAN and QUAL research methodologies 
together. MM has the advantages of drawing on the positive aspects from both QUAN and QUAL 
methodologies (see table 2.3) and these types of studies may  access knowledge or insights 
unavailable to either QUAN or QUAL studies undertaken independently [318]. 
QUAN methods may be the best way to answer questions that ask “what is there?” [320] whilst 
QUAL methods are the best way to answer questions that ask “why is this the case?” [321]. In this 
study, there is a need to identify “what is the treatment variation” within the population with QUAN 
methods, investigate reasons as to “why this variation occurs” using QUAL methods and apply these 
theories back to the wider population with QUAN methods, thus justifying a mixed methods study 
design. 
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 Advantages Disadvantages 
QUAN Large sample so conclusions can be 
generalised to target population 
 
Statistical validity 
 
Efficient data analysis 
 
Demonstrate relationships 
 
Examine probable cause and effect 
(confirmatory) 
 
Bias controlled or limited 
 
People like numbers 
Impersonal, dry 
 
Do not hear the words of the participants 
 
Limited understanding of context of 
participants 
 
Largely researcher driven 
 
Superficial understanding of participants’ 
thoughts and feelings 
 
Biases of the researcher in interpretation of 
results are seldom discussed 
QUAL Detailed perspectives of a few people: rich, 
in-depth data 
 
Can hear voices of participants  
 
Understand participants’ experiences and 
behaviours within context 
 
Built from views of participants, not 
researcher 
 
People like stories 
Small sample so limited generalizability to 
target population 
 
Soft data, not as hard as numbers 
 
Few people studied 
 
Highly interpretive, subjective – not 
conclusive 
 
Reliance on participant minimizes 
researcher’s expertise 
 
Bias can be introduce by researcher in the 
execution and analysis 
Table 2.2: Summary of the advantages and disadvantages of quantitative (QUAN) and qualitative 
(QUAL) research. 
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QUAN MM QUAL 
Pre-determined instrument 
 
 
Instrument-based questions 
 
 
Performance, attitude, 
observation, census data 
 
 
Statistical analysis 
 
Statistical interpretation 
Pre-determined and 
emerging methods 
 
Both open and closed ended 
questions 
 
Multiple forms of data 
drawing on all possibilities 
 
 
Stats and text analysis 
 
Across database 
interpretation 
Emerging methods 
 
 
Open-ended questions 
 
 
Interview, observation, 
document and audio-visual 
data 
 
Text and image analysis 
 
Themes, patterns 
interpretation 
Table 2.3: Comparison of QUAN, MM and QUAL methods (adapted from [319]). 
 
2.5.3. Why use MM research? 
Undertaking a MM research study has the advantages of overcoming the limitations of a single 
design study, providing strengths that help counterbalance the weaknesses of either QUAN or QUAL 
studies undertaken alone [310]. Specific reasons may include the following [310, 322-327]: 
 Triangulation: looking for convergence or corroboration by using different methods, 
 Complementary: one method elaborates, enhances or clarifies results from the other 
method. 
 Offsetting: using a combination of methods with different strengths that offset the 
weaknesses of each method. 
 Development: uses results from one method to develop or inform the other method. 
 Expansion: using different methods extends the breadth and range of inquiry. 
 Comprehensiveness: using both methods allow an issue to be addressed more fully. 
 Salvaging: a second method is used after one has failed. 
 Sampling: where a combination of methods also different sampling methods of a 
population. 
In the context of this thesis, a MM approach was chosen for a combination of these reasons, 
including triangulation, complementary, development and expansion/comprehensiveness. More 
specifically, for example, results from the semi-structured interviews were used to develop a 
bespoke questionnaire. Results from each of the strands were also compared and contrasted, 
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searching for explanations and to corroborate the findings. Figure 2.2 shows the relationship 
between the strands in more detail. 
 
Figure 2.2: Interconnecting relationships between research strands. 
2.5.4. Development of a mixed methods research project 
When conducting MM projects there are several factors to consider in the design development 
[310]: 
 Determining the level of interaction between the QUAN and QUAL strands. 
The level of interaction between strands may be considered independent (where the data 
collection and analysis of each strand is kept separate and mixing occurs when drawing 
conclusions during the overall interpretation at the end of the study) or interactive (where the 
results from one strand may inform the development of the next strand). 
 Determining the priority of the QUAN and QUAL strands. 
The study may be weighted, so that greater emphasis is placed on either the QUAN 
(quantitative priority) or QUAL (qualitative priority) strands, or there may be equal priority, 
where both play an equally important role in addressing the research question. 
 Determining the timing of the QUAN and QUAL strands. 
 76 
 
The timing of the MM design can be considered as concurrent (where both QUAN and QUAL 
phases are implemented together in a single phase of the study), sequential (where the data 
collection and analysis of one strand occurs following that of the other), or multiphase 
combination (where multiple phases including sequential and/or concurrent timing are 
implemented over a program of study). 
 Determining where and how to mix the QUAN and QUAL strands. 
Mixing of the two approaches may occur at several points during the research process – during 
interpretation, during data analysis, during data collection, or at the level of design 
There have been several typologies of MM designs created in order to help the researcher address 
these factors [310, 322], however these tend to be theoretical, and are not necessarily based on the 
actual conduct of MM research [323]. Figure 2.3 demonstrates some of the most common MM 
study designs.  
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Figure 2.3: Examples of some common MM designs. 
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In order to answer the study research question and to address the aims and objectives of the study, 
a multi-level approach containing a nested sequential exploratory design has been adopted.  
The development of the questionnaire using the exploratory interview findings can be seen as a 
nested sequential exploratory design within the wider multi-level project where all the QUAN+QUAL 
findings are reviewed and interpreted together at the end. Figure 2.4 shows how the individual 
strands inform one another. 
 
 
Figure 2.4: Schematic overview of the interaction between each strand within the study. 
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2.6. Project development 
This thesis forms part of a NIHR funded programme grant (RP-PG-1209-10071) ‘Bridging the Age Gap 
in Breast Cancer’ focusing on addressing the variation in treatment practice for older women with 
operable breast cancer. Further details can be found in Appendices 1&2. 
The current project was developed by Lynda Wyld, Karen Collins, Malcolm Reed and Jenna Morgan 
with input from individuals on the Bridging the Age Gap in Breast Cancer Trial Management Team 
and others in developing specific components of the study: 
 Meta-analysis: Breast Cancer Cochrane Group 
 Registry component: Paul Richards, Sue Ward, Matthew Francis, Gill Lawrence, Catherine 
Lagord, Sarah Lawton, Thompson Robinson. 
 Interview component: Karen Collins, Maria Burton. 
 Questionnaire survey component: Thompson Robinson, Kwok-Leung Cheung, Riccardo 
Audisio. 
 DCE component: Thompson Robinson, Stephen Walters.  
2.7. Ethics and research governance 
All components of the study were conducted with appropriate ethics and research governance 
approvals, details of which can be found under each study component chapter and in Appendices 2, 
5, 6 and 7. 
2.8. Funding 
This thesis presents independent research funded by the National Institute for Health Research 
(NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-
PG-1209-10071 (See Appendix 3). The views expressed are those of the author and not necessarily 
those of the NHS, the NIHR or the Department of Health. 
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Section I: What is the extent of 
variation in practice across the UK? 
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Chapter 3: Systematic Review and 
Meta-analysis  
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3.1. Abstract 
3.1.1. Introduction: 
Since primary endocrine therapy (PET) was introduced and proven to be effective in the early 1980s, 
it has become a popular management strategy as an alternative to surgery for the treatment of 
operable breast cancer in older women. However, with continuing advances in the field, it is unclear 
how much of the published evidence remains relevant to the treatment of older women with 
operable breast cancer.  
3.1.2. Methods: 
A systematic review of the literature pertaining to the use of PET was performed between the dates 
of January 1980 to July 2014. Meta-analysis of relevant studies was also performed.  
3.1.3. Results: 
Six randomised controlled trials (RCTs), 31 non-randomised studies and 37 population studies were 
identified. Available data demonstrate an advantage for surgery over PET in terms of disease control 
and a likely survival benefit in patients with a predicted life expectancy of five years or more. 
Patients treated with aromatase inhibitors (AIs) for their primary endocrine therapy had superior 
rates of disease control when compared to those treated with tamoxifen. 
3.1.4. Conclusion: 
Primary endocrine therapy should be reserved for patients with reduced predicted life expectancy 
(e.g. less than five years). Unless there are contra-indications, AIs should be the preferred agent for 
PET as its efficacy is superior to tamoxifen. 
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3.2. Introduction 
As discussed in Chapter 1, the standard treatment for operable breast cancer in women of all ages 
was surgery until the early 1980s when primary endocrine therapy (PET) was first described as an 
alternative to standard therapy in older women [328, 329]. Primary endocrine therapy rapidly 
gained popularity in the UK as a management strategy for older women, leading to a number of 
randomised controlled trials (RCTs) being conducted internationally. These aimed at comparing the 
efficacy of tamoxifen PET against surgery in older patients [219, 225, 227, 231, 330-332]. In 2006, a 
Cochrane review of these 6 RCTs demonstrated superior local control with surgery but no difference 
in survival between the two treatments [214, 215]. 
Since the introduction of PET more than 30 years ago, there have been significant advances in the 
treatment of operable breast cancer. Tamoxifen has largely been replaced in post-menopausal 
women  by the introduction of third generation aromatase inhibitors (AIs) as first line treatment for 
both PET and adjuvant endocrine therapy [9]. The testing of oestrogen receptor (ER) status, rarely 
performed when these RCTs were conducted, has now become routine practice in all patients with a 
new diagnosis of breast cancer [9]. Additionally, improvements in anaesthetic and surgical 
techniques, including the recent trend towards less invasive techniques, such as sentinel lymph node 
biopsy, mean that breast surgery today, even in the older, frailer patient has a very low morbidity 
and mortality [333]. These changes in the field serve to limit the applicability of the RCT data to 
modern clinical practice.  
More recently, there continue to be new data published from non-randomised studies assessing the 
use of PET in a more up-to-date clinical setting. Given the potential flaws with the published RCT 
data to date, these non-randomised studies provide another source of data on the use of PET in 
modern clinical practice. The aim of this systematic review was to analyse the data pertaining to PET 
that has been published in the literature since it was introduced as a treatment for operable breast 
cancer. 
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3.3. Methodology 
3.3.1. The use of RCTs as evidence in this clinical setting 
Randomised controlled trials, although considered to be high-quality in terms of study design when 
compared to other non-randomised methodologies, may not always be the most appropriate study 
method to answer a clinical question.  
In the case of PET vs surgery, the main limitation of the RCTs was that the women recruited to the 
trials had to be fit for surgery under general anaesthesia. The fact that the RCT study groups were 
able to go back and reanalyse data at 20 years and even 28 years, with long-term survivors at these 
stages, suggests that they recruited a very fit group of older women [67, 335]. In current UK practice, 
PET tends to be reserved for the less fit, older age groups and in practice, these two groups of 
women would not be comparable in terms of co-morbidity or frailty. None of the RCTs stratified for 
or even recorded  co-morbidities which may have had a significant impact on survival, and even 
those older women who are fit for surgery often die of co-morbid diseases, thereby reducing the 
survival advantage of any breast cancer therapies [106].  
The average age of the women recruited to these RCTs was relatively young, being in the early to 
mid-70s; women in this age group can be expected to have a median life-expectancy of 17 years 
[336] – considerably longer than the duration of benefit that can be expected with PET [224, 337-
341]. 
In addition, a recent attempt at recruiting to a multi-centre RCT comparing PET and surgery, using 
more currently acceptable eligibility criteria, known ER+ cancers and the optimal anti-oestrogen 
(aromatase inhibitor rather than tamoxifen) was unsuccessful due to lack of equipoise amongst both 
patients and clinicians so few women were offered or accepted randomisation [342].  
 
3.3.2. Cochrane review meta-analysis. 
Meta-analysis of high quality RCTs are generally regarded to be the highest level of evidence in 
evidence-based medicine [343], with Cochrane reviews being considered to have greater 
methodological rigor compared with other types of systematic reviews and meta-analyses [344]. 
This is because they base their findings only on RCTs which meet certain quality criteria [345]. 
However, this places limitations on the evidence that can be included and may result in large 
quantities of potentially relevant data being discarded, with the results becoming less generalizable 
 85 
 
as a consequence. Meta-analyses in general are also limited to the outcomes assessed and reported 
by the included trials and these must be comparable in order to draw any meaningful conclusions. 
In the case of the PET versus surgery meta-analysis, the results of the Cochrane study were limited 
by the inclusion of only a few small studies, discarding data from several non-randomised studies 
that also sought to address the same question.  
 
3.3.3. The use of non-randomised cohort studies in this clinical setting 
The non-randomised data in the literature provides a unique opportunity to compare the different 
types of PET in the “real-life” setting, and to explore the survival difference between studies that 
treated all women, regardless of ER status, fitness for anaesthesia and comorbidities, in this manner 
versus those who only used PET to treat ER positive women. In effect what would normally be 
regarded as a source of bias can be used to get a better understanding of real world outcomes in 
clinical practice.  
Additionally, there are tools available that allow assessment of the methodological rigour of these 
types of studies, in a manner similar to that performed on RCTs in a Cochrane review [346-348]. Ten 
distinct areas are rated on a 4-point scale (very poor to good), including: title and abstract; 
introduction and aims; methods; sampling; data; analysis; ethics and bias; results; transferability or 
generalizability; implications and usefulness. Each paper is then given an overall score between 10 
and 40, indicating its methodological rigour. 
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3.4. Methods 
3.4.1. Search methods. 
Relevant studies were identified by searching the following electronic databases: 
 MEDLINE*^ 
 EMBASE*^ 
 CINHAL^ 
 PsychINFO^ 
 CENTRAL* 
 The Cochrane Breast Cancer Group Specialised Register* 
 WHO International Clinical Trials Registry Platform (ICTRP)* 
 ClinicalTrials.gov* 
*denotes searches were undertaken by the Breast Cancer Cochrane Group. 
^denotes searches were undertaken by JM. 
Hand searching of references was also performed in an attempt to identify all relevant studies. 
In view of the fact that breast cancer mainly affects women and the use of PET was first described in 
the early 1980s, several limits were placed on the search: 
 Date: 1980-present day. 
 Participants: Humans, Females. 
 Language: Articles in English. 
Several searches were performed, using a combination of the following search terms: 
 Breast cancer, breast neoplasm, breast tumour, mammary cancer, mammary neoplasm, 
mammary tumour. 
 Primary endocrine therapy, endocrine, tamoxifen, anastrazole, letrozole, exemestane, 
femara, arimidex, aromasin. 
 Primary, sole, versus, neo-adjuvant, only. 
 Cohort study, population study, longitudinal study, randomised controlled trial, randomized 
controlled trial, RCT. 
 Elderly women, older women, over 70 years, over 65 years, over 80 year. 
For the full search strategies, please see Appendix 4. 
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3.4.2. Results of the search 
A total of 6,634 results were generated by these initial searches. Abstracts and titles were reviewed 
for relevance and compared to the inclusion criteria and full text articles were obtained. Where it 
was unclear from the title/abstract whether the studies met the inclusion criteria, full text articles 
were also obtained and a decision made based on the entire paper.  
Figure 3.1 shows the review process in diagrammatic form. 
After excluding ineligible and duplicate abstracts, 271 papers were deemed potentially eligible and 
the full papers were retrieved. 
References of relevant papers were hand searched to identify additional studies missed by the 
primary search. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Flow diagram showing review process. 
 
Records identified through 
database searching 
(n = 6,634) 
Additional records identified 
through hand searching 
references (n = 12) 
Total number of citations assessed 
(n = 6,646) 
 
Excluded based on title or 
information in abstract 
(n = 6,375) 
 
Full-text articles retrieved for 
the review (n = 271) 
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3.4.2.1. Assessment of eligible papers 
Inclusion criteria for RCTs 
Articles describing randomised controlled trials (RCTs) were deemed to meet the inclusion criteria if 
they included older women with potentially operable primary breast cancer (i.e. stages I-IIIa) that 
were randomised to PET vs. some form of surgical treatment. 
 
Inclusion criteria for case-series and cohort studies 
Non-randomised studies were deemed to meet the inclusion criteria if: 
 They included patients with potentially operable primary breast cancer (i.e. stages I-IIIa). 
 They pertained to the management of older or frail women. 
 They included patients treated with primary endocrine therapy (PET). 
 They included patients treated with neo-adjuvant endocrine therapy for at least 6 months 
prior to surgery. 
o They reported response to neo-adjuvant endocrine therapy prior to surgery being 
performed. 
 
Exclusion criteria 
Articles were excluded from the overall analysis if: 
 More than 30% of the patients had non-operable disease (stage IIIb – where the tumour has 
spread to the skin of the breast or the chest wall – or metastatic disease). 
  Neo-adjuvant therapy was given for less than 6 months. 
 
3.4.3. Data extraction 
3.4.3.1. Data extraction for RCTs 
Data was extracted pertaining to the number of patients, type of anti-oestrogen used, ER status, 
complete response rate (CR), partial response rate (PR), static disease (SD), progressive disease (PD), 
clinical benefit rate (CR + PR + SD), disease progression, breast cancer-specific survival (BCSS) and 
overall survival (OS). Data analysis was performed using SPSS® software version 20 (IBM®) and 
Review Manager version 5.2.  Associations were identified using Chi2 analysis. 
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3.5. Results 
3.5.1. Results of the search 
Of the 271 papers that were examined, 74 were deemed relevant for inclusion in the reviews, these 
included articles pertaining to: 
 Seven RCTs comparing PET vs. surgery in older women [219, 225, 227, 229, 231, 330-332, 
335, 349, 350]. 
 Thirty case-series looking at cohorts of women treated with PET [74, 218, 220, 222, 228, 328, 
329, 337-341, 351-369]. 
o Seven of these were also cohort studies that compared women treated with PET 
against a surgically-treated control group [355, 357, 361, 364, 365, 367, 369]. 
 Thirty-seven large population studies looking at the overall treatment of older women, 
including the non-surgical management, but without data on PET efficacy, were also deemed 
relevant [44, 45, 68, 69, 75, 77, 78, 83-85, 88-92, 201, 370-394]. 
 
3.5.1.1. Characteristics of included studies 
Characteristics of included RCTs 
To date, there have been seven RCTs that have compared primary tamoxifen with surgery for the 
treatment of operable breast cancer in older women. The characteristics of these studies are shown 
in table 3.1. 
 
Characteristics of included case series 
To date there have been 30 published case series that have examined women treated with PET. 
These studies have been divided into those using tamoxifen only, those using an AI only and those 
studies including patients treated with both tamoxifen and AIs or where it was unclear from the 
paper which type of PET had been used. The characteristics of these studies are shown in tables 3.2-
3.4. 
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Study n PET* Surgery Adjuvant 
anti-
oestrogen 
Average 
Age 
ER Status Stage Follow-
up 
Nottingham 
I, UK [67, 
227, 229, 
349] 
66 TAM Wedge 
Mx, 
limited 
axillary 
surgery 
No >70 Not 
assessed 
I-II Up to 
21-27 
years 
Nottingham 
II, UK [219] 
94 TAM Wedge 
Mx, 
limited 
axillary 
surgery 
Yes (TAM) 78 All mod/ 
strong 
+ve H 
score 
>100 
I-II Over 10 
years 
Naples, 
Italy [330] 
37 TAM Mx or WLE Yes (TAM) >70 Not 
assessed 
T1-3, 
N0-1 
Over 10 
years 
GRETA, Italy 
[331] 
235 TAM Mx or WLE 
with DTx 
Yes (TAM) 77 Not 
assessed 
T1-3, 
N0-1 
80 
months 
St Georges, 
UK [225, 
395] 
100 TAM Mx or WLE 
without 
DTx 
No 75.5 Not 
assessed 
T1-4 Up to 
28 
years 
EORTC 
10851, UK 
[332] 
82 TAM Mx, full 
ANC 
No 76.3 Not 
assessed 
Upto 
T3,N1 
Up to 
14 
years 
CRC, UK 
[231, 396] 
230 TAM Mx or WLE 
without 
DTx 
Yes (TAM) 76  
(70-90) 
Not 
assessed 
I-III Up to 
16 
years 
TAM = tamoxifen; Mx = mastectomy; WLE = wide local excision; ANC = axillary node clearance; DTx 
= radiotherapy 
Table 3.1: Characteristics of RCTs comparing PET with surgery. 
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Study 
 
n PET 
type* 
Comparison Average 
Age 
ER status Stage Follow-
up (m) 
Gävle, 
Sweden [352] 
27 TAM None 80 Not stated I-II 6-40 
Dundee I, UK 
[329] 
67 TAM None 78 Not stated I-III 36 
Mayday I, UK 
[357] 
161 TAM Surgery/ 
radio-therapy/ 
medical 
77  
(70-98) 
Unselected I-III 60 
Newcastle, 
UK [355] 
61 TAM Surgery 77 Unselected 70% 
stage I 
14 
Royal 
Marsden I, 
UK [356] 
42 TAM None 62  
(29-84) 
Not stated I-III 19  
(6-42) 
Mayday II, UK 
[328, 357] 
51 TAM None 78  
(70-91) 
Not stated I-III 36 
Southampton 
I, UK [337] 
58 TAM None 78  
(59-94) 
Not stated I-II 19 
Edinburgh I, 
UK [223, 224] 
100 TAM None >70 Unselected  I-IV 59 
Florence, 
Italy  [338] 
62 TAM None 78  
(70-91) 
Not stated I-III 48 
Southampton 
II, UK [358] 
56 TAM None 70-93 Not stated I-III 60 
Dundee II, UK 
[353] 
113 TAM None 82  
(68-93) 
Unselected I-II 29 
(1-103) 
Radboud, 
Netherlands 
[339] 
40 TAM None >70 Unselected I-III 24 
Edinburgh II, 
UK [218] 
59 TAM None >70 ER+ I-II >6 
NKI/DdHK, 
Netherlands 
[228] 
84 TAM None 83  
(69-93) 
Unselected I-III 60 
Royal 
Marsden II, 
UK [359] 
54 TAM None elderly Unselected I-IV 23 
(14-55) 
Nottingham 
II, UK [354] 
47 TAM None >70 Unselected Not 
stated 
Not 
stated 
Ireland [74] 68 TAM None >70 Unselected I-IV Not 
stated 
Leicester, UK 
[397] 
70 TAM None 79  
(70-93) 
ER+ Not 
stated 
70  
(9-119) 
Tilberg, 
Netherlands 
[361] 
113 TAM Surgery 84 Unselected Not 
stated 
49 
Table 3.2: Characteristics of Case Series using tamoxifen (TAM) only. 
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Study 
 
n PET 
type* 
Comparison Average 
Age 
ER 
status 
Stage Follow-up 
(m) 
Luton, UK 
[362] 
104 LET None 83  
(58-98) 
ER+ Not 
stated 
56  
(4-106) 
Hanover, 
Germany 
[340] 
56 AI None 74 (52-
102) 
ER+ I-IV 51 
(19-78) 
Hull II, UK 
[341, 351] 
45 LET None 87 (70-
101) 
ER+ I-III 60 
Valencia, 
Spain [363] 
56 LET None 79  
(66-91) 
ER+ I-III 12 
*ANZ = Anastrazole, LET = Letrozole 
Table 3.3: Characteristics of Case Series using Aromatase Inhibitors only (AI). 
 
Study 
 
n PET 
type* 
Comparison Average 
Age 
ER status Stage Follow
-up 
(m) 
Nottingham 
I, UK [220] 
50 NS None 75-96 Unselected I-IIIa 28 
(3-97) 
Hull I, UK 
[365] 
62 TAM 
/AI 
Surgery 82 ER+ Not 
stated 
20  
(2-
150) 
Nottingham 
III, UK [366] 
84/
64 
TAM 
/ANZ 
None 81  
(62-93) 
ER+ Not 
stated 
24  
(6-72) 
Sunderland, 
UK [367] 
99 TAM  
/LET 
Surgery 80 ER+ Not 
stated 
76 
Wales [368] 82 TAM 
/AI 
None 81  
(62-93) 
ER+ Not 
stated 
24  
(6-72) 
Nottingham 
IV, UK [364] 
616 TAM 
/AI 
Surgery 81  
(70-99) 
ER+ I-III 41  
(1-
202) 
Queen 
Mary’s, UK 
[222] 
91 TAM 
/AI 
None 80  
(50-96) 
ER+ I-IV 18  
(2-70) 
Eindhoven, 
Netherlands 
[369] 
184 TAM 
/AI 
Surgery 84  
(75-89) 
Unselected I-III 31  
(1-
102) 
*TAM = tamoxifen, ANZ = Anastrazole, LET = Letrozole, NS = Not Specified 
Table 3.4: Characteristics of Case Series using a combination of TAM/AI or Not Specified (NS). 
 
Characteristics of large cohort/populations studies 
To date there have been 37 cohort studies published, investigating the differences in the treatment 
of older women, although not all of them examined the effect of non-surgical management in these 
larger cohorts. The characteristics of these studies can be seen in tables 3.5 and 3.6. 
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Study Source Date range n Average Age Non-surgical n 
treatment % 
Canada [45] Quebec tumour 
registry or 
Quebec hospital 
1988-1994 1174 417/1174 aged 
70+ 
Not stated 
US I [44] San Antonia 
breast cancer 
database;  SEER 
registry 
1973-1995 50828;  
256287 
23053/50828 
aged 65+ 
126/35154 
(<1%) 
US II [377] Mount Sinai 
Medical Centre 
1978-1998 1126  
(206 aged 70+) 
70+ cohort: 
mean 77 years 
(71-92) 
8/206 (3.9%) 
UK I [69] North Trent 
Cancer Network 
March-August 
2002 
378 (167 aged 
70+) 
70+ cohort: 
median 78.9 
(70-98) 
70/167 (40.3%) 
UK II [378] Glenfield 
Hospital, 
Leicester 
1997-2000 2209 Not stated 534/2209 
(24.2%) 
US V [201] Four US regions 1997-1999 689 269 aged 75+  None 
Germany I [91] University of 
Ulm 
1992-2005 1922 563 aged 70+ Not stated 
Australia [380] Australian 
National Breast 
Cancer Audit 
1998-2006 57100 
(6100 aged 70+) 
70+ cohort: 
mean +/- SD 
78.0 +/- 5.3 
years 
213/57100  
(3.5%)  
UK VI  [85] Eastern Cancer 
Registry 
Information 
Centre 
1999-2003 9051 
(2945 aged 70+) 
2945/9051 
aged 70+ 
789/2945 
(26.8%) 
Netherlands II  
[83, 90] 
National Cancer 
Registry 
1995-2005 127805 38.6% aged 65+ Shown as % for 
each age range 
per year 
UK VII [89] Eastern Cancer 
Registry 
Information 
Centre 
1999-2007 14048 ~40% aged 70+ 4840/14048 
(34.5%) 
Netherlands IV 
[84] 
National Cancer 
Registry 
2005-2008 31520 
(6561 aged 75+) 
75+ cohort: 
median 82.5 
years 
1411/31520 
(4.5%) 
Germany II 
[381] 
Breast Unit 
Heidelberg 
2003-2010 3338 
(810 aged 65+) 
Median age 57. 
 
45/3338 (1.3%) 
Switzerland II 
[372] 
University 
Women’s 
Hospital Basel, 
Switzerland 
1990-2005 523 
(151 aged 80+) 
80+ cohort: 
mean 84.3 
years (80-95) 
18/151 
(11.9%) 
Table 3.5: Characteristics of Cohort Studies of Older Women with a Younger Cohort for Comparison. 
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Study Source Date 
range 
n Average 
Age 
Non-surgical n 
(%) 
Italy [382] North-East Clinical 
Cooperative Group in 
Italy 
- 72 All 70+ 2/72 (2.8%) 
Netherlands I 
[77] 
Sophia Hospital 1980-1992 210 All 70+ 34/210 (16.2%) 
treated with PET 
France I [75] Rene-Huguenin Centre 1978-1992 1143 All 70+ 131/1143 
(11.5%) 
Switzerland I 
[78] 
Geneva cancer registry 1989-1999 407 All 80+ 132/407 (32.4%) 
treated with 
PET. 
US III [92] Memorial Sloan-
Kettering Hospital 
1997-2000 96 All 75+ None 
France II [394] Institut Curie, Paris 1981-1995 1755 Median 75 
(70-94) 
None 
US IV [379, 383, 
384] 
Six US healthcare 
systems 
1990-1994 1837 All over 65 22/1859 (1.2%) 
UK III [68] North Western Cancer 
Registry 
1999 480 >64 years 67/480 (14.0%) 
UK IV [398] Breast units Greater 
Manchester 
2002-2003 76 All >64 12/76 (15.8%) 
UK V [385] Royal Marsden Hospital 1980-2000 950 All over 70 366/950 (38.5%) 
US VI [386] Four US geographic 
regions 
1997-2006 660 All 65+ 17/660 (2.6%) 
Spain I [387] Lluis Alcanyis Hospital 2005-2006 91 76 (70-92) None 
US VI [88] SEER 1992-2003 49 
616 
All 67+ 1.7% 
France III [388] Institut Curie, Paris 1995-1999 538 All 70+ 29/538 (6.4%) 
Netherlands III 
[389] 
Comprehensive Cancer 
Centre East registry 
2001-2006 2336 All 60+ 112/2336 (4.8%) 
Spain II [371] Hospital Universitari Vall 
d’Hebron 
1990-2009 259 Median 84 84/259 (32.4%) 
US VIII [390] MD Anderson Center, 
Texas 
1989-2004 212 Median 
83.5 (80-
97) 
7.1% treated 
with PET 
Wales [391] Nevill Hall Hospital 2003-2006 57 All 75+ 29/57 (50.1%) 
UK VIII [392] Royal Bolton Hospital 2008 43 All 70+ 8/43 (18.6%) 
UK IX [393] Nottingham Hospital 1973-2010 1758 Median 77 
(70-99) 
855/1758 
(48.6%) 
UK X [374] Northern & Yorkshire 
and West Midlands 
registries 
1997-2005 2303
8 
All over 65 
years 
14.3% of stage I-
III. 
Netherlands V 
[373] 
National cancer registry; 
5 regional hospitals 
1995-
2005; 
1990-2005 
1086
51 
Median 
85.9 (75.0-
97.7) 
187/108651 
(<1%) 
UK XI [375] 22 English breast cancer 
units 
2010-2013 800 All >69 136/800 (17%) 
Table 3.6: Characteristics of large cohort/populations studies looking solely at older women. 
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3.5.2. Differences in the treatment of older women with operable breast 
cancer. 
The population studies confirmed that older patients are more likely to have higher stage disease at 
diagnosis with larger, more strongly ER+ tumours [44, 45, 69, 84, 88-91, 377, 380, 388, 389, 399].  
The main finding of the large population studies was that older women are less likely to receive 
standard treatment, including surgery, for their operable breast cancer when compared to younger 
women [68, 78, 83, 84, 88-91, 374, 375, 377, 378, 385, 388, 389, 391, 398, 399]. This is constant 
across all countries studied but varies by the degree to which this is seen. Table 3.7 shows the rates 
of non-surgical treatment by country. 
Country Rates of non-surgical 
treatment 
Netherlands [77, 83, 84, 90, 373, 389] 1-16% 
Sweden [78, 399] 12-32% 
Spain [371, 387] 0-32% 
France [75, 388, 394] 0-11% 
Ireland [74] 26% 
Italy [382] 2.8% 
Germany [91] 1.3% 
United States of America [44, 88, 201, 377, 379, 383, 386, 
390] 
0-7.1% 
Australia [380] 3.5% 
Table 3.7: Rates of non-surgical treatment by country. 
 
They also demonstrated that breast cancer was a relatively less important cause of death in older 
compared to younger patients [44, 88-90], with Bastiaannet and colleagues [90] demonstrating that 
almost 100% of patients aged 15-65 years who died, died of their breast cancer, compared to only 
20% in the 90+ group. Diab and colleagues [44] showed similar findings, with breast cancer 
responsible for 73% of all deaths in the 50-54 year olds with breast cancer vs. 29% of deaths for 
patients aged 85+, as did Ali and colleagues [89], with the proportion of patients dying of breast 
cancer relative to other causes declining from 70% in the 50-69 year olds to only 39% in the over 
80s. 
Rates of non-surgical management in older patients were found to vary according to region [374] 
and between hospitals [85], with patients in district general hospitals less likely to receive surgery 
than at a university hospital [68]. 
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3.5.3. Reasons for the use of PET in older patients. 
Several reasons were stated for the use of non-surgical treatment in these older cohorts, including 
old age, co-morbidity, lack of fitness, overall health status, patient choice and frailty [222, 362, 369, 
373, 378]. 
Increasing levels of co-morbidity and a reduction in functional status are more common with 
increasing age [45, 201] and were associated with a reduction in rates of surgery in older patients 
[374, 375, 398]. However Hamaker and colleagues found that co-morbidity accounted for only 6% of 
decisions to omit surgery and overall health status for only 5% [373]. Rai and colleagues found that 
the reasons for not treating older patients with early surgery was due to either extreme age or being 
unfit for surgery in 60% [378] and in the study by Balakrishnan and colleagues, 29% of patients were 
treated with PET due to co-morbidities and 46% due to frailty [362]. Additionally, Ayantunde and 
colleagues found that 32% of patients treated with PET were treated thus due to them being unfit 
for surgery [222] and in 35% of the patients treated with PET in the study by Wink and colleagues 
this was due to the treating physician declaring the presence of co-morbidities as the reason [369]. 
Patient request was also found to be a commonly stated reason for the omission of surgery, 
including in 32% of patients in the study by Hamaker and colleagues [373], in 16% according to 
Balakrishnan and colleagues [362] and in 18% of patients in the study by Ayantunde and colleagues 
[222]. This is in contrast with the findings of Rai and colleagues [378] who found only 4% of patients 
treated without early surgery were due to patient choice, although this study related to a specialist 
elderly breast clinic run in combination with a geriatrician where the patients receive extensive 
counselling and comorbidity and frailty assessments, so may not be reflective of normal UK practice. 
Lavelle and colleagues [375] found that lower rates of surgery were unlikely due to patients actively 
opting out of surgery. Interestingly, Rao and colleagues [365] found that clinician choice in the 
absence of co-morbidities was the most common reason for patients receiving PET. 
 
3.5.4. The evidence for the use of PET as a treatment for older women with 
breast cancer 
3.5.4.1. Efficacy of PET 
The efficacy of PET is measured according to tumour response using the RECIST Response Criteria 
[400]: 
Using the sum of the longest diameter of the palpable lesion: 
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 Complete Response (CR): Complete disappearance of disease. 
 Partial Response (PR): At least a 30% decrease in the size of the lesion relative to baseline. 
 Progressive Disease (PD): At least a 20% increase in the size of the lesion relative to the 
smallest measurement since start of treatment or an increase in the total number of 
palpable lesions. 
 Static Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD. 
Patients with complete, partial or static responses are said to experience clinical benefit (CB). 
Patients may experience a period of clinical benefit prior to subsequently relapsing – these patients, 
together with the initial progressive disease patients are often combined to give a failure rate. 
 
Efficacy reported in RCTs 
The CR, PR, SD, PD and failure rates are summarised in table 3.8 below for the RCTs published to 
date. 
Study n PET ER Status Clinical Benefit Rate PD 
Rate 
Failure 
Rate 
Nottingham 
I, UK [67, 
227, 229, 
349] 
66 TAM Not assessed 74% 
(CR 50%; PR 17%; SD 8%) 
26% 62% 
Nottingham 
II, UK [219] 
94 TAM All mod/ 
strong +ve H 
score >100 
97%  
(CR 30%; PR 44%; SD 
24%) 
3% 32% 
Naples, Italy 
[330] 
37 TAM Not assessed 73%  
(CR 14%; PR 22%; SD 
38%) 
27% 35% 
GRETA, Italy 
[331] 
235 TAM Not assessed 99%  
(CR 9%; PR 32%; SD 55%) 
1% 45% 
St Georges, 
UK [225, 
395] 
100 TAM Not assessed Not stated Not 
stated 
25% 
EORTC 
10851, UK 
[332] 
82 TAM Not assessed Not stated Not 
stated 
68% 
CRC, UK 
[231] 
230 TAM Not assessed Not stated Not 
stated 
53% 
Table 3.8: Response to PET as reported in Published Randomised Controlled Trials. 
Efficacy reported in case series and cohort studies 
The CR, PR, SD, PD and failure rates are summarised in tables 3.9-3.11 below for the non-
randomised studies published to date. The studies are separated according to treatment type. 
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Study 
 
n PET 
used* 
ER Status Clinical Benefit Rate PD Failure 
rate  
Gävle, 
Sweden [352] 
27 TAM Not stated 93%  
(CR 56%; PR 22%; SD 7%) 
7% 19% 
Dundee I, UK 
[329] 
67 TAM Not stated 73% 
(CR 27%; PR 21%; SD 25%) 
27% 31% 
Mayday I, UK 
[328] 
161 TAM Unselected 86% 
(CR 27%; PR 34%; SD 24%) 
14% 60% 
Newcastle, 
UK [355] 
61 TAM Unselected 77% 
(CR 18%; PR 39%; SD 20%) 
23% 38% 
Royal 
Marsden I, 
UK [356] 
42 TAM Not stated 95% 
(CR 2%; PR 55%; SD 38%) 
5% 31% 
Mayday II, UK 
[357] 
51 TAM Not stated 54% 
(CR 18%; PR 24%; SD 12%) 
20% Not 
stated 
Southampton 
I, UK [337] 
58 TAM Not stated 69% 
(CR 17%; PR 17%; SD 35%) 
31% 66% 
Edinburgh I, 
UK [223] 
100 TAM Unselected  90% 
(CR 40%; PR 28%; SD 22%) 
10% Not 
stated 
Florence, 
Italy [338] 
62 TAM Not stated 96% 
(CR 11%; PR 40%; SD 45%) 
3% 31% 
Southampton 
II, UK [358] 
56 TAM Not stated 59% 
(CR 21%; PR 29%; SD 9%) 
29% 34% 
Dundee II, UK 
[353] 
113 TAM Unselected 79% 
(CR 34%; PR 15%; SD 30%) 
21% 62% 
Radboud, 
Netherlands 
[339] 
40 TAM Unselected 82% 
(SD 40%) 
18% Not 
stated 
Edinburgh II, 
UK [218] 
59 TAM ER+ 54% 
(CR 24%; PR 22%; SD 8%) 
34% 46% 
NKI/DdHK, 
Netherlands 
[228] 
84 TAM Unselected 85% 
(CR 14%; PR 24%; SD 46%) 
15% 44% 
Royal 
Marsden II, 
UK [359] 
54 TAM Unselected 94% 
(CR 7%; PR 50%; SD 37%) 
6% 24% 
Nottingham 
II, UK [354] 
47 TAM Unselected 83% 
(CR 4%; PR 30%; SD 49%) 
17% Not 
stated 
Ireland [74] 68 TAM Unselected 57% 
(SD 28%) 
31% Not 
stated 
Nottingham 
III, UK [366] 
84 TAM ER+ 100% 
(CR 8%; PR 18%; SD 74%) 
0% Not 
stated 
Leicester, UK 
[397] 
70 TAM ER+ 77% Not 
stated 
84% 
Tilberg, 
Netherlands 
[361] 
113 TAM Unselected 62% 2% Not 
stated 
Table 3.9: Response to PET as Reported in Published Case Series/Cohort Studies using tamoxifen 
(TAM) only. 
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Study 
 
n PET 
used* 
ER 
Status 
Clinical Benefit Rate PD Failure 
rate  
Nottingham III, UK 
[366] 
64 ANZ ER+ 97% 
(CR 9%; PR 30%; SD 
58%) 
3%  Not 
stated 
Luton, UK [362] 104 LET ER+ 82% 
(CR 23%; PR 40%; SD 
18%) 
18% 37% 
Hanover, Germany 
[340] 
56 AI ER+ 100% 
(CR 11%; PR 77%; SD 
13%) 
0% 20% 
Hull II, UK [341, 351] 45 LET ER+ 60% 4% Not 
stated 
Valencia, Spain [363] 56 LET ER+ 100% 
(CR 25%; PR 52%; SD 
23%) 
0% Not 
stated 
Table 3.10: Response to PET as Reported in Published Case Series/Cohort Studies using  
Aromatase Inhibitors (AI) only. *ANZ = Anastrazole, LET = Letrozole 
 
Study 
 
n PET 
used* 
ER Status Clinical 
Benefit Rate 
PD Failure 
rate  
Nottingham I, 
UK [220] 
50 Not 
stated 
Unselected 98% 
(CR 52%; PR 
34%; SD 12%) 
2% 12% 
Hull I, UK [365] 62 TAM /AI ER+ Not stated Not 
stated 
55% 
Sunderland, UK 
[367] 
99 TAM / LET ER+ Not stated Not 
stated 
37% 
Wales [368] 82 TAM /AI ER+ Not stated Not 
stated 
15% 
Nottingham, 
UK [364] 
616 TAM /AI ER+ 84% 
(CR 26%; PR 
30%; SD 29%) 
16% 45% 
Queen Mary’s, 
UK [222] 
91 TAM /AI ER+ 78% 
(CR 17%; PR 
45%; SD 16%) 
16% Not 
stated 
Eindhoven, 
Netherlands 
[369] 
184 TAM /AI Unselected 58% 
(SD 11%) 
13% 35% 
Table 3.11: Response to PET as Reported in Published Case Series/Cohort Studies using a combination 
of TAM/AIs or not stated. 
 
Effect of ER status on women treated with PET 
Twelve of the thirty non-randomised studies [218, 222, 341, 351, 362-368, 397, 401], including 1,417 
patients, treated only women with only ER positive tumours. Eleven non-randomised studies [74, 
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220, 223, 228, 328, 339, 353-355, 359, 361, 369] treated women regardless of ER status, and seven 
[329, 337, 338, 352, 356-358] didn’t assess for ER status, giving a total of 1,348 patients in the 
studies that included both ER positive and negative patients. 
Comparing the clinical benefit rate (CR+PR+SD) according to ER status demonstrates a significantly 
higher clinical benefit rate for studies who included only ER positive patients (86% vs. 75%, p<0.001), 
as would be biologically expected however the rate of disease progression was the same in both 
groups (41% vs. 41%). Unfortunately analysis of time taken to progress, the more clinically relevant 
aspect, was not possible due to the variation in length of follow-up between studies. 
 
Effect of PET type on clinical benefit 
Nineteen of the thirty non-randomised studies [74, 218, 223, 228, 328, 329, 337-339, 352-359, 361, 
366, 397], including 1,256 patients used tamoxifen only and five studies [340, 341, 362, 363, 366] 
used AIs only (three used letrozole, one anastrazole and one did not specify) with 325 patients. Six 
studies [222, 364, 365, 367-369] used both tamoxifen and AIs and one study [220] didn’t specify the 
type of PET used. 
Clinical benefit (CR+PR+SD) was significantly higher in patients treated with AIs compared to patients 
treated with tamoxifen (88% vs. 77%; p<0.001) and the rate of disease progression was lower in 
patients treated with AIs compared to tamoxifen (31% vs. 46%; p<0.001). 
 
3.5.5. Surgery vs. PET. 
A Cochrane meta-analysis has been performed on the data from the RCTs looking at survival 
advantages [214, 215]. Since this review was published, the St George’s group have released their 
long-term results at 28-years follow-up [395] and the Cochrane review has been updated as part of 
this PhD [402]. The results are reviewed here. 
It was also possible to meta-analyse some of the results from the cohort studies in a similar manner 
[403]. This analysis is limited by the outcomes reported, with only seven studies reporting a surgical 
comparison cohort alongside their PET cohorts [355, 357, 361, 364, 365, 367, 369]. Six reported on 
overall survival (OS) and six reported on breast cancer-specific survival (BCSS).  Below is an overview 
of the RCT meta-analyses, followed by the cohort data meta-analyses. 
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3.5.5.1. Overall survival (OS) 
OS in RCTs 
There were no significant differences between the two treatment arms, however the results 
favoured the surgical group in the surgery plus adjuvant endocrine therapy versus PET analysis. 
 Surgery only vs. PET (EORTC 10851, Nottingham I, St Georges): HR 0.98, 95% CI 0.74-1.30, 
p=0.9 (see figure 3.2). 
 Surgery plus adjuvant endocrine therapy versus PET (Nottingham II, CRC, GRETA): HR 0.86, 
95% CI 0.73-1.00, p=0.06 (see figure 3.3). 
 
 
 
 
 
 
 
 
Figure 3.2: Forrest Plot 1 – Overall survival (Surgery alone vs. PET), reproduced from [402]. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Forrest Plot 2 – Overall survival (Surgery + ET vs. PET), reproduced from [402]. 
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Overall survival in cohort studies 
Six cohort studies compared OS in their PET groups compared to a surgically-treated comparison 
group [355, 357, 361, 365, 367, 369]. Combining this data and using the Chi2 test to assess 
significance, there was a significantly higher OS rate in patients treated with surgery when compared 
to those treated with PET (67% v 49%, p<0.001).  
 
Overall survival in population studies 
Lack of surgical management was also found by some of the larger population studies to result in 
poorer overall survival when compared to those patients surgically treated [78, 85, 371] but not all 
[84].  
 
3.5.5.2. Breast cancer-specific survival (BCSS) 
BCSS in RCTs 
Mustacchi and colleagues published a meta-analysis of individual patient data from the CRC and 
GRETA studies [404]. Their results favoured surgery plus adjuvant endocrine therapy: HR 0.7, 95% CI 
0.51-0.95. 
Gazet and colleagues [335] published long-term follow-up data that included BCSS after 28 years of 
follow-up, by which time all recruited patients had died. They reported 43/100 of the surgical arm 
compared with 40/100 in the PET arm died from breast cancer, demonstrating no significant 
difference between the two interventions for this outcome. 
These 2 studies differed in that Gazet did not use adjuvant endocrine therapy in the surgery group 
which may explain in part the lack of relative benefit of surgery compared to the CRC and GRETA 
trials which did use adjuvant endocrine therapy in the surgical arm. 
 
BCSS in cohort studies 
Six of the cohort studies examined BCSS between their PET cohort and a “control” cohort of women 
treated with surgery [355, 357, 361, 364, 365, 367]. Combining this data and using the Chi2 test to 
assess significance, the surgically treated arm was associated with a higher BCSS than PET (90% vs. 
85%, p<0.001).    
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BCSS in population studies 
Breast cancer-specific survival in the population studies was found to be worse in older patients 
treated without surgery compared to those treated with surgery [78, 88, 371]. 
3.5.5.3. Disease-free survival 
Disease-free survival in RCTs 
Dividing the RCTs into those who assessed surgery only against PET and those that looked at surgery 
plus adjuvant endocrine therapy (ET) against PET, only one trial in each category provided data, both 
favouring the surgical arm over PET in this outcome: 
 Surgery only vs. PET (EORTC 10851): HR 0.55, 95% CI 0.39-0.77, p=0.0006. 
 Surgery plus ET vs. PET (GRETA): HR 0.65, 95% CI 0.53-0.81, p=0.0001 (see figure 3.4). 
 
 
 
 
 
 
 
 
 
Figure 3.4: Forrest Plot 3 – Local Control (Surgery + ET vs. PET), reproduced from [402]. 
 
3.5.5.4. Quality of life 
Only the CRC trial collected information on quality of life [396] using a socio-demographic 
questionnaire and the General Health Questionnaire (GHQ; 28 items). They found no difference 
between the two groups in their ability to manage household tasks and no significant difference in 
the psychosocial morbidity between the two groups [396]. However the GHQ is not a true measure 
of quality of life but is a screening tool for psychiatric disorders, such as anxiety and depression 
[405]. Quality of life has never been rigorously assessed in this population using a validated quality 
of life instrument. 
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3.5.6. Quality of the evidence 
3.5.6.1. Quality assessment of the RCTs 
The results of the Cochrane meta-analysis of RCTs are limited by the inclusion of only a few small 
studies. Meta-analyses in general are also limited to the outcomes assessed and reported by the 
included trials and these must be comparable in order to draw any meaningful conclusions. The 
Cochrane Collaboration provides a method for assessing the quality of RCTs [345] and each of the 
studies were assessed according to these criteria, including generation of allocation sequence, 
comparability between groups at baseline, and inclusion of all randomised patients in the analysis. 
Other quality issues are also examined here. 
 
Generation of allocation sequence 
Three trials stated adequate generation of their allocation sequence [67, 227, 229, 231, 331, 349]; 
CRC used computer-generated random numbers, GRETA used random numbers and Nottingham I 
used random card allocation. 
The remaining four trials [219, 225, 330, 332, 395] didn’t state their method, although both EORTC 
10851 and St George’s stated their allocation sequence was “randomised”. No evidence of bias 
could be identified in the published reports, however an inadequate randomisation process can lead 
to inequality between groups at baseline, introducing bias. 
 
Comparability of groups at baseline 
Five of the studies reported that their groups were “well-balanced”, “comparable” or “similar” which 
was considered adequate [219, 227, 231, 331, 332, 349, 350]. St George’s [225, 395] reported that 
there were more T4 tumours in the PET group (14/100 vs. 7/100) however due to small numbers, 
this may have had limited significance. Naples did not report data on this [330].  
 
Inclusion of all randomised participants in the analysis 
Five studies analysed on an intention-to-treat basis [67, 219, 227, 231, 331, 332, 349]. St George’s 
did not report any exclusions [225, 395] and Naples did not report adequate data to comment on 
this [330]. 
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Lack of ER status assessment 
Perhaps the most important flaw in the RCTs was the lack of ER status assessment, resulting in the 
treatment of women with ER negative tumours with endocrine therapy. Only the Nottingham II trial 
recruited only ER positive patients [219]. Those women with ER negative disease and treated in the 
PET arms of these trials can be considered a control group treated with placebo at best. 
 
Lack of adjuvant endocrine treatment 
Another significant difference in the methodology compared with modern practice, was the absence 
of any adjuvant endocrine treatment in the surgical arms of the Nottingham I, EORTC 10851 and St 
George’s trials [67, 225, 227, 332, 349, 395]. In today’s clinical practice all ER positive women treated 
with primary surgery would also receive adjuvant endocrine therapy unless contraindicated as it has 
been proven to improve survival and reduce recurrence rates [48, 163]. By not doing this, these 
three trials were effectively under-treating the surgical group. 
 
Tamoxifen versus AIs 
All seven RCTs used tamoxifen as PET and the three trials using adjuvant endocrine therapy also 
used tamoxifen in this setting [67, 219, 225, 227, 231, 330-332, 349, 395, 404, 406]. Since these trials 
were conducted, AIs have largely replaced tamoxifen , both in the PET and adjuvant settings in post-
menopausal women as they have superior efficacy [187]. The beneficial effect of AI across both 
groups may have balanced and therefore not affected the differential outcome however. 
Additionally, though all seven trials used tamoxifen, they did not use the same treatment regimes, 
with Nottingham I and CRC trials using 40mg daily [67, 227, 231, 349] and the remaining five trials 
using 20mg daily [219, 225, 330-332, 395, 406]. 
 
Variation in surgical treatment 
There was large variation between the RCTs in terms of their surgical treatment. Both Nottingham I 
and II [219] used “wedge” mastectomy as their surgical intervention to the breast, a procedure 
usually only performed in modern practice in very frail patients where a quick and simple operation 
is needed as it leaves residual breast tissue on the chest wall. It is quicker to perform than a standard 
mastectomy which may be an advantage in frail patients where a short anaesthetic is desirable.  
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EORTC 10851, Nottingham I and Nottingham II all used only mastectomy as their breast surgery 
control [219, 332, 350], whereas St Georges, CRC, GRETA and Naples all used either mastectomy or 
wide local excision [225, 231, 330, 331, 395]. In addition, it is unclear whether adequate surgical 
margins were achieved as this was not commented on by the papers. 
Of the trials using wide local excision, St Georges and CRC did not report the use of adjuvant 
radiotherapy in combination with this treatment [225, 231, 395]. Both GRETA and the Naples trials 
however did give breast radiation following wide local excision [330, 331] – a practice that is routine 
following this procedure in modern treatment strategies and one that has been shown to reduce 
local recurrence by two thirds [36, 41]. 
In addition, the St George’s group used breast conservation surgery to treat women with large T3 
and T4 tumours [225, 395] which may be associated with a high recurrence risk unless combined 
with either neo-adjuvant therapy and/or post-operative radiotherapy. 
 
RCTs versus clinical setting. 
These randomised-controlled trials recruited women who were fit for surgery into both of their 
treatment arms.  By modern standards these are not the women who are routinely offered PET who 
tend to be frailer women where the risks of general anaesthesia would be higher. None of the RCTs 
stratified for co-morbidities which may have a significant impact on survival in this age group of 
women. [106]. 
 
3.5.6.2. Quality assessment of the case series and cohort studies 
In an attempt to assess the methodological quality of these types of non-randomised studies, 
ranking scales have been designed to score these types of “lower ranking” studies [346-348]. The 
studies were rated on the following areas: title and abstract; introduction and aims; methods; 
sampling; data; analysis; ethics and bias; results; transferability or generalizability; implications and 
usefulness. Each paper was then given an overall score between 10 (poor) and 40 (excellent), 
indicating its methodological rigour. 
The scores for methodological quality ranged from 17 [352] to 33 [364] out of a possible score of 40. 
The median score was 24, suggesting that the majority of cohort studies were of moderate quality.  
This group of studies were heterogeneous in their methodology, analysis and interpretation. Some 
of these issues are considered here, together with some additional quality factors. 
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Variability in disease stage 
There was considerable variation between studies with regards to the included patients. One study 
declared they included a large number (47%) of T4 tumours and performed “limited” staging, 
resulting in the inclusion of patients with distant metastases (9%) [223]. Four other studies included 
stage I-IV disease (in all of these metastatic patients represented <30% of the overall cohort) [74, 
222, 223, 340, 359]. In comparison, four studies included only patients with stage I or II disease [218, 
337, 352, 353] and one stated that 70% of their patients had stage I disease. Nine studies did not 
state the stage of disease they included in their analysis [341, 354, 361, 362, 366, 368, 397].  
Disease stage has a significant impact on overall survival [407], and possibly the clinical effect, with 
patient who have a high disease load potentially responding more slowly, or with PR, rather than CR.  
In addition if the percentage of patients in one arm or other of those with stage 4 disease was 
higher, as may be the case with PET then this would strongly bias the results in favour of surgery. 
This is the reason for excluding studies with a significant proportion of Stage IIIb or IV patients. 
 
ER status 
Not all studies measured ER status for all their patients (see tables 3.2-3.4), with only 12 of the 
included studies including only ER positive women in their analysis [218, 222, 340, 341, 362-368, 
397]. This has obvious implications for the efficacy of PET as well as how transferable the results are 
to modern day clinical practice, where only women with moderately or strongly ER positive tumours 
would be treated in this way.  
 
Co-morbidity assessment 
The co-morbid status and ages of the patients varied greatly between included studies. Mansi and 
colleagues [356] included a 29 year old patient in their study which, in terms of modern day practice, 
would be considered a wholly inappropriate indication for PET. The majority of studies took 70 years 
as a cut off for “older” or “elderly” and the majority did not comment on the level or type of co-
morbidities. 
 Allan and colleagues [224] commented that 38% of their study population had significant co-
morbid conditions, meaning that 62% did not and were assigned to treatment based purely 
on their age. 
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 Okunade and colleagues [366] stated that all included patients were deemed unfit for 
surgery or refused, but did not explore the reasons patients were considered “unfit”. 
 Ayantunde and colleagues [222] reported that 32% of included patients were “unfit for 
surgery” and 18% declined surgery but 27% were assigned to treatment with PET based 
solely on advanced age. It is interesting that despite the high proportion of “unfit” and 
“advance aged” patients, this study had a 93% 5-year survival rate. 
 Balakrishnan and colleagues [362] stated frailty as a reason for treatment choice in 46%, co-
morbidity in 29%, patient preference in 16% and old age in 9%. 
 Bergman and colleagues [228] found that patients had been treated with PET for multiple 
documented reasons, including physical or mental condition in 38%, age in 36% and patient 
choice in 35%. 
 Co-morbidities were a reason for treatment with PET in 35% in Foudraine and colleagues’ 
study [339]. Other reasons included patient refusal (38%) and age (15%). 
 Hille and colleagues [340] stated that of the 56 patients in their study, 25% were considered 
“ineligible for surgery”; in 20% the decision was made based on old age and 57% of patients 
refused. 
 Hooper and colleagues [74] reported that 61% of their group had significant co-morbidity. 
Age was a factor in 14% and patient preference was a contributing factor in 11%. 
 Rao and colleagues [365] commented that the decision to treat patients with PET was down 
to consultant decision in 47%, patient decision in 18% and due to co-morbidity in 27%. 
 In the study by Wink and colleagues [369], treatment with PET was due to patient choice in 
41%, age in 15% and co-morbidity in 35%. 
 Osborn and colleagues [368] in their study were the only authors to use a formal assessment 
of co-morbidity. They used the Charlson Index and reported that only 34% of their patients 
had greater than a 2% chance of surviving 10 years, with only 6 patients having a greater 
than 50% chance of surviving 10 years. The majority of these six patients also had some form 
of dementia. Fourteen (17%) of the patients in this cohort eventually needed to undergo 
surgical treatment due to disease progression, and this was performed under local 
anaesthetic. 
Co-morbidities have a significant impact on survival, and even those older women who are fit for 
surgery in this age group are quite likely to die of co-morbid diseases, thereby potentially reducing 
the survival advantage of any breast cancer therapies [106]. 
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Allocation bias 
With respect to the cohort studies that compared non-randomised groups of women treated with 
either surgery or PET, it is important to examine the differences in the characteristics of the two 
groups – particularly with regards to co-morbidity levels which will impact on all-cause overall 
survival rates. One might expect that, in view of the reasons quoted by authors for choosing PET as a 
treatment – many of which include factors that impact on mortality, such as co-morbidity or 
extremes of age – that the women in the PET arms were more likely to have reduced survival for 
reasons other than treatment allocation.  
Of the seven cohort studies, only two compared any characteristics between the two groups: 
 Dordea and colleagues [367] compared outcomes between patients treated with surgery 
and PET and reported a significant difference in ASA grades between the two groups.  
 Syed and colleagues [364] also compared surgical and PET cohorts but didn’t report rates of 
co-morbidity but they did state that the patients in the PET arm were relatively older that 
those in the surgical group. This is likely to be of significance as the incidence of co-
morbidities increases with age [408] and life expectancy is decreased.  It therefore 
represents a significant but expected bias in all-cause mortality. 
 
Treatment 
Another significant source of heterogeneity is the drug used as PET. The early studies had all used 
tamoxifen, with later studies tending to use AIs (see table 3.2 and 3.3). Some studies included 
patients treated with both, with patients recruited earlier into the cohort using mainly tamoxifen 
and those recruited later in the study being treated with an AI (see table 3.4).  
As seen in the sub-group analysis performed looking at the type of drug used as PET, patients 
treated with AIs seem to have a better clinical benefit rate and lower rate of progression compared 
with those treated with tamoxifen.  
 
Follow-up length 
There was also huge variation in the length of follow-up between studies, which will have an impact 
on the number of patients who went on to develop progressive disease. Syed and colleagues [364] 
had both the shortest and longest follow-up with a range between one and 202 months. 
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Assessment of response 
One study required patients to have repeat mammograms every three months to assess response 
[338] and another repeated mammographic surveillance at 1, 2, 4, 6, 9, 12 and every 6 months 
thereafter [352]. One study also required patients to undergo three biopsies to assess biomarker 
response [359]. In terms of intensity of follow-up, these protocols would seem inappropriate for this 
frail older population. Response assessment methods were variable between studies and largely 
based on clinical assessment which is less reliable than imaging assessment. 
 
Cross-over 
Many of the studies commented on further treatment required by patients who subsequently 
relapsed following initial successful results – several studies went on to treat these patients 
surgically [74, 223, 228, 337, 340, 353, 355, 358, 362, 368, 406]. This suggests that at least some of 
the included women were fit to have surgery from the outset and therefore may have been more 
appropriately treated in this way, although it is accepted that many older women chose PET when 
given a choice due to borderline fitness. 
 
3.5.6.3. Quality assessment of population Studies 
There are several other issues pertaining to the quality of the data from the population-based 
studies which is inherent to all registry-based data, including selection bias due to unrecorded 
factors (for example if there are differences in assignment of patients to treatment [409], missing 
data that results from the coding process, as well as being non-randomised. Up to 50% of patients 
had missing ER status [373] and this figure increased with increasing age [88]. Lavelle and colleagues 
[374, 375] showed that rates of surgery fell with increasing co-morbidity and worsening functional 
status but most studies didn’t account for this when assessing overall survival.  
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3.6. Discussion 
3.6.1. Use of PET 
In the UK, the use of PET to treat older women is common, with studies demonstrating that 40% of 
women over the age of 70 years [69, 70] and 55% of women over the age of 80 years [71] are 
treated solely with hormone therapy. This is mirrored in the published population studies 
documenting between 14 and 50% of older breast cancer patients treated without surgery [68, 69, 
85, 89, 92, 374, 375, 378, 385, 391-393, 398]. Studies published in the rest of Europe show lower 
rates but demonstrate that non-surgical treatment still forms a significant part of the management 
of these patients, with rates of up to 30% [74, 75, 77, 78, 83, 84, 90, 91, 371, 373, 382, 387, 388, 394, 
399]. However in the United States of America and Australia [44, 88, 201, 377, 379, 380, 383, 386, 
390], rates of non-surgical management are much lower, although in the USA drivers of medical 
practice are often dominated by medico-legal and financial considerations which may make PET less 
attractive to clinicians.  
 
3.6.2. Efficacy of PET is generally high 
When examining  the efficacy of PET, clinical benefit rates in older women with ER positive breast 
cancers are generally high and overall the cancer reduces in size or fails to progress in 75% of cases 
[402]. However, most of the original published RCTs recruited patients regardless of their ER status. 
Patients with moderate to strongly ER positive breast cancer can expect a good response in around 
79-90%, this is in comparison to up to a 100% progression rate in patients with ER negative tumours 
[217, 218, 220, 221, 331]. This can be seen from the non-randomised data where there is a 
significantly higher response rate for those trials that included only ER positive patients.  
Efficacy of PET also appears higher for patients treated with AIs rather that tamoxifen, which is 
consistent with the findings from studies in other settings for this population, including the adjuvant, 
neo-adjuvant and metastatic settings, where AIs are well-established as the superior option [180, 
187, 191, 200].  
 
3.6.3. Is PET or surgery associated with a survival benefit? 
3.6.3.1. Meta-analysis of RCTs shows no overall survival benefit 
In terms of overall survival benefit, there is no clear advantage to either treatment shown by the 
meta-analysis of the RCTs published to date. However, many of these trials were flawed by modern 
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standards, particularly with regards the treatment given; three out of the seven trials used a 
comparison of surgery only – when in current clinical practice, all patients undergoing operative 
intervention would be treated with adjuvant endocrine therapy where appropriate. This is without 
taking into account modern surgical techniques, with adequate margins and the routine addition of 
radiotherapy to patients who undergo wide-local excision. 
Three of the RCTs have published data pertaining to BCSS and meta-analysis of two of these studies 
favoured surgery plus adjuvant endocrine therapy over PET [404], although the third study reported 
no significant difference between the two therapies [335]. However, this study did not use adjuvant 
therapy in their surgery group which may in part explain the lack of relative benefit of surgery. 
As discussed above, it is worth bearing in mind the limitations of the RCT data and that they may not 
be representative of current UK practice.  The main limitation is that all of the women recruited to 
the RCTs were fit for surgery under general anaesthesia and the average age of the groups was in 
the early to mid-70s 
 
3.6.3.2. Meta-analysis of case series shows survival benefit in favour of surgery 
Looking at the non-randomised case series, the combined data showed an advantage in terms of 
both overall and breast-cancer specific survival in favour of surgery. However, it must be noted that 
due to the selection criteria for these two groups of patients, particularly in terms of fitness for 
surgery and co-morbidities, the overall health status of the two populations are likely to be 
inherently different which will result in confounding when looking at OS as it includes all-cause 
mortality, something that would be expected to be higher in a less fit cohort.  
Breast cancer specific survival should be less subject to bias associated with baseline fitness levels 
between groups than overall survival and as this also favours surgery, this is of potential clinical 
significance. It suggests that in studies of what may be regarded as ‘normal clinical practice’ (as 
opposed to the artificial conditions imposed by RCTs) there is still some advantage to surgery except 
in women with a very high burden of comorbidity or frailty who die of non-breast cancer related 
diseases within a few years of diagnosis.  However there is another potential source of bias to 
consider: that of death certification. If a woman has had surgery and has no evidence of local 
recurrence and dies of unrelated illness, breast cancer may not be mentioned on the death 
certificate. If she is on PET and still has a palpable or visible breast cancer, she may be more likely to 
have the breast cancer listed as a contributing cause, even when this was not the case. This 
 113 
 
phenomenon is increasingly recognised as a potential bias in observational studies using death 
certification to assess cause of death [410-414]. 
The non-randomised case-series data has provided a unique opportunity to compare the different 
types of PET in the “real-life” setting, and to explore the survival difference between studies that 
treated all women, regardless of ER status, fitness for anaesthesia and comorbidities, in this manner 
versus those who only used PET to treat ER positive women. In effect what would normally be 
regarded as a source of bias can be used to get a better understanding of real outcomes in clinical 
practice.   
3.6.3.3. Population data suggests under treatment is associated with poorer survival 
Several of the population studies demonstrated a survival advantage for both overall and breast 
cancer-specific survival for patients treated with “guideline therapy” – that is surgery and 
appropriate adjuvant therapy, compared to those receiving non-standard therapy [78, 85, 88, 89, 
201, 371, 390], although this was not true for all [84]. Due to the size of these studies, non-standard 
therapy may include patients who refused any kind of treatment and only two population studies 
compared cohorts of surgically treated patients with PET specifically, both of which found worse 
BCSS in the PET groups [78, 371]. This may be due to a genuine difference in matched cases but may 
also reflect subtle case selection bias (stage may have been higher in those offered PET and 
therefore surgery more complex and less likely to be tolerated, and in some cases patients with 
metastatic disease at presentation will have been included in this group as registry staging accuracy 
is often imperfect). 
Again, death certification is a potential source of error and bias in these studies, as with the case 
series [410-414] and this is further compounded by problems with missing data. Again, as with all 
observational studies, allocation bias is an inherent flaw with this type of study and will affect 
survival outcomes.  
 
3.6.3.4. Quality of life 
There are currently very little data on quality of life outcome measures comparing surgery and PET. 
What there is demonstrates no long term difference in psychosocial morbidity between the two 
treatments [240, 396]. However each treatment may carry different risks that may affect quality of 
life and complications of surgery in particular may limit functional independence in the short term 
post-operatively by necessitating admission, affecting arm mobility [230, 250] and worsening 
cognitive and functional ability following general anaesthesia [203].  
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There is evidence to suggest older women are more interested in understanding the impact of 
treatment on their functional independence and quality of life [127, 226, 286], that older patients 
may prioritise quality of life over quantity [415] and patient choice is commonly stated as a reason 
for treating patients with PET [128, 369]. 
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3.7. Summary 
Based on the current evidence in the literature, there are currently no definite answers about the 
treatment of older women with operable primary breast cancer. It is clear that this is a 
heterogeneous group of patients, and older women presenting with a new diagnosis of breast 
cancer should be treated on an individual basis. 
Whilst RCT data suggests little or no survival advantage for surgery over PET, these trials were 
flawed.  Cohort study data, which is also subject to innate bias, does appear to suggest a survival 
advantage favouring surgery and hence fit and healthy older women should probably be treated 
according to standard practice, using the same strategies as are used in younger women, i.e. a 
choice of surgical treatment with the appropriate adjuvant therapies. 
Very frail women at the extremes of age, or those with multiple significant co-morbidities, so that 
their predicted life-expectancy is significantly reduced, may benefit from treatment with PET. 
Only those women with strongly ER positive cancers should be considered for treatment with PET. 
For those women in whom PET is considered appropriate on the basis of reduced life expectancy, an 
AI should be used in preference to tamoxifen where it is not contra-indicated, and letrozole appears 
to be the most effective of these in the literature to date. 
All women who are treated in this manner should have regular clinical follow-up to assess the 
response of the primary tumour. If there are signs of disease progression then surgery if they are fit 
for it or second-line hormone therapy should be considered. 
This review highlights the need for further research to define criteria for selection of PET in terms of 
age/comorbidity and frailty cut offs as a safe and effective treatment option.  
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Chapter 4: Retrospective Analysis of 
Eight Years’ UK Cancer Registry Data 
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4.1. Abstract 
4.1.1. Introduction:  
Wide variation in the rates of non-operative management of breast cancer in older women exists 
across the UK. Some of this may be explained by variation in socio-economic status which may 
impact on levels of co-morbidity, education, screening uptake and stage at presentation, all factors 
that may contribute to treatment decision. It is therefore important to correct treatment variance 
for differences between populations by adjusting for patient and tumour characteristics to 
understand whether these explain variation in treatment.  
4.1.2. Methods:  
Data from two UK cancer registries between 2002 and 2010 were analysed to identify whether 
variation in treatment observed at hospital and clinician level persisted following adjustment for 
case mix. Expected case-mix adjusted surgery rates were derived by logistic regression using the 
variables age, proxy Charlson Co-morbidity Score, deprivation quintile, method of cancer detection, 
tumour size, stage, grade and nodal status. 
4.1.3. Results:  
Data on 17154 women over 70 with ER+ operable breast cancer were analysed. There was 
considerable variation in rates of surgery at both hospital and clinician level. Despite adjusting for 
case mix, this variation persisted at hospital level, although not at clinician level. 
4.1.4. Conclusion:   
This study demonstrates variation in selection criteria for older women for operative treatment for 
early breast cancer, meaning that some older women may be under or over treated and may partly 
explain the inferior disease outcomes associated with this age group.  It emphasises the urgent need 
for evidence based guidelines for selection criteria in older women with breast cancer. 
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4.2. Introduction 
 
As discussed earlier, there is considerable variation in the management of older women with breast 
cancer across the UK, with regional rates of non-operative treatment of patients over 70 years 
varying between 12 and 40% [73]. There is a 37-fold difference between the highest (37 per 10 000) 
and lowest (1 per 10 000) rates of surgery in the over 65s depending on where they live [416]. This 
variation in surgical treatment rates of cancer patients has been deemed a healthcare inequality 
[94]. 
Several factors may contribute to varying treatment rates in the older breast cancer population, 
including clinical factors such as tumour stage and patient health status which will impact HCP 
decision-making, as well as patient preference and local social and economic factors. There is 
evidence that more deprived populations are less likely to receive surgery to treat cancer [417] as 
variation in socio-economic status may impact on levels of co-morbidity, education, screening 
uptake and stage at presentation which are all factors that may contribute to the treatment 
decision. To date, studies that have examined the variation in surgical treatment rates for older 
breast cancer patients have failed to take account of these factors, which may in part explain some 
of the variation observed. 
Several studies have used registry data to identify factors affecting the receipt of surgery in the older 
breast cancer patients, but none have examined the variation in treatment assignment according to 
individual hospital and clinician [85, 89, 374]. This component of the study aimed to analyse UK 
practice relating to older women with operable, ER-positive breast cancer to establish whether the 
variation observed at hospital and clinician level persists following adjustment for the patient and 
tumour characteristics. 
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4.3. Methodology 
4.3.1. Choice of cancer registration data analysis 
In the UK, all diagnoses of cancer are registered by one of the UK’s eleven cancer registries, now part 
of Public Health England, an executive agency of the Department of Health. Cancer registration data 
therefore allows analysis of large cohorts of patients treated in everyday, normal clinical practice. In 
terms of breast cancer, data collected include information on patient characteristics, including age 
and postcode, and tumour characteristics including stage, and treatment received.  
At the time of data collection, the West Midlands Cancer Intelligence Unit (WMCIU) was the National 
Cancer Intelligence Network (NCIN) lead registry for breast cancer, providing data on 4,000 cases per 
year for the West Midlands region (population 5.3 million) and undertaking annual collation of all UK 
registry data on breast cancer through the NHS Breast Screening Programme & the Breast Cancer 
Clinical Outcomes Measures Project (BCCOM Audit) [73, 418]. The Northern and Yorkshire Cancer 
Intelligence Unit region serves a population of 6.6 million and combined the two registry regions 
collect data on diagnoses representing a quarter of all breast cancer cases in the UK. The populations 
covered by these registries are demographically representative of the UK as a whole. 
The WMCIU breast dataset has data from the 1980s and  includes date of birth, ethnic origin, cancer 
stage (NPI), grade of tumour, laterality, ER status (from 2002), HER2 status (from 2004) method of 
diagnosis, treatment type (surgery, radiotherapy, chemotherapy, hormone therapy, other), date of 
diagnosis, recurrence rates and mortality including date and cause of death. The data from the 
Northern and Yorkshire region is less complete (see table 4.1). 
The routine nature of data collection through hospital coding teams makes this type of observational 
data less prone to selection bias. However, this method is hampered by missing data and potential 
coding inaccuracies which is a limitation that needed to be addressed as, in order to adjust for case 
mix, it is important to account for the fact that some of the variables in the adjustment are not 
completely observed. Table 4.1 shows the data quality for the items collected. 
Data item % complete 
 West Midlands Northern and Yorkshire 
ER status 85.5% 8.3% 
Grade 82.1% 79.7% 
Nodal status 54.6% 48.0% 
Tumour size 60.6% 73.7% 
Table 4.1: Data completeness for each registry region. 
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4.3.1.1. Linkage of patient data to Hospital Episode Statistics (HES) and Proxy Charlson 
Index 
Individual patient data can be linked, by means of linking individual  NHS numbers to the Hospital 
Episode Statistics (HES) database, which is a record-based system that collects data on all 
admissions, outpatient appointments,  A&E attendances and diagnostic codes [419]at NHS hospitals 
in England. HES data can act as a surrogate indicator of co-morbidity levels  [114, 117, 420, 421], 
permitting derivation of a proxy Charlson Index [422] based on the International Classification of 
Diseases (ICD) codes for each individual’s admissions to hospital. A large number of instruments 
have been developed to identify comorbidity in patient populations using administrative data, 
mainly from US data [423-427] and most are adaptations of the validated Charlson co-morbidity 
index developed in 1987 [115] that uses ICD codes [428]. However these Charlson-based 
instruments have also been validated using HES data in England [117]. 
The Charlson co-morbidity index allows prediction of ten-year mortality based on a patient’s 
comorbid conditions [115, 116]. The index includes a total of 22 conditions which are scored as in 
table 4.2. The scores may then be summed to provide a total score which can be used with age to 
predict mortality (see table 4.3). 
 
4.3.1.2. Calculation of deprivation 
The 2010 Index of Multiple Deprivation (IMD) is a composite measure of deprivation made up of 
seven Lower layer Super Output Area (LSOA) level measures reflecting the broad range of 
deprivation that people can experience [429]. The seven domains are weighted and relate to: 
income deprivation, employment deprivation, health deprivation and disability, education skills and 
training deprivation, barriers to housing and services, living environment deprivation and crime 
[429]. The IMD is determined at the LSOA level, census zones with socio-economically homogenous 
populations with a minimum population size of 1000 individuals.  
For this analysis, a geographical measure of deprivation was recorded as quintiles of the income 
domain of the English Indices of Multiple Deprivation 2010 [429, 430], derived from the patient’s 
postcode of residence at diagnosis, using the same methods as other English registry analyses [431-
435]. 
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Comorbid condition Score assigned 
Myocardial infarction 1 
Congestive heart failure 
Peripheral vascular disease 
Dementia 
Cerebrovascular disease 
Chronic lung disease 
Connective tissue disease 
Ulcer 
Chronic liver disease 
Diabetes 
Hemiplegia 2 
Moderate or severe kidney disease 
Diabetes with end organ damage 
 Malignant tumour 
Leukaemia 
Lymphoma 
Moderate or severe liver disease 3 
Metastatic malignant tumour 6 
AIDS 
Table 4.2: Weighting of comorbid conditions in the Charlson Index [115]. 
Comorbidity-age combined score Predicted 10-year survival (%) 
0 99 
1 96 
2 90 
3 77 
4 53 
>5 21 
Each co-morbidity rank is equivalent to one decade of age, with 40 years taken as the zero-rank for 
age (e.g. a patient who was 50 who had a co-morbidity index of 2 would have a score of 3, a patient 
who was 70 who had a co-morbidity index of 2 would have a score of 5). 
Table 4.3: Predicted 10-year mortality from combined comorbidity and age [115]. 
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4.3.2. The multiple imputation by chained equations (MICE) approach to 
missing data 
4.3.2.1. Options for dealing with missing data 
There are several potential ways of handling missing data in statistical analysis, those most 
commonly used in registry data analysis include: Complete Case Analysis and imputation of the 
missing values [436].  
Complete Case Analysis involves deleting all cases that have missing data from the analysis. This may 
cause obvious problems in analyses where a large proportion of cases have missing data as the 
dataset become substantially reduced and Complete Case Analysis is usually only recommended 
where less than 5% of data are missing. More importantly in this case, the probability of a case 
having complete data is related to the outcome measure (having surgery or not) as patients who do 
not have surgery do not have histological assessment of a surgical specimen which is the main 
source of data for cancer registries and as such this would not be a valid method of dealing with 
cancer registration missing data as the complete sample would no longer be representative.  
Multiple imputation by chained equations (MICE) is a more complex method of dealing with missing 
data that has emerged as a principle method of addressing missing data in large datasets such as 
these [437-439]. Multiple imputation involves filling in the missing values multiple times, creating 
multiple “complete” datasets. Because multiple imputation involves creating multiple predictions for 
each missing value, the analyses of multiply imputed data takes into account the uncertainty in the 
imputations. It is therefore less prone to bias than other methods [437]. This technique can be used 
with datasets that contain different type of variables, e.g. continuous, categorical, etc. 
 
4.3.2.2. The method of MICE: 
The multiple imputation for this analysis was performed by another researcher from the Bridging the 
Age Gap study team, PR.  
The procedure for MICE can be broken down into several steps: 
1. A simple imputation (or “best guess”), such as imputing the mean is performed for every 
missing value in the data set.  
2. The “best guess” values for one variable are set back to missing and a regression model* is 
used to predict the values based on all the other covariates. 
*The type of regression model used will depend on the covariate – i.e. continuous, 
categorical, etc. 
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3. These predictions replace the “best guess” values for that variable. 
4. The model continues performing step 2 and 3 for each of the covariates that have missing 
data. At the end of this “cycle” all the missing values for each covariate have been replaced 
by imputed values. 
5. The model will run several “cycles” setting back the imputed values of each covariate to 
missing and re-running the regression model until the regression models do not 
demonstrate any upward or downward trend – i.e. they converge to a range of values. 
6. Using the converged model you can produce several completed data sets to work with – 
each of these will have different predicted values replacing the missing one – i.e. they will 
have variability within the missing data. These data sets should be checked to ensure that 
the distribution of the missing values appear consistent with the observed values, and that 
there are no invalid values (for example, negative tumour diameter). 
7. Statistical analyses are performed on each of the data sets and the results combined to take 
into account the variability within the imputed data [440]. 
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4.4. Methods 
4.4.1. Research governance 
4.4.1.1. Ethics approval 
Research Ethics Committee (REC) approval was granted for this component of the study as part of 
the wider Bridging the Age Gap Project (NREC approval: 12/LO/1808). Details of these approvals can 
be found in Appendices 1&2. 
 
4.4.1.2. National Information governance board (NIGB) approval 
This component of the study was also approved by the NIGB to process patient identifiable 
information without consent (NIGB approval: ECC 8-04 (g)/2013).  This permission was needed to 
permit the linkage of the cancer registry and HES datasets which was performed independently by 
registry staff so no identifiable patient data was actually released to the research team. Full details 
can be found in Appendix 5. 
 
4.4.1.3. Confidentiality 
The received database contained no patient identifiable information except for date of death. All 
other patient identifiers, including patient name, date of birth, postcode and NHS number was not 
retained for analysis and did not form part of the obtained dataset. Clinician and hospitals were 
pseudo-anonymised by West Midlands Cancer Registry prior to data transfer. 
Data obtained were password protected and stored on a secure, password protected university 
computer drive in accordance with the Data Protection Act 1998.  
 
4.4.2. Sample and setting 
Records on new invasive breast cancer diagnoses in women aged 70 years and over between the 
years of 2002 and 2010 were acquired from two UK cancer registry regions (West Midlands, 
Northern and Yorkshire). This time period was chosen as data quality prior to 2002 was not as high, 
for example ER status was not routinely collected by any registry region until this date, however the 
BCCOM audit data collection started in 2002, massively improving data quality nation-wide [73, 
418].  
Data on patient and tumour characteristics and deprivation were included (see table 4.4). 
Deprivation was recorded as quintiles of the English Indices of Multiple Deprivation 2010 [430], 
 125 
 
derived from the patient’s postcode. Data were also obtained from a linked, matched Hospital 
Episode Statistics (HES) dataset and a proxy Charlson Comorbidity Index [115] was calculated for 
each patient using the diagnostic codes recorded for any hospital admission in the year before 
diagnosis of their breast cancer. The cancer component of the Charlson Comorbidity Index was taken 
from the registry data and added to scores obtained from HES, in a method consistent with other 
similar registry data analyses [374, 421]. Higher scores indicate higher levels of comorbidity. 
Characteristics included in analysis 
Patient Characteristics Age 
 Deprivation 
 Co-morbidity 
Tumour Characteristics ER status 
 Tumour size 
 Nodal status 
 Tumour Grade 
 TNM stage 
 Method of tumour detection 
Treatment Surgery 
 Endocrine therapy 
Table 4.4: Characteristics obtained for analysis. 
 
4.4.2.1. Data cleaning 
The raw data sets were combined by WMCIU and password encrypted before transfer. Data were 
cleaned, coded and missing data imputed by another researcher (PR) using the method of MICE (as 
described above), resulting in 25 unique complete datasets for analysis by the primary researcher 
(JM).  
 
Missing data handling 
Missing data on disease characteristics and co-morbidity was handled using the method of multiple 
imputation by chained equations (MICE)[441] to produce 25 imputed data sets and combining the 
results [440]. It was judged that 25 imputed datasets would be enough to account for the variability 
within the imputations. Covariates with over 50% missing data, such as HER2 status, were not 
included in the regression models. 
 
4.4.2.2. Inclusion/exclusion criteria 
Analyses were restricted to patients with operable, oestrogen receptor positive (ER+) disease at 
diagnosis.  Patients with oestrogen receptor negative (ER-) disease, metastatic disease at diagnosis 
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or pre-invasive disease (ductal carcinoma in situ or pure Paget’s disease of the nipple) were 
excluded. Patients who died within 91 days of diagnosis were also excluded from the analysis as they 
were likely to have had advanced disease or other terminal illness which would have influenced 
treatment decision-making. Figure 4.1 shows how the final study populations were derived. 
 
Assumptions made regarding ER positivity 
Oestrogen receptor status was only recorded for 43.5% (n=10 429) of the population, due in part to 
this information not being routinely collected in the Northern & Yorkshire registry until 2009. 
However the completeness of data regarding receipt of hormone therapy is more comprehensive 
and reliably documented (70.0%) [73]. As such, it was assumed that patients with unknown ER status 
who received hormone therapy were ER+ (as hormone therapy is only used in these patients). 
Patients with unknown ER status who did not receive hormone therapy were assumed to be ER- and 
were excluded. 
 
4.4.3. Statistical analyses 
4.4.3.1. Dependent variable 
Primary treatment was dichotomised as surgery or no surgery according to whether or not the 
patient had an episode of breast surgery recorded within 6 months of diagnosis (OPCS4 codes: 
B27.1-6, B27.8-9, B28.1-9, B34.1-4, B35.2-3, B37.4, B40.1, B40.8-9, B32.3, B32.8, B37.8). The 
proportion of patients undergoing surgery was calculated for each clinician and hospital. Only 
hospitals and clinicians that treated 10 or more patients were included in the analysis (excluding 
2.9% of hospitals and 3.1% of clinicians) as statistically, assessing variability in units with small 
numbers proves problematic – for example the average rate for surgery overall may by 58% but in a 
unit only treating 2 patients, it is highly feasible that both may be treated with surgery by chance but 
including this unit in the analysis will contribute a rate of 100% due to small numbers which would 
be misleading. A cut off of 10 patients was chosen pragmatically by JM and PR to include as many 
units as possible whilst maintaining statistical validity. 
 
 
 
 
 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Determining the study population. 
 
Death <92 days from 
diagnosis  
(n = 577) 
Assumed operable ER+ 
(n = 17 129) 
Original data (n=23 960) 
Flagged as metastatic 
disease  
(n = 1 511) 
Not flagged as metastatic 
(n = 22 449) 
Flagged as non-
invasive/Paget’s disease (n = 
111) 
Invasive breast cancer 
(n = 22 338) 
Flagged as ER- 
(n = 1 480) 
ER+ or unknown 
(n = 20 858) 
ER unknown & no hormone 
therapy (n = 3 152) 
ER+ or unknown treated 
with hormone therapy (n = 
17 706) 
Treated in a hospital treating 
<10 patients (n = 475) 
Total patients included in 
hospital analysis: n = 16 654 
Total patients included in 
clinician analysis: n = 16 606 
Treated by a clinician 
treating <10 patients (n = 
523) 
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4.4.3.2. Logistic regression 
Multivariable logistic regression was used to estimate the probability of a woman undergoing 
surgical treatment based on patient level factors, including her age, proxy Charlson co-morbidity 
score, level of socioeconomic deprivation, tumour detection method (screened versus non 
screened), size, Bloom and  Richardson grade, TNM stage and nodal status, all of which may have an 
impact on treatment decision-making.  
 
4.4.3.3. Case mix adjustment 
Expected rates of surgical treatment were calculated for each clinician and hospital by summing the 
individual patient probabilities estimated from the logistic regression model. Risk adjusted rates of 
surgery were produced by dividing the observed rate by the expected rate for each clinician and 
hospital and multiplying this by the national rate [442].  
 
4.4.3.4. Funnel plots 
Both unadjusted and adjusted rates of surgery at clinician and hospital levels were displayed 
graphically as funnel plots to allow examination of the variability at each level and identification of 
outlying practice. Funnel plots contain two limits; under the hypothesis that treatment choice is 
randomly determined and independent of clinician or hospital, 95% of units would lie within the 
inner limits (2 standard deviations from the mean) and 99% within the outer limits (3 standard 
deviations from the mean). 
 
4.4.3.5. Subgroup analysis 
A subgroup analysis of patients with dementia was also performed to identify the impact of a 
diagnosis of dementia on treatment. Patients with dementia were identified using matched records 
from the linked HES dataset. Patients were classed as having dementia if one or more of the ICD10 
diagnostic codes for dementia (F000-F039, F051, G300-G311) were recorded for any in-patient or 
day-case hospital admission in the 18 months prior to their breast cancer diagnosis. Patients for 
whom a matched HES record was not identified were excluded from the subgroup analyses as no 
comorbidity data was available for these patients, however baseline characteristics for this cohort 
are presented for comparison in order to assess the potential for bias due to missing data.  
The proportion of patients undergoing surgery was calculated for patients with and without 
dementia. The chi-squared test was used to test whether or not there was a difference in the 
 129 
 
proportion of surgically treated patients by dementia status. The joint effect of dementia and age on 
the odds of surgical treatment was assessed using multivariable logistic regression. 
 
4.4.3.6. Data handling 
Logistic regressions and Chi2 tests were performed in IBM SPSS Statistics version 21 and multiple 
imputations were performed using the open source statistical programming language R (version 
3.0.1), with the remaining data handling and analysis performed in Microsoft Excel for Windows 7. 
 
  
 130 
 
4.5. Results 
4.5.1. The study population 
The registries provided records on 23 960 patients over the age of 70 years diagnosed with invasive 
breast cancer between the years 2002 and 2010. After applying the exclusion criteria (as described 
above) 17 129 records remained for analysis (see figure 1). On the basis of the assumptions made to 
define ER status, it was estimated that 77% of women with non-metastatic disease had ER+ tumours.   
This is lower than observed in previous cohort studies;  for example Diab and colleagues [44] 
reported 90% of women over 75 diagnosed with breast cancer in the US had ER+ disease, although 
this percentage varies in published studies according to the precise method of ER analysis and the 
cut off used.  Most UK breast units score ER status using either the H score or the Allred score and 
published data using these techniques would suggest that in this age cohort, 81% is reasonable and 
compares favourably with the 77% identified in this study [393]. 
The median age of the included population was 79 years (range 70-103 years). Of the 17 129 
women, 9 955 were treated with surgery, giving an overall rate of 58.1%. Once again this is in 
keeping with other published data from the UK [73]. Patient and disease characteristics are shown in 
table 4.5. The proportion of older women being treated with surgery varied with patient and disease 
characteristics, with a woman being more likely to undergo surgery if she was younger, living in a 
less deprived area, having fewer or no co-morbidities, presenting through screening and having a 
smaller, node negative, Stage I or grade III cancer.  
 
4.5.2. Treatment according to age 
Rates of surgical treatment decreased with increasing age, with the proportion receiving surgery 
declining from 91.1% at age 70 to 38.5% at age 85 and less than 3% at age 95 and over, consistent 
with other published studies [78, 90, 398].  This is unsurprising as rates of comorbidity increase with 
age and life-expectancy becomes shorter, thereby decreasing the benefit of more aggressive 
treatments for breast cancer, such as surgery [106]. 
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Patient and tumour 
characteristics 
 Prevalence 
(%) 
Number who 
underwent surgery 
Rate of surgical 
treatment 
  17129 9955 58.1% 
Age at diagnosis (years)     
 70-79 9158 (53) 7307 79.8% 
 80-89 6605 (39) 2538 38.4% 
 90+ 1366 (8) 110 8.1% 
 Mean 79.6 years 76.6 years  
Deprivation Quintile     
 1 (least deprived) 2785 (16) 1800 64.6% 
 2 3540 (21) 2178 61.5% 
 3 3390 (20) 2012 59.4% 
 4 3636 (21) 1977 54.4% 
 5 (most deprived) 3779 (22) 1989 52.6% 
Comorbidity (HES proxy 
Charlson) 
    
 0 12160 (71) 8719 71.7% 
 1 1253 (7) 588 46.9% 
 2 629 (4) 279 44.4% 
 >2 337 (2) 77 22.9% 
 Missing 2750 (16) 292 10.6% 
Method of detection     
 Symptomatic 16014 (93) 8888 55.5% 
 Screening 1115 (7) 1067 95.7% 
Tumour Size (mm, 
invasive component) 
    
 (<10) 762 (4) 680 89.2% 
 (10-20) 3702 (22) 3154 85.2% 
 (20-50) 6465 (38) 4844 74.9% 
 (>50) 862 (5) 555 64.4% 
 Missing 5338 (31) 722 13.5% 
Nodal Status     
 Negative 5107 (30) 4847 94.9% 
 Positive 3881 (23) 3480 89.7% 
 Missing 8141 (47) 1628 20.0% 
TNM Stage     
 I 4215 (25) 3412 80.9% 
 II 6617 (38) 5097 77.0% 
 III 1295 (7) 877 67.7% 
 Missing 5002 (29) 569 11.4% 
Bloom Richardson Grade     
 1 2720 (16) 1783 65.6% 
 2 8567 (50) 5516 64.4% 
 3 3200 (19) 2385 74.5% 
 Missing 2642 (15) 271 10.3% 
Table 4.5: Characteristics of the included population.   
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4.5.3. Treatment by deprivation 
Rates of surgical treatment decrease with increasing deprivation, a finding also described by Lavelle 
and colleagues in their prospective cohort of 800 women [375] The average difference in absolute 
rates of surgery between the top and bottom quintiles was 13.5% for each age at diagnosis in this 
range. For women aged over 85, no deprivation effect was observed. Similar to age, increasing 
deprivation has been shown to be associated with increasing levels of comorbidity [443] and 
affluence is also associated with lower levels of smoking, greater longevity and education [444], 
thereby promoting better health and discussion of treatment options.  
 
4.5.4. Treatment according to levels of comorbidity 
Increasing levels of comorbidity were associated with decreasing rates of surgical treatment, a 
finding reported by other studies [105, 375]. Again this is unsurprising as increasing rates of 
comorbidity result in a reduction in life-expectancy, thereby decreasing the benefit of more 
aggressive treatments for breast cancer, such as surgery [106]. 
 
4.5.5. Treatment according to method of diagnosis 
Over 95% of women recorded as presenting via screening were treated surgically, though it should 
be noted that screening was not routinely offered to this population [445]. It has been shown that 
there is a positive association with screening adherence, higher educational attainment [101, 446] 
and higher income [447, 448]. These factors in turn may promote better health status and treatment 
discussion. 
 
4.5.6. Treatment according to tumour factors 
Tumour factors were also associated with treatment type, with larger, node positive tumours being 
less likely to be treated surgically which may represent patients and clinicians trying to avoid more 
major surgery, such as mastectomy and axillary node clearance. These results corroborate and 
update those found by Lavelle and colleagues in their study of 23 038 women aged 65 years and 
over between 1997 and 2005 [374].  
Higher tumour grade was associated with increasing rates of surgery, this may represent the 
assumption that more aggressive disease should be treated with more aggressive treatment, i.e. 
surgery. 
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4.5.7. Treatment rates at hospital level 
4.5.7.1. Unadjusted treatment rates at hospital level 
The unadjusted rates of surgery varied substantially between hospitals (see figure 4.2a), with 25 of 
68 (36.8%) falling outside of the outer 99% limits, and 39 of 68 (57.4%) falling outside of the inner 
95% limits on the funnel plots, meaning that they statistically differ from the expected norms (that is 
the average overall rate of surgery). 
 
4.5.7.2. Adjusted treatment rates at hospital level 
Taking account of patient level characteristics and adjusting for case mix did not significantly reduce 
the variation in surgery rates between hospitals, with 15 of 68 (22.1%) still falling outside of the 
outer 99% limits and 30 of 68 (44.1%) falling outside of the inner 95% limits on the funnel plot (see 
figure 4.2b). 
 
 
Figure 4.2: Funnel plots showing the proportion of patients treated surgically by each hospital. 
Hospitals falling outside the control limits show greater than expected variation in practice. Figure (a) 
shows the unadjusted rates and figure (b) shows the rates following adjustment for case mix. 
a) Unadjusted b) Case mix adjusted 
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4.5.8. Treatment rates at clinician level 
4.5.8.1. Unadjusted treatment rates at clinician level 
The unadjusted rates of surgery varied substantially between clinicians (see figure 4.3a), with 36 of 
167 (21.6%) falling outside of the outer 99% limits, and 73 of 167 falling outside of the inner 95% 
limits on the funnel plots, meaning that they statistically differ from the expected norms. 
 
4.5.8.2. Adjusted treatment rates at clinician level 
Adjusting for case mix did appear to reduce the variation in surgery rates at clinician level, with 7 of 
167 (4%) falling outside of the outer 99% limits and 17 of 167 (10.2%) falling outside the inner 95% 
limits on the funnel plot (see figure 4.3b). It was felt that this may be a result of the smaller numbers 
of cases per individual consultant, making any variation by clinician too small to identify. It may also 
reflect a cluster effect where consultants working within the same hospital unit have similar 
practices, thereby reducing any individual clinician-level variation. 
 
4.5.9. Effect of dementia on treatment 
Matched HES comorbidity data were available for 14 380 (83.9%) of the 17 130 eligible patients. Of 
these, 246 (1.7%) had a recorded diagnosis of dementia. Patients without a match in HES tend to be 
older and the majority are treated non-surgically. Table 4.6 shows the age and treatment of those 
patients (n=2750) who were unmatched in HES. 
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Figure 4.3: Funnel plots showing the proportion of patients treated surgically by each clinician. 
Clinicians falling outside the control limits show greater than expected variation in practice. Figure 
(a) shows the unadjusted rates and figure (b) shows the rates following adjustment for case mix. 
 
Age 70-74 276 
75-79 410 
80-84 746 
85-89 766 
90+ 552 
Treatment Surgery 292 
PET 2458 
Table 4.6: Age and treatment of the 2750 patients without a matched HES record. 
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Patient characteristics of both dementia and control groups are shown in table 4.7.  
 Control Dementia Total 
n % n % n % 
 
Number of patients 14134 - 245 - 14379 - 
 
Age 70-79 8420 59.6 52 21.2 8472 58.9 
80-89 4940 34.9 153 62.5 5093 35.4 
90+ 774 5.5 40 16.3 814 5.7 
median 78 - 84 - 78 - 
 
Surgery Yes 9632 68.1 31 12.7 9663 67.2 
No 4502 31.9 214 87.3 4716 32.8 
 
Income deprivation 
quintile 
1 (least) 2320 16.4 22 9.0 2342 16.3 
2 2927 20.7 47 19.2 2974 20.7 
3 2792 19.8 33 13.5 2825 19.6 
4 3012 21.3 61 24.9 3073 21.4 
5 (most) 3082 21.8 82 33.4 3164 22.0 
Missing 1 0.0 0 0.0 1 0.0 
 
Charlson Comorbidity 
Index (excluding 
dementia) 
0 12160 86.0 158 64.5 12318 85.7 
1 1095 7.7 42 17.1 1137 7.9 
2 587 4.2 22 9.0 609 4.2 
>2 292 2.1 23 9.4 315 2.2 
 
Screen detected Yes 1062 7.5 0 0.0 1062 7.4 
No 13072 92.5 245 100.0 13317 92.6 
 
Tumour diameter 
(mm) 
< 10 692 4.9 5 2.0 697 4.9 
10-20 3388 24.0 19 7.8 3407 23.7 
20-50 5761 40.8 67 27.3 5828 40.5 
>50 769 5.4 6 2.5 775 5.4 
Missing 3524 24.9 148 60.4 3672 25.5 
 
Nodal Status Negative 4853 34.3 20 8.2 4873 33.9 
Positive 3718 26.3 15 6.1 3733 26.0 
Missing 5563 39.4 210 85.7 5773 40.1 
 
Grade 1 2268 16.0 40 16.3 2308 16.1 
2 7247 51.3 107 43.7 7354 51.1 
3 2911 20.6 23 9.4 2934 20.4 
Missing 1708 12.1 75 30.6 1783 12.4 
Table 4.7: Characteristics of the control population compared with the dementia population. 
 
Due to the high proportion of missing data in the dementia group it was not possible to reliably test 
whether or not there are differences in baseline disease characteristics between the dementia and 
control groups, however the distributions of tumour size, nodal status and grade appear similar 
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between the groups for whom data is available. Patients recorded as having dementia are more 
likely to have additional co-morbidities (87/246, 35.4%) than the control group (1 974/14 134, 
14.0%, p <0.001). 
Patients with a diagnosis of dementia were significantly less likely to receive surgery compared to 
those without (12.7% vs 68.1%; p<0.001, see figure 4.4).   
 
 
Figure 4.4: Treatment according to Dementia status, (p<0.001). 
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4.6. Discussion 
4.6.1. Effect of patient and tumour factors on surgery rates 
Between 2002 and 2010, 17 129 women were treated for assumed operable, ER+ breast cancer in 
the regions of the West Midlands and Northern & Yorkshire registries. Of these, 9 955 were treated 
surgically, with the remaining 7 174 (41.8%) having non-surgical management – this figure is in 
keeping with the rate of PET for these two registry areas in previous studies [73]. 
The analysis demonstrates that increasing age at diagnosis is associated with a reduced likelihood of 
receiving surgical treatment which is consistent with other similar studies [68, 84, 89, 90, 375, 398]. 
Deprivation level was also associated with treatment type, with the most deprived group being less 
likely to undergo surgical management, a finding also described by Lavelle and colleagues in their 
prospective cohort of 800 women [375]. This may be due to the fact that affluence is associated with 
lower levels of comorbidity and smoking, and greater longevity and education [444], thereby 
promoting better health and facilitating discussion of treatment options. Higher levels of 
comorbidity were also associated with non-surgical treatment, which is also consistent with other 
published studies, where co-morbidity is stated as a major reason for choosing PET over surgery 
[128, 362, 365]. Tumour factors were also associated with treatment type, with larger, node positive 
tumours being less likely to be treated surgically which may represent patients and clinicians trying 
to avoid more major surgery, such as mastectomy and axillary node clearance. These results 
corroborate and update those found by Lavelle and colleagues in their study of 23 038 women aged 
65 years and over between 1997 and 2005 [374].  
 
4.6.2. Effect of case mix correction on surgery rates 
There was considerable variation in the rates of surgical treatment across the 68 hospitals and this 
variation persisted, despite case-mix adjustment, with 44.1% of units remaining outside the 95% 
limits on funnel plot analysis. Sixteen hospitals had significantly higher and 14 hospitals had 
significantly lower rates of surgery than could be explained by the case mix information available.  
There was also substantial variation in rates of surgical treatment between 167 clinicians, although 
this variability lessened with case-mix adjustment, with only 10.2% falling outside the 95% limits on 
funnel plot analysis. However, this still showed that 12 clinicians had significantly higher and 4 had 
significantly lower rates of surgery than could be explained by case mix alone. It should be noted 
that there were much smaller numbers available for analysis at clinician level and so these results 
are less reliable than the hospital level data. It is possible that the persistence of variability in 
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treatment at hospital level but not at clinician level is a result of a “cluster effect” – in that clinicians 
working within the same hospital are likely to have trained locally, will work together within a multi-
disciplinary team and may subscribe to a local protocol, thereby having similar practices, resulting in 
magnified effect at hospital level when the data from individuals is combined.  
 
4.6.3. Persistent variability may be due to multiple factors 
This persistence of variation in the treatment of older women with operable, ER+ breast cancer at 
hospital level is due to factors not included in the case-mix adjustment. One possible cause is 
clinician preference for either treatment. Current guidelines on the use of PET in the older breast 
cancer population state it should only be used in patients with a short life expectancy (less than 2-3 
years), when significant comorbidities preclude surgery, or in patients who refuse surgery [9, 127]. It 
is left to the treating clinicians’ judgement as to which patients should be offered PET as an 
alternative treatment option to surgery. Patient preference or refusal of surgery is also often stated 
as a possible reason for variation in treatment, which may reflect clinician preference and how the 
treatment options are presented, as was proposed by Hamaker et al [373]. Qualitative research in 
this older group of patients has suggested more passive decision-makers, relying on the advice of 
healthcare professionals [226, 279].  
This persistent variation at hospital level may also be a result of other unobserved patient factors 
not taken into account by case-mix adjustment, for example frailty, level of education, being married 
or widowed, or caring for an unwell spouse may all impact on treatment decisions for older breast 
cancer patients. 
 
4.6.4. Effect of dementia on treatment 
The findings of the sub-group analysis demonstrate that older breast cancer patients with a 
diagnosis of dementia were less likely to receive surgery. However it is important to note that no 
adjustment was made for disease characteristics, including stage at diagnosis, due to high rates of 
missing data in the dementia group. Previous studies have shown that patients with dementia may 
present with later stage disease [449] and this may be in part due to poor symptom recognition and 
impaired communication among these patients [450, 451]. They are also unlikely to volunteer for 
screening which is associated with better disease stage [452].  
It is perhaps unsurprising that patients with dementia are less likely to be treated with surgery, given 
the direct impact of dementia on life expectancy and the link to other comorbid diseases. Similar 
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patterns are seen in other types of cancers where patients with dementia are less likely to receive 
standard treatment, including surgical resection and adjuvant chemotherapy for colorectal cancer 
[453]. It is also more technically challenging to treat patients with dementia surgically. They may not 
be able to cooperate with surgery under local anaesthesia or with the induction phase of general 
anaesthesia. In addition anaesthetic and post-operative analgesic drugs may cause anxiety and 
confusion which may be distressing. Admission to hospital may also have a destabilising effect. 
 A similar study conducted in the USA also demonstrated lower rates of surgery in dementia 
patients, however as PET is not a widely used treatment option in the USA the reported rates of 
surgery were considerably higher for both dementia and control populations (96.4% and 99.0%, 
respectively) [449]. A population-based study of breast cancer patients in the Netherlands 
demonstrated less extensive treatment for patients with co-existing illnesses, including but not 
limited to dementia. They reported that patients aged over 80 years with comorbidities were more 
likely to be treated with PET than those without comorbidities (21% vs. 14%) [105].  
Registry studies conducted elsewhere have reported a comparably low prevalence of dementia, with 
Gorin and colleagues reporting a rate of 3.8% and Louwman and colleagues reporting 2.7% [105, 
449], although both figures are higher than found in our study population (1.4%). These figures 
however represent substantially lower proportions than are reported to exist in the general UK 
population where the rate is thought to be 7.1% of over 65 year olds [454]. One possible explanation 
for this is the HES-based method used to identify patients with dementia within our study 
population. For a patient to be categorised as having dementia, they must have been hospitalised in 
the 18 months prior to and including their breast cancer diagnosis, and at least one admission must 
have been associated with an ICD-10 diagnostic code indicating dementia. The majority of patients 
with dementia are treated in the community setting and so will not be recorded in HES unless they 
are admitted to hospital for another cause, with their dementia coded as a co-existing comorbidity. 
This analysis will therefore have selected out those with either more severe dementia or dementia 
linked to other comorbidities severe enough to require admission which may have biased the 
analysis to the more extreme end of the disease spectrum. 
It is unclear whether the differences in treatment are a result of active decision-making by 
healthcare professionals to omit treatment for dementia patients, or a conscious choice made by 
patients and/or their families, or a mixture of the two. It is recognised that quality of life issues may 
influence treatment decisions and that older cancer patients may opt for less invasive therapies for 
these reasons [415]. However, there are no guidelines or data available to help clinicians, patients 
and their families to make informed choices and decisions about breast cancer treatment. 
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4.6.5. Strengths and weaknesses of this analysis 
Cancer registry data allows analysis of large cohorts of women treated in everyday, normal clinical 
practice. The routine nature of data collection through hospital coding teams makes this type of 
observational data less prone to selection bias. However, this method is hampered by missing data 
and potential coding inaccuracies which is a limitation of this component of the study. Multiple 
imputation is less prone to bias than other commonly used methods to account for missing data, 
such as complete case analysis or inclusion of “missing” as a category in factor variables [437]. 
However, whilst exploratory analysis of the imputed data suggested that the values were plausible, 
it is not possible to verify the extent to which the distribution of the imputed data accurately 
represents that of the missing values. By using 25 imputations, uncertainty around the missing data 
is incorporated into the probabilities used to adjust for case mix which mitigates against any small 
biases due to problems with the imputation model.  
Data were only obtained from two of the UK’s 11 cancer registration regions and these two regions 
have been shown to have higher PET rates than other regions [73] which may potentially limit the 
generalisability of these results. However the population analysed represents a quarter of all breast 
cancer cases in the UK and the areas covered by these registries are demographically representative 
of the UK as a whole, making it reasonable to cautiously extrapolate these findings to the UK 
population generally.  
Despite this model containing several clinically-relevant variables, not all covariates could be 
included due to large quantities of missing data, e.g. HER2 and progesterone receptor (PR) status. 
Additionally, assumptions had to be made regarding the ER status of the patients, with the resulting 
proportion of ER+ patients in the population being considerably smaller that reported in other 
studies [44]. 
Another limitation of this analysis is the proxy Charlson score using HES data. Data are only available 
from HES if a patient who has had a hospital admission in the year preceding their cancer diagnosis 
and relies heavily on accurate and complete coding of the relevant co-morbidities at the hospital 
level, and the accuracy of coding within both HES and cancer registries has previously been 
questioned [455]. This method may under-score patients who have chronic co-morbidities which are 
well-controlled and managed in the community, such as diabetes or dementia, as these alone are 
unlikely to precipitate a hospital admission. 
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The case-mix adjustment may also have been inadequate, due to lack of data on important 
covariates, such as frailty, which are not captured by registry data. Detailed data on every aspect of a 
patient’s care that could influence treatment choice cannot be collected in this setting, so factors 
such as frailty, patient choice, family input, social circumstances and clinician preference have not 
been included but may all play a part when deciding on a treatment modality in the older 
population. It is therefore possible that some other variables are confounding the results presented 
in this analysis. 
In the dementia sub-group analysis 14.3% of patients were not matched with a HES record, and 
therefore their comorbidity data are missing and they cannot be assigned to either the dementia or 
control group. This group of patients is older and were more likely to have been treated non-
surgically than the matched control group. It is possible that some of these patients will have had 
dementia at the time of diagnosis but it is not possible to verify this from the current data. The high 
proportion of patients treated non-surgically would be consistent with an elevated proportion of 
dementia in this subgroup. In order for this issue to change our conclusion that dementia is 
associated with a lower probability of surgical treatment, the prevalence of dementia in this 
unmatched subgroup would have to be lower than that for the matched cohort. It is not expected 
that this would be the case. 
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4.7. Summary 
This study demonstrates that whilst the majority of UK hospitals and clinicians have similar decision-
making practices, there are some units where practice varies substantially from this norm and is not 
compensated for by case mix adjustment.  Many factors influence treatment choice, as discussed 
above and examining how these vary in relation to treatment may provide evidence to help explain 
the variability in treatment of older patients across the UK. Whilst this study has identified outlying 
practice, it is not clear why they are out-with normal practice, nor whether this outlying practice is 
unreasonable. Outlying status could be explained by data quality or confounders as previously 
discussed. However this variation should not be ignored, but further research to determine why 
practice varies forms further components of this research thesis in Section II below.   
Further work is also required to determine how much treatment allocation for dementia patients is a 
result of active decision-making by healthcare professionals to omit treatment for dementia patients 
and this also forms further components of this research thesis which will be discussed in subsequent 
chapters. 
Significant variation in practice is important, particularly in view of the fact that literature on this 
topic suggests that patients who are treated with PET have inferior outcomes compared to those 
treated with surgery [78, 83-85, 88, 390]. Continuation of this varying practice may result in a post-
code lottery and further guidelines on the management of older women with operable breast cancer 
are urgently needed. 
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Section II: Why does the variation in 
treatment across the UK exist? 
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Chapter 5: Semi-structured Qualitative 
Interviews with Healthcare 
Professionals  
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5.1. Abstract 
5.1.1. Introduction 
Current guidelines on the management of older women with operable breast cancer provide little 
guidance to HCPs on which patients may be unfit for surgical management and as such it is left up to 
them to determine which patients may be offered alternative treatment modalities, such as PET. 
Additionally, it may be appropriate to offer PET to some older patients as an alternative treatment 
and allow them to decide which is best for them. There is currently little in the published literature 
examining how HCPs determine which older patients should be offered surgery, PET or a choice of 
either. 
5.1.2. Methods 
Semi-structured qualitative interviews were undertaken with specialist HCPs from regions of high 
and low PET rates across the UK. Data analysis was performed using the Framework method to 
identify themes in the data. 
5.1.3. Results 
Thirty-four HCPs (20 breast surgeons; 13 nurse specialists; 1 geriatrician) were interviewed from 14 
sites across the UK. There was an overriding view that PET is not suitable for patients under the age 
of 80 unless there are significant comorbidities. Opinion was split regarding the best way to treat 
patients with dementia. Opinion varied on whether patients over the age of 70 should be offered 
PET as an alternative treatment option.  
5.1.4. Conclusions:  
Opinions differ on the best way to treat women over 70 with operable breast cancer, especially if 
they have co-existing dementia, as well as whether they should be offered PET as a treatment 
option. This may be a significant cause of treatment variation in the UK. 
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5.2. Introduction 
Current guidelines from the National Institute of Clinical Excellence (NICE) state that PET should only 
be used where there is “significant comorbidity that precludes surgery” [9] and recommendations 
from the International Society of Geriatric Oncology (SIOG) and the European Society of Breast 
Cancer Specialists (EUSOMA) suggest that PET should only be offered to patients with a “short 
estimated life expectancy (<2-3 years), who are considered unfit for surgery… or who refuse surgery” 
[127]. However, neither specify which comorbidities may preclude surgery or what constitutes being 
unfit for surgery. As such it is left to the treating clinician to decide which breast cancer treatments a 
patient should be offered. This may be a causative factor in the considerable variability in the 
treatment practice for older women with breast cancer across the UK,  where rates of non-surgical 
management range from 12-40% depending on region [73].  
Rates of local control are inferior in patients treated with PET compared to those treated surgically 
[402]. In addition disease progression with PET may necessitate a change in management when the 
patient is less fit [222, 340, 362]. Despite this, no survival disadvantage has been demonstrated 
between surgical and PET patients, except in the youngest age sub-groups (70-75 years) in meta-
analysis of randomised trial data although cohort studies do suggest a small survival advantage for 
surgery [402, 404]. Furthermore, quality of life studies and patient opinion studies show that both 
treatment types are well tolerated by this age group [226, 240] and evidence suggests that some 
older patients may prioritise quality of life over quantity [415]. In today’s health service, where there 
is a greater emphasis placed on shared decision-making (SDM) and ensuring patients are fully 
informed about their possible treatment options [268, 277, 456], for some older women it may be 
appropriate to offer PET as an alternative to standard surgical treatment and allow them to  
ultimately make the choice about their personal preference. 
To date, there is little in the published literature examining how clinicians determine which older 
patients should be offered surgery, PET or a choice of both. This chapter describes the findings from 
interviews with health care professionals (HCPs) specifically, breast surgeons, breast clinical nurse 
specialists (CNS), oncologists and geriatricians, exploring factors deemed important when 
determining what treatment options to offer older patients with operable breast cancer. The 
interviews also examined HCP views and experience on the use of both surgery and PET in this 
population, as well as investigating their subjective opinions on the decision-making process.   
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5.3. Methodology 
5.3.1. Choice of qualitative interviews 
Qualitative research broadly has several overriding objectives and may be used to [457]: 
 Define concepts. 
 Record the range and nature of phenomena. 
 Generate typologies or classifications. 
 Uncover associations. 
 Find explanations. 
 Develop strategies. 
Which strategy is employed depends on the original questions under investigation. This phase of the 
study aimed to record the variation in views of HCPs, uncover possible associations related to the 
decision-making in the treatment of older women and ultimately identify potential explanations for 
these varying opinions. 
Semi-structured interviews are a common way of acquiring rich qualitative data that may be used to 
examine a topic of interest [458]. They also provide an opportunity to explore additional themes 
that emerge from the participants themselves (emergent themes). It was felt this approach would 
lend itself to this type of research as it allows analysis within and between participants, facilitating 
investigation of complex inter-related themes [457]. 
  
5.3.2. Qualitative data analysis options 
There are a number of qualitative analysis approaches and several were considered in the early 
stages of this study. These included the framework approach [459-461], content analysis [462] and 
grounded theory [463].  
Content Analysis involves coding and counting the frequency of codes to determine where the 
emphasis lies as well as identifying relationships between these codes and applying statistical 
analysis.  
Grounded Theory involves coding before grouping these codes into concepts and categories which 
form the basis for the creation of a theory or reverse engineered hypothesis. 
Table 5.1 shows a comparison of these methods. 
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Content Analysis Framework Approach Grounded Theory 
Devoid of theoretical base. Investigational objectives set in 
advance so thematic 
framework identified a priori. 
Theory isn’t applied to data, 
data generates theory. Theory 
is discovered rather than 
verified. 
More open enquiry. Can allow 
for both quantitative and 
qualitative analysis. 
More structured data collection 
to address specific questions.  
Formulaic in nature as opposed 
to open enquiry. 
Inherently reductive, and 
disregards the context that 
produced the text, particularly 
with complex texts. 
Reductive but maintains the 
integrity of participants’ 
narrative. 
Reductive – data is deliberately 
fractured to open up new 
avenues of data analysis. 
More anecdotal, descriptive 
and less reflective. 
Allows analysis across 
participants and themes. Can 
identify associations and 
provide explanations. 
Generates new theory that is 
“grounded in” the data 
collected. 
  Can what is generated really be 
considered theory? 
Table 5.1: Comparison of qualitative analysis methods. 
 
5.3.2.1. The framework approach 
The framework approach is a matrix-based method to manage and analyse qualitative data 
developed by social policy researchers at the National Centre for Social Research in the 1980s [460]. 
It is an interpretive process which can provide insight into complex epistemological issues, 
developing meaningful themes to expand on or test existing theory [461].  
It was viewed as a rigorous, structured, organised approach to data collection and analysis based on 
the needs of the research. It was an approach that enabled the researcher to explore the breadth 
and depth of large volumes of textural data but with an emphasis on maintaining the transparency 
of the process and the links between each stage of analysis The use of the matrix to allow data 
analysis enables exploration of the data at many levels; thematic; participant; rates of PET; and 
hence the framework approach was felt to be the appropriate choice for the qualitative analysis of 
this study. 
 
5.3.2.2. The method of framework approach 
The framework approach is a systematic analytic process that guides the researcher through the 
principles of qualitative analysis in a series of structured, interconnected stages to elicit and manage 
the data [460]. It allows organisation and classification of the data collected according to key a priori 
ideas, as well as emerging concepts, in condensed and manageable chunks prior to further analysis. 
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Despite its structured approach, the analysis relies on the researcher’s ability to interpret meaning, 
salience and connections [457, 464]. 
The framework approach has several key characteristics: 
 It has the capacity to analyse large quantities of descriptive textural data, allowing all 
information to be comprehensively and systematically included. 
 It is grounded in the original data; it retains the participants’ ‘voice’ as the participants’ own 
words are summarised into ‘in-vivo’ codes [460], thus staying true to the source data. This is 
a fundamental principle of the framework approach. 
 It is dynamic, with the series of interconnected stages allowing the analyst to move back and 
forth between the data until an overall picture emerges [460]. 
 It is straightforward and accessible, the logical and systematic process remains visible 
throughout and maintains rigor in the analytic process. 
 It allows direct comparison between datasets facilitating identification of relationships 
between themes; data is extracted in two dimensions from the outset (participant 
characteristics, etc. vs. theme) and then arranged in a matrix, facilitating exploration of the 
data within and across themes and cases in a flexible way. 
 There is an emphasis on transparency of the analytic process; links are retained between the 
comments and the source data, as well as between each stage of the analysis [459-461]. This 
“audit trail” ensures findings are more credible due to the rigor of the processes [460]. 
The process of framework analysis is performed in a step-wise fashion with five key processes [457, 
464]: 
1. Familiarisation 
This stage is undertaken at the start of the analysis that involves full immersion into the raw 
data by listening to recordings, reading transcripts and observational notes as well as 
studying the aims and objectives of the research proposal. In this way, the researcher gains 
an overview of the body of material gathered as a whole and becomes familiar with the 
range and diversity of ideas, attitudes, behaviours and motivations within the data. By 
focussing on a priori and recurring issues, views and experiences that emerge from the data, 
the initial themes and concepts can be identified and outlined, beginning the process of 
abstraction and conceptualisation. 
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2. Identifying a thematic framework 
Once the key issues, concepts and themes have been identified in step 1, a detailed index, or 
‘framework’ is constructed. This stage permits data to be examined and referenced in a 
systematic way. Some index categories may follow the interview questions and are regarded 
as a priori issues that are introduced by the researcher through the topic guide. Others are 
emergent issues, raised by the participants themselves, or analytic themes which arise from 
recurrent opinions or other patterns within the data. These initial themes are then sorted 
into broader, higher order categories, ensuring that the original research questions are being 
addressed. This process of devising and refining the conceptual framework requires 
analytical, logical and intuitive thinking on the part of the researcher, who will need to make 
inferences and judgements regarding the relevance and meaning of the data. 
3. Indexing/Coding 
The thematic framework developed in stage 2 is then applied to all the transcripts in a 
systematic manner. Texts are re-read and annotated with indexing references recorded in 
the margins. In this way, data can be linked back to the original transcripts, making the 
process visible and accessible to others. Inferences and judgements are made regarding the 
relevance and meaning of the emerging data. 
 
4. Charting 
In this stage, data is lifted from its original context. It is then distilled into summaries of the 
opinions and experiences of the participants, before being rearranged and brought together 
according to the appropriate thematic reference within a framework chart. This process 
then allows the researcher to build up a picture of the entire dataset. The information within 
the chart should contain enough information to draw meaning without losing content or 
context so as to prevent having to go back to the original interview. However it should not 
be so detailed as to be unreadable and therefore requires care and judgement. Every 
attempt should be made to keep data in the participants own words so as to retain the 
language of the participants and page references and quotes should be marked to allow 
source data to be traced. Some themes overlap and therefore data occasionally appear in 
more than one thematic column. Equally, some thematic columns may be blank, perhaps if a 
particular question was not asked to all participants or certain issues were not relevant to 
every participant, however this should be documented within the chart to indicate the 
reasons for absent data. 
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5. Mapping and interpretation 
The entire dataset can now be analysed as a whole with reference to the research question 
by reviewing concepts, associations and patterns and exploring possible explanations. This 
systematic process of detection allows the researcher to examine the individual interview 
content as well as its position within the dataset in its entirety in order to draw necessary 
conclusions. The researcher explores descriptive accounts, identifying similarities and 
differences in an attempt to understand how and why accounts are similar or different, 
leading to the identification of factors describing clinician’s opinions, preferences and 
practice. The researcher can then investigate explanatory accounts, where an explanation is 
sought as a cause for the identified variation. Explanations may be explicit – where 
conclusions are drawn based on the participants own explicit statements; or implicit – where 
conclusion are based on the interpretation of the data by the analyst. The researcher may 
also seek wider applications for the explanations generated by the analysis. 
 
5.3.3. Ensuring quality within qualitative research 
With all the different approaches to qualitative research methodology there have been widespread 
concerns about quality and the importance of ensuring robust and rigorous research practice. 
Several quality frameworks [464-468] have been produced to aid researchers in the pursuit of this. 
In order to develop this part of the study, these guidelines, were thoroughly examined and use as a 
guide throughout.    
Table 5.2 summarises the points in the Quality Framework Assessment [464] of qualitative research, 
together with how these have been met within this study. 
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 Appraisal Question How addressed 
Findings How credible are the 
findings? 
The data on which the findings are based can be viewed in 
Appendix 15. 
Corroborating evidence is used to support and refine the 
findings within the broader thesis in this MM study. 
How has knowledge/ 
understanding been 
extended by the 
research? 
Full literature review has been performed summarising the 
knowledge and key issues raised by previous research. 
Findings are discussed in context with what is previously 
known and compared with other strands of the study. 
Discussion of limitations of the study and further research 
required can be found in sections X and X. 
How well does the 
evaluation address 
its original aims and 
purpose? 
Study aims and objectives clearly stated. 
Review of findings chapter (chapter X) links findings back 
to the purposes of the study. 
Discussion of limitations of the study can be found in 
sections X. 
Scope for wider 
inference 
Use of MM design in order to generalise QUAL findings to 
the wider UK breast HCP population. 
Use of purposive sampling from wide areas across UK, 
including high/low PET units to increase applicability of 
findings to wider population. 
Limitations on drawing wider inference discussed in 
section X. 
Design How defensible is 
the research design 
See section X for discussion of how the overall research 
strategy was designed to meet aims of study, together 
with the rationale for study design. 
Sample How well defended 
is the sample design? 
Details of the sampling process and a description of how 
and why this was chosen can be found in section X. 
Sample composition 
– how well is the 
eventual coverage 
described? 
Table 2.1.2 documents the actual versus expected 
recruitment per site and reasons for non-participation. 
Data 
Collection 
How well was the 
data collection 
carried out? 
Audio recordings and verbatim transcripts were used. Full 
details of data collection methods and 
charting/transcription conventions can be found in section 
X. 
Analysis How well has the 
approach to, and 
formulation of, the 
analysis been 
conveyed? 
Use of NVivo data management tool. Development of 
themes from original coding can be found in Appendix 14. 
 
Contexts of data 
sources – how well 
are they retained 
and portrayed? 
Framework method using NVivo facilitates within and 
across case description and analysis whilst preserving 
context by electronically linking summarised text within 
the framework matrix back to the original transcript. 
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How well has 
diversity of 
perspective and 
content been 
explored? 
Purposive sampling used to encourage diversity of 
perspectives and examination of these within the context 
of HCP profession type and high/low PET regions to 
identify differences. 
How well has detail, 
depth and 
complexity (i.e. 
richness) of the data 
been conveyed? 
Explorations of both explicit and implicit explanations (for 
example when examining the influence of age – see 
section X). 
Representative quotes used throughout to demonstrate 
the data complexity. 
Reporting How clear and 
coherent is the 
reporting? 
Findings fully reported (see section X) and linked back to 
the aims and objectives in the study in the Review of 
findings section (chapter X). 
Reflexivity & 
Neutrality 
How clear are the 
assumptions/ 
theoretical 
perspectives that 
have shaped the 
form and output of 
the evaluation? 
Full discussion of the ideological perspectives and 
philosophies of the researcher can be found in section X. 
Reflections on the impact of the researcher on the 
research process can be found in the discussion chapter 
(section X). 
Ethics What evidence is 
there of attention to 
ethical issues? 
Full ethical approval was sought (see section X). Written 
consent was obtained from all participants (section X). 
Discussion of confidentiality and data handling can be 
found in section X. 
Auditability How adequately has 
the research process 
been documented? 
Strengths and weakness of the study are discussed in 
sections X. 
Copies of all study documents can be found in Appendices 
6, 7, 8, 9, 10, 11, 12 and 13. 
Table 5.2: Ensuring quality within the qualitative interview strand of the project using the  Quality 
Framework Assessment [464]. 
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5.4. Methods 
5.4.1. Research Governance 
5.4.1.1. Ethics approval 
The study was undertaken in accordance with the recommendations guiding physicians in 
biomedical research involving human subjects, adopted by the 18th World Medical Association 
General Assembly, Helsinki, Finland, June 1964, amended at the World Medical Association General 
Assembly, Seoul, Korea, October 2008. Informed written consent was obtained from the clinicians 
prior to entry into the study. The right of a participant to refuse participation without giving reasons 
was made explicit and respected. The participants remained free to withdraw at any time from the 
study without giving reasons and without prejudicing further treatment. The study was conducted in 
accordance with the principles of GCP according to EU Directive 2005/28/EC [469]. 
Research Ethics Committee (REC) approval was not required for this study as the participants were 
NHS staff recruited by virtue of their profession. The study protocol was reviewed by the University 
of Sheffield Medical School’s Ethics Review Committee and approval was granted on 22nd November 
2012 (ref: SMBRER243; see Appendix 6 & 7). 
 
5.4.1.2. Research and development approval (R&D) 
Approval was sought from the R&D department of each NHS trust participating in the interview 
phase of the study via the national Integrated Research Application System (IRAS) system (see 
Appendix 8 & 9).  
 
5.4.1.3. Informed consent 
Fully informed written consent was taken from each participant before commencement of the 
interviews. A copy of the consent form can be found in the study protocol, in Appendix 10. 
 
5.4.1.4. Confidentiality 
Interview transcripts were pseudo-anonymised to protect participant identifiers. Databases were 
password protected and stored in a locked office in the university in accordance with the Data 
Protection Act 1998. The list of participant names was stored separately from participant details, 
again in accordance with the Data Protection Act 1998. No information that would allow clinicians to 
be identified was released into the public domain. If a participant withdrew consent for their data to 
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be used then it would have been confidentially destroyed. However this did not occur within this 
study. 
 
5.4.2. Sample and setting 
5.4.2.1. Sampling 
In order to gain insight into the variation seen across the UK, breast units were purposively sampled 
from within UK regions known to be high and low in terms of their use of non-surgical treatment of 
older women according to the national BCCOM audit [73] – the average (mean) PET rate across all 
regions was 23% - those regions above this level were classified as “High” and those below “Low”. 
This information was then inserted into the framework so it could be analysed across themes.  
Units were also purposively selected on the basis of geography to ensure representation of units 
from both the North and South of the UK. 
Semi-structured interviews were conducted with both breast surgeons and breast clinical nurse 
specialists (CNS), with the aim of recruiting at least one surgeon and one CNS per site. In practice this  
was not feasible due to the  availability of both researcher and participants, no response from 
potential participants, administrative difficulties and delays obtaining research and development 
approvals for some sites. 
 
5.4.2.2. Saturation of themes 
Recruitment continued until saturation of themes was reached. The size of purposive samples 
typically relies on the concept of “saturation” – the point at which no new information or themes are 
observed in the data [470-472]. There are no guidelines as to how many qualitative interviews will 
produce saturation of themes and in general the rule of recruitment is to keep going as long as you 
are getting different answers [471]. In this case, saturation occurred at around 30 interviews which is 
a similar number to that found by Mason [470] in his study examining 560 qualitative PhD studies. 
 
5.4.2.3. Inclusion/exclusion criteria 
Inclusion criteria: 
 Permanent staff within the breast unit, e.g. consultant breast surgeon, associate specialist, 
breast CNS. 
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 Other permanent staff regularly involved in the treatment of newly diagnosed breast cancer 
in older women, e.g. geriatrician or oncologist in specialised older patient breast clinics. 
Exclusion criteria: 
 Non-permanent staff, e.g. training specialist registrars who move from unit to unit. 
 Staff not regularly treating older women with newly diagnosed breast cancer. 
 
5.4.3. Interview schedule 
An interview schedule was developed based on review of the relevant literature [226] and members 
of the wider study steering committee which included breast surgeons and  oncologists (see figure 
5.1). The schedule was designed to act as a prompt sheet to enable the interviews to explore key 
issues but also give opportunity for free expression of views with open questions.  
 
5.4.4. Recruitment and data collection 
5.4.4.1. Recruitment 
The local NHS Trust principle investigator (PI) (see Appendix 11) was identified by direct contact by 
e-mail. The PIs were asked to provide a list of names of suitable HCPs (including breast surgeons, 
breast clinical nurse specialists, oncologists, geriatricians) working within their local breast units who 
would be happy to be contacted by email to receive information about the study. Identified 
individuals were sent a study pack by e-mail containing a participant information sheet (PIS) and an 
outline of the topics to be covered (see Appendices 12 & 13). Interviews were conducted in person 
and a date was scheduled by e-mail that was convenient for both the HCP and the researcher (JM).  
A total of 20 trusts were approached and agreed to take part in the study.  However, due to 
problems of obtaining local research and development approval or closure of the study due to 
saturation of themes, 14 Trusts took part in this phase of the study. These included eight teaching 
hospitals and six district general hospitals 
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What treatment options would you normally consider for an older woman (over 70) with operable primary 
breast cancer? 
Prompts: Would surgery form part of your potential management plan in all patients? 
 Is PET an option for all patients in this group? 
What do you feel are the risks and benefits of surgery and PET for this age group? 
Prompts: Morbidity and mortality of surgery 
 Local recurrence risks, local control 
 Compliance 
What factors influence your choice of management for a particular patient with primary operable breast 
cancer? 
Prompts: Age of patient at diagnosis 
 Frailty of patient 
 Co-morbidities, including dementia 
 Anaesthetic considerations 
 Optimisation of other health issues 
 Patient choice 
 Carer preferences 
 Guidelines 
 Stage/operability of cancer 
 Cancer biology (e.g. ER and HER2 status, mucinous subtype) 
 Pre-operative assessment: anaesthetic assessment, formal geriatric assessment, “end of 
the bed” assessment 
Are there any other factors that influence your overall practice in this patient group? 
Prompts: Influence of cancer targets 
 Influence of costs 
If in such patients there is the potential for choice of either surgery or primary endocrine therapy, what level 
of involvement does the patient play in the management decision?  
What factors have influenced your personal strategy for dealing with these patients? 
Prompts: Literature evidence 
 Patient preference 
 Experience of cases over the years 
 Unit policy 
 Training and mentoring 
 Breast care nurse input 
What affects the amount of information you relay to a patient following a diagnosis of breast cancer? 
Prompts: Patient wishes 
 Patient cognitive status 
 Relative and carers information needs 
What do you think older women feel about primary endocrine therapy? 
Prompts: Easier than having surgery 
 Safer than having surgery 
 Less certainty of a cure 
 Less hassle 
What do you think older women feel about having surgery? 
Prompts: Fear of death 
 Disfigurement or loss of the breast 
 Fear of hospitalisation 
 Burden on others 
 Loss of independence 
 Complications (e.g. arm swelling) 
Any additional comments the participant would like to add 
Figure 5.1: Interview schedule. 
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Table 5.3 shows the sites according to their allocated site number, with the number of participants 
recruited. 
Trust (high/low PET 
rate) 
Number invited Number recruited  Issues 
Surgeon CNS Other Surgeon CNS Other 
T001 (high) 3 1 0 2 1 0  
T002 (low) 1 1 0 1 1 0  
T003 (low) 2 1 0 2 1 0  
T004 (high) 2 1 0 1 0 0  
T005 (high) 2 1 0 2 1 0  
T006 (low) 1 1 0 0 1 0  
T007 (high) 2 2 0 1 1 0  
T008 (high) 1 1 1 1 1 1  
T009 (high) 2 1 0 1 1 0  
T010 (high) 2 1 0 2 1 0  
T011 (low) 2 1 0 1 1 0  
T012 (low) 1 1 0 2 1 0  
T013 (high) 2 0 0 2 1 0  
T014 (low) 2 1 0 2 1 0  
T015 (low) - - - 0 0 0 Delay with R&D 
T016 (high) - - - 0 0 0 Delay with R&D 
T017 (low) - - - 0 0 0 No response 
T018 (low) - - - 0 0 0 No response 
T019 (high) - - - 0 0 0 No response 
T020 (high) - - - 0 0 0 Delay with R&D 
Total 25 14 1 20 13 1 Grand Total: 34 
Table 5.3: Interview recruitment per site. 
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5.4.4.2. Data collection 
All participants were contacted the day before their interviews to ensure they still wished to proceed 
and were given the opportunity to decline if they so wished. It was explained to all interviewees that 
they could terminate or pause the interview at any point without stating a reason for doing so and 
that their participation was entirely voluntary. Fully informed, written consent was taken prior to the 
interview. Interviews were conducted by one researcher (JM) at a location convenient to the 
participant. Questions were initially focussed around the interview schedule, however as the study 
progressed, further topics were raised (emerging themes) and participants views pertaining to these 
were also explored. 
All interviews were digitally recorded with the participants consent and these were then transcribed 
verbatim. All data collected was pseudo-anonymised.  
 
5.4.4.3. Data analysis 
Framework analysis was undertaken on the transcripts using the steps described (see section 
5.3.2.2). Familiarisation and initial coding was performed on paper whist themes were emerging – 
the initial coding categories and their relationship to the final themes and subthemes can be found 
in Appendix 14. Ten percent of transcripts (three in total) were double coded by a second researcher 
(MB) to ensure inter-rater reliability and a more rigorous analysis. Formal coding and charting was 
performed using QSR NVivo 10 software – this software had the facility to electronically link 
summarised text within the framework matrix back to the original transcript so the charted text was 
read in context (see figure 5.3) – this removed the need for including page numbers within the 
framework matrix. 
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Figure 5.2: QSR NVivo 10 screen shot demonstrating linked text. 
 
Once charting was complete, mapping and interpretation could be performed by analysing the 
dataset in its entirety. The main interpretations were concerned with: 
 mapping the range and nature of the data 
o Identifying the range of responses across themes to identify the range of 
HCP opinions and map polarities regarding the treatment of older women 
with operable breast cancer. 
 Finding associations 
o Recognising patterns of responses and identifying certain characteristics 
which may produce a certain view – for example, linking specific patterns of 
opinion to the HCPs role (surgeon vs. CNS) and regional PET rate (high or 
low) 
 Providing explanations 
o Explaining and illuminating HCP’s attitudes, experiences, behaviours and 
beliefs. 
 
5.4.4.4. Charting conventions 
During the charting process, attempts were made to condense the text whilst retaining the meaning 
and the voice of the participant. Table 5.4 shows the adopted charting conventions. 
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Font & Format Meaning 
Black text highlighted Summarised verbatim text, linked to original transcript in NVivo 
Purple text highlighted Direct quote, linked to original transcript in NVivo 
Green text Researchers comments, analysis 
N.B. transcript page numbers are not shown within the matrix as NVivo software doesn’t use page 
numbers but directly links quotes back to the original paragraph of the transcript. 
Abbreviations 
PET / ET / HT Primary Endocrine Therapy / Endocrine Therapy / Hormone Therapy 
Rx Treatment 
Pt Patient 
BC Breast Cancer 
Mx Mastectomy 
WLE Wide Local Excision 
RTx Radiotherapy 
Op Operation 
Info Information 
HCP Healthcare professional 
BCN / CNS Breast care nurse / Clinical nurse specialist 
Tam Tamoxifen 
Comorbs Comorbidities 
DM Decision-making 
Table 5.4: Adopted charting conventions. 
The full framework can be viewed in Appendix 15. 
 
5.4.4.5. Transcription conventions 
In order to clarify direct quotation in the results section, table 5.5 shows the transcription 
conventions that were adopted. 
Formatting Meaning 
Italics Direct quotation 
Bold Indicates a word emphasised by the participant. 
(S02-MH) 
(N06-FL) 
Appears after a quotation and indicates the participant from whom the 
quotation was taken and their characteristics 
 (S = surgeon, N = nurse, G = geriatrician; M = Male, F = Female; H = High 
PET unit, L = Low PET unit). 
… Ellipsis points have been use to identified where a quotation has been 
abridged 
[word] A word within square brackets within a quotation indicates a note of 
clarification by the author. 
N.B. transcript page numbers are not shown following a quotation as NVivo software doesn’t use 
page numbers but directly links quotes back to the original paragraph of the transcript. 
Table 5.5: Transcription conventions. 
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5.5. Results 
5.5.1. Recruitment 
Thirty-four healthcare professional (HCP) interviews were undertaken. These included 20 surgeons, 
13 breast clinical nurse specialists (CNS) and one geriatrician with a specialist interest in women with 
newly diagnosed breast cancer. All interviews were conducted by the primary researcher (JM). 
Interviews lasted between 15:05 and 57:39 (minutes: seconds), with a mean time of 33 minutes, 11 
seconds. Data continued until saturation of themes occurred. HCP characteristics are shown in table 
5.6 below.  
HCP identifier Profession Sex Unit PET rate Interview length 
(minutes:seconds) 
S01 Surgeon Female High 29:02 
S02 Surgeon Male High 18:44 
S03 Surgeon Male Low 15:05 
S04 Surgeon Male Low 28:27 
S05 Surgeon Male Low 44:42 
N06 CNS Female Low 16:33 
S07* Surgeon Female High 24:06 
S08 Surgeon Male High 24:08 
N09 CNS Female High 31:42 
S10 Surgeon Male High 21:47 
N11 CNS Female Low 39:27 
N12 CNS Female High 23:51 
N13 CNS Female High 34:47 
S14 Surgeon Male High 21:34 
S15 Surgeon Female High 55:40 
G16 Geriatrician Male High 55:23 
N17 CNS Female High 47:08 
S18 Surgeon Female High 29:49 
N19 CNS Female High 32:41 
S20 Surgeon Male High 45:41 
S21* Surgeon Female High 32:33 
N22 CNS Female High 33:13 
N23 CNS Female Low 57:39 
S24 Surgeon Male Low 29:30 
S25 Surgeon Female Low 34:42 
S26 Surgeon Male Low 36:13 
N27 CNS Female Low 20:15 
S28 Surgeon Female Low 27:23 
S29 Surgeon Female Low 41:20 
N30 CNS Female Low 26:26 
N31 CNS Female High 46:32 
S32* Surgeon Female High 42:19 
S33 Surgeon Female High 25:13 
N34 CNS Female High 34:47 
Table 5.6: HCP interviewee characteristics; *denotes double coded by a second researcher (MB). 
Copies of two sample interview transcripts can be found in Appendix 16. 
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5.5.2. Findings 
Four key themes were raised during the interviews and these can be seen in table 5.7.  
Theme Subthemes 
Attitudes towards treating 
older women with breast 
cancer 
Impact of age on the treatment of breast cancer 
Factors influencing treatment in older patients 
Assessment of older patients 
Variation in treatment of older patients 
Experience of surgical 
treatment in older women 
with breast cancer 
Opinions on surgery as a treatment in older patients 
Pros and cons of surgical treatment for older patients 
Perceptions of older patients views of surgery 
Their experience of older patients refusing surgery 
Opinions regarding the use of local anaesthetic surgery 
Experience of Primary 
Endocrine Therapy as a 
treatment for older 
women with breast cancer 
Opinions on PET as a treatment in older patients 
Pros and cons of PET as a treatment for older patients 
Perceptions of older patients views of PET 
Practicalities of treating older women with PET 
Views on the decision-
making process in older 
women 
Patients preconceptions & prior knowledge 
Information giving 
Decision-making in older women 
Their experience of older patients refusing treatment 
Influence of healthcare professional on the DM process 
Offering choice 
Making recommendations 
Timing 
Table 5.7: Themes (and their subthemes) raised during healthcare profession interviews. 
 
5.5.2.1. Views regarding the treatment of older women with breast cancer 
Impact of age of the treatment of breast cancer 
Most HCPs (n=19) were of the view that it was important to treat an older patient in the same way 
that you would treat any patient and most said that age itself was not a factor when deciding 
treatment. In some cases, it seemed that HCPs were keen not to be seen as being prejudiced against 
older patients or considered “ageist”. 
 “You give the patient treatment that the cancer deserves and not an age deserves… I would 
never differentiate on age because I wouldn't want that to be done to me and so why would I 
do it to someone else?” (S05-ML). 
However despite this, some (n=9) HCPs, particularly those from High PET units (n=7), contradicted 
themselves by describing age-related cut-offs for discussing non-standard treatment and a couple 
implied subconscious age-related bias by comparing older patients to “normal” patients. Only a 
minority (n=3) felt that clinicians were inherently biased towards older patients and acknowledged 
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that age was actually an important factor when deciding what treatment they would consider for 
this age group. This group felt it was important to account for age due to its effect on tumour 
biology, patient physiology and life expectancy – this was commonly termed “biological age” as 
opposed to chronological age. 
“everyone does take age into account, and you can’t help it. But it’s correct to encourage 
people to make decisions based on, you know this thing known as biological age… if you’re in 
your 90s your physiological reserve renal function is 25% of what it was when you were in 
your 20s, which has a huge impact on your ability to withstand certain treatments, including 
surgery” (S02-MH) 
HCPs talked about less aggressive treatment in some older patients, with limited use of 
reconstruction, trying to avoid axillary clearance and offering PET as an alternative. These HCPs felt 
older patients would not tolerate these or they would significantly impact on their quality of life. 
 “If you do an op and you rid them of the cancer but you leave them with a very poor quality 
of life because of the after-effects then you’ve achieved nothing” (S25-FL)  
There was also an overriding opinion that the definition of “old” has changed and that decisions 
between surgery and PET were no longer appropriate for those under the age of 80. 
“I would say 70’s not really my cut off now, it’s more like 80… This kind of drive to do more 
surgery for elderly patients has actually raised the definition of ‘elderly’ from 70 to 80” (S24-
ML)  
 
Factors influencing treatment of older patients 
HCPs mentioned many factors that influenced their decision-making and opinion regarding 
appropriate treatment for older women with breast cancer. These included: 
 Tumour factors such as degree of ER-positivity, PR status, HER2 status, suitability for breast-
conserving surgery and the histological sub-type (specifically mucinous types). 
 Patient factors such as their fitness or level of co-morbidity, presence of dementia, frailty, 
functional status, social circumstances and their preferences. 
 Other external factors, such as family opinion, cultural issues and the opinion of other HCPs 
such as their anaesthetist. 
Most important were the patient factors, particularly fitness for surgery which was an issue raised by 
nearly all of the participants.  
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“Often boils down to… is this patient fit for standard treatment” (S15-FH) 
There was variation in HCP opinion on what constituted being fit or unfit for surgical treatment. 
Some (n=18) HCPs equated this to the co-morbidity status of the patient and others emphasising the 
importance of frailty (n=16) although there was no clear definition for this. In terms of which co-
morbidities where considered important, again this varied considerably amongst HCPs. One said 
they operated on all patients unless they had a significant other cancer that would limit their life-
expectancy to a few months whereas others mentioned more chronic conditions such as 
hypertension, cardio-respiratory disease, diabetes and even arthritis. 
Another factor that divided opinion of the HCPs was that of women with breast cancer AND a 
diagnosis of dementia. Approximately half of the HCPs interviewed were of the view that patients 
with dementia should be treated surgically due to issues with compliance and distress around 
continued follow-up. The other half of HCPs felt that PET was the preferred treatment of choice (as 
opposed to surgery) as there was no distress associated with admission and being away from their 
own environment, coupled with the problem of informed consent.  
“Dementia is the one indication for PET in my book” (S24-ML) 
“These patients [with dementia] need double consenting and surgery” (S03-ML) 
Many of the HCP interviewed stated that life expectancy was the most important factor in deciding 
which treatments to offer, with other factors, such as comorbidity, frailty and dementia only being 
relevant because they impacted on a patient’s expected life expectancy and, consequently, the 
benefit derived from standard treatment. 
“If you’ve got… a predicted survival of less than two to three years there’s no additional 
benefit from surgery” (S02-MH). 
Several HCPs (n=13) stated patient preference was one of the most important factor in deciding 
treatment; even those who didn’t offer a choice of treatment claimed they would use PET if a 
patient refused to undergo surgery. 
 “Patient views obviously have the primacy” (S01-FH) 
 
Assessment of older patients 
Most HCPs did not use any form of comprehensive geriatric assessment in their routine practice. The 
main form of assessment to determine whether a not a patient is deemed fit for surgery was an 
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anaesthetic assessment. Some stated that this was to gain a clearer understanding of the surgical 
risk rather than determine which treatment they should undergo since they often had already made 
that decision. Some however, seemed to defer the decision as to whether or not to operate to the 
anaesthetist. 
 “…we leave it to the anaesthetists to decide” (S25-FL) 
However, as one surgeon pointed out, different anaesthetists also have different opinions. 
 “Different anaesthetists have different thresholds for who’s fit for a GA” (S01-FH) 
Many surgeons (n=14) explained that the decision to operate was based on an “end of the bed” type 
of assessment. 
“There’s a lot of patients you can eyeball, if they can go up a flight of steps, they can walk 
from the entrance to your clinic, you know they’ll be ok for a GA” (S28-FL) 
Some HCPs thought that more formal assessments might provide impartiality in the DM process, 
however one in particular felt these assessments had potential limitations. 
“…you ask… ‘can you walk upstairs?’ and they say ‘no, I live in a bungalow’… you can very 
easily take their independence away from them.” (N17-FH) 
 
Variation in treatment of older patients 
HCPs raised several important factors that were deemed to contribute to the variation in the 
treatment in the older breast cancer population, including the heterogeneity within the population 
combined with the need to individualise treatment. 
“…you’ve got your tennis playing 75, 78, 80 years olds and you’ve got your decrepit 71 year 
olds” (S33-FH) 
Others commented on the variation in opinions of clinicians and whether patients are offered a 
choice and how that choice is offered. 
“you have a surgeon who always operates… and you have someone who would always… puts 
them on medication – I’ve got a feeling that we should blame the HCPs more rather than the 
patients” (S20-FL) 
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5.5.2.2. Experience of surgical treatment in older women with breast cancer 
Opinions on surgery as a treatment in older patients 
Most HCPs (n=24) were of the view that surgery was considered a safe and superior treatment 
option for most patients. 
 “Surgery is the gold standard” (N12, FH) 
The two main benefits of surgery over PET were stated as providing superior local control and 
increased survival benefit, although these were deemed more relevant in the younger, fitter older 
breast cancer population.  
“what the surgery gives you is enhanced local control ” (S01-FH) 
“surgery probably does have a (survival) benefit as long as you haven’t got severe co-
morbidities” (S02-MH) 
However, despite these perceived benefits of surgery, HCPs were also mindful of the possibility of 
“over-treatment” in this group of patients, commenting that most patients would die with their 
cancers rather than because of them. 
“People say that you can get any patient through breast cancer surgery, though why would 
you want to if she’s not likely to benefit?” (S15-FH) 
 
Pros and cons of surgical treatment for older patients 
Although the general consensus was that surgery is safe with low complication rates, some HCPs felt 
that there were potential risks when operating on older patients. These included general  
complications of breast surgery, such as bleeding, infection and the development of lymphoedema, 
as well as those more likely to occur in the older population, such as myocardial infarction and loss 
of independence. However some HCPs commented that although breast cancer surgery can usually 
be performed as a day case procedure, recovery may not be as straightforward in older patients. 
“A complication… causes a much bigger set-back and a much bigger impact on their quality 
of life” (S33-FL) 
The effect of surgery, in particular of mastectomy, on a patient’s body image was also mentioned 
within a number of the interviews.  This was particularly raised by the nurses at interview, with 
surgeons seeming to deem it less important in the older compared to the younger breast cancer 
population. 
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 “…there’s a small number of people, despite their age, still would feel a great sadness at 
losing their breast and having an altered body image” (N19-FH) 
 “At that stage of life most women are less concerned about disfigurement” (S25-FL) 
 
Perceptions of older patients views of surgery 
Most HCPs (N=17) felt that surgical management was a source of anxiety for older patients, 
particularly in relation to the anaesthetic and the risks of complications.  
“having surgery is scary… having an anaesthetic, they worry, are they going to come round 
from it? Having an, in their eyes, a “big” operation, if it’s a mastectomy… the recovery’s 
going to be harder… if they’re isolated… that panics them more” (N06-FL) 
It was felt that those who do have it are pleasantly surprise by how easy it is. 
 “Patients’ perceptions about the risks are completely different from the actual risk” (S04-ML) 
A few (n=6) commented that some patients simply considered surgery to be a hassle and they would 
rather choose, what they deemed as, an easier option. 
“you offer them an operation and they go “no, I really don’t want one… I don’t want any 
more messing, just leave me alone”… they just don’t want to be bothered, they just don’t 
want an operation” (S07-FH) 
 
Their experience of older patients refusing surgery 
Almost all HCPs had experienced older patients who had refused surgical treatment for their breast 
cancer and of those HCPs who claimed they didn’t get many patients refusing surgery, most were 
from low PET units (n=3 versus n=1). 
What was interesting was the variation in response to this type of refusal. Some accepted that this 
was a valid treatment choice and so would use PET in these circumstances. There were others 
however, who felt strongly that surgery was the best treatment and so would try and convince 
patients that this was the best treatment, especially for younger, fitter older patients. 
 “They are the ones I would like to persuade towards surgery” (S28-FL) 
 
 170 
 
Use of local anaesthetic surgery 
When asked about the use of local anaesthetic surgery performed on older patients, there were a 
variety of responses, with some never using this technique, as they felt it was inferior in terms of 
being unable to perform axillary surgery, and others performing it on a regular basis. 
 “Majority of my elderly patients will have their wide local excision under local” (S24-ML) 
 
5.5.2.3. Experience of PET as a treatment in older women with breast cancer 
Views on PET as a treatment in older patients 
HCP opinion on PET as a treatment varied, with some considering it a valuable treatment option and 
others viewing it as the inferior option. 
 “It does seem to be a fairly long-term good treatment” (N13-FH) 
 “I feel… PET is writing somebody off” (S28-FL) 
One HCP explained that he didn’t even consider PET a treatment for breast cancer. 
“I see endocrine therapy as adjuvant, and sometimes neo-adjuvant but I don’t see it as a 
stand-alone treatment” (S04-ML) 
A common theme that emerged from the data was the issue of variability in both the response rate 
and duration of response. Interestingly, HCPs from high PET units tended to think PET had a longer 
duration of response than HCPs from low PET units. 
“you see women who are on tamoxifen for 10 years without a single sign of the tumour re-
growing and no problems at all… but then for some women… two years down the line they’re 
worse off… but you don’t know at the outset… you can’t tell can you?” (S07-FH) 
 
Pros and cons of PET as a treatment option for older patients 
The main benefit of PET over surgery was that it avoided an operation and the need for admission to 
hospital.  
“It avoids them coming into hospital, having an operation, avoids radiotherapy” (S15-FH) 
A few (n=7) mentioned there being the potential for non-compliance, but the main disadvantage of 
PET that nearly all (n=27) HCPs talked about was the risk of disease progression at a later date when 
surgery may no longer be a viable option. 
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“Endocrine therapy is going to stop working, and they’re going to be a couple of years older, 
maybe not fit for surgery at that point” (N17-FH) 
Also mentioned by around half of HCPs, were the potential side-effects of PET, including 
osteoporosis and deep vein thrombosis, although a couple pointed out that this was not really a 
disadvantage of PET over surgery as patients having surgery will also be having adjuvant endocrine 
therapy. 
 
Perceptions of older patients views of PET 
HCP’s were of the view that the majority of older patients who received PET were pleased and 
relieved about not having an operation. 
“I think those ladies that are on primary endocrine therapy are happy to be on primary 
endocrine therapy because I think they’re generally the people who have, kind of, steered 
clear of surgery” (N12-FH) 
It was also thought that older women considered PET low-risk in comparison to surgery. 
“they all think that PET is great because it’s the no risk scenario in some respects, certainly 
to start with” (S01-FH) 
However, nearly half of the HCPs felt that patients may be uncomfortable with the idea of PET as the 
cancer remains in-situ. 
 “They don't like the idea that they still have a cancer within the body” (N13-FH) 
In contrast, around half of the HCPs felt that older women are reassured if they can feel a palpable 
lump shrink and soften. Many suggested that older women are usually just relieved that they do not 
need an operation as it is seen as the easier option. 
Practicalities of treating older women with PET 
Although most specified that they would use letrozole as a first line for PET, there were HCPs that 
used alternatives including anastrozole and tamoxifen. 
There was also considerable variation in the methods of tumour assessment, with some HCPs using 
US scanning to perform a volume assessment, others using bi-dimensional caliper measurements 
whilst others just measured the size of the lump informally on clinical examination. Timings of 
follow-up also varied, with some bringing patients back on an intensive regime, every three months 
until the patients achieve a good response, and then patients were seen six-monthly or yearly for 
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the duration of treatment. There were others, however, who discharged patients after 6 months or a 
year from follow-up, leaving it to the GP to review the response in the community. 
Many of the participants commented on the variability in duration of response to PET, although 
there was variation in the average duration HCPs believed PET usually maintained control for. HCPs 
from high PET units tended to believe that PET had a longer duration of control than those from low 
PET units. 
“Some women obviously go a long time on endocrine therapy and others don’t even get that 
first response” (N12-FH) 
There was also variation in the reaction of HCPs when patients did experience loss of tumour control 
during treatment with PET. Some believed that patients with progressive disease should undergo 
surgery straight away if they were still fit enough. Others would simply try an alternative anti-
oestrogen and others commented that they occasionally used radiotherapy as second-line 
treatment, especially if patients were no longer fit enough for an operation. 
 
5.5.2.4. Views on the decision-making process in older women 
Information giving 
The amount of verbal information provided by HCPs varied, with most stating they tailored it to the 
individual, depending on their preferences for information as well as their ability to absorb it. 
“See how the patient is accepting or digesting the information, some of them are happy to 
accept everything, so I tell them everything. Some of them, they don’t like it, they like just 
‘cancer’ or ‘not cancer’, ‘give me the treatment, let me go home’ ” (S10-MH) 
In terms of written information, several HCPs mentioned that they had standard packs of 
information that they tended to give out to all patients.  
“We have a standard pack and then we give additional information on top of that… some of 
which are not relevant for every patient” (N06-FL) 
There was a suggestion that HCPs felt that older patients required less information that younger 
patients, although there were no reasons why this might be. 
“A lot of the older population I feel, don’t want information… They don’t want to be 
empowered with information like the younger population” (N12-FH) 
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The breast CNSs appeared to do the majority of the information-giving with patients, as they were 
able to spend longer with them.  
“In a busy clinic, as a surgeon, I can do only so much from that [information-giving] point of 
view. I’ll make sure that my specialist nurse is sitting with me… then we’ve got a separate 
room whereby she goes and explains a bit more” (S26-ML) 
 
Decision-making in older women 
HCPs varied on their opinions regarding the DM styles of older women; some believed older patients 
preferred a more doctor-centred approach whilst others felt they wanted a more patient-centred 
DM approach. 
“They want the surgeon... to tell them what is the best option, they don’t want to make 
decisions about their care... I find that a lot in the older population” (N12-FH) 
“I think elderly patients are usually quite switched on. They’ve often already made up their 
mind… so they’ve made a decision which is not necessarily that well informed but they’ve 
nevertheless made a clear decision. It can be extremely difficult to change their mind once 
they’ve got a set opinion” (S18-FH) 
Patients’ preconceived ideas about themselves, breast cancer and cancer treatments were identified 
by HCPs as factors that influenced patients’ treatment preference. Particular issues raised included a 
belief by patients that they were too old for treatment (particularly surgery), the notion that quality 
of life was prioritised over quantity, and the impact of previous experiences of cancer, either 
themselves or of family and friends. 
 
Experience of older patients refusing treatment 
Almost all HCPs had experience of older patients refusing treatment, particularly surgical treatment. 
Most of those who didn’t feel this was a common problem were from low PET units. There was a 
feeling that older patients didn’t want to be bothered with surgical treatment. 
There was however variation in the way HCPs, and in particular surgeons, responded to this refusal, 
with some simply respecting their choices and others trying to convince them, especially younger, 
fitter patients, to undergo what they considered the optimal treatment. 
“As a physician, if you tell them what’s best for them they would eventually come around to 
your point of view” (S05-ML) 
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“A lot is about what they want and even the fittest people don’t want something doing and 
you know it’s about not judging that and just doing what they want you to do” (N13-FH) 
 
Influence of healthcare professional on DM process 
This theme raised some interesting aspects in terms of contradictions within the interviews. Most 
HCPs declared that the treatment decision was down to the patient. 
“It’s a patient-driven decision, rather than a surgeon-driven decision” (S05-ML) 
However, the same HCPs also admitted that although the ultimate decision was left with the patient, 
there was an acknowledgement that the framing of the way in which the information about either 
treatments enabled older women to make their treatment decision. This is crucially important in 
terms of a patient deciding between two treatment options if only one option is provided. 
“It always depends on how a surgeon puts it... if I want to take them down the endocrine 
route only – then they’d go with it. Or if I said you need to have surgery, then they’d go with 
that” (S05-ML) 
Interestingly, the nurses that were interviewed seemed more aware of patients being led by the 
clinicians than the surgeons themselves. 
“a personal opinion can sway people’s approach, a lot of the time I do feel it’s to do with the 
preference of the surgeon” (N11-FH) 
“I think doctors these days are getting better at talking about all of the options but possibly 
steering them more now towards the surgical option” (N12-FH) 
 
Offering choice 
There was considerable variation between HCPs regarding whether or not older patients with 
operable breast cancer should be offered a choice of treatments between surgery or PET. The 
majority (n=20), who tended to be from high PET units (n=14), felt that there were a sub-group of 
patients, who tended to be older, frailer and less fit, who were suitable to be offered a choice as it 
would not impact on their overall survival. However, a few HCPs from units with lower rates of PET 
(n=5), felt that, as they considered it an inferior option, it was not appropriate to offer PET as a 
choice. 
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“that group of patients where we’re uncertain whether surgery’s going to have a benefit or 
not, it’s definitely an issue for patient choice. So no pressure on the patient for making a 
decision… and genuinely trying to advise them that it’s an equivocal decision” (S02-MH) 
“I give my advice…The literature suggests that at the moment, if they’re operable they 
should be offered an operation and so that’s what I offer them. So I don’t give them a choice 
between surgery and primary endocrine therapy” (S04-ML) 
 
Making recommendations 
The majority of HCPs felt comfortable recommending surgery to most older patients as it was seen 
as the superior treatment option. However when patients were offered a choice of treatment but 
were deemed to be passive decision-makers, willingness to recommend in this scenario varied - 
some were quite happy to advise patients and others felt very uncomfortable with it. 
“…’no doctor, you decide what’s best for me, I don’t know, I’m not the expert’ I mean I’ve had 
that said to me many times and in that situation you say ‘Well I’ll tell you a little bit and let 
you have a little think about it and then if you want me to decide then I’ll decide for you’ ” 
(S01-FH) 
“If they ask me well what do I think, I will tell them… ‘You choose what is right for you, not 
what is right for me… I don’t know how I will choose if I was sitting where you’re sitting so it 
really is your choice’ ” (S21-FH) 
“I think deciding for them is uncomfortable for me” (S33-FH) 
 
Timing 
Giving the patient time to reach a treatment decision was viewed as important by HCPs. 
“Giving them time to think through it, the pros and cons, is very important” (S28-FL) 
Some HCPs also used PET as a method of “buying time” whilst the patient took time to think about 
whether or not they wanted to have an operation. 
“…there’s no harm in most of them in starting them on the tablets and giving them some 
time to think” (S01-FH) 
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5.6. Discussion 
This study reports new findings on the factors underlying treatment decision-making by HCPs in 
relation to older women with operable breast cancer and their views regarding the use of PET and 
surgery in this group. 
 
5.6.1. Factors considered in the treatment decision-making process 
Several factors were considered by HCPs when deciding what treatment to offer older patients with 
operable breast cancer. Although initial responses were generally consistent with current guidelines 
[8, 127], particularly with regards to the influence of age, further investigation revealed variation 
from the UK recommendations, with many HCPs offering less aggressive treatments, including PET, 
to the older and frailer, less fit patients. This may in part be due to the fact that increasing age is 
inextricably linked to both decreasing life-expectancy and increasing comorbidity rates, which in turn 
may decrease the survival advantage of more aggressive breast cancer therapies [106]. Both 
comorbidity and life-expectancy were also considered important in their own right. 
 
5.6.2. Variation in clinician opinion regarding factors considered 
HCPs unanimously agreed that “fitness for surgery” was an important consideration in treatment 
decision-making for older patients. However there was considerable variation among clinicians 
regarding key features that constituted being fit for surgery. This was specifically the case in older 
women with breast cancer and dementia. There are currently no guidelines pertaining to the 
treatment of cancer patients with dementia and this variation in opinion may reflect this. A further 
explanation for such differing views may be that dementia was not defined, and HCPs clinical 
judgement of dementia may vary in the absence of formal assessments. 
Another source of variability was the assessment process by which HCPs determined fitness of their 
patients. This is unsurprising as the older population make up a very heterogeneous group and as 
SIOG points out that although CGA may be useful, it is not clear which patients will benefit nor which 
method is best [127]. 
 
5.6.3. Variation in clinician opinion regarding treatment options 
As with any real world situation, the findings demonstrated a broad spectrum of beliefs, attitudes 
and behaviours. Perhaps the most striking division of opinion was regarding the use of PET as a 
treatment for older patients with operable breast cancer, with some HCPs believing it a valuable 
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treatment option and others declaring they did not consider it a treatment at all. This may reflect 
uncertainty in the published evidence to date and the variability in response and duration of benefit, 
with the length of time to progression varying greatly from nine to 132 months [337, 339, 341, 364, 
401]. 
Another point of variability was in the use of local anaesthetic surgery. Despite the fact that the use 
of local and regional anaesthesia for breast surgery in patients who are unable to undergo GA is 
well-established [473], some HCPs did not utilise this option with their patients, instead tending to 
treat them with PET. 
 
5.6.4. Variation in clinician opinion regarding choice 
Evidence suggests that older patients may prioritise quality of life over quantity [415] and patient 
choice is commonly stated as a reason for treating patients with PET [128, 369]. SDM dictates that 
patients should be informed of their treatment options and allow the patient to decide what is best 
for them [277], however there was considerable variation in the importance placed on offering 
treatment choices and informing patients (particularly those who are fit and healthy) that PET may 
be an alternative they may wish to consider. There was also clear evidence from numerous HCPs 
that the practice of steering a patient towards their preferred choice, whilst paying lip service to 
offering SDM, was widespread.   
 
5.6.5. Variation between high and low PET regions 
There appeared to be some variation in opinions of HCPs from high and low PET units, with those 
from high units tending to use more age-related cut-offs for discussing PET as a treatment option. 
HCPs from high PET units also tended to be more likely to offer a choice of treatments, with those 
from low units tending to feel that offering PET as an option was not appropriate.  This latter opinion 
is in contrast with SDM ideals that have become more important in today’s NHS [268, 277, 456], 
particularly since evidence suggests that older patients may prioritise quality of life over quantity 
[415]. 
Interestingly, HCPs from low PET units stated that they had less experience of older patients refusing 
surgical treatment for their breast cancer. This may in part be due to the fact that these HCPs tended 
not to offer choice and so patients may not have known there was an alternative. Indeed, it has 
been suggested that clinician preference and how treatment options are presented are significant in 
determining treatment [373] and there was clear evidence of this in these interviews. 
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HCPs from high PET units also tended to believe that PET had a longer duration of control than those 
from low PET units. One of the major drawbacks of PET is the short duration of response and most 
patients will suffer a relapse [227] with recurrence or progression of their disease after a mean 
duration of 18-24 months [216]. However long-term follow-up studies have shown that over one 
third of women treated with PET had disease control for more than 5 years, and more than 15% still 
had control up to 10 years [219]. It may be that HCPs using PET more often have experience with 
patients who have been on PET for longer periods or that this difference in opinion regarding the 
duration of clinical benefit is the reason why HCPs either do or don’t use PET. 
This variation in opinion between individuals from high and low PET units may be a contributing 
factor to some of the variation seen in the UK. 
 
5.6.6. Strengths and weaknesses of this analysis 
Semi-structured qualitative interviews have provided a rich data source, enabling documentation of 
unique first-hand perspectives of HCPs that would be difficult to gather by any other method. 
Utilising open-ended questions and a conversational style has allowed flexibility within the interview 
schedule and has aided the collection of emerging themes in addition to pre-determined ones. 
However this method of data collection and analysis can be prone to bias. In view the fact that all 
participants were contacted via personal communication by the lead researcher (JM), this may have 
led to selection bias, however this was minimised by purposively selecting from units across the 
country and including individuals that were both known and not known to the researcher prior to 
the study. A further source of bias can be considered as the interviewer themselves as they lead the 
questions and, whilst it cannot be said that participants intentionally wish to mislead, they may try 
and respond in a way that they think the interviewer wants them to. 
Interviews of peoples experiences is also prone to potential recall bias due to retrospective 
recollection, although all HCPs involved were currently practicing in the area of study. Additionally, it 
has previously been shown that most UK breast surgeons do not formally audit their practice in 
terms of PET [128], so it may be possible that for some questions participants have used a best-guess 
that may inaccurately represent their current clinical practice. 
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5.7. Summary 
In conclusion, HCP opinions differ on the most appropriate way to treat older women with operable 
breast cancer, especially if they have co-existing dementia, and whether they should be offered PET 
as a treatment option. This may be a significant cause of the variation in treatment of older women 
with breast cancer in the UK and is explored further in later chapters of this thesis to identify 
whether some of the themes raised here are generalizable to the UK as a whole.  
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Chapter 6: Clinician Questionnaires – 
Survey of Opinion 
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6.1. Abstract 
6.1.1. Introduction: 
PET may be a viable alternative to surgery in selected older women but there are no reliable 
evidence-based guidelines on which to base this decision and rates of surgery vary widely. This 
component of the study aimed to quantify and generalise the findings from the previous interview 
study in relation to factors underpinning the treatment decision-making in older women with 
operable breast cancer. 
6.1.2. Methods: 
A bespoke questionnaire was developed based on the results from a systematic literature review, 
expert opinion and qualitative interviews with HCPs. The final questionnaire was administered by 
post, distributed via the UK Association of Breast Surgery (ABS). 
6.1.3. Results: 
Of the 641 questionnaires distributed, 258 were returned (40.2%). The presence of comorbidities 
was considered the most important factor in determining how to treat older women with operable 
breast cancer with age being considered as one of the least important factors. Dementia was 
considered an important factor in determining treatment but opinion was divided as to whether 
these patients should be treated with PET (41.1%) or surgery (58.9%). Only around a quarter 65/244 
(26.6%) felt that all patients over the age of 70 should be offered PET as an alternative treatment 
option.  
6.1.4. Conclusions: 
HCP opinion regarding the treatment of older women with operable breast cancer differ particularly 
regarding the optimal way to treat patients with co-existing dementia and as to whether patients 
should be offered both surgery and PET as a treatment option. These factors may be having an 
impact on the variation in the treatment of older women with breast cancer across the UK.  
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6.2. Introduction 
As previously discussed, PET may be a viable alternative to surgery in selected older women with a 
limited life expectancy.  However, currently there are no reliable evidence-based guidelines on 
which to base this decision and rates of surgery vary widely across the UK, Europe and the world.  
Chapter 5 explored some of the issues which clinicians take into account when making this 
treatment choice (between PET and surgery) using qualitative interviews.  This identified a number 
of factors which were viewed as important.  A questionnaire was developed based on the systematic 
review and the issues raised within the qualitative phase of the study. The aim being to examine the 
relative importance of each factor identified through these stages and to increase the 
generalisability of these finding. 
A similar survey of specialist HCPs was published during the recruitment phase of this part of the 
study [128]. Wylie and colleagues aimed to examine UK practice of PET in the treatment of patients 
70 years or over with surgically resectable early breast cancer. Their study only surveyed breast 
surgeon members of the Association of Breast Surgery (ABS) and had a response rate of 228/489 
(47%). They found that the vast majority of surgeons used PET in older women who were unfit for 
surgery or owing to patient preference and that three-quarters used letrozole. The percentage of 
older patients treated in this way varied considerably (<10-70%) and the majority of surgeons had 
not formally audited their practice. In addition, Wylie and colleagues also found that the over 70% of 
surgeons underestimated the expected life expectancy of an average 80 year old woman [128]. Their 
study had a response rate that would be expected for this population based on other similar 
questionnaire studies [474], however the authors have limited their study to surgeons only, thereby 
excluding other potential useful opinions of HCPs also involved in the care of these patients. There is 
also no discussion in their report as to how the questions within the survey were designed and 
chosen. Their study reports findings mainly related to clinical practice and do not explore opinions or 
reasons why HCPs practice in this way, excepting one question on estimating life-expectancy, the 
results of which are quite interesting in this context.  
The study presented in this chapter aimed to investigate specialist  HCP opinion relating to factors 
they consider important when choosing treatment, examined both PET and surgery as treatment 
options and included breast CNSs and other HCPs involved in the care of older breast cancer patients 
in order to gain a greater breadth of knowledge on this subject. It aimed to complement the 
qualitative interviews by quantifying the factors that were found to underlie treatment decision-
making among HCPs relating to older women with breast cancer and optimise the generalisability of 
the findings. 
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6.3. Methodology 
6.3.1. Choice of Questionnaire Surveys 
Questionnaire surveys are a common method of gathering information from a population on their 
knowledge, beliefs, attitudes and behaviours [475, 476], and can be used to quantify findings 
collected as part of a mixed methods study in order to give breadth and generalisability to the 
findings [477]. They have the advantage of being cheap and easy to administer and can collect data 
efficiently from a large population [475, 478].  
 
6.3.1.1. Response rates 
Care must be taken when designing questionnaires to ensure they are acceptable and 
understandable to the participants in order to obtain an adequate response rate. Questionnaires 
that are overly long, incomprehensible or offensive are unlikely to be successful. Several techniques 
may be employed to increase response rates [475, 479-481], including:  
 Using official headed paper. 
 Using a covering letter or participant information sheet. 
 Addressing the mail to the participants personally. 
 Using stamps rather than mass franking. 
 Enclosing a stamped-addressed reply envelope. 
 Having the survey sponsored or endorsed. 
 Ensuring anonymity and confidentiality of responses. 
 Sending out reminders when response rates drop off. 
 
6.3.1.2. Question design 
Questions should be short and clear, avoiding ambiguous words such as “often, regularly or some” 
as perceptions vary between individuals [481]. The decision to use closed or open questions should 
also be considered – closed questions are more straightforward to analyse however they may 
restrict the depth of responses [478].  
Likert scales are ordinal scales that measure levels of agreement/disagreement and can be 
particularly useful in determining preference or opinions [478, 482]. There is some controversy 
regarding whether or not to include a neutral point, e.g. neither agree nor disagree, as whilst 
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excluding it  forces participants to make a choice, removing it may lead to irritation and non-
response bias [482]. 
How the questions are framed is also important in terms of avoiding bias in results. Questions may 
be positively or negatively framed [483] depending on whether the focus of the question is centred 
on gains or losses. Framing has been shown to influence people’s choices, preferences, attitudes and 
behaviours differently [484]; people tend to be more risk-averse when considering gains but are risk-
seeking when considering losses [483-486]. As such, it is important to use a combination of framing 
styles within a questionnaire to avoid bias from framing. 
 
6.3.2. Questionnaire psychometrics 
 Questionnaires should be reliable, valid and acceptable and these attributes may be assessed by the 
use of pilot studies. 
Reliability refers to the ability of a questionnaire to yield consistent results so that any differences 
yielded result from differences between participants and not from how the questions are 
understood or interpreted [481, 487]. The reliability of a questionnaire can be assessed by applying 
the instrument to the same individual at different time points (test-retest reliability) or by asking the 
same question in different ways within the same questionnaire (internal reliability) [487]. When 
designing the questionnaire, similar questions using both positive and negative framing can be 
included to ensure reliability and the pilot phase can be used to apply the questionnaire to the same 
individuals twice over a period of time to ensure test-retest reliability. 
Validity refers to the ability of a questionnaire to measure what it claims to measure [475]. There 
are several types of validity: 
 Content validity refers to the ability of a questionnaire to measure all elements of the topic 
being studied. It assesses whether the questions within the instrument are a well-balanced 
sample of the content domain to be measured [475]. In order to ensure content validity it is 
important to research the subject area being studied in depth prior to constructing the 
instrument. 
 Face validity is similar to content validity but assesses whether the questionnaire appears to 
measure what it is supposed to measure and is evaluated by the individuals being assessed 
[487]. This is an important element to be assessed during the pilot study. 
 Criterion or concurrent validity refers to how well the questionnaire compares with other 
similar or validated instruments [475, 487].  
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 Construct validity applies when abstract constructs, such as intelligence, are being studied 
and refers to how well the questionnaire results compare with a set of theoretical 
assumptions [475]. This has little application in this study where the area being studied is 
not an abstract concept. 
Acceptability refers to whether the questionnaire is tolerated by the individuals being tested – 
for example, it doesn’t take too long to complete and the questions are worded so as to not 
cause offence – it is assessed qualitatively by the individuals who complete the questionnaires 
[487] and should also be evaluated during the pilot phase.   
Section 6.4.2.3 demonstrates how these psychometrics have been addressed within the study.  
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6.4. Methods 
6.4.1. Research Governance 
6.4.1.1. Ethics approval 
Research Ethics Committee (REC) approval was not required for this study as the participants were 
NHS staff recruited by virtue of their profession. The study protocol was reviewed by the University 
of Sheffield Medical School’s Ethics Review Committee and approval was granted on 22nd November 
2012 (ref: SMBRER243; see Appendices 6 & 7). 
 
6.4.1.2. Consent 
Individual participant consent was implied by the return of the questionnaire to the study team. A 
covering letter explaining the study and informing the individual that participation is voluntary was 
included with the questionnaire pack (see Appendix 17). 
 
6.4.1.3. Confidentiality 
Questionnaire responses were anonymous unless individual participants requested personal 
feedback about publication of the study results, in which case their identities were anonymised for 
purposes of analysis.  
Databases, including the list of names and addresses of ABS members, were password protected and 
stored in a locked office in the university in accordance with the Data Protection Act 1998. No 
information that would allow clinicians to be identified was released into the public domain. 
 
6.4.2. Questionnaire design 
6.4.2.1. Pre-piloting phase 
A preliminary questionnaire was developed by the primary researcher (JM) based on the literature 
review (Chapter 3), the results of the qualitative interviews and the expert opinion of the members of 
the study team and the extended “Bridging the Age Gap in Breast Cancer” study team (LW, MWR, KC, 
MB, LC, RAA, KLC, TGR) to ensure content validity. Table 6.1 shows the topics explored within the 
questionnaire and the sources used to develop them. 
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Questionnaire topic Source from which derived 
Effect of patient age on treatment Literature, Interviews, Expert opinion 
Effect of tumour biology on treatment Literature, Interviews, Expert opinion 
Effect of tumour stage on treatment Literature, Interviews, Expert opinion 
Effect of patient factors (such as frailty, function, 
comorbidity) on treatment 
Literature, Interviews, Expert opinion 
Effect of patient preference on treatment Literature, Interviews, Expert opinion 
Effect of dementia on treatment Literature, Interviews 
Effect of family members on treatment Interviews, Expert opinion 
Variability in clinical practice Literature, Interviews, Expert opinion 
Table 6.1: Sources use to construct questionnaire. 
 
6.4.2.2. Piloting phase 
This preliminary questionnaire was then piloted with members of the surgical team locally in 
Sheffield and those on the “Bridging the Age Gap in Breast Cancer” trial management team, to 
maximise content and face validity, comprehensibility and usability. During piloting, individuals were 
asked to examine the length, acquiescent response set, flow, salience, ease of administration and 
response and acceptability [481]. Specifically, participants were asked to indicate how long it took 
them to complete the questionnaire and were invited to comment on any questions which were 
difficult to interpret or to answer. The results of the pilot phase are shown in table 6.2 below, 
including the feedback received and remedial action taken to address each of the comments. 
 
6.4.2.3. Psychometrics of the questionnaire  
As part of the piloting phase, the psychometrics of the questionnaire were assessed. 
 Reliability: Similar questions using both positive and negative framing were included, 
particularly in section 3 of the questionnaire using the Likert scales to ensure internal 
reliability.  However, some of these questions had to be removed upon receiving feedback 
from the wider study team who felt they were too repetitive, in order to balance internal 
reliability with acceptability. Test-retest reliability was not examined due to the small 
number of individuals within the pilot study. 
 Content validity: The questionnaire was designed following a full systematic literature 
review, in collaboration with experts in the field and after performing exploratory interviews 
with a sample of potential participants in order to ensure content validity. 
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Pilot HCP Comments Remedial Action 
Surgeon, Female Questionnaire seems too long and each 
section should be on a separate page. 
 
Delete repeat questions in section three. 
 
Remove year of qualification and 
shorten options for profession in section 
one. 
Remove 4 questions from section two. 
 
Remove neutral option from section 
three. 
 
Less options for % patient treated with 
PET. 
 
Remove four questions from section 
four. 
Repeat questions removed 
and formatted so each 
section begins on separate 
page. 
Number of questions in 
section three halved. 
Questions remove from 
section one. 
Questions removed from 
section two. 
Neutral option removed 
from section three. 
% options changed from 5% 
increments to 10%. 
Questions removed from 
section four. 
Surgeon, Male Too many repeats of the same question 
asked in different ways. 
Too many HER2+ scenarios in DCE. 
 
 
Undecided category should be changed 
to “no preference” or similar. 
Takes about 20 minutes to answer. 
Number of questions in 
section three halved. 
Orthogonal design altered to 
include 3 levels in tumour 
biology section to reduce 
this. 
Changed to “prefer both 
equally”. 
Surgeon, Male Change last category of maintenance of 
control to 5+ years as literature states 
can maintain control for up to 10 years. 
Two of the DCE scenarios not clinically 
realistic. 
Takes 15-20 minutes to complete. 
Changed last category to “5 
years or more”. 
 
DCE scenarios removed. 
Surgeon, Male Reads well and is self-explanatory. 
Consider use of ET to down-stage to 
make operable? 
Decided not to include 
questions on neo-adjuvant 
as the study is mainly 
concerned with PET. 
Surgeon, Male No comments on content or lay-out. 
Takes around 20 minutes to fill in. 
 
Geriatrician, Male Standardise age criteria across 
questionnaire (currently >70, over 70) – 
should be ≥70. 
Remove neutral option from section 
three questions. 
Three DCE scenarios unrealistic. 
Predicted life-expectancy given for each 
of the DCE scenarios. 
Changed to ≥70. 
 
Neutral option removed. 
 
Scenarios removed. 
Table 6.2: Feedback received from the questionnaire pilot phase. 
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 Face validity: Face validity was ensures during the pilot phase when members of the study 
team were asked to comment on whether the questionnaire appeared suitable for the 
purposes of the study and whether they felt anything was missing. 
 Criterion or concurrent validity: In this case, there are no other validated questionnaire 
instruments available and so this was not assessed. 
 Construct validity: This has little application in this study where the area being studied is not 
an abstract concept and so was not assessed. 
 Acceptability: This was assessed by the pilot study in terms of length of time taken to 
complete, comprehensibility and usability. Specific comments relating to increasing 
acceptability can be seen in table 6.2.  
 
6.4.2.4. Final instrument design 
Based on the feedback, final modifications were made to the design and content of the questionnaire 
and a final version was submitted for ethical approval along with the letter of invitation. These 
documents and the letter granting approval can be found in Appendices 6, 7, 17 and 18. 
The final questionnaire consisted of five sections and is shown below: 
1. Background and demographic information of the participant. 
2. Factors considered when discussing treatment options with older women with operable 
breast cancer. 
3. Questions regarding HCPs views about the choice between surgery and PET. 
4. Questions relating to the HCPs personal experience of treating older women with operable 
breast cancer 
5. Discrete choice experiment scenarios (this section will be discussed in Chapter 2.3). 
Where categorical choices were used, for example “respondent profession”, an “other” option was 
included with space for free text to ensure full and complete data collection. 
Where Likert style questions were used, only four options were included and the “opt out” middle 
category (e.g. no preference/unsure) was removed to encourage participants to make a choice as 
advised by two of the experts in the pilot study.   
The full and final questionnaire can be seen below. 
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 Variation in Clinician Preferences for Treatment of 
Older Women with Operable Breast Cancer 
 
 
Health Care Professional Questionnaire 
 
All information that you provide will remain strictly confidential 
 
When you have finished please post the questionnaire back in the 
FREEPOST envelope provided. You do not need a stamp. 
 
  
 
 
 
If you have any queries about this questionnaire or the study, 
please contact Lynda Wyld (Senior Lecturer and Consultant Breast 
Surgeon), EU36, University of Sheffield Medical School, Beech Hill 
Road, Sheffield. Telephone 0114 2268640. 
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This sheet is intentionally blank. 
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Section One 
This section requires you to give brief information about your professional background 
 
   1. What is your age in years?   …     
 
 
  2. What is your gender? (please tick appropriate box) 

 Male  Female
 
 
3. What is your profession or speciality?  (please tick appropriate box) 
 

Breast Surgeon 
 
 Oncologist 
 
 
 
 
 
 
Breast Care Nurse Specialist 
 
 Other (specify)………… 
 

 
 
4. Which area do you currently work in? (please tick appropriate box) 
Eastern 
 
 North West 
 
 
 
 
 
 
Northern & Yorkshire 
 
 Northern Ireland 
 

Oxford 
 
 Scotland 
  

South West  Thames 
Trent 
 
 Wales 
West Midlands  Other (specify)………… 
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Section Two 
The table below contains factors that may be considered when discussing treatment options 
with an older patient with operable breast cancer.  Please rate the importance of each of 
these factors in shaping your advice regarding treatment options in an older woman (≥70) in 
whom you are considering the choice between surgery and primary endocrine therapy. 
   
For each factor place your tick in the relevant box that best describes how important 
you think each factor is. Please only tick one box per question. 
 
Patient Characteristic 
Very 
important 
Important 
Some 
importance 
Not 
important 
Patient age 1 2 3 4 
Breast cancer ER positivity 1 2 3 4 
Breast cancer Her 2 receptor status 1 2 3 4 
Size of tumour (e.g. suitability for 
WLE) 
1 2 3 4 
Presence of axillary nodal disease 1 2 3 4 
Suitability for surgery under local or 
regional anaesthesia in a frail patient 
1 2 3 4
Estimated life expectancy of the 
patient 
1 2 3 4 
Patient’s preference for operation or 
PET 
1 2 3 4 
Functional status (level of 
independence, ability to perform 
activities of daily living) 
1 2 3 4 
Cognitive function (dementia) 1 2 3 4 
Co-morbidity (are they fit and well or 
do they have multiple health 
problems?) 
1 2 3 4 
Patient’s anxiety level about breast 
cancer 
1 2 3 4 
Patient’s anxiety levels about an 
operation 
 
1 2 3 4 
Family member/carer preference for 
operation of PET 
1 2 3 4 
 
  
 194 
 
Section Three 
The following questions relate to your views about the choice between surgery and primary 
endocrine therapy.  
For each of the statements below please circle one box to indicate yours views about the 
validity and accuracy of the statement: 
1)  All women ≥70 with operable breast cancer should be offered an operation, regardless of 
age. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
2) All women ≥70 with operable ER+ve breast cancer, who have multiple co-morbidities 
such that anaesthesia may carry an increased risk of morbidity and mortality, should be 
treated with PET. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
3) All women ≥70 with operable ER +ve breast cancer, who have significant dementia, 
(unable to give informed consent) should be treated with PET. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
4) Primary endocrine therapy may be offered to any woman ≥70 with ER+ve disease as 
there is no proven survival disadvantage. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
5) Surgery is almost always possible for older women ≥70 with operable breast cancer under 
local or regional anaesthesia. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
6) Most older women ≥70, if given a choice of treatment would prefer to have non-surgical 
treatment for their breast cancer. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
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Section Four 
The following questions relate to your experiences with treating older women ≥70 with 
operable breast cancer. For each of the questions below please tick the box of the answer 
that is most similar to your experiences. 
1) What percentage of women ≥70 receive PET in your unit? 
Less than 10% 
 
 10 to 20% 
 
 
 
 
 
 
20 to 30%  30 to 40% 
More than 40%   
2) In your experience, how long on average does PET maintain local control? 
6 months 
 
 12 months 
 
 
 
 
 
 
18 months  24 months 
3 years  5 years 
3) What action would you take if your first line anti-oestrogen failed to achieve a response in 
a patient being treated with PET? 
Start second line anti-oestrogen  Advise operative management 
 
 
Advise radiotherapy  Other (specify)……………….. 
4) In your experience, are anaesthetists in your unit happy to perform regional blocks to 
allow you to undertake surgical excision in women ≥70 who have multiple co-morbidities 
where a general anaesthetic may carry increased risk or morbidity and mortality? 
Never perform regional blocks in this 
group 
 Rarely perform regional blocks in 
this group 
 
 
 
 
 
Regularly perform regional blocks in 
this group 
 
5) In your experience, is surgery under general anaesthesia well-tolerated in women ≥70 
with operable breast cancer? 
Yes  No  Not sure  
6) In your experience, is surgery under local anaesthesia well-tolerated in women ≥70 with 
operable breast cancer? 
Yes  No  Not sure  
7) In your experience, is PET well-tolerated in women ≥70 with operable breast cancer? 
Yes  No  Not sure  
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6.4.3. Recruitment 
Recruitment to this part of the study was via the Association of Breast Surgery (ABS). The ABS is the 
association representing HCPs (breast surgeons and breast CNS) treating malignant and benign 
breast disease in the UK, Ireland and worldwide. It focuses on education, audit and guidelines to 
enhance the treatment of patients with breast disease. This recruitment strategy was viewed as 
being a potentially appropriate and effective method in which to contact the majority of HCPs 
treating older women with breast cancer in the UK.  The president of the ABS was contacted by 
personal communication by the study lead (LW) and permission was granted to contact members. 
The questionnaire was posted to all 641 members of the Association of Breast Surgery (ABS).  
Questionnaire packs were prepared and included the finalised questionnaire (see Appendix 18), a 
letter of invitation to participants written on headed paper (see Appendix 17), and a stamped 
addressed return envelope. These were then mailed to each individual member of the ABS 
personally in a stamped envelope to try and increase recruitment. 
A record of the number of packs sent out was be kept and correlated with the number returned to 
give the response rate. An electronic reminder was sent out by the ABS after eight weeks to remind 
members who had not completed the questionnaire to do so.  No further reminder was sent 
although during the study period the questionnaire study was presented to the ABS meeting to raise 
its profile and a poster was put up at the meeting.  However this seemed to have little effect (see 
table 6.3). 
Recruitment phase Response rate 
Total population of ABS: 641 - 
Initial posting of questionnaires 229 (35.7%) 
Electronic reminder 11 (1.7%) 
Presentation at ABS meeting 18 (2.8%) 
Total 258 (40.2%) 
Table 6.3: Response rate at each phase of recruitment. 
 
6.4.3.1. Power calculation 
Given the sample population (641 members of the ABS) and using standard 95% confidence levels, it 
was calculated using sample size calculation software that we would need at least 240 responders to 
the survey for the results to be reasonably precise (confidence interval of +/-5%) [488]. This means 
that if 41% of the participants agree with a questionnaire statement, we can be 95% sure that the 
actual figure of the total population that would agree with this statement lies between 36% and 46% 
(41% +/- 5%). 
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It was estimated, based on previous similar studies, that 240 responders would be an achievable 
response rate [128, 474]. 
 
6.4.4. Data handling and statistics 
6.4.4.1. Data handling 
Data were initially entered into a Microsoft Excel 2010 spreadsheet and coded before being 
transferred to IBM SPSS (version 21) for analysis. Graphs were drawn in Microsoft Excel 2010. 
 
6.4.4.2. Statistical analysis 
Descriptive questions were analysed using percentages, median responses and ranges. Chi-squared 
test and Fisher’s exact test were used to identify associations between preferences indicated and 
the demographic categories of participants. All statistical analyses were performed in IBM SPSS 
(version 21).  
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6.5. Results 
6.5.1. Response rate 
Of the 641 questionnaires distributed, 258 were returned (40.2% response rate). Of these, 6 were 
not completed at all, leaving 252 for analysis (39.3% of those distributed), and a small percentage 
were not completed in full, meaning that some questions have small numbers of missing data (<5%). 
However, despite this,  the response rate was still high enough for the study to be adequately 
statistically powered based on the calculations above (see section 6.4.3.1.) and based on previous 
similar studies, this rate was judged to be reasonable [128, 474].  
Table 6.4 shows the characteristics of participants and the percentage response by region compared 
with the percentage distribution of surgeons within these regions [73], demonstrating that each 
region is relatively well represented.  
Characteristic  n (%) Number of 
surgeons (and % 
for comparison) 
eligible to take 
part in each 
region (based on 
the Year 3 
BCCOM figures 
[73]). 
Region of high 
or low PET rate 
as based on 
the rate of 
non-surgical 
treatment in 
the Year 3 
BCCOM figures 
[73]. 
Age Median 50 years 
Range 28-69 
years 
 
Sex Male 115 (45.6) 
Female 134 (53.2) 
Profession Breast surgeon 190 (75.4) 
Clinical nurse 
specialist 
55 (21.8) 
Oncologist 2 (0.8) 
Breast physician 1 (0.4) 
Plastic surgeon 2 (0.8) 
Region (based on 
UK cancer 
registration 
regions) 
Eastern 26 (10.3) 42 (8.6%) High 
North West 23 (9.1) 66 (13.5%) Low 
Northern & 
Yorkshire 
37 (14.7) 55 (11.3%) High 
Northern Ireland 6 (2.3) 16 (3.2%) High 
Oxford 5 (2.0) 18 (3.7%) Low 
Scotland 20 (7.9) 46 (9.4%) High 
South West 37 (14.7) 56 (11.5%) Low 
Thames 42 (16.7) 77 (15.7%) Low 
Trent 14 (5.6) 35 (7.2%) High 
Wales 14 (5.6) 28 (5.7%) Low 
West Midlands 22 (8.7) 49 (10.0%) High 
Table 6.4: Characteristics of questionnaire participants. 
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6.5.2. Findings 
6.5.2.1. Factors considered when discussing treatment options with older women with 
operable breast cancer. 
The presence of comorbidities was the most important factor determining treatment decisions for 
older women with operable breast cancer. All HCPs 248/248 (100%) rated this factor as having at 
least some importance (see figure 6.1). Age was considered as one of the least important factors 
considered by HCPs when making decisions about surgery vs PET, with only 12/245 (4.9%) rating it as 
very important and a further 59/245 (24.1%) rating is as important (see figure 6.1). Other patient 
factors that were considered important included patient preference, life expectancy and functional 
status and these were rated as either important or very important by 236/249 (94.8%), 208/245 
(84.9%) and 217/249 (87.1%) respectively. 
 
 
Figure 6.1: Patient and tumour characteristics and their importance in shaping the advice HCPs 
would give to an older patient in whom a choice of PET and surgery may be considered (n=252). 
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Tumour factors, such as stage and size of the disease were viewed as being less important in 
determining treatment than patient health and fitness measures (see figure 6.1) as although 
216/247 (87.4%) rated tumour factors as of at least some importance, only 56/247 (22.7%) regarded 
it as very important.  Axillary disease was rated as slightly more important with 68/247 (27.5%) HCPs 
rating it as very important. This may be due to the fact that surgery is likely to be more extensive in 
patients with axillary disease or higher tumour stage. ER status was regarded as important or very 
important by most surgeons (216/248; 87.1%) but HER2 status much less so (123/245; 50.2%). This 
may be explained by the fact that HER2 tumours are less responsive to anti-oestrogens [489].   
 
6.5.2.2. Views regarding the choice of PET vs surgery 
Over three quarters (199/249) of HCPs agreed with the statement “All women ≥70 with operable 
breast cancer should be offered an operation regardless of age” (see figure 6.2). However only 
65/244 (26.6%) agreed that PET may be offered to any older woman with ER positive disease as 
there is no proven survival advantage (see figure 6.3). There was also a predominant but not 
universal view (217/247; 84.6%) that older women, if given the choice between PET or surgery, 
would choose surgery.   
 
Figure 6.2: HCP opinion regarding offering all patients an operation, regardless of age. 
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Figure 6.3: HCP opinion regarding offering PET to any woman over 70 years. 
 
Again, comorbidities were considered important, with nearly two thirds (155/246; 63.0%) agreeing 
with the statement “All women ≥70 with operable ER+ breast cancer, who have multiple 
comorbidities such that anaesthesia may carry an increased risk of morbidity and mortality, should 
be treated with PET” (see figure 6.4).  
 
Figure 6.4: HCP opinion regarding treating patients with significant comorbidity. 
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operable ER+ breast cancer, who have significant dementia (unable to give informed consent) should 
be treated with PET” and the remainder (146/248; 58.9%) disagreeing (see figure 6.5). 
 
 
Figure 6.5: HCP opinion regarding the treatment of patients with dementia. 
 
6.5.2.3. Personal experience of treating older women with operable breast cancer 
Almost all (241/245; 98.4%) HCPs stated that in their experience, surgery under GA was well 
tolerated in older women. However, experience with the usage of local anaesthetic (LA) and regional 
techniques was more variable, with only 43/244 (17.6%) stating that they had an anaesthetist who 
would happily perform regional blocks to allow surgical excision in patients where GA may carry an 
increased risk. Nearly two-thirds (156/244; 63.9%) felt that surgery under LA was well tolerated in 
older women and 148/246 (60.2%) agreed with the statement “surgery is almost always possible for 
older women ≥70 with operable breast cancer under local or regional anaesthesia”. 
Despite this, PET is still used to treat women across the UK, although its use is variable, with 17/240 
(7.1%) stating that more than 30% of women ≥70 were treated this way, 65/240 (27.1%) stating that 
20-30% of women ≥70 were treated with PET, 67/240 (27.9%) stating that 10-20% of women ≥70 
received PET and 91/240 (37.9%) stating that PET was used in less than 10% of women ≥70 years 
(see figure 6.6). 
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Figure 6.6: HCP experience of PET use in their breast unit. 
 
There was variation regarding how long HCPs felt that PET was effective in maintaining local tumour 
control, with 64/238 (26.9%) stating 5 years or more; 74/238 (31.1%) stating 3 years, 70/238 (29.4%) 
stating 2 years and 30/238 (12.6%) stating 18 months or less (see figure 6.7).  
 
Figure 6.7: HCP experience of how long PET maintains tumour control on average. 
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“other” – most HCPs in that ticked “other” commented that they would consider more than one of 
these options or the decision would depend on the individual patient (see figure 6.8). 
 
Figure 6.8: Action taken by HCP if first-line anti-oestrogen failed to achieve a response in a patient 
being treated with PET. 
6.5.2.4. Effect of HCP demographics on responses 
Participant responses were examined according to gender, age category, profession and region 
(categorised as high and low PET rates according to the cancer registration region, see figure 6.8) 
[73]. 
 
Figure 6.8: Regions according to High (red) or Low (blue) PET rates [73]. 
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There were no significant differences between answers given by male and female HCPs in the 
majority of questions. Gender appeared to make a difference in how important HCPs felt age was 
when making a treatment decision for older patients with operable breast cancer, with men tending 
to think age was more important than women (p=0.006). Additionally, women also appeared to rate 
patient anxiety as more important than men, both patient anxiety over breast cancer (p=0.001) and 
patient anxiety over surgery (p=0.22). 
There were statistically significant differences between the responses given by doctors compared to 
nurses: nurses rated cancer size (p=0.009), axillary disease (p=0.012), patient anxiety – both regards 
to breast cancer (p=0.001) and surgery (p<0.001), and preference of family (p=0.001) as more 
important when deciding treatment compared to doctors. Conversely, doctors rated life expectancy 
(p=0.005) as more important when deciding treatment in comparison to nurses. 
There were no significant differences between responses from participants working in regions of 
high or low PET rates, except that they felt patients would always choose PET if given the choice. 
HCPs from low PET regions were more likely to agree that patients would always choose PET if they 
were given the choice compared with HCPs from high PET regions (21.2% vs 10.5%, p=0.022). HCPs 
from low PET regions also appeared to have more access to regional blocks compared to those from 
high PET regions (p=0.030), see table 6.5. 
Age of participants appeared to have no effect on the answers provided. 
 
Use of regional blocks Low PET region High PET region 
Never use 21.8% 38.3% 
Rarely use 56.3% 49.2% 
Regularly use 21.8% 13.3% 
 
Table 6.5: Use of regional anaesthetic blocks by region. 
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6.6. Discussion 
6.6.1. Factors considered in the treatment decision-making process 
In 2008 the UK’s Department of Health established the National Cancer Equality Initiative (NCEI) 
aimed at lowering the inequality in cancer outcomes for all, including those of older patients [94]. 
Recent guidelines suggest that PET should only be offered to patients with a “short estimated life 
expectancy (<2-3 years), who are considered unfit for surgery… or who refuse surgery” [127] and 
that PET should only be used where there are “significant comorbidities that precludes surgery” [9]. 
The HCPs studied here appear to be adhering to these guidelines when considering treatment 
options offered to older patients with operable breast cancer. Although several studies have 
explored the issue of increasing age being associated with “under treatment” of older women with 
operable breast cancer [68, 84, 90, 375], these results show that HCPs consider age one of the least 
important factors in determining which treatment options to offer. However, as age increases so 
rates of comorbidities rise, both of which have an impact on life expectancy and so may to 
potentially reduce the survival advantage of more aggressive breast cancer therapies [106] and 
comorbidities are often stated as a reason for treating patients with PET [128, 362]. It is not 
surprising then that the presence of comorbidities was the most important factor HCPs considered 
when deciding treatment options for older patients with operable breast cancer. These results also 
show that life-expectancy was also considered relatively important. However a recent UK 
questionnaire study found that surgeons are poor at gauging life-expectancy of older patients, with a 
tendency to under-estimate it [128]. 
Tumour factors were considered less important in treatment decision-making than patient factors, 
even though larger tumours are more likely to require mastectomy rather than breast conservation 
surgery. Nodal status was considered slightly more important and this may be due to the fact that 
surgery to clear the axilla under local anaesthesia is not technically possible and therefore surgery to 
clear an involved axilla would be precluded in women who were too frail to undergo GA. Despite the 
fact that HER2 positive cancers are known to be generally less likely to respond to endocrine therapy 
[489], it was considered much less important than ER status.   
 
6.6.2. Offering choice 
Patient preference was stated as one of the most important factors that HCPs take into account 
when deciding which treatment options to offer older patients with operable breast cancer, and 
patient choice is commonly stated as a reason for treating patients with PET [128, 369]. Some 
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evidence suggests that older patients may prioritise quality of life over quantity [415] however, in 
this study, there was a strong view that older women, if given the choice, would choose surgery over 
PET.  Whether this statement’s response would have changed had the questionnaire contained a 
different, older, age cut-off we are unable to confirm but current UK practice would suggest this to 
be the case.   
However, in order for patients to express a preference for a particular treatment, they must first be 
informed of the different treatment options as advocated in shared decision-making (SDM) [277], 
which means that for some older women  it may be appropriate to offer PET as an alternative to 
‘standard’ surgical treatment and allow the patient to decide what is best for them. These results 
show that only around a quarter of HCPs agreed that PET may be offered to any older woman with 
ER positive disease as there is no proven survival advantage, suggesting that not all older patients 
are able to take part in SDM, although the number here is more than three times the number found 
by Wylie et al [128]. In addition, not all older patients want to engage in SDM, with many preferring 
a more passive role [88, 278-280] so it is perhaps for this reason why not all patients are offered a 
choice of the two treatments. 
  
6.6.3. Variation in practice 
The use of PET for the treatment of older breast cancer patients across the UK is variable [73] and 
this study supports these findings, with over a third of HCPs stating they treat less than 10% of this 
population in this way and over a third of HCPs stating they treated more than 20% of this 
population with PET. 
This component of the study also identified major variation in the way PET is used in respect of the 
type of first-line anti-oestrogen prescribed, the assessment methods and follow-up regimen used. 
This corroborates the findings by Wylie et al [128] and is most likely due to a lack of guidelines on its 
usage. A recent review on this subject advocates the use of AIs for PET, unless otherwise 
contraindicated [403] but there have been no studies that determine how best to follow these 
patients up.  
The major drawback of PET is the risk of development of progressive disease which most patients 
will eventually suffer from [227]  although the length of time to progression varies greatly from nine 
to 132 months [337, 339, 341, 364, 401]. The duration of response is generally shorter in women 
who have only exhibited a partial response to PET, compared to those with a complete response 
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[217, 337]. This may explain why there was so much variation in these results of HCP opinion as to 
how long PET maintains tumour control. 
The use of local and regional anaesthesia for breast surgery in patients who are unable to undergo 
GA is well-established [473], with nearly two thirds of HCPs feeling that surgery in older patients was 
well-tolerated under LA. However, it seems that a limiting factor in the utilisation of regional 
techniques is the availability of a suitably-experienced anaesthetist. 
 
6.6.4. Opinions on patients with dementia 
For those older breast cancer patients who are unable to make a decision due to significant 
dementia, opinion was divided regarding the best treatment approach. Although it appeared to be 
an important factor affecting treatment decision-making for HCPs, around 40% felt patients with 
dementia should be treated with PET with the remainder feeling they should be treated with 
surgery. As dementia predominantly affects older age groups, this represents a significant problem 
in this population. Studies show that older patients with dementia are less likely to receive standard 
cancer therapies [449] and that this is often stated as a reason for selecting PET over surgery [69, 
368]. However, there are currently no guidelines for the treatment of operable breast cancer in this 
complex group of patients which may reflect the lack of consensus amongst HCPs surveyed here. A 
further explanation for such differing views may be that dementia was not defined in terms of 
severity in the survey, and HCPs clinical judgement of dementia may vary in the absence of formal 
assessments. 
 
6.6.5. Strengths and weaknesses of this analysis 
Limitations of this study include the low response rate to the questionnaire, although this is 
comparable with other similar studies [128, 474], but limits the generalizability of the results.  
Additionally, it has previously been shown that most UK breast surgeons do not formally audit their 
practice in terms of PET [128] and so will have had to have estimated in some areas, such as the 
percentage of patients treated with PET.  
The findings from this survey component of the study support those found in the interview of 
component, helping to generalise these findings to the wider UK breast HCP population. 
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6.7. Summary 
In conclusion, HCP opinions regarding the treatment of older women with operable breast cancer 
differ, particularly regarding the optimal way to treat patients with co-existing dementia. There is 
also divided opinion as to whether patients should be offered both surgery and PET as a treatment 
option. These factors may impact on the variation in the treatment of older women with breast 
cancer across the UK.  
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Chapter 7: Clinician Questionnaires – A 
Discrete Choice Experiment 
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7.1. Abstract 
7.1.1. Introduction:  
Despite current guidelines that state PET should only be used for patients with “significant 
comorbidity” or “reduced life expectancy”, there are many factors which HCPs consider important 
when determining treatment for older breast cancer patients.   
7.1.2. Methods:  
A Discrete Choice Experiment (DCE) was used to determine the impact of key variables on healthcare 
professionals’ (HCP) treatment preferences for operable breast cancer among older women. 
Distribution was by postal questionnaire via the Association of Breast Surgery (ABS) to their 
professional membership. Multinomial logistic regression was used to identify associations between 
treatment and clinical characteristics (patient age, comorbidity, cognition, functional status, cancer 
stage, cancer biology). 
7.1.3. Results:  
Forty percent (258/641) of questionnaires were returned. Five variables (age, co-morbidity, 
cognition, functional status and cancer size) independently demonstrated a significant association 
with treatment preference (p<0.05). On multivariable analysis, functional status was omitted from 
the model due to collinearity, with all other variables correlating with a preference for operative 
treatment over no preference (p<0.05). However, only co-morbidity, cognition and cancer size 
correlated with a preference for PET over no preference (p<0.05).  
7.1.4. Conclusion:  
The majority of HCPs selected treatment in accordance with current guidelines, however in some 
scenarios, opinion was divided. Additionally, age did appear to be an independent factor that HCPs 
considered when making a treatment decision in this population. This study demonstrates that HCP 
preferences for managing older breast cancer patients are not uniform, which may contribute to the 
treatment variation seen in this population. 
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7.2. Introduction 
As demonstrated in previous chapters, HCPs take a variety of factors into account when determining 
treatment options for older women with operable breast cancer, and vary in their opinions on how 
this population should be treated. Despite current guidelines stating that PET should only be used 
for patients with “significant comorbidity” or “reduced life expectancy” and that age itself should 
not be taken into account [9, 127], there is evidence that age is one of the many key variables that 
HCPs consider important when determining treatment for older breast cancer patients [68, 89, 90].   
As discussed in Chapter 1.2, case mix does not seem to fully explain the wide variation in practice 
that can be seen across the UK [73]. Variation in clinician preference and opinion may be a source of 
some of this variation [373] and this may exert a potent influence on patient choice [88].  
The aim of this component of the study was to use Discrete Choice Experiment (DCE) methodology 
to determine the impact of key variables on healthcare professionals’ (HCP) treatment preferences 
for the management of operable breast cancer in older women and to further quantify the 
importance of these factors. 
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7.3. Methodology 
7.3.1. Choice of Discrete Choice Methodology 
There are several methods of eliciting preference in surveys, including Discrete Choice Experiment 
(DCE) and Conjoint Analysis which are types of stated preference techniques. Table 7.1 shows a 
comparison of these two methods. 
 
DCE Conjoint Analysis 
Measures preferences at an individual level Measures preferences at an individual level 
Allows estimation of trade-offs an individual is 
willing to make when evaluating several 
attributes together 
Allows estimation of trade-offs an individual is 
willing to make when evaluating several 
attributes together 
Individuals must choose between alternatives – 
in this case, choose a treatment based on the 
scenario characteristics. 
Individuals rank scenarios – in this case, rank the 
scenarios according to how likely they are to 
offer a particular treatment, e.g. surgery. 
More realistic and more closely resembles 
clinical practice. 
Unrealistic, does not resemble clinical practice as 
HCPs consider patients on an individual basis and 
not together. 
Table 7.1: A comparison of DCE and Conjoint Analysis. 
 
A DCE design was chosen for this component of the study as it is a rigorous survey methodology 
capable of eliciting individuals’ preferences in controlled experimental conditions, through 
responses to hypothetical scenarios. It was felt it had superiority over other stated preference 
techniques, such as conjoint analysis in this research area in its ability to establish the relative 
importance of difference variables according to individuals HCPs [490] and would provide more 
clinically realistic choices [491], making the survey more acceptable to HCPs. 
 
7.3.2. The methodology of DCEs 
Discrete choice experiments are based on the assumptions that the healthcare intervention, service 
or in this case, the patient, can be described by their characteristics or attributes and that an 
individual’s (in this case the HCP) valuation depends on the levels of these characteristics [492]. 
Discrete choice scenarios provide information on the relative weights individual professionals attach 
to the various dimensions (variables) involved in the decision-making process and how willing they 
are to trade these off against each other in reaching a decision. 
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7.3.2.1. Establishing variables 
The initial step in development of a DCE tool is to identify the main characteristics or variables [493] 
which depends on the researchers ability to correctly identify the relevant attributes. This requires 
an understanding of the situation to be studied and of the target population’s perspective [494, 
495]. Methods for developing variables include: literature review and expert review, however it is 
highly recommended that exploratory qualitative work is also carried out [496]. 
There are no restrictions on the number of variables that can be included in a DCE, however most 
contain less than 10 to prevent the questionnaire becoming unwieldy and to prevent participants 
from adopting a simplified approach to answering the questions [497]. 
 
7.3.2.2. Assigning attribute levels 
The levels within a variable should be exhaustive, so as to reflect the range of situations HCPs might 
expect to experience [498]. There must also be a finite number of mutually exclusive levels, in order 
for the analysis to be meaningful. Ensuring realistic and meaningful levels within an attribute 
increases the precision of the analysis [495].  
 
7.3.2.3. Designing the scenarios 
In determining the choice sets, in this case, the patients scenarios, the hypothetical alternatives 
must be generated and combined [498]. A full factoral design which lists all possible combinations of 
the variable levels may be generated, however in is usually impractical to use all possible 
combinations, as for example a DCE with 5 attributes each with four levels will produce 1024 
possible scenarios (45). As such a selection of scenarios are usually produced as a choice set using an 
orthogonal factoral fractional design which aims to produce a choice set that is both orthogonal 
(statistically independent) and balanced with minimal overlap [499, 500]. 
It is important to consider how many scenarios participants can view before boredom sets in, and 
this will depend on their complexity and the characteristics of the target population [498].  
It is also important to clinically review the scenarios to ensure they are clinically realistic (for 
example in this case to have a scenario with a woman with severe dementia but who was living 
independently is not realistic). 
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7.3.2.4. Designing the questionnaire 
The majority of DCEs in the healthcare setting provide two options for the participants to choose 
between, in this case, recommending the treatment options of either PET or surgery. However it is 
recognised that decision-making in healthcare is more complex and an opt-out response may be 
required to improve realism and therefore response rates. This type of opt-out response is usually a 
“prefers neither” response [501]. 
The questionnaire should be piloted to ensure the content is plausible to potential participants and 
contains realistic scenarios comprised of attributes that individuals are willing to trade between to 
arrive at a decision. In addition, if the questionnaire is to be self-administered, it is important that a 
clearly presented and understandable introduction is included with the scenarios [498]. 
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7.4. Methods 
7.4.1. Research Governance 
7.4.1.1. Ethics approval 
Research Ethics Committee (REC) approval was not required for this study as the participants were 
NHS staff recruited by virtue of their profession. The study protocol was reviewed by the University 
of Sheffield Medical School’s Ethics Review Committee and approval was granted on 22nd November 
2012 (ref: SMBRER243; see Appendices 6 & 7). 
 
7.4.1.2. Consent 
Individual participant consent was implied by the return of the questionnaire to the study team. A 
covering letter explaining the study and informing the individual that participation is voluntary was 
included with the questionnaire pack (see Appendix 17). 
 
7.4.1.3. Confidentiality 
Questionnaire responses were anonymous unless individual participants requested personal 
feedback about publication of the study results, in which case their identities were anonymised for 
purposes of analysis.  
Databases, including the list of names and addresses of ABS members, were password protected and 
stored in a locked office in the university in accordance with the Data Protection Act 1998. No 
information that would allow clinicians to be identified was released into the public domain. 
 
7.4.2. Establishing variables and levels 
The DCE method was chosen to establish HCP preferences in controlled experimental conditions 
using hypothetical scenarios. Key variables were identified and selected using the relevant literature 
and previous qualitative research with a selection of the target population of HCPs (see Chapter 5). 
These variables were subsequently subdivided into levels of clinical severity based on clinical expert 
peer review by members of the study team. Table 7.2 shows the variables and levels.  
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Variable Levels 
Patient age 70-74 75-79 80-84 85+ 
Co-morbidity None Mild Moderate Severe 
Cognition Normal Mild impairment Moderate 
Impairment 
Severe Impairment 
Functional 
status* 
Independent Mild dependence Moderate 
dependence 
Severe 
dependence 
Cancer size Small tumour, 
node negative 
Small tumour, 
node positive 
Large tumour, 
node negative 
Large tumour, 
node positive 
Cancer 
biology 
ER positive, HER2 
positive 
ER positive, HER2 
negative 
ER strongly positive, HER2 
negative 
*denotes not included in final model analysis 
Table 7.2: Discrete choice variables and levels. 
 
7.4.3. Determining the choice sets 
Based on previous research done in our unit, it was felt that HCPs could potentially review up to 25 
scenarios with 5 factors (with up to five levels for some of the factors) before the questionnaire 
becomes unacceptably long for participants [474, 502]. Twenty-five scenarios were randomly 
generated using IBM SPSS version 21 Orthoplan software out of 3,072 potential scenarios. For each 
scenario the participants were asked to indicate a preference for recommending either PET or 
operative treatment for a hypothetical older woman with operable breast cancer. In order to 
optimise reality in clinical practice, an “opt out” option was included, whereby participants could 
indicate no preference for either treatment choice [503], which would be equivalent to offering the 
patient a choice of both treatments. It was felt that this would more closely reflect clinical decision-
making and therefore enhance response rates compared to the more conventional pair-wise choice 
design [501]. 
 
7.4.4. Piloting the scenarios 
To be effective, scenarios must be plausible and so the questionnaire was piloted with a selection of 
experienced clinicians who identified eight of the 25 scenarios as being unrealistic. These were 
excluded from the final instrument.  
An experienced geriatrician examined the plausible scenarios and estimated the predicted life-
expectancy for each hypothetical patient based on their age, levels of co-morbidity, cognition and 
functional status, which were categorised as <2 years, 2-5 years and >5 years.  Life expectancy of less 
than 2 years would be an indicator that primary endocrine therapy would be a good choice with 
minimal morbidity in a woman in whom the breast cancer is unlikely to contribute to the cause of 
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death.  Conversely as literature suggests that the median duration of disease control with PET is 2 
years, use of this treatment option for a woman with an estimated life expectancy of more than 5 
years would be unlikely to result in long term disease control without change of management.   The 
predicted life expectancy of each patient scenario was NOT shown to the questionnaire participants 
as this information would not be routinely available in normal clinical practice. Figure 7.1 illustrates a 
scenario example.  
 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Please indicate your preferred choice of recommendation for treatment (i.e. in favour 
of operative treatment or primary endocrine therapy (PET), by placing a tick () in the 
relevant box below the scenario description.  Please assume that each hypothetical 
patient has asked you to advise them on what treatment option they should choose. 
Figure 7.1: DCE scenario example. 
 
7.4.5. The final DCE instrument 
The final 17 discrete choice scenarios were incorporated into a postal questionnaire that was mailed 
to all clinician and nurse members of the UK Association of Breast Surgery (ABS) – see Chapter 6 for 
further details. A copy of the DCE section of the questionnaire can be found below (also found in 
Appendix 18). The DCE section of the questionnaire contained a detailed explanation of the task and 
variable levels to aid self-completion of the questionnaire.  An electronic reminder was sent via 
email to all members after four months and the study was advertised at the national ABS conference 
after this in order to try and increase response rates (see Chapter 6 for further details). 
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7.4.6. Statistical Analysis 
Since the outcome for each scenario had three nominal levels (“prefer operation”, “prefer PET”, 
“prefer both equally”) multinomial logistic regression was used to identify associations between the 
outcome variable (treatment preference) and the various clinical characteristics given in the 
scenarios (patient age, comorbidity, cognition, functional status, cancer stage, cancer biology). A 
multinomial logistic model was fitted in Stata (Statacorp version 13) with “prefers either” as the 
reference category.  
With a 3-level nominal categorical outcome, the multinomial logistic model will estimate two sets of 
regression coefficients: one for the effect of preferring operation versus prefers both options 
equally, and another for prefers PET versus prefers both options equally. These regression 
coefficients (relative risk ratios; RRR) correspond to the probably of each treatment preference (for 
operation or PET) relative to the base category (prefers either) and are calculated for each unit of 
change in the corresponding variable (clinical characteristic) against the reference level for each 
variable (the reference unit was taken as the first level of each clinical characteristic: 70-74 for age, 
no comorbidity, no cognitive impairment, functionally independent, small node negative tumour, 
ER+HER2+).  
The cluster option was used to calculate confidence intervals and P-values since outcomes were 
clustered by participant to take into account the lack of response independence (as each participant 
answered 17 scenarios). 
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Section Five: Introduction 
This section comprises a series of 20 clinical scenarios on which you are asked to make a 
hypothetical decision. They are concerned with the importance that you place on various 
factors influencing your preferred option for surgery or PET in individual women ≥70 with 
operable breast cancer. PLEASE NOTE: the option for surgery may include operations 
under General, Regional or Local anaesthetic if this is how you would treat the patient. 
Please tear out this double-sided sheet to use as a reference when working through the 
scenarios 
 
1.  Patient age (years) Divided into the following age bands: 
70 – 74   75 – 79 
80 – 84   85 and over 
2.  Co-morbidity            Divided into the following: 
1) No co-morbidity 
2) Mild co-morbidity, e.g. arthritis, hypertension 
3) Moderate/well-controlled co-morbidity, e.g. diabetes, 
coronary heart disease, moderate COPD 
4) Severe co-morbidity, e.g. disabling stroke, congestive 
cardiac failure, severe COPD 
3. Cancer Stage                    Divided into the following: 
1) Small tumour, no nodal involvement 
2) Small tumour, nodal involvement 
3) Large tumour, no nodal involvement 
4) Large tumour, nodal involvement 
4. Cancer Biology      Divided into the following: 
1) ER++/HER2- (ER strongly positive, HER2 negative) 
2) ER+/HER2- (ER moderately positive, HER2 negative) 
3) ER+/HER2- (ER moderately positive, HER2 positive) 
5. Functional Status      Divided into the following: 
1) Fully independent 
2) Mild dependence; requires weekly help for domestic 
activities, e.g. shopping 
3) Moderate dependence; requires daily help with washing, 
dressing, continence management, etc. 
4) Severe dependence; requires 24 hour care, e.g. resides in 
a residential or nursing home 
6. Cognitive Function  Divided into the following: 
1) Normal cognitive function 
2) Mild cognitive impairment; functions normally in society 
3) Moderate cognitive impairment; unable to cope without 
help 
4) Severe cognitive impairment; requires daily social services 
input or lives in residential or nursing home 
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Section Five: Patient Scenarios 
For each of the 20 scenarios below, based on the information provided, please 
indicate your preferred choice of recommendation for treatment (i.e. in favour of 
operative treatment or primary endocrine therapy (PET), by placing a tick () in the 
relevant box below the scenario description.  Please assume that each hypothetical 
patient has asked you to advise them on what treatment option they should choose. 
Scenario 1 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 2 
PATIENT AGE (YEARS) 70-74 
CO-MORBIDITY 
TUMOUR STAGE 
SEVERE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 3 
PATIENT AGE (YEARS) 70-74 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 4 
PATIENT AGE (YEARS) 70-74 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
MODERATE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 5 
PATIENT AGE (YEARS) 75-79 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 6 
PATIENT AGE (YEARS) 80-84 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 7 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 8 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
SEVERE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 9 
PATIENT AGE (YEARS) 75-79 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 10 
PATIENT AGE (YEARS) 80-84 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
MODERATE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 11 
PATIENT AGE (YEARS) 70-74 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 12 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 13 
PATIENT AGE (YEARS) 80-84 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 14 
PATIENT AGE (YEARS) 70-74 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 15 
PATIENT AGE (YEARS) 80-84 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 16 
PATIENT AGE (YEARS) 70-74 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 17 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
MODERATE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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7.4.7. A priori sample size calculation 
We calculated that in order to estimate the preference for a given scenario with a reasonable degree 
of precision of +/-6% (assuming a 50% preference) i.e. 95% confidence interval 44% to 56% would 
require 250 responders to the survey. 
 
7.4.8. Ethical considerations 
University of Sheffield Research Ethics Committee approvals were obtained (SMBRER243) (see 
Appendix 7). 
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7.5. Results 
7.5.1. Response rate 
Questionnaires were sent out in February 2014.  Of the 641 questionnaires distributed, 229 (35.7%) 
were initially returned before the reminder was sent out. After this a further 29 were returned, 
meaning a total of 258 were returned (40.2% response rate): 45.6% male, 53.2% female, 75.4% 
breast surgeons, 21.8% clinical nurse specialist, 2.0% others (oncologists, breast physician, plastic 
surgeons). The median age of participants was 50 years (range 28-69 years). Of these, 4 did not 
complete the DCE section as they were oncologists or plastic surgeons and therefore did not 
routinely make these treatment decisions.  
 
7.5.2. Findings 
7.5.2.1. Preference for surgery vs. PET 
The 258 responders answered 4,281 of the 4,386 scenarios (258 x 17). In 53% (2,279/4,281) of the 
scenarios responders’ preferred operative treatment, 25% (1063/4281) PET and 22% (939/4281) 
preferred both equally. Seventy-eight percent (199/254) of responders demonstrated a preference 
for operative treatment in the majority of the scenarios they rated, 9% (22/254) a preference for 
PET, and 13% (33/254) an equal preference for surgery and PET. Table 7.3 summarises the results by 
scenario.  
There was no relationship between participant age, gender or region and their preference for 
treatment. However participant profession did demonstrate an association with treatment 
preference, with surgeons more likely to prefer surgery over choice (RRR=1.33, p=0.039) and PET 
over choice (RRR=1.64, p=0.002) when compared to nurses. That is nurses were more likely to be 
undecided or offer choice when compared to surgeons, which is perhaps unsurprising in view of 
their role in helping patients with decision-making. 
Five of the six variables (age, co-morbidity, cognition, functional status and cancer size) 
independently demonstrated a statistically significant association with treatment preference on 
univariate analysis (p<0.05). The variable cancer biology (receptor status) was associated with a 
treatment preference for operation over no preference (p<0.001) but not for PET (p=0.966) i.e. had 
a weaker effect on preference than the other variables. However, it should be noted that all options 
were ER positive so this is not surprising. 
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On multivariable analysis, functional status had to be omitted from the model due to collinearity; 
this is most likely due to the close association between this variable and the variables co-morbidity 
and cognition (e.g. a patient with moderate or severe co-morbidity and or cognitive dysfunction 
must inevitably also have moderate or severe functional dependence) and so the model could not 
determine whether an observed effect was due to functional status or co-morbidity/cognition. Table 
7.4 summarises the multivariable analysis results. Overall, all five variables in the model were 
associated with a preference for operative treatment over no preference. However, only co-
morbidity, cognition and cancer size were associated with a preference for PET over no preference. 
The goodness of fit of the multivariable model in table 7.4 can be assessed by the pseudo R2 value. In 
this case, the pseudo R2 value for the model is 0.31, suggesting this model including these five 
covariates is better than a model including no covariates by 31%, but is worse than the theoretical 
perfect fitting model (which would have a pseudo R2 value of 1.0). 
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Scenario Patient 
Age 
Co-
morbidity 
Cognition Functional status Cancer size Cancer biology Predicted life 
expectancy 
Preference 
for Surgery 
Preference 
for PET 
Prefer both 
equally 
1 85+ Severe Normal Severe dependence Small, node negative ER+, HER2+ <2 years 15 
(5.9%) 
218 
(86.2%) 
20 
(7.9%) 
2 85+ None Severe impairment Moderate dependence Small, node positive ER++, HER2- <2 years 32 
(12.6%) 
155 
(61.3%) 
66 
(26.1%) 
3 70-74 Severe Normal Moderate dependence Large, node negative ER+, HER2+ <2 years 64 
(25.3%) 
111 
(43.9%) 
78 
(30.8%) 
4 80-84 None Moderate impairment Severe dependence Small, node negative ER+, HER2+ <2 years 63 
(25.1%) 
108 
(43.0%) 
80 
(31.9%) 
5 70-74 None Severe impairment Severe dependence Large, node negative ER+, HER2- <2 years 30 
(12.0%) 
156 
(62.2%) 
65 
(25.9%) 
6 85+ Moderate Moderate impairment Mild dependence Large, node negative ER++, HER2- 2-5 years 33 
(13.1%) 
115 
(45.6%) 
104 
(41.3%) 
7 75-79 Moderate Normal Severe dependence Large, node positive ER++, HER2- 2-5 years 55 
(22.0%) 
100 
(40.0%) 
95 
(38.0%) 
8 80-84 Moderate Mild impairment Moderate dependence Small, node negative ER+, HER2- 2-5 years 98 
(39.2%) 
39 
(15.6%) 
113 
(45.2%) 
9 85+ None Mild impairment Independent Large, node positive ER+, HER2+ 2-5 years 172 
(68.3%) 
20 
(7.9%) 
60 
(23.8%) 
10 70-74 Mild Moderate impairment Moderate dependence Large, node positive ER+, HER2- 2-5 years 182  
(72.2%) 
16 
(6.3%) 
54 
(21.4%) 
11 70-74 None Normal Mild dependence Large, node positive ER+, HER2- >5 years 231 
(92.0%) 
6 
(2.4%) 
14 
(5.6%) 
12 85+ Mild Normal Independent Small, node negative ER+, HER2- >5 years 198 
(78.3%) 
3 
(1.2%) 
52 
(20.6%) 
13 80-84 None Normal Mild dependence Small, node positive ER+, HER2- >5 years 210 
(83.7%) 
2 
(1.2%) 
39 
(15.5%) 
14 70-74 Moderate Normal Independent Small, node positive ER+, HER2+ >5 years 227 
(90.4%) 
2 
(0.8%) 
22 
(8.8%) 
15 70-74 None Normal Independent Small, node negative ER++, HER2- >5 years 251 
(99.2%) 
0 
(0.0%) 
2 
(0.8%) 
16 75-79 None Mild Impairment Independent Large, node negative ER+, HER2- >5 years 223 
(88.1%) 
5 
(2.0%) 
25 
(9.9%) 
17 80-84 Mild Normal Independent Large, node negative ER++, HER2- >5 years 195 
(77.4%) 
7 
(2.8%) 
50 
(19.8%) 
*highlighted area demonstrate participants overall preference for surgery, PET or both equally by scenario 
Table 7.3: Results by DCE scenario (maximum N=254 responders). 
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Variable  Surgery vs equal preference PET vs equal preference 
 Levels RRR  95% C.I. P-value RRR 95% C.I. P-value 
Age 70-74 Ref - - Ref - - 
75-79 0.12 0.06-0.22 <0.001 2.05 0.88-4.77 0.096  
80-84 0.06 0.03-0.11 <0.001 2.48 0.98-6.25 0.055  
85+ 0.11 0.06-0.19 <0.001 1.84 0.78-4.34 0.166  
  
Co-morbidity None Ref - - Ref - - 
Mild 0.67 0.46-0.99 0.043 0.24 0.12-0.46 <0.001 
Moderate 0.11 0.07-0.17 <0.001 0.95 0.33-2.74 0.923 
Severe 0.05 0.03-0.09 <0.001 20.70 8.44-50.73 <0.001 
  
Cognition Normal Ref - - Ref - - 
Mild impairment 2.46 1.63-3.72 <0.001 0.74 0.35-1.55 0.424  
Moderate impairment 0.32 0.24-0.42 <0.001 3.67 2.07-6.48 <0.001 
Severe impairment 0.01 0.01-0.03 <0.001 21.45 7.01-65.57 <0.001 
  
Cancer size Small, node- Ref - - Ref - - 
Small, node+ 1.77 1.22-2.56 0.003 0.18 0.09-0.40 <0.001 
Large, node- 0.47 0.30-0.76 0.002 0.53 0.29-0.97 0.039 
Large, node+ 0.25 0.15-0.43 <0.001 1.68 0.81-3.44 0.161 
  
Cancer biology ER+,HER2+ Ref - - Ref - - 
ER+, HER2- 1.44 1.11-1.86 0.006 1.41 0.76-2.60 0.273 
ER++, HER2- 4.51 2.26-8.98 <0.001 2.27 0.53-9.72 0.269 
N = 248 responders; RRR = Relative Risk Ratio 
 
Table 7.4: Influence of DCE variable over treatment choice. 
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7.5.2.2. Factors influencing treatment preference 
Influence of age on treatment preference: 
Figure 7.2 and table 7.4 illustrate how HCPs’ preference for treatment is influenced by a patient’s age. 
The upper section of figure 7.2 compares a preference for surgery against no preference for either 
treatment (which will be considered to be prefers to offer the patient a choice); the lower section 
compares a preference for PET against no preference/choice. Along the vertical axis, treatment 
preferences for patients of increasing age are compared with those in the 70-74 year old category. 
Boxes represent the relative risk ratios (RRR), whiskers the 95% confidence intervals (CI); those not 
crossing the vertical line at 1 are statistically significant. To the left of the vertical line 1, HCPs are more 
likely to prefer to offer the patient a choice of treatment; to the right of the vertical line 1, HCPs prefer 
the specific treatment option (surgery in the upper section, PET in the lower section). 
As can be seen in figure 7.2, age has a statistically significant influence on treatment preference 
(p<0.001), with HCPs being less likely to prefer surgery as age increases. There is also the suggestion that 
HCPs are more likely to prefer PET with increasing age, although this is less marked than when choice 
and surgery are compared and does not reach statistical significance. 
 
 
Figure 7.2: Impact of patient age on treatment preference. Boxes represent RRR, whiskers the 95% CI; 
statistically significant results do not cross 1. Results to the left 1 represent a preference of choice and to 
the right of 1 a preference of surgery (upper section) or PET (lower section). 
 
Patient age (years) 
Log odds scale 
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Influence of comorbidity on treatment preference 
Comorbidity significantly influenced HCPs treatment preference (p<0.05). With increasingly severe 
comorbidity, HCPs demonstrated an increasing preference for choice rather than surgery (none vs. 
severe comorbidity; RRR=0.05, p<0.001) and PET rather than choice (none vs. severe comorbidity; RRR 
20.70, p<0.001). Interestingly, when comparing patients with mild comorbidities to those with none, 
HCPs favoured choice over both surgery and PET (RRR=0.67, p=0.043 and RRR=0.24, p<0.001 
respectively). Figure 7.3 and table 7.4 illustrate the effect of comorbidity on treatment preference. 
 
Figure 7.3: Impact of patient comorbidity on treatment preference.. 
 
Influence of cognition on treatment preference 
Cognitive impairment significantly influenced HCPs treatment preferences (p<0.001). With increasingly 
severe levels of cognitive impairment, HCPs were less likely to prefer surgery (none vs. severe 
impairment; RRR=0.01, p<0.001) and more likely to prefer PET (none vs. severe impairment; RRR=21.45, 
p<0.001). However when comparing patients with milder cognitive impairment to those without 
impairment, HCPs were more likely to prefer surgery over choice (none vs. mild impairment; RRR=2.46, 
p<0.001) and seemed to also prefer choice over PET, although this did not reach statistical significance. 
Figure 7.4 shows how cognition affects HCPs’ preference for treatment. 
Level of comorbidity 
Log odds scale 
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Figure 7.4: Impact of patient cognitive impairment on treatment preference. 
 
Influence of tumour stage on treatment preference 
Tumour stage significantly influenced HCPs treatment preferences (p<0.001). Large, node positive 
tumours were associated with an increasing preference for choice over surgery (small, node negative vs 
large, node positive; RRR=0.25, p<0.001) and also for PET over choice, although this was not statistically 
significant. When comparing smaller, node positive tumours with small, node negative tumours, HCPs 
were more likely to prefer surgery over choice (RRR=1.77, p0.003) and choice over PET (RRR=0.18, 
p<0.001). When comparing smaller, node positive tumours with larger, node negative tumours, HCPs 
were more likely to prefer choice over both surgery and PET (RRR=0.47, p=0.002 and RRR=0.53, p0.039 
respectively). Figure 7.5 shows how tumour stage affects HCPs’ preference for treatment. 
 
Figure 7.5: Impact of tumour stage on treatment preference. 
 
Level of cognitive impairment 
Log odds scale 
Tumour stage 
Log odds scale 
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Influence of tumour biology on treatment preference 
Tumour biology significantly influenced HCPs treatment preferences (p<0.001). Comparing HER2 
negative tumours with ER positive/HER2 positive tumours, HCPs preferred surgery over choice and also 
seemed to prefer PET over choice, although this was not statistically significant. Figure 7.6 shows how 
tumour biology affects HCPs’ preference for treatment. 
 
 
Figure 7.6: Impact of tumour biology on treatment preference.  
 
Influence of functional status on treatment preference 
Functional status could not be included in the multivariate logistic model due to collinearity – the model 
could not distinguish between the effects due to functional status and those due to comorbidity and 
cognition. However independently, functional status had big impact on treatment preference as can be 
seen in table 7.5; with increasingly severe dependence HCPs were less likely to prefer surgery and more 
likely to prefer PET (independent vs severe dependence; RRR = 0.10, p<0.01 and RRR=12.77, p<0.01 
respectively).  
 
 
 
 
Log odds scale 
Tumour biology 
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Response  RRR P value Lower 95% CI Upper 95% CI 
Prefers Either Baseline category 
Prefers Operation Independent Ref - - - 
Mild dependence 0.50 <0.01 0.42 0.61 
Moderate 
dependence 
0.20 <0.01 0.16 0.25 
Severe dependence 0.10 <0.01 0.08 0.14 
Prefers PET Independent Ref - - - 
Mild dependence 4.47 <0.01 2.83 7.05 
Moderate 
dependence 
5.89 <0.01 3.71 9.35 
Severe dependence 12.77 <0.01 7.87 20.71 
Table 7.5: Univariate analysis of the effect of functional status on treatment preference. 
 
7.5.2.3. Treatment preference and predicted life expectancy 
The majority of HCPs selected treatment in accordance with the patients predicted life expectancy for 
most scenarios, preferring surgery for patients with life expectancies of >5 years and PET for patients 
with life expectancies of <2 years, which is consistent with current guidelines [127]. There was more 
variation in opinion for the patients with life expectancies 2-5 years, with a preference for surgery in 
some scenarios and PET for others.  In addition, opinion was more evenly divided for those scenarios in 
the medium life-expectancy category, for example scenario 7 (see table 7.3). 
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7.6. Discussion 
7.6.1. Factors important in determining treatment preference 
This DCE has confirmed the influence of several predictable factors on HCP decision-making in the 
management of older patients with operable breast cancer. To our knowledge, this is the first 
application of a DCE in this setting. The results must be interpreted with a note of caution due to the 
overall response rate of 40% which limits their generalizability, although we can still estimate the 
preference for different scenarios with a reasonable degree of precision as the study was adequately 
powered according to the a priori power calculation. 
 
7.6.1.1. Impact of age on determining treatment 
Recent national guidelines state that patients with operable breast cancer should be treated with 
surgery, and not PET, “irrespective of age” unless this is precluded by comorbidities [9]. However, age 
appears to be an independent factor that HCPs consider to be important when making a treatment 
decision in this population (see figure 7.2 and table 7.4). This is consistent with findings from several 
previous studies that have identified a reduction in surgery rates with increasing age for older patients 
with operable breast cancer [68, 89, 90, 398]. This is most likely due to  chronological age often being 
used by clinicians as a surrogate marker for other factors that are more difficult to quantify, such as life 
expectancy and frailty [87].  
 
7.6.1.2. Impact of comorbidity on determining treatment 
Increasing rates of comorbidity with age may undermine the survival benefit of more aggressive breast 
cancer therapies [106] and in chapter 1.2 we can see that higher levels of comorbidity are associated 
with non-surgical treatment. Additionally, although current guidelines recommend that PET should only 
be offered to patients with “short estimated life expectancy (<2-3 years), who are considered unfit for 
surgery… or who refuse surgery” [127], they do not specify which comorbidities may preclude surgery or 
what constitutes being “unfit” and as such it is left to the treating clinician to determine which patients 
are considered unsuitable for surgery based on the clinical information available.  
These results confirm that the degree of comorbidity is a significant factor for HCPs in determining 
treatment options for older patients with operable breast cancer (see figure 7.3 and table 7.4), thus 
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arguably reflecting why comorbidities are often presented as a reason for treating patients with PET 
[128, 362]. 
 
7.6.1.3. Impact of cognitive function on determining treatment 
Dementia, predominantly affecting older age groups, represents a significant problem in this population, 
though there are currently no guidelines for the treatment of operable breast cancer in this group. 
Furthermore there appears to be a lack of consensus among HCPs regarding the optimal way to treat 
this group as can be seen in Chapters 2.1 and 2.2. Older patients with dementia are less likely to receive 
standard cancer therapies [449] and this is often stated as an explanation for selecting PET over surgery 
[69, 368]. These results confirm that HCPs are less likely to prefer surgery and more likely to opt for PET 
for patients with moderate and severe cognitive impairment. Interestingly, HCPs were more likely to 
prefer surgery for individuals with milder cognitive impairment compared to those with no cognitive 
impairment. This may be related to the fact that milder forms of cognitive impairment have less effect 
on life expectancy but clinicians may still feel they are less able to weigh up treatment options to make a 
choice.  
 
7.6.1.4. Impact of tumour factors in determining treatment 
Tumour factors were also shown to have an independent influence over the HCPs treatment preference. 
Larger tumours were associated with lower rates of preference for surgery. This may reflect the fact that 
larger tumours are more likely to require mastectomy rather than breast conservation surgery and 
clinicians may wish to avoid more major surgery. Interestingly, preference for surgery significantly 
increased with increasing ER status but preference for PET did not. This is contrary to what might be 
expected as response rates for PET are generally higher for patients with greater ER positivity [504]. 
Additionally, preference for surgery increased for HER2 negative tumours but there was no difference in 
preference for PET, despite the fact that HER2 positive cancers are less likely to respond to endocrine 
therapy [489]. However, the scenarios only contained limited information on the receptor status and 
combined ER and HER2 status, making the results slightly more difficult to interpret.  
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7.6.1.5. Impact of functional status on determining treatment 
Although functional status was not included in the final model, on univariate analysis it was significantly 
associated with treatment preference, with worsening functional dependence associated with lower 
rates of preference for surgery and higher rates of preference for PET. These findings may be 
unsurprising given the impact of comorbidities, cognition and other more difficult to measure factors 
(such as obesity, mobility, etc.) on function which may in turn impact on a patient’s fitness to undergo 
surgery and general anaesthesia. This in turn is likely to be the cause of the failure of the model to 
converge (i.e. collinearity). 
 
7.6.1.6. Impact of life expectancy on determining treatment 
The International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists 
(EUSOMA) recommend that PET should only be offered to patients with “short estimated life expectancy 
(<2-3 years), who are considered unfit for surgery… or who refuse surgery” [127] and these data show 
that the majority of HCPs selected treatment in accordance with this for most scenarios, preferring 
surgery for patients with life expectancies of >5 years and PET for patients with life expectancies of <2 
years. However, life expectancy is impossible to accurately assess with any certainty, with a recent study 
demonstrating that surgeons are poor at gauging life-expectancy of older patients, with a tendency to 
under-estimate it [128].  
 
7.6.2. Variability in treatment preference 
Whilst a majority of HCPs within this study selected treatment in accordance with current guidelines 
relating to the presence of significant comorbidity and predicted life expectancy, this was not universal. 
Additionally, although just over three quarters of HCPs surveyed demonstrated a preference for 
operative treatment overall, the remainder exhibited a preference for PET (9%) or no preference (13%). 
This demonstrates a certain amount of variation in the way that HCP prefer to manage older breast 
cancer patients, suggesting this may be a contributing factor to the treatment variation seen in this 
population. There was no relationship between treatment preference and participant region identified, 
which may be due to the small numbers of participants from each region. Doctors were more likely to 
choose a specific treatment compared to nurses who were more likely to prefer choices (p<0.05). This is 
perhaps unsurprising in view of their role in helping patients with decision-making. 
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7.6.3. Strengths and weaknesses of this analysis 
The DCE design has enabled us to establish the relative importance of difference variables according to 
individuals HCPs [490] under experimental conditions using clinically realistic scenarios. This adds to the 
survey analysis where participants assess the importance of factors individually and allows assessment 
of these factors influence on decision-making and how they interact.  
Again, a limitation of this study includes the low response rate to the questionnaire, although this is 
comparable with other similar studies [128, 474], but this limits the generalizability of the results. 
In addition, not all relevant variables could be included in the DCE and so there may be other 
confounding factors contributing to treatment allocation that were not measured here. It was felt, 
based on previous research done in our unit, that HCPs could potentially review up to 25 scenarios with 
5 factors (with up to five levels for some of the factors) before the questionnaire becomes unacceptably 
long for participants [474, 502]. The variables chosen for the DCE were deemed the most important by 
the study team based on review of the literature and interview findings. 
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7.7. Summary 
In conclusion, the majority of HCPs within this study selected treatment in accordance with current 
guidelines relating to the presence of significant comorbidity and predicted life expectancy. However, in 
some scenarios, opinion was divided and age did appear to be an independent factor that HCPs 
considered when making treatment decisions in this population. This study demonstrates that HCP 
preferences for managing older breast cancer patients are not uniform, which may contribute to the 
treatment variation seen in this population.  
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Chapter 8: Review of Findings 
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8.1. Aim: 
 
 
 
 
This study investigated the variability in the treatment of older women with operable breast cancer, 
providing new insights and a fuller understanding of the mechanisms behind how clinicians determine 
what treatment options to offer to these patients.  
Using a mixed methods approach, it has clearly been demonstrated that case mix alone does not 
account for the variation in treatment of older women with breast cancer and that some of this 
remaining variation is likely to be due to differences in how clinicians determine what treatment options 
to offer to patients and whether or not they present patients with a choice. 
8.2. Objectives and findings 
 
The systematic review found that the rate of non-surgical treatment of older breast cancer patients in 
the UK varies between 14 and 50% in the published literature [68, 69, 73, 85, 89, 92, 374, 375, 378, 385, 
391-393, 398]. 
Examining the retrospective registry data for 17 129 patients aged 70 years or more with assumed ER+ 
operable breast cancer, 9 955 were treated with surgery, giving an overall rate of 58.1%. Significant 
variation of surgery rates existed across the different hospitals examined and this persisted following 
adjustment for case mix, with 23.5% having a much higher rate of surgery than expected and 20.6% 
having a much lower rate than expected. 
Objective:  To determine the level of variance in the treatment of older women with 
operbale breast cancer. 
Finding: There is considerable variation in the rate of surgical treatment of older 
women with operable breast cancer in the UK and this is not accounted for by 
case mix. 
To examine the variability in the treatment of older women with operable breast cancer, after 
controlling for case mix, in relation to the views of specialist healthcare professionals. 
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Results from surveying members of the UK Association of Breast Surgery (ABS) demonstrated variable 
use of PET, with 17/240 (7.1%) stating that more than 30% of women ≥70 were treated this way, 65/240 
(27.1%) stating that 20-30% of women ≥70 were treated with PET, 67/240 (27.9%) stating that 10-20% 
of women ≥70 received PET and 91/240 (37.9%) stating that PET was used in less than 10% of women 
≥70 years. 
Responses from the 254 HCPs to the 17 discrete choice experiment scenarios varied, with 78% 
(199/254) of responders demonstrating a preference for operative treatment in the majority of the 
scenarios they rated, 9% (22/254) a preference for PET, and 13% (33/254) an equal preference for 
surgery and PET. 
 
Qualitative methodology comprising semi-structured interviews highlighted that most HCPs viewed 
surgery as a safe and superior treatment option for most patients when compared to PET in view of the 
enhanced rate of local control. Some also viewed surgery as having a survival advantage over PET in 
selected older patients. In terms of the use of local anaesthetic surgery HCPs opinion varied, with some 
treating most patients in this way and others never utilising this option, instead treating their patients 
with PET. 
A quantitative survey with members of the ABS showed that 60% (148/246) agreed with the statement 
“surgery is almost always possible for older women ≥70 with operable breast cancer under local or 
regional anaesthesia” and nearly all (98.4%; 241/245) HCPs stated that in their experience, surgery 
under GA was well tolerated in older women. However experience with the usage of local anaesthetic 
(LA) and regional techniques was more variable; as although nearly two-thirds (156/244; 63.9%) felt that 
surgery under LA was well tolerated in older women, only 43/244 (17.6%) had an anaesthetist who 
would happily perform regional blocks to allow surgical excision in patients where GA may carry an 
increased risk. 
 
Objective:  To explore the views of specialist healthcare professionals towards the 
management of older women (>70yrs) with operable breast cancer, 
particularly in terms of PET versus surgery. 
Finding: Surgery was generally considered to be the gold standard treatment for any 
patient with operable breast cancer, including those aged over 70 years. 
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Semi-structured interviews with 34 HCPs from across the UK demonstrated a broad spectrum of beliefs, 
attitudes and behaviours in relation to the use of PET as a treatment for older patients with operable 
breast cancer. Some HCPs felt PET to be a valuable treatment option and others declaring they did not 
use it and did not consider it a treatment for operable breast cancer in patients of any age. 
Opinions also varied regarding both response rates and duration of response, with HCPs from high PET 
units tending to think PET had a longer duration of response than HCPs from low PET units. 
Analysing the responses from the quantitative survey, there was again variation regarding how long 
HCPs felt that PET was effective in maintaining local tumour control, with 64/238 (26.9%) stating 5 years 
or more; 74/238 (31.1%) stating 3 years, 70/238 (29.4%) stating 2 years and 30/238 (12.6%) stating 18 
months or less. 
 
Qualitative interviews with HCPs revealed considerable variation in opinion regarding whether or not 
older patients with operable breast cancer should be offered a choice of treatments between surgery or 
PET. The majority, who tended to be from high PET units, felt that there were a sub-group of patients, 
who tended to be older, frailer and less fit, who were suitable to be offered a choice as it would not 
impact on their overall survival. However, a few HCPs from units with lower rates of PET, felt that as 
they considered it an inferior option, it was not appropriate to offer PET as a choice. 
When quantitatively surveying a wider group of HCPs, over three quarters (199/249) of HCPs agreed 
with the statement “All women ≥70 with operable breast cancer should be offered an operation 
regardless of age”, however only 65/244 (26.6%) agreed that PET may be offered to any older woman 
with ER positive disease as there is no proven survival disadvantage.  
In addition patient preference was stated as one of the most important factors that HCPs take into 
account when deciding which treatment options to offer older patients with operable breast cancer, and 
there was a strong view that older women, if given the choice, would choose surgery over PET. This was 
Finding: HCPs varied in their opinions on the use of PET as a treatment for older 
patients with operable breast cancer. 
Finding: HCPs varied in their opinions of whether older patients with operable breast 
cancer should be offered a choice of treatment options. 
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slightly incongruent with the interviews where it was clear that a significant number of HCPs steered 
their patients to their own preferred choice and in some cases did not offer choice when they felt it not 
in the patient’s best interest. 
 
When interviewing HCPs, most said that age was not a factor when deciding treatment, however some, 
particularly those from high PET units, still talked about age-related cut-offs for discussing non-standard 
treatment and a couple implied subconscious age-related biases by comparing older patients to 
“normal” patients. There were a minority that openly acknowledged the importance of accounting for 
age due to its effect on tumour biology, patient physiology (senescence) and life expectancy. 
Analysing the questionnaire data, age was considered as one of the least important factors considered 
by HCPs when making decisions about surgery vs PET, with only 4.9% (12/245) rating it as very 
important and 24.1% (59/245) rating it is as important. 
However, using DCE methodology, age was seen to be statistically associated with treatment preference 
on univariate (p<0.05) and multivariate (p<0.001) analysis, with HCPs being less likely to prefer surgery 
as age increases.  
This can also be seen in the retrospective registry analysis, with rates of surgical treatment decreasing 
with increasing age, so that the proportion receiving surgery declines from 91.1% at age 70 to 38.5% at 
age 85 and less than 3% at age 95 and over. 
 
Around half of HCPs interviewed (18/34) felt that fitness for surgery equated to the comorbidity status 
of the patient. Although there was variability in which comorbidities HCPs felt caused a patient to be 
unfit for surgical treatment.  
Objective:  To identify the factors underlying treatment decision-making by health care 
professionals relating to older women with breast cancer. 
Finding: Patient age remains a factor underlying treatment decision-making by HCPs, 
despite many believing it should not influence treatment decision-making. 
Finding: Comorbidity is an important factor considered by HCPs when determining 
treatment for older women with operable breast cancer, and increasing 
comorbidity is associated with a reduction in rates of surgical treatment. 
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The questionnaire data showed the importance that HCPs placed on comorbidities when deciding 
treatment options for older women with operable breast cancer, with 100% (248/248) rating this as 
having at least some importance and 63.0% (155/246) agreeing with the statement “All women ≥70 with 
operable ER+ breast cancer, who have multiple comorbidities such that anaesthesia may carry an 
increased risk of morbidity and mortality, should be treated with PET”. 
The effect of comorbidity on treatment preference was also seen on analysis of the DCE scenarios, 
where it significantly influenced HCPs treatment preference (p<0.05). With increasingly severe 
comorbidity, HCPs were more likely to prefer PET (none vs. severe comorbidity; RRR 20.70, p<0.001) and 
less likely to prefer surgery (none vs. severe comorbidity; RRR=0.05, p<0.001). 
This effect could also be seen in the retrospective registry data where increasing levels of comorbidity 
were again associated with decreasing rates of surgical treatment. 
 
Analysis of 14 380 patients from the retrospective registry data with matched HES comorbidity data 
revealed that patients with a diagnosis of dementia were significantly less likely to receive surgery 
compared to those without (12.7% vs 58.8%; p<0.001). 
During qualitative interviews, HCPs were divided in their opinion regarding the best way to treat older 
patients with breast cancer and a diagnosis of dementia, with approximately half believing they should 
be surgically treated and the remainder expressing that they felt these patients should be treated with 
PET.  
This division of opinion was mirrored in the quantitative questionnaire survey, with 41.1% (102/245) of 
HCPs agreeing with the statement ““all women ≥70 with operable ER+ breast cancer, who have 
significant dementia (unable to give informed consent) should be treated with PET” and the remainder 
(146/248; 58.9%) disagreeing. What was clear is that nearly all (89.8%; 220/245) HCPs consider the 
presence of dementia as important in making treatment decisions in older breast cancer patients. 
Finding: HCPs are divided in their opinion regarding the best way to treat older 
patients with operable breast cancer who have cognitive impairment, 
however increasing rates of cognitive impairment are associated with 
decreasing rates of operative treatment. 
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In the DCE scenarios, cognitive impairment was again seen to be significantly associated with treatment 
preference (p<0.05), with increasingly severe cognitive impairment associated with a reduction in 
preference for surgery and an increase in preference for PET. 
 
Frailty was mentioned by around half (n=16) of the HCPs during semi-structured qualitative interviews 
as an important factor in determining treatment of older breast cancer patients, however it was difficult 
to define exactly what people meant by this term and for some it seemed to equate to their functional 
ability. 
Functional status was a factor included in the quantitative survey of HCPs and was considered an 
important factor in deciding treatment in this population by 87.1% (217/249). 
In the DCE section of the questionnaire, functional status showed the greatest association with 
treatment preference on univariate analysis (p<0.05), with HCPs being less likely to prefer surgical 
treatment for patients with higher rates of functional dependence. However it could not be included in 
the multivariable analysis due to collinearity – that is the model could not distinguish between the effect 
due to functional status and that due to comorbidity and cognition which are intimately linked.  
 
Analysis of retrospective registry data demonstrated that tumour factors were associated with 
treatment type, with larger, node positive tumours being less likely to be treated surgically. Higher 
tumour grade was associated with increasing rates of surgery, possibly representing the assumption that 
more aggressive disease should be treated with more aggressive treatment. 
During the semi-structured interviews, HCPs mentioned a variety of tumour factors that they took into 
account when determining treatment of older women with operable breast cancer, including the degree 
of ER-positivity, PR status, HER2 status, suitability for breast-conserving surgery and the histological sub-
type (specifically mucinous types). 
Finding: Frailty and functional status were considered by some HCPs to be inter-
related and were factors considered important in determining treatment, 
with increased rates of functional dependence associated with a reduced 
preference for surgery. 
Finding: HCPs consider a variety of tumour factors important in the treatment 
decision-making process for older women with operable breast cancer. 
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The quantitative survey revealed that although tumour factors, such as stage and size of disease were 
important to HCPs in the clinical decision-making, with 87.4% (216/247) rating them as of at least some 
importance, they were viewed as less important than patient health and fitness measures. The presence 
of axillary disease was rated as slightly more important with 27.5% (68/247) rating it as very important. 
ER status was regarded as important or very important by most surgeons (87.1%; 216/248) but HER2 
status much less so (50.2%; 123/245). 
Tumour factors were assessed using DCE methodology with variables of tumour biology and tumour 
stage. Both tumour biology and tumour stage significantly influenced HCPs treatment preferences 
(p<0.001). HCPs were more likely to prefer surgery for larger, node positive tumours compared to 
smaller node negative tumours and also interestingly, for HER2 negative tumours compare to HER2 
positive tumours. 
 
Several HCPs (n=13) during semi-structured interviews state that patient preference was one of the 
most important factor in deciding treatment; even those who didn’t offer a choice of treatment claimed 
they would use PET if a patient refused to undergo surgery, although this should not be surprising as 
they have little alternative in a patient who refuses consent to surgery.  However, as mentioned above, 
and in contrast to this expressed opinion, many of the HCPs implied at interview that they often steer 
patients towards their own preferred treatment option.  This may reflect a lack of insight or a desire to 
be politically correct during the interview. 
Patient preference was also considered important by 94.8% (236/249) of HCPs answering the 
quantitative survey. 
 
Examining the goodness of fit of the multivariable model used to analyse the DCE scenario results, the 
variables of patient age, comorbidity level, cognitive function, tumour biology and tumour stage can be 
Finding: Patient preference was considered highly important to HCPs when 
determining treatment choices for older women with operable breast cancer. 
Objective:  To quantitatively assess the above factors on a wide group of healthcare 
professionals to determine whether they account for variation in treatment. 
Finding: The factors examined here account for some of the treatment variation seen 
in older women with operable breast cancer but not all. 
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seen to account for 31% of the treatment choice by HCPs (using the pseudo R2 value). This suggests that 
69% of the treatment decision-making is affected by factors not included in this model. It was not 
possible to include all factors, which may also have been affected by specific comorbidities, educational 
level, perceived patient preference and also the innate opinion of the HCP themselves. 
Using the retrospective registry data to account for patient age, comorbidity, tumour size, tumour 
grade, nodal status, method of presentation and deprivation quintile, there remained variability in 
surgery rates at hospital level, suggesting that factors other than those accounted for in the case mix 
analysis contribute towards the treatment variation seen.  
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8.3. Benefits of adopting a MM approach 
8.3.1. Triangulation 
As can be seen above, the results from each strand were compared and the major findings were 
corroborated by using the different methods. 
 
8.3.2. Complementary 
Using a mixed methods design has allowed the study of this complex problem from a variety of 
perspectives, with the richness of the qualitative findings enhancing those from the quantitative strands.  
 
8.3.3. Development 
The findings from the systematic review, meta-analysis and qualitative interviews informed the design 
of the quantitative survey, allowing the creation of a bespoke instrument to assess to specifically 
address the research question.  
 
8.3.4. Sampling 
Using different methodologies allowed us to take advantage of different sampling techniques. Purposive 
sampling could be used for the qualitative interviews to ensure opinions were gathered from HCPs in 
areas of high and low PET, as well as both surgeons and breast clinical nurse specialists. The 
questionnaire survey in combination with the DCE component enabled generalisation of the qualitative 
findings to a larger sample of the HCP population being studied. Finally, the registry population included 
all diagnoses of operable ER positive cancers treated over a consecutive 8 year period. As the findings 
are broadly concordant between sampling methods this suggests that they are generalizable more 
broadly. 
 
8.3.5. Offsetting 
Each method had its own strengths, and by combining methods, this helps to offset the weaknesses of 
any individual method. For example, the registry data provide information of the complete population 
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being studied, however because of limitations with accessing these data, they are a few years out of 
date. However the interviews and questionnaires studied a much smaller sample of the population but 
they provide a more current view of the issues being studied. 
 
8.3.6. Expansion and comprehensiveness 
Overall, use of this complex mixed methods design has extended both the breadth and range of 
investigation, allowing the research question to be addressed more fully.  
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Chapter 9: Discussion 
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Breast cancer is an increasingly common disease in older women and outcomes are inferior to those in 
younger women partly due to a lack of screening and awareness [101, 102], resulting in delayed 
diagnosis but also due to treatment variance from the recognised norms. One of the main areas in which 
treatment varies is the fact that a significant proportion of older women do not undergo surgery [68, 84, 
89, 90].  Rates of surgery are highly variable across the UK [73] due to a lack of evidence based 
guidelines.  This work has explored both the extent to which this variance occurs across the UK using 
registry data analysis corrected for case mix variation and has also examined some of the factors that 
influence health care professionals to make these treatment decisions using a mixed methods approach. 
The work has shown that the variability cannot be fully accounted for by patient variables and that 
variation in clinician opinion exists and likely accounts for a significant percentage of this treatment 
variability.  This variation may be to the detriment of patient outcomes and indicates that there is a 
need for more structured guidelines for treatment decision making in this population. 
9.1. Treatment variation according to age 
As previously discussed, increasing age is associated with decreasing rates of surgery in patients with 
operable breast cancer [68, 78, 84, 90]. This study supports these findings, within the systematic 
literature review (Chapter 3), in the analysis of retrospective registry data (Chapter 4) and using the 
discrete choice experiment (DCE) methodology (Chapter 7).  
Across the large population studies identified within the systematic review, women were less likely to 
receive standard treatment, including surgery, with increasing age [68, 78, 83, 84, 88-91, 374, 375, 377, 
378, 385, 388, 389, 391, 398, 399].  
Within the registry analysis, rates of surgical treatment also decreased as age increased, with the 
proportion receiving surgery declining from 91.1% at age 70 to 38.5% at age 85 and less than 3% at age 
95 and over. 
The DCE component of the study also confirmed that age of the patient statistically affected the 
treatment preference of HCPs (p<0.001), being less likely to prefer surgery as age increases. 
Non-standard treatment of breast cancer in older patients has been associated with poorer outcomes 
[78, 85, 371]. However a Cochrane review of seven randomised controlled trials comparing surgery with 
PET found no difference in overall survival [214, 215, 402] but did identify better local control in the 
surgery group. In this study, a review of the published non-randomised studies comparing surgery and 
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PET has suggested a difference in overall and breast cancer-specific survival in favour of surgery, 
however these results need to be interpreted with caution due to the evident selection-bias within the 
studies. They do however provide real-life evidence of the results of current clinical practice. 
9.2. Regional variation in treatment of older breast cancer patients 
There is considerable variation across the UK in the way older patients with operable breast cancer are 
treated, with regional rates of non-surgical treatment in this population varying between 12 and 40% 
[73]. This variation has also been reported by the Royal College of Surgeons and Age UK in their report 
“Access all ages 2” where they found a 37-fold difference between the highest (37 per 10 000) and 
lowest (1 per 10 000) rates of surgery for breast cancer in the over 65s depending on where they live 
[416]. This study has looked at the variability in treatment of older women with breast cancer across the 
UK and found similar variation exists. 
The systematic review found that the rate of non-surgical treatment of older breast cancer patients in 
the UK varies between 14 and 50% in the published literature [68, 69, 73, 85, 89, 92, 374, 375, 378, 385, 
391-393, 398]. 
Examining the retrospective registry data, significant variation of surgery rates existed across the 
different hospitals examined and this persisted following adjustment for case mix, with 23.5% having a 
much higher rate of surgery than expected and 20.6% having a much lower rate than expected. 
The questionnaire survey also demonstrated variable use of PET amongst the membership of the UK 
Association of Breast Surgery (ABS), with 17/240 (7.1%) stating that more than 30% of women ≥70 were 
treated this way, 65/240 (27.1%) stating that 20-30% of women ≥70 were treated with PET, 67/240 
(27.9%) stating that 10-20% of women ≥70 received PET and 91/240 (37.9%) stating that PET was used 
in less than 10% of women ≥70 years. 
The variation in surgical treatment rates of cancer patients has been deemed a healthcare inequality by 
the National Cancer Equality Initiative (NCEI) [94], and the National Institute for Health and Care 
Excellence (NICE) have identified the rate of surgically treated older women with breast cancer as a 
quality indicator as part of their recently published quality standards report [505].  
When looking at variation in treatment rates, it is vital to establish whether this “under treatment” is 
actually inappropriate since there are several acceptable and important grounds why some older 
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patients may not be treated according to standard protocols. These reasons include patient fitness 
measures which may render a patient “unfit” to undergo surgical management, as well as patient 
choice, when a patient may decide they do not wish to have operative management. According to 
published national and international guidelines on the management of older women with breast cancer, 
these factors, together with a short (2-3 years) predicted life-expectancy, are considered appropriate 
justifications to treat a patient with PET [9, 127]. 
As such, when examining the treatment variation in the eight years of retrospective registry data at 
hospital and clinician levels, a case mix adjustment was performed to account for variations in factors 
which might explain the treatment allocation, including patient age, deprivation quintile, level of 
comorbidity, method of diagnosis, cancer size, nodal status, tumour grade. However, as can be seen in 
Chapter 4, not all the treatment variation can be explained by case mix, particularly at hospital level 
where a significant proportion of units (44.1%) had surgery rates far outside the expected ranges. 
In addition, the low pseudo R2 value (0.31) of the HCP DCE questionnaire supports the case-mix 
adjustment findings that clinical factors available to clinicians do not account for patterns of treatment 
variation observed (Chapter 7). The clinical factors included as DCE variables (patient age, patient 
comorbidity level, patient cognition, tumour size and biology) all significantly influenced HCP treatment 
responses, however the pseudo R2 value of 0.31 indicates that these variables only account for 31% of 
responses given. This in turn implies that there are other factors that influence HCP treatment decision-
making, accounting for the remaining 69% of responses. 
9.3. HCPs take a variety of factors into account when determining 
treatment 
9.3.1. Fitness for surgery 
One explanation for the persistent treatment variation seen in Chapters 4 and 7 may be that there are 
other factors which HCPs consider important when determining treatment options for older, operable 
breast cancer patients, such as fitness for surgery. There was no consistent definition of what HCPs 
considered as “fit” for surgery within the qualitative interviews and HCPs varied in what factors they 
considered when making this decision. This again is likely to be a source of some of the variation in 
treatment seen within the older breast cancer population. 
 257 
 
Specific factors considered important by HCPs in both qualitative interviews and the quantitative survey 
questionnaire included age, life expectancy, comorbidities, cognitive function, frailty, functional status, 
tumour factors and patient preference. These are each discussed below.  
 
9.3.2. Age and life expectancy 
Although most HCPs interviewed in chapter 5 claimed that they did not consider age when deciding 
treatment for older women with operable breast cancer, some still mentioned age-related cut-offs for 
discussing non-standard treatment and there was the implication of subconscious age-related biases by 
some. Again, age was considered as one of the least important factors considered by HCPs when making 
decisions about surgery vs PET within the questionnaire survey, with only 4.9% (12/245) rating it as very 
important and 24.1% (59/245) rating it is as important. 
However, using DCE methodology, age was seen to be statistically associated with treatment preference 
on univariate (p<0.05) and multivariate (p<0.001) analysis, with HCPs being less likely to prefer surgery 
as age increases. This was also seen in the retrospective registry analysis, with rates of surgical 
treatment decreasing with increasing age. 
As age increases so rates of comorbidities rise, in turn potentially reducing the survival advantage of 
more aggressive breast cancer therapies [106]. Short life-expectancy, also stated to be a reasonable 
justification for treating patients with PET [127], is also inextricably linked to age [334] and as a recent 
UK questionnaire study found that surgeons are poor at gauging life-expectancy of older patients [128], 
age may be commonly used as a surrogate marker for predicted life-expectancy.  
 
9.3.3. Comorbidities, including dementia 
Within the interviews, fitness for surgery was equated with comorbidity status for around half the HCPs 
interviewed, although variability remained over specifically which comorbidities were important. The 
questionnaire data confirmed the importance that HCPs place on comorbidities when deciding 
treatment options for older women with operable breast cancer, with all HCPs rating it as having at least 
some importance. 
The effect of comorbidity on treatment preference was also seen within the DCE analysis, with HCPs less 
likely to prefer surgery and more likely to prefer PET as comorbidity increases (p<0.05). A similar effect 
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could also be seen in the retrospective registry data where increasing levels of comorbidity were again 
associated with decreasing rates of surgical treatment. 
Comorbidities are often stated as a reason for treating patients with PET [128, 362]. Increasing 
comorbidity burden impacts on life expectancy and in turn, may reduce the survival advantage of more 
aggressive breast cancer therapies such as surgery [106].  
Dementia in particular has been suggested to influence treatment allocation of older breast cancer and 
studies examining the use of PET in small cohorts of older patients have suggested that the presence of 
dementia may have been a contributing factor in treatment decision-making in some patients [74, 224, 
228, 339, 368].  
Analysis of the registry data showed that patients with a diagnosis of dementia were significantly less 
likely to receive surgery compared to those without (12.7% vs 58.8%; p<0.001) and in the DCE analysis, 
increasing cognitive impairment was seen to be significantly associated with with a reduction in 
preference for surgery and an increase in preference for PET (p<0.05). 
Interestingly, during qualitative interviews, HCPs were divided in their opinion regarding the best way to 
treat older patients with breast cancer and a diagnosis of dementia, with approximately half believing 
they should be surgically treated and the remainder expressing that they felt these patients should be 
treated with PET. This division of opinion was mirrored in the questionnaire survey, however what was 
clear is that nearly all HCPs consider the presence of dementia as important in making treatment 
decisions in older breast cancer patients. 
Cognitive impairment is an important comorbidity in this population, and to some degree affects up to 
10% of people over the age of 65, being is more prevalent in women, where the rate increases to 20% 
for women aged between 85-89 years of age [454].  
There are several reasons why HCPs may be less inclined to operate on patients with dementia. 
Moderate to severe cognitive impairment may preclude surgery under local anaesthesia, and cognitive 
and functional ability may worsen following general anaesthesia [152]. Previous studies have also shown 
that patients with dementia may present with later stage disease [449], partly owing to poor symptom 
recognition and impaired communication among these patients [450, 451]. They also unlikely to 
volunteer for screening which is associated with better disease stage [452] and so may require more 
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extensive surgical options. In addition, dementia is associated with a significantly reduced life-
expectancy [506] which is one of the acceptable reasons for treating a patient with PET [127]. 
 
9.3.4. Frailty and functional status 
Frailty can be defined as “the condition of being weak and delicate” or “a distinctive health state related 
to the ageing process in which multiple body systems gradually lose their built in reserves” [507] and 
contributors include diminished organ function, comorbidities, impaired physical function and geriatric 
syndromes. This makes it difficult to quantify. Frailty was mentioned by around half of HCPs during 
qualitative interviews, however it was again difficult to define exactly what people meant by this term 
and for some it seemed to equate to their functional ability. 
There are a range of tests available for identifying frailty, many of which assess a person’s ability to 
function normally, but the accuracy of these is uncertain [507]. Functional status however is much easier 
to measure and was considered important by 87% of HCPs in the questionnaire survey. Additionally, 
within the DCE section of the questionnaire, functional status showed the greatest association with 
treatment preference on univariate analysis (p<0.05), with HCPs being less likely to prefer surgical 
treatment for patients with higher rates of functional dependence. Unfortunately it could not be 
included in the multivariable analysis as the model was unable to distinguish between the effect due to 
functional status and that due to comorbidity and cognition.  
A reduction in functional status is associated with a reduced life expectancy [508, 509], again  one of the 
acceptable reasons for treating a patient with PET [127]. Both factors may impact on a patient’s fitness 
to undergo surgery and general anaesthesia, explaining why they were considered important by HCPs in 
determining treatment options for older breast cancer patients. 
 
9.3.5. Tumour factors 
Tumour factors considered important by HCPs in determining treatment options for older breast cancer 
patients included tumour size, nodal status and hormone receptor status. Within the registry analysis, 
larger node positive tumours were less likely and higher grade tumours more likely to be treated with 
surgery.  
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The quantitative survey revealed that although stage and size of disease were important to HCPs in the 
clinical decision-making, they were viewed as less important than patient health and fitness measures. 
The presence of axillary disease was rated as slightly more important and ER status was regarded as 
important or very important by most surgeons but HER2 status much less so. 
Tumour factors were assessed using DCE methodology with variables of tumour biology and tumour 
stage. Both tumour biology and tumour stage significantly influenced HCPs treatment preferences 
(p<0.001). HCPs were more likely to prefer surgery for larger, node positive tumours compared to 
smaller node negative tumours and also interestingly, for HER2 negative tumours compare to HER2 
positive tumours. 
Tumour size and nodal status may impact the type of surgery required, larger tumours are more likely to 
require mastectomy rather than breast conservation surgery and node positive disease requires surgery 
to clear the axilla, both of which may be considered more extensive procedures. Additionally, 
performing axillary clearance under local anaesthesia is not technically possible and would be precluded 
in women who were too frail to undergo GA. Mastectomy under general anaesthetic can be done but it 
is not easy or pleasant.  
The degree of ER positivity impacts on whether the tumour will respond to endocrine therapy and PET is 
only considered an appropriate treatment for ER positive patients. In addition, HER2 positive cancers are 
known to be generally less likely to respond to endocrine therapy [489]. Higher tumour grade was also 
associated with increasing rates of surgery, possibly representing the assumption that more aggressive 
disease should be treated with more aggressive treatment. 
9.4. HCPs vary in their opinion of which factors are important when 
determining treatment 
Whilst current guidelines suggest PET is a suitable treatment option for patients who are “considered 
unfit for surgery” [127] or where “significant comorbidity that precludes surgery” [9], they do not 
specify what constitutes being “unfit” nor which comorbidities may “preclude” surgery [9, 127]. As such 
it is left to the treating clinician to determine treatment, potentially resulting in the wide variation in 
practice observed.  
During qualitative semi-structured interviews, HCPs unanimously agreed that “fitness for surgery” was 
an important consideration in treatment decision-making for older patients. However there was 
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considerable variation among clinicians regarding key features that constituted being fit for surgery. This 
was specifically the case in older women with breast cancer and dementia. There are currently no 
guidelines pertaining to the treatment of cancer patients with dementia and this variation in opinion 
may reflect this. Another source of variability was the assessment process by which HCPs determined 
the fitness of their patients. This is unsurprising as the older population make up a very heterogeneous 
group and as SIOG points out, that although CGA may be useful, it is not clear which patients will benefit 
nor which method is best [127]. 
The data from the DCE suggest that there is considerable variance in the level of fitness that HCP 
consider significant in making these decisions and this implies that standardised guidelines would be 
helpful. Whilst the majority of HCPs had fairly similar treatment choices for most patients and selected 
treatment in accordance with the patients’ predicted life expectancy for most scenarios, as per current 
guidelines [127], there were some scenarios where opinion was divided, for example scenarios 3, 4 and 
7 (see table 9.1). This demonstrates there may be personal preferences at play of a lack of 
understanding of the potential impact of the precise frailty and life expectancy impact of a particular set 
of personal patient attributes. Additionally, a recent study has shown that surgeons are poor at gauging 
life-expectancy of older patients, with a tendency to under-estimate it [128].  
  Age Co-
morbidity 
Cognition Function Cancer 
size 
Cancer 
biology 
Predicted 
life 
expectancy 
Prefer 
PET 
Prefer 
surgery 
Prefer 
both 
equally 
3 70-74 Severe Normal Moderate 
dependence 
Large, 
node 
negative 
ER+, 
HER2+ 
<2 years 64 
(25.3%) 
111 
(43.9%) 
78 
(30.8%) 
4 80-84 None Moderate 
impairment 
Severe 
dependence 
Small, 
node 
negative 
ER+, 
HER2+ 
<2 years 63 
(25.1%) 
108 
(43.0%) 
80 
(31.9%) 
7 75-79 Moderate Normal Severe 
dependence 
Large, 
node 
positive 
ER++, 
HER2- 
2-5 years 55 
(22.0%) 
100 
(40.0%) 
95 
(38.0%) 
Table 9.1: DCE scenarios showing a division in HCP opinion on the best way to treat older women with 
operable breast cancer. 
9.5. HCPs vary in their opinion of whether patients should be offered 
treatment choice 
In this study, HCPs varied in their opinions of whether older patients with operable breast cancer should 
be offered a choice of treatment, in particular surgery or PET. This was particularly evident within the 
qualitative interviews where the range of responses can be mapped more easily. There was also a 
suggestion that HCPs from high PET units tended to feel that offering a choice to some patients was 
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appropriate compared to a few HCPs from low PET units who considered it an inferior option and so did 
not consider PET a suitable treatment option to offer as a choice. Amongst the wider group of HCPs 
surveyed using the questionnaire around a quarter agreed that PET may be offered to any older woman 
with ER positive disease as there is no proven survival advantage. In addition patient preference was 
stated as one of the most important factors that HCPs take into account when deciding which treatment 
options to offer older patients with operable breast cancer. 
Shared DM is increasingly considered to be relevant in preference sensitive health care decisions such as 
this, with patients and HCPs working together to make health care decisions that are based on clinical 
evidence and patients’ informed preferences [268, 277, 456]. Shared Decision-Making (SDM) suggests 
that patients should be informed of their treatment options [277] and for some older women  it may be 
appropriate to offer PET as an alternative to ‘standard’ surgical treatment and allow the patient to 
decide what is best for them. However this study found a considerable proportion of HCPs did not offer 
a choice of treatment options to their older breast cancer patients, despite the fact that evidence 
suggests that older patients may prioritise quality of life over quantity [415] and that patient choice is 
commonly stated as a reason for treating patients with PET [128, 369].  
Hamaker and colleagues [373] suggested that variation in treatment may reflect underlying clinician 
preference influencing communication of treatment options. This seems a plausible explanation, 
especially in view of Schonberg and colleague’s findings that the most influential factor affecting older 
women’s breast cancer treatment decisions was the surgeon’s recommendation [88]. Indeed, this study 
demonstrates multiple areas of variation in HCP opinion supporting this.  
It is also important to recognise that not all older patients engage in SDM, with many preferring a more 
passive role [88, 278-280], and that encouraging a patient to take an active role in decision-making 
when they prefer a more passive role may increase anxiety and cause distress [295, 296], but may also 
reinforce the variation due to clinician preferences.    
9.6. Impact of clinician preference on decision-making and treatment 
patterns 
Treatment decision-making for older patients with operable breast cancer can be considered a complex 
process with many interacting components. These components can be divided into several categories: 
 Patient clinical factors (such as comorbidity, age, cognition, functional status) 
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 Tumour factors (such as tumour size, nodal status, hormone receptor status) 
 Patient intrinsic factors (also considered to be patient preference and previous experiences) 
 Clinician factors (HCPs beliefs and opinions regarding the treatment of this population). 
The first two, patient clinical factors and tumour factors, we can try and account for using case-mix 
adjustment as discussed above, but this does not appear to account for even half of the variation in 
treatment allocation of older breast cancer patients, as can be seen by the low pseudo R2 value of 0.31 
within the DCE analysis, suggesting these factors account for only 31% of the treatment choice by HCPs. 
This is supported by the registry data, where there remained variability in surgery rates at hospital level 
despite adjusting for case mix. 
Patient preference is difficult to assess, although a recent study has determined that lower rates of 
surgical treatment amongst older breast cancer patient are unlikely to be due to patient choice [375]. 
However patient preference and clinician factors are intricately linked. For instance, a patient presented 
with two treatment options may express a preference for one over the other; however a patient 
presented with only one treatment option may be unaware of the alternatives and therefore unable to 
express a preference. This differs from patient refusal to undergo surgery, which some HCPs in this 
study stated was the only circumstances under which PET was offered as a treatment alternative.  
Additionally, as discussed above, patients rely heavily on the advice of their doctor which has been 
found to be the most influential factor affecting older women’s breast cancer treatment decisions [88]. 
Therefore it is not just the options presented to a patient that may impact upon their choice, but the 
way in which the information surrounding treatment options are presented. 
This study demonstrates that variations in clinician opinions are almost certainly contributing to the 
variation observed in the treatment of older women with operable breast cancer. 
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9.7. Limitations of the study 
This study has a clear theoretical and methodology base but this approach is not without its challenges. 
The pragmatic grounding for the project has allowed the use of multiple methodologies best suited to 
answering the research question, the strengths and weaknesses of each of these methods have been 
discussed within the individual chapters. Limitations of the overall study are discussed here in broad 
terms. 
 
9.7.1. Replication of findings 
Every attempt has been made to demonstrate each phase in development of the project to allow other 
researchers to replicate the findings should they wish. Whilst we have not used validated instruments 
within some strands, in particular the questionnaire, the content was determine from multiple sources, 
including the prior qualitative interviews, literature review and feedback from experts within the field. In 
addition, this instrument was developed using recognised Likert style questions and assessed for 
psychometric rigour.  
 
9.7.2. Population sampling 
The use of different methodologies has allowed a variety of sampling methods within the study 
population. Although each sampling method has its weaknesses, these are offset by using multiple 
methods, each with their own benefits: 
 Registry analysis: Cancer registry data allows analysis of large cohorts of women treated in 
everyday, normal clinical practice.  Whilst data were only obtained from two of the UK’s 11 
cancer registration regions, all 23 960 new diagnoses of breast cancer in women over 70 years 
were analysed from an eight year period. However, it should be noted that these two regions 
have higher PET rates than other regions [73] which may potentially limit the generalisability of 
these results. Despite this, the population analysed represents a quarter of all breast cancer 
cases in the UK and the areas covered by these registries are demographically representative of 
the UK as a whole, making it reasonable to cautiously extrapolate these findings to the UK 
population generally.  
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 Qualitative interviews: Whilst the qualitative interview strand sampled only a small number of 
the target population, this provided a rich data source, enabling documentation of unique first-
hand perspectives of HCPs that would be difficult to gather by any other method. In addition, 
purposive sampling of both surgeons and CNS’s from units with high and low PET rates from 
right across the UK aimed to provide the broadest range of opinions. Findings from the 
interviews were then used to construct the questionnaire in order to better generalise the 
findings.  
 Questionnaire survey and DCE: This strand was applied to all surgeon and nurse members of 
the Association of Breast Surgery, however the overall generalisability of the results is limited by 
the questionnaire response rate. HCPs, in particular doctors, are considered a problematic 
population from which to collect survey data [510] and response rates to questionnaire studies 
been shown to have fallen further in recent years due to increasing demands on HCPs to 
participate in research [511, 512] and the response rate of 40% is similar to other similar studies 
[128, 474].  
 
9.7.3. Selection bias 
Selection bias may be relevant within the study, particularly within the interview component where the 
participants were contacted via personal communication by the lead researcher (JM), however this was 
minimised by purposively selecting from units across the country and including individuals that were 
both known and not known to the researcher prior to the study.  
In addition, research participants are a self-selected group and may potentially have different 
characteristics to those who did not take part [513]. Many of the behaviours and attitudes of interest to 
survey researchers correlate strongly with willingness to participate in research [514]. For instance, 
research participants are more likely to have an interest or be active in the area being studied [515-518] 
and may therefore have different practices from the rest of the non-sampled population. 
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9.7.4. Complexity of the problem 
Decision-making in health care is a complex issue with many inter-related factors that need to be 
considered, and not all of them can be accurately measured or assessed. In this study, these factors 
have broadly been classified as:  
 Patient clinical factors (such as comorbidity, age, cognition, functional status) 
 Tumour factors (such as tumour size, nodal status, hormone receptor status) 
 Patient intrinsic factors (also considered to be patient preference and previous experiences) 
 Clinician factors (HCPs beliefs and opinions regarding the treatment of this population). 
Although by using a variety of methods to approach the problem it can be examined more thoroughly, 
not all of these factors can be examined together. This is particularly relevant for the registry and DCE 
analysis where the results showed that factors other than those assessed in the case mix analysis are 
playing a part in treatment variation. Whilst variation in clinician preference is likely to account for some 
of this, there may be other factors involved that have not been identified or assessed, for example 
patient intrinsic factors, such as patient preference which is often cited as a reason for treating patient 
with PET [128, 369] and is one of the accepted reasons for doing so [127].  
 
9.7.5. Improving the project 
This study could have been further enriched by including a patient perspective on the decision-making 
process to better account for the patient intrinsic factors such as previous experience and preference. 
However this would have been difficult to account for within the current study components and would 
not have specifically improved the accuracy of the any of the results presented. Exploration of patient 
opinion on this subject forms another phase of work within the wider Bridging the Age Gap study which, 
together with this body of work, will bring us a step closer to understanding the complex relationship in 
the decision-making process between HCPs and older women with operable breast cancer. 
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9.8. Future work 
This study has highlighted the need for more comprehensive guidelines for the treatment of older 
women with operable breast cancer. To this end, further research is required to determine the impact 
that patient factors (such as comorbidities, dementia, functional status) have on survival outcomes in 
both surgical and PET treatment groups. Ideally this would take the form of a randomised controlled 
trial (RCT) based on modern day practice using up-to-date surgical techniques and aromatase inhibitors. 
However a recent attempt at recruiting to such an RCT (the ESTEEM trial [342]) failed as patients wanted 
to be involved in their treatment choice and so were not happy to be randomised. The Bridging the Age 
Gap (BTAG) in Breast Cancer research project is a programme of study that includes a large, multi-centre 
non-randomised cohort study, collecting good quality patient, tumour and treatment data on women 
aged over 70 with primary operable breast cancer. To date the study has recruited over 1600 patients 
and will continue to collect prospective data for the next 2 years. This will allow the examination of the 
interaction between patient and tumour factors on survival outcomes in patients treated with both PET 
and surgery to hopefully address some of these questions. The aim of the BTAG study is to develop a 
decision-aid that will help both patients and clinicians tailor treatment towards the individual patient 
based on multiple factors. 
In addition, it is important to examine the effect of patient opinion regarding both treatments 
themselves, and the provision of treatment choice in this situation. Further research is needed to 
identify whether patients would rather be offered a choice of treatments and be allowed to make their 
own decisions, even if their HCP deems one treatment may be inferior to another. It is also important to 
examine the impact of change in management and progressive disease on quality of life outcomes in 
patients treated with PET as there is little in the current literature pertaining to this. Importantly these 
studies would contain data on decision regret. 
Finally, further research is needed to examine the influence of HCP opinion on patient decision-making. 
As variability in HCP opinion regarding the treatment of this patient population may be in-turn 
influencing patient decision-making by the level of information presented. Video recording of clinician-
patient consultations at diagnosis would be the best way to monitor this interaction however would 
require substantial ethical consideration and would be difficult to determine whether the recorded 
practice was in line with true clinical practice.  
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Chapter 10: Conclusions 
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10.1. Conclusions 
There are currently no definite answers about the best way to treat of older women with operable 
primary breast cancer. It is clear that this is a heterogeneous population, and older women presenting 
with a new diagnosis of breast cancer should be treated on an individual basis. 
Surgical treatment does appear to be superior to PET in terms of local control and there is probably also 
a survival advantage favouring surgery for patients with a life expectancy more than 5 year. As such, fit 
and healthy older women should probably be treated according to standard practice, using the same 
strategies as are used in younger women, i.e. a choice of surgical treatment with the appropriate 
adjuvant therapies. 
Very frail women at the extremes of age, or those with multiple significant co-morbidities, so that their 
predicted life-expectancy is significantly reduced, may benefit from treatment with PET. If PET is to be 
used, it should be reserved for patients with strongly ER positive cancers and an AI should be used in 
preference to tamoxifen where it is not contra-indicated. Letrozole appears to be the most effective of 
these in the literature to date. All women treated with PET should have regular clinical follow-up to 
assess the response of the primary tumour. If there are signs of disease progression then second-line 
hormone therapy or surgery under local or regional anaesthetic should be considered. 
Currently, the exact guidelines regarding which patients may benefit from PET and which should have 
surgery are open to interpretation. UK healthcare professionals have a variety of opinions on which 
factors are important in determining who should be offered PET or surgery or both. The result is a wide 
variation in practice, resulting in a potential healthcare inequality. In view of the lack of definitive 
criteria, it may be appropriate to offer some patients a choice of treatments, in the process of shared 
decision-making, and allow the patient to consider the options and decided for them self. What is also 
clear, however, is that HCPs also vary as to whether they feel that patients should be offered PET as a 
treatment alternative and this is further compounding the variation of treatment across the UK.  
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Section 3. Executive (Lay) Summary 
The UK population is ageing with average life expectancy increasing from 50 years,  100 years ago to over 80 today.  
The level of fitness of older people is also increasing with many still healthy and fully independent in their 70s and 
80s.  Health technologies are also rapidly advancing with improvements in the survivability of health interventions 
such as surgery making them safe even for many people who would have been considered too frail 20 years ago. 
Despite this, there is still a perception that once a person crosses the age threshold of 65 or 70 years they are 
classed as ‘elderly’ and often subjected to age bias in their medical care.  These decisions are often non evidence 
based as little research has been done on older people to define optimal practice.  In addition, research done in 
the fairly recent past may no longer be valid today due to the rapid changes in technology and the rapidly 
improving health status and life expectancy of our population. 
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In the field of breast cancer, age related practice variance is widespread.  The gold standard of care for early breast 
cancer is surgical removal of the primary cancer, sentinel node biopsy of the axillary and adjuvant therapies which 
may include chemotherapy, trastuzumab, anti-oestrogens and radiotherapy.  There is consistent evidence that 
older women are often denied surgery, chemotherapy, radiotherapy and trastuzumab based on the premise that 
there is no evidence of efficacy.  It is known that cancer specific outcomes in older women with breast cancer are 
significantly worse that those in younger women and can no longer be simply attributed to competing causes of 
death. 
In the case of surgery, up to 40% of older women do not get surgery for their breast cancer, with treatment being 
with anti-oestrogen tablets alone, known as primary endocrine therapy (PET).  This type of treatment was shown 
to be effective in several trials in the 1980s, with the trials showing no survival disadvantage although rates of local 
control were sub-optimal.  Life expectancy has moved on by almost 10 years since then and fitness levels have 
improved and surgcial and anaesthetic techniques are much safer and yet many clinicians continue to use non 
surgical strategies in a significant proportion of women over 70.   
Undoubtedly there are some older women for whom surgery is associated with significant risks and many older 
women have a preference for minimalist treatment for a variety of reasons.  It is therefore appropriate to use anti-
oestrogens in this way in some older women.  The problem we have is that there is no guidance on the 
characteristics of older women which suggest they will do better with surgery or PET.   
In a similar vein, chemotherapy is part of the gold standard of care for many women with aggressive, oestrogen 
receptor (ER) negative, breast cancer.  However the rate of chemotherapy usage in older women is very low, with 
a lack of research evidence to support its use and concerns about its safety in older women.  Older women with 
these more aggressive cancers are often denied this treatment.  Clearly there will be some women for whom 
chemotherapy will be inappropriate and others for whom benefit may be gained. 
The Age Gap study will use state of the art statistical and modelling techniques to determine the age, comorbidity, 
frailty and disease characteristics of women over 70 with early breast cancer to provide guidance on 2 primary 
questions: 
1. What are the personal and cancer characteristics of women who can be safely advised that surgery is 
unlikely to confer any advantage for them? 
2. What are the personal and cancer characteristics of women who should be advised to have adjuvant 
chemotherapy after surgery? 
A preliminary disease and outcome statistical model will be derived using pre-existing data from the UK primary 
breast cancer registry held by the West Midlands Cancer Intelligence Unit (WMCIU).  These data have certain 
recognised areas of weakness, in particular relating to the completeness of and quality of comorbidity data (limited 
to the rather crude Hospital Episode Statistics (HES) data) and contain no data on frailty and independence 
measures which are an important determinant of life expectancy in older people.  In addition, staging data may be 
less accurate in women treated non surgically as there will be no post-operative pathology data returns.  To 
overcome these limitations a UK wide data collection exercise to gather detailed data on older women, their 
primary disease, health status and treatment details and medium term outcomes will be performed.  These new 
data will be used to revise and validate the preliminary statistical model.  The statistical models will also be used to 
develop a health economic model to estimate long-term health outcomes and costs for different intervention 
strategies. 
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The final stage of the project will be to use the model to develop a web-based algorithm to support clinicians in 
decision making related to older women with breast cancer which will be responsive to their personal and cancer 
characteristics. 
Section 4. Study Algorithm 
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Section 5.  Background to the study 
5.1 An ageing population 
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The developed countries of the world are currently facing a growing crisis caused by their ageing populations.  Life 
expectancy has increased by 30 years over the course of the 20
th
 century, from 50 at the turn of the century, to 80 
by the end of it and predictions are that children born today may have an average life expectancy of 100
1
.  Whilst 
much of the early gains in this trend were due to improvements in infant and child mortality rates, the age group 
where the gains are now being made are in the elderly, which represent the most rapidly increasing  population 
group  in developed nations
2
.  The quality of this increased life expectancy is also improving
1 3
 in part because of 
improved disease prevention, but also because many chronic diseases are now better controlled and diagnosed: 
the elderly therefore live longer even in the presence of chronic health problems.   
This changing population age distribution means that determining best practice using trial data that are more than 
20 years old may be inappropriate.  The heterogeneity of the health status of this group is significant, with some 
75 year olds running marathons, whilst some are too frail to live independently.  It is therefore vitally important 
that our age limits for standard practice remain fluid and responsive to the changing demography of our 
population.  This can only occur if chronological age and health status are decoupled and we continually research 
at the new boundaries of practice.  
5.2 Breast cancer in the elderly 
Breast cancer is the most common cancer to affect women with 44 000 diagnosed each year (UK Office for 
National Statistics) and some 12 000 die of the disease
4
.  One third of all breast cancers occur in women over the 
age of 70, some 13 000 women in the UK.  Breast cancer in older women tends to have a slightly different disease 
biology than in younger women, with higher rates of oestrogen sensitivity
5-6
, lower rates of Her-2 receptor 
expression
5
  and a slower growth rate
5
.  Balanced against these positive features, older patients more frequently 
present with more advanced disease
7
: the size of the primary tumour is larger
8
 
5
 
7
 with increased  rates of locally 
advanced
9
 and metastatic disease
10
 
11
.   This may relate to the discontinuation of routine breast screening, reduced 
breast cancer awareness in older women
12-13
, and lower rates of regular self examination
14
. 
The clinical significance of breast cancer is proportionately less in older women as breast cancer specific mortality 
is overtaken by other cause mortality once a woman is in her early 80s.  So whereas breast cancer causes 73% of 
deaths in breast cancer patients in their early 50s, it is responsible for only 23% of deaths in women in their mid 
80s
5
.   This is not due to the innate features of the cancer itself, but to the rapidly rising mortality rates from other 
causes.  Age, co-morbidity and most importantly frailty interact with the features of the breast cancer in a way 
which significantly affects disease outcome and treatment related problems.  It is difficult to disentangle this 
interaction but there is convincing evidence that women over the age of 80 have a higher risk of dying of their 
breast cancer than women in their 70s, which may be due to sub-optimal treatment
7
. Clinician awareness of these 
interactions would enable treatment to be optimised to prevent over- or under-treatment.   
Currently there are several tools to assess co-morbidity: some more complex than others.  The Comprehensive 
Geriatric Assessment (CGA
15
 
16
 
17
) is detailed but is time consuming and requires specialist training to administer. 
Simpler tools have also been evaluated such as the Activities of Daily Living Score (ADL),  Instrumental Activities of 
Daily Living Score, (IADL) or the Charlson Index, which may have predictive value in terms of morbidity and 
mortality in the older cancer patient population
15
 
18
 
19
.  There is an urgent requirement for high quality studies 
which link simple, well validated co-morbidity assessments with disease biology, life expectancy and treatment 
type in this age group.  Recently, web-based co-morbidity tools have started to appear but most are not geared to 
the complex interactions of age and multiple co-morbidities which affect the older patient, (Adjuvant On-Line
20
  or 
the Prognostigram
21
).    
5.3 Surgical treatment of breast cancer in the elderly 
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As has previously been stated, for some older women, the diagnosis of breast cancer poses little or no threat to life 
due to other, co-existent, disease processes.  These same disease processes may also increase the morbidity and 
mortality associated with some of the treatments for breast cancer, altering the risk to benefit equation away from 
the therapy. The need for surgery for some older women is questionable as disease control may be achieved 
simply by use of anti-oestrogen drugs such as tamoxifen, (primary endocrine therapy, PET).  Up to 90% of breast 
cancers in older women are oestrogen sensitive
5
,
6
 and therefore respond very well to anti-oestrogens.   This has 
the advantage that the woman may avoid the need for anaesthesia with its risks of cardio-respiratory 
complications and the avoidance of the physical and psychological morbidity of surgery.   
A Cochrane review of the randomised controlled trials (RCTs) evaluating the role of surgery versus endocrine 
therapy alone in older women with operable breast cancer has been undertaken
22
.  Although the reviewed trials 
were flawed by modern standards, meta-analysis demonstrated no survival difference between the 2 treatment 
groups.   Only one study demonstrated any survival benefit and this was only seen at long-term (12 year) follow 
up
23
.  There was however a clear benefit in terms of local disease control for those women who had surgery. An 
update of one of the earliest of these trials which compared surgery alone with Tamoxifen alone, showed no 
survival advantage to surgery after 28 years of follow up when all trial participants had died.  This trial is flawed by 
modern standards however because no adjuvant Tamoxifen was given to the women in the surgical arm which 
would have given a potential survival advantage to the surgical arm patients and no Oestrogen  Receptor (ER) 
testing was done on tumour tissue which is obligatory today
24
.  
Studies by our research group have demonstrated a high degree of satisfaction with treatment in older women 
treated by both surgery and PET
25
.  Factors cited in favour of PET are avoidance of hospitalisation and surgery, a 
desire to retain independence, fear of anaesthesia and a desire for minimal disruption to life
25
.   
Since these randomised trials were performed the practice of PET has moved on: all women are now tested to 
ensure they have oestrogen sensitive tumours and we now have a new range of anti-oestrogen drugs, the 
aromatase inhibitors, which are more potent than tamoxifen in all treatment settings
26
 
27
  
28
 
29
.  PET may therefore 
be more efficacious if potential candidates are selected appropriately. 
There has been a wide variation in practice in the UK where some regions have up to 40% non-operative treatment 
rates for older women with breast cancer compared to other areas where the rate is only 10%
30
.   Clearly some 
women in the low surgery rate regions will be inappropriately denied surgery and run into problems later requiring 
a change of management.  In contrast, in the high surgery rate regions many women may have been subject to the 
morbidity or even mortality of surgery for no benefit.   
The ESTEEM trial set out to provide clear guidance regarding selection criteria for either surgery or PET, but closed 
early due to patients expressing a treatment preference rather than accepting randomisation
31
. It is unlikely 
therefore that the data we need to provide guidance on selection criteria for PET versus surgery will ever be 
acquired via an RCT.    The present study will therefore gather data via cancer registries and a cohort study of UK 
older women treated with either surgery or PET, adjust for selection bias between groups and use statistical and 
modelling techniques to determine the variables which predict an optimal outcome from PET or surgery. 
5.5 Choice of a Cohort Study Design 
The pre-eminence of the RCT in the hierarchy of research evidence was called into question recently by Professor 
Sir Michael Rawlins, Chairman of NICE
36
.  He suggested that there should be acceptance of data from more diverse 
evidence sources, including observational and cohort studies to reflect the fact that the RCT may be inappropriate 
to answer all types of research questions. 
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There are precedents for such studies and the high quality data they can generate:  The Adjuvant on Line system
37
 
20
 and the Nottingham Prognostic Index
38
 were not based on RCT data but cohort data from large data sets.   This 
study will obtain high quality, contemporary, population specific data from National Cancer Registry sources to 
develop a preliminary disease model, and then test and validate this model using data from a UK wide, 
prospectively collected, cohort study.  The cohort study will also allow us to collect Quality of Life (QoL) data and 
more detailed health economic data to validate the model.  The current management of these patients across the 
UK creates very large subgroups or cohorts which can be compared (PET versus surgery, chemotherapy versus no 
chemotherapy).  Comorbidity indices can be calculated from HES data which is available via the cancer registries 
and also supplemented by more detailed data from the cohort study.  Unlike an RCT where follow-up for 5 or even 
10 years is needed to determine outcomes in a disease like breast cancer where events may occur over many 
years, this technique of meshing together recent retrospective data with data from relatively short term follow-up 
from a cohort study will allow us to predict outcomes, make data available more quickly and keep costs to a 
minimum.  This approach has recently been used comparing the Adjuvant-on-line outcome prediction tool with a 
large Dutch Cohort study and a high level of correlation was found
39
.  Therefore by use of an accurate model based 
on UK population based outcome data we can use surrogate end points to predict longer term outcomes from our 
cohort study data.  In effect, the study plans to conduct a ‘virtual RCT’. 
 
Section 6. Aims and Objectives 
6.1 Primary Endocrine Therapy 
 
1. To determine the patient and cancer characteristics which predict whether Primary Endocrine Therapy 
(PET) is a safe and effective breast cancer treatment in older women with ER+ breast cancer by means of 
statistical modelling based on both retrospective registry data and prospective cohort study data.   
 
2. To develop a simple scoring system, based on co-morbidity, dependency, age and tumour characteristics, 
which will enable prediction of those women best treated with PET or surgery. 
 
3. To develop a web-based algorithm based on the developed model to aid clinician  decision making. 
6.3 Secondary Objectives 
1. To determine post-operative surgical outcomes in older women undergoing surgery for breast cancer and 
correlate outcomes with age and co-morbidity. 
2. To determine chemotherapy adverse events in older women undergoing adjuvant chemotherapy for breast 
cancer and correlate these with patient age, comorbidity and frailty. 
3. To determine QoL outcomes in older women undergoing surgery, chemotherapy or PET for breast cancer 
and correlate outcomes with age, comorbidity and frailty. 
4. To determine the factors underlying treatment decision making in health care professionals relating to 
older women with breast cancer. 
6.4 Further Objectives 
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1. Data from this study will be made available to collaborators developing a patient Decision Support 
Instrument (DSI) to facilitate patient decision making by enabling detailed, patient specific outcomes to be 
predicted.  (This will be part of a separate ethics application). 
 
2. The study will request ethics approval for long-term access to the cancer registry data and outcomes of all 
women enrolled in the cohort study to permit further longer term analysis of outcomes and add value to 
the project. 
6.5 Translational studies 
Patients enrolled in the cohort study will also be asked to provide permission for future access to archived tumour 
samples by study researchers.  It is intended that once medium and long-term disease outcomes and treatment 
responses are collected for this cohort of patients, the project team will apply for further funding to permit 
analysis of more detailed tumour biological markers to determine how these correlate with outcomes. 
 
Section 7.  Registry Data Collection 
7.1. The West Midlands Cancer Intelligence Unit  
The West Midlands Cancer Intelligence Unit (WMCIU) is the National Cancer Intelligence Network (NCIN) lead 
registry for breast cancer.  It provides data on 4,000 cases per year for the West Midlands region (population 5.3 
million) and undertakes annual collation of all UK registry data on breast cancer through the NHS Breast Screening 
Programme and the Breast Cancer Clinical Outcomes Measures Project (BCCOM Audit).  The WMCIU data quality is 
excellent. Data back to the 1980's includes date of birth, ethnic origin, cancer stage (NPI), grade of tumour, 
laterality, ER status (from 2002), Her2 status (from 2004) method of diagnosis, treatment type (surgery, 
radiotherapy, chemotherapy, hormone therapy, other), date of diagnosis, recurrence rates and mortality including 
date and cause of death.  
In addition the registry collects linked Hospital Episode Statistics (HES) Data (NHS information about inpatient and 
outpatient activity) for each patient with cancer.  HES data can act as a surrogate indicator of co-morbidity levels
40
, 
permitting derivation of a proxy Charlson Index
19
 based on the International Classification of Diseases (ICD) codes 
for each individual’s admissions to hospital.  In the first stage of model development HES data will be used as a 
proxy for co-morbidity.  The quality of the HES data will also later be compared with actual comorbidity data 
dervied from the cohort study (see section 9).  
7.2. Data items 
The WMCIU database will be interrogated for the following data items between 2004 and 2011 on all UK women 
with breast cancer diagnosed after 70 years of age: 
Cancer Characteristics 
 
Patient Characteristics Treatment 
Primary Size (mm) Age at diagnosis Surgery type 
Nodal status Means of diagnosis  Timing of surgery 
Number of positive nodes In Patient HES Proxy Charlson 
Index 
Primary endocrine therapy 
Metastatic disease Other HES co-morbidities Chemotherapy 
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Grade (1,2 or 3) Survival (overall) Radiotherapy 
ER status Cause of Death Trastuzumab 
Her-status Disease free survival Death or 30 day readmission due 
to treatment 
Derived NPI Recurrence/progression Treatment for recurrence 
UICC stage Out-patient HES data  
A more comprehensive list is provided in Appendix 6. 
It is expected that data for patients whose cancers were detected through screening will have more complete 
data, as will cases whose data has been checked as part of the BCCOM audit.  In particular, the data from the 
recent recurrence and metastatic disease audit will be closely examined to estimate missing or inaccurate data in 
previous time periods. 
Data will be checked for completeness and compared with published data series to validate them.   
In addition, data will also be collected, from women with breast cancer in the 50-70 age range.  This will serve as a 
comparator for chemotherapy useage rates in the non-elderly population, the complications, indications and types 
used. 
The data will then be used to develop a model of breast cancer outcomes according to patient, disease and 
treatment characteristics in older women. 
7.3. The Cognitive Function and Ageing Dataset (CFAS) 
The model will incorporate the MRC Cognitive Function and Ageing (CFAS) Dataset
41
.  The CFAS study investigated 
long-term cognitive decline, co-morbidity and mortality in a sample of over 18 000 people in the UK aged over 65 
years. The project has approved access to this dataset.  This dataset recorded co-morbidity using a number of 
different measures and this will enable the model to estimate how these co-morbidity measures affect life 
expectancy. As well as demographics, the dataset has longitudinal information on cognitive and functional ability.  
The comorbidities collected in the CFAS data-set include assessment of the extent of suffering from angina, 
peripheral vascular disease (intermittent claudication), the extended mental state exam (EMSE), the Cambridge 
Cognitive Examination, Activities of Daily Living (ADL)
42
, Instrumental Activities of Daily Living (IADL) scores
43
, the 
Modified Townsend Disability Scale, the Blessed Dementia Scale, the Hachsinki Ischaemic Score, and a Mini-Mental 
State Examination (MMSE)
44
, as well as social class/employment, the Townsend Deprivation Index and other 
demographic data. Together these data provide information on clinical, cognitive and functional health status.  
Recent work by the CFAS collaboration has included modelling of life expectancy with and without specific diseases 
45
 and modelling trends in long-term population size and structure 
46
. 
Merging the retrospective data from WMCIU and CFAS and our planned prospective cohort study, we will have 
access to a comprehensive dataset which will be used to predict survival and other cancer outcomes in older 
women. 
Section 8. Statistical Model Development 
8.1 Model design 
We will fit various risk models to the time to breast cancer recurrence, breast cancer and non-breast cancer death, 
employing relevant covariates, including treatment modality, from the two datasets.  The cancer registry data sets 
provide the data to model time to breast cancer recurrence and time to breast cancer mortality. The CFAS dataset 
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will separately provide models of all-cause mortality with covariate adjustment for co-morbidities. The central aim 
is to produce models which will enable detailed analysis of the competing risks of breast cancer and other causes 
of mortality. 
Observational data typically suffer from selection bias and do not directly provide unbiased estimates of treatment 
effect. Patients are not allocated to treatments at random and their actual treatment received depends on other 
factors. In the case of breast cancer, older women or those with higher levels of co-morbidities may be less likely 
to want to undergo surgery or receive chemotherapy. Therefore, the observed and unobserved baseline 
characteristics of the patients will not be balanced between the PET and surgery treatment groups or the chemo or 
no-chemotherapy groups. Another factor affecting treatment allocation is the treating physician and/or centre at 
which the patients present themselves. This is known to vary significantly. 
Statistical methods for dealing with selection bias in the analysis of observational data include matching, 
stratification, and/or covariate adjustment based on patient characteristics known before assessments were taken.  
The aim of the analysis is to obtain an unbiased estimate of the treatment effect that might have been observed if 
patients had been randomised to treatments.   
The statistical model will be built to adjust for the imbalances in patient characteristics and the non-random 
allocation to treatment. .This will be done by modelling allocation based on observed covariates using propensity 
scoring methods as well as adjusting for the effects of other covariates directly in the model.  We will explore the 
use of propensity score methods by including as many baseline characteristics in the model as possible.  
The recognition that treatment effects are biased leads to a subjective judgement about the extent of the bias that 
might not be fully captured with available covariates using the propensity score approach.  In the first stage, we 
will have addressed the availability of baseline characteristics in relation to known prognostic effects.  
8.2 Model Analysis 
We will employ a Bayesian approach building on the models proposed by Basu and colleagues
47
 to undertake 
statistical modeling to predict cancer outcomes and how these interact with frailty, age and co-morbidity.  The 
survival curves will provide both mathematical and visual descriptions for an individual woman with specified 
covariates.  Most importantly, we will also compute competing risk probabilities over time e.g. the probability that 
by 2 years post-treatment she is either recurrence-free, has local or metastatic recurrence or has died from breast 
cancer or non-breast cancer causes.  Depending on the form of the survival curves these computations may be 
achieved analytically or via Monte Carlo sampling from randomly generated event histories for the woman 
concerned given the competing risk curves.  Thus, we will examine co-morbidity and frailty thresholds for women 
beyond which surgery may be of little or no benefit in women with ER+ cancers or in whom chemotherapy may 
confer no benefit in women with ER- cancers.  This will provide the statistical input to the web-based clinical 
decision algorithm. 
8.3. Modelling Software 
The statistical package ‘R’ will be the primary tool used for the analysis of the retrospective cohort data and for the 
modelling of breast cancer and health economic outcomes.  The package OpenBUGS will be used for any Bayesian 
analyses which require Monte Carlo Markov Chain (MCMC) procedures.  Other packages may be used for specific 
analyses where appropriate.  
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Section 9. Cohort Study 
9.1 Research Governance 
9.1.a. Ethics 
Research Ethics Committee approval will be obtained for all sites registered for the study.  A Mental Capacity Act 
(MCA) compliant ethics committee will be used for the study.  
9.1.b. NHS Research and Development Approval 
R & D site specific approval will be obtained for each site registered for the study. 
9.2 Trial Design 
A non-randomised, pragmatic, cohort study.   
9.3 Sample Size 
9.3.a. PET versus surgery analysis 
The study aims to recruit from multiple UK centres.  For this analysis women over the age of 75, who might be 
deemed suitable for either PET or surgery by their clinician, regardless of the treatment they ultimately receive will 
be eligible if they have ER+ cancers.  Women over 75 make up 25% of the breast cancer population so each centre 
will see 75 per year, of which 85% will have ER+ cancers (64 per year).  Over 2 years, if we have a minimum of 20 
recruiting centres, this will give us a potential population of 2560 patients.   
As the study is very low risk, with no change of management and a simple (and optional) requirement to complete 
QoL questionnaires, we anticipate that recruitment rates will be high.   
9.4 Recruitment 
Centres and patients may choose one of 3 levels of participation (none of which involve any change of 
management or intervention other than completion of questionnaires): 
9.4.a. Full participation 
9.4.b. Partial participation 
Women will be asked permission for data collection, including a research nurse completed baseline health 
questionnaire which may be derived from the case notes, but will not be asked to complete any of the above 
questionnaires. 
9.4.c. Data collection only 
For women with significant cognitive impairment in the opinion of their treating clinican (usually formally classified 
as a MMSE of less then 18, although this will not be formally measured in these individuals), next of kin or carers 
will be asked to assent to data collection only, including collection of baseline health status data from case notes, 
proxy completion of some of the health questionnaires (IADL, ADL, Charleson), long-term survival outcomes from 
the cancer registry and archival tissue access.  A specially adapted relative or carer assent form and modified 
Patient Information Sheet (PIS) will be used for this purpose (PIS in Appendix 8 and assent for in appendix 10). 
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Data items to be routinely collected for all 3 groups of patients will include: cancer type,  grade, nodal status, 
tumour size, oestrogen, progesterone and Her-2 receptor status, treatments and outcomes (overall and disease 
specific survival, disease free and progression free survival, whether a change of management was required).  In 
addition, in women on PET the treating clinician will assess the primary tumour response based on the RECIST 
Criteria
56
.  
All levels of participation will involve requesting permission for access to stored tumour tissue (archival only: no 
new biopsies will be required).   
The study also request ethics approval for long-term access the linked records held by the cancer registries for 
long-term follow up purposes of all participating patients.  
A summary of visits and the data items to be collected for each level of participation and at each time point is 
shown (in section 9.18), the Visit Schedule. 
9.5 Participating UK Breast Units 
The following centres have agreed to participate in the study: 
No. Town Hospital Local PI Annual no. 
breast cancers 
cases 
1 Sheffield Royal Hallamshire Hospital Ms Lynda Wyld 500 
2 Leicester Glenfield Hospital Ms Anne Stotter 800 
3 Nottingham City Hospital Ellie Gutteridge?  
4 Nuneaton George Eliot Hospital Mr Medy Tsalic  
5 Whiston St Helen’s and Knowsley 
NHS Trust 
Professor Riccardo Audisio  
6 Hull Castle Hill Hospital Mr Peter Kneeshaw  
7 Dartford Darent Valley Hospital Ms Seema Seetharam  
8 Newcastle Royal Victoria Infirmary Mr Richard Bliss and Mr Andy 
Griffiths and Professor Tom 
Lennard 
 
9 Weston Super 
Mare 
Weston General Hospital Mr Nick Gallegos  
10 Chesterfield Chesterfield Royal 
Infirmary 
Mr Steve Holt  
11 Coventry University Hospital Mr Martin Lee  
12 Cardiff University Hospital of 
Wales 
Professor Robert Mansel  
13 Bristol Frenchay Hospital Mr Mike Shere  
14 Milton Keynes Milton Keynes NHS Trust Ms Amanda Taylor  
15 Dundee Ninewells Hospital Professor Alistair Thompson ?include as nee 
d sep ethics 
16 Southend Southend Breast Unit Mr Neil Rothnie  
17 Plymouth Derriford Hospital Mr Roger Watkins  
18 Liverpool Liverpool University 
Hospital 
Mr Chris Holcombe  
19 Derby Derby Royal Infirmary Mr KL Cheung 500 
20 Grantham Grantham and District Mr AK Modi  
21 Scarborough Scarborough Hospital Sister Alison Ames, (Oncology  
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Research Nurse) 
22 Wakefield Pinderfields Hospital Mr Jit Parmar  
23 Reading Royal Berkshire Hospital Mr Stephen Courtney  
24 Doncaster Doncaster Royal Infirmary Ms Clare Rogers 450 
25 York York Royal Infirmary Ms Rana Nasr  
26 London Guy’s Hospital Mr Michael Douek  
27 Dudley Russells Hall Hospital Mr Paul Stonelake  
28 Birmingham Queen Elizabeth Hospital Ms Adele Francis  
29 Walsall Manor Hospital Ms Marlies Heitmann  
30 Stoke on Trent University Hospitals of 
North Stafford 
Mr Robert Kirby  
31 London King’s College Hospital Professor Arnie Purushotham  
32 Leeds St James Hospital Mr Kieran Horgan  
33 Oxford Radcliffe Royal Infirmary ??  
34 Bristol University Hospitals Bristol Ms Zoe Winters  
35 London St Bartholomew’s Hospital Professor Andrew Baildam  
36 Rhyl, North 
Wales 
Glan Clwyd District General 
Hospital 
Mr Tibor Kovacs  
37 Rotherham Rotherham District General Mr Inder Kumar 150 
38 Barnsley Barnsley District General 
Hospital 
Ms Julia Dicks 150 
39 Truro Royal Cornwall Hospital Professor Philip Drew  
40 Southampton University Hospital Mr David Rew  
 
9.6 Eligibility Criteria 
The algorithm below is a simplified schematic of the broad eligibility criteria for the different components of the 
cohort study.   
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9.6.a Inclusion Criteria 
(1) Female 
(2) Aged  over 70 years of age at the time of diagnosis of cancer  
(3) Primary operable (TNM categories: T1, T2, T3, N0, N1, M0; please refer to appendix 3 for further details) 
invasive breast cancer (core biopsy or diagnostic incision biopsy  
(4) Tumour ER and Her-2 status available and categorised according to accepted scoring systems e.g. H score 
6
 
or Allred score  
57
 for ER and for Her-2, IHC score 1-3 plus FISH testing if IHC equivocal. 
(5) Ability to give informed consent if considering full or partial trial participation (see below). 
(6) Willing to complete the questionnaires for the additional trial evaluations if considering full trial 
participation. 
(7)  If suitable for data collection only, the patient does not need to give consent but participation in the data 
collection exercise should be agreed and assented to by their next of kin, friend or carer.  (Appendix 10 for 
Assent form). 
(8)  Women aged 70-75 are only eligible for the chemotherapy analysis and therefore will be recruited post 
operatively once they are known to have breast cancer which fulfils any of the following 3 criteria (based on 
those of the ACTION Trial) suggesting a high risk of relapse (~30% at 10 years).   
 Her-2 positive disease (IHC 3+ or IHC 2+ with +ve FISH testing) or 
 ER- disease, (Allred score of 0-2, H score of <50/300) or 
Primary 
Operable Breast 
Cancer 
Aged 70-75 
years 
Non-Aggressive 
cancer 
phenotype 
In-eligible 
Aggressive 
cancer 
phenotype 
Age Gap 
(Chemotherapy 
analysis) 
Aged 75-79 
years 
All cancer types 
Age Gap,  either 
analysis 
Aged over 80 
years 
ER + 
Age Gap (PET 
versus Surgery 
Analysis) 
ER - In-eligible 
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 High risk ER+ disease (grade 3 with 4+ positive nodes).  
 
(9)  Women aged over 80 are only eligible for the PET versus surgery comparison (rates of chemotherapy use in 
this age group are negligible, Alistair Ring, personal communication). They are only therefore eligible if they 
have ER+ tumours (Allred score >/=3 or H score >50/300). 
(10)  Women aged 75-79 are eligible for either arm of the study and may be invited to participate regardless of 
tumour biology and will be included in the analysis depending on their treatment pathway. 
9.6.b. Exclusion Criteria 
(1) Disease unsuitable for surgery e.g. inoperable or metastatic disease. 
(2) Multifocal or bilateral invasive breast cancer. 
(3) Previous invasive breast cancer. 
 (4)  There is no restriction for people who are unable to speak English.  Translation of study documents and 
translators will be undertaken by recruiting centres if required. 
(5)  For patients considered for the PET versus surgery comparison, use of concurrent Hormone Replacement 
Therapy (HRT) or therapy with any other oestrogen containing preparation is an exclusion criteria, unless 
treatment is discontinued for 4 weeks before the study starts. 
(6) There is no restriction for any co-morbidity or frailty as the study aims to capture data on management and 
outcomes in these cases. 
(7)  Patient without capacity being considered for the data collection only arm of the study but for whom there is 
no consultee available.  
9.7. Policy relating to non-English speaking participants 
Data from the 2001 UK Census show that UK wide ethnic minorities make up 7.6% of the total population.  
However, unlike the majority white population where 16% are over the age of 65, this percentage is much less in 
minority ethnic groups with less than 5% of the population being in the over 65 age group.  By these figures, the 
percentage of over 65s of ethnic minority origin will be approximately 1/3
rd
 of the percentage in the white 
population, equating to about 2%.  This figure drops still further in the over 70 age group.  This lack of ethnic 
diversity in the older age groups is partly a result of the timing of the main migrations from different international 
areas and is highly variable between areas of the UK.  For those areas with significant ethic minority population 
groups we will offer to provide specific translations of PISs and consent forms and support the cost of ‘Language 
Line’ telephone translation services for research consultations.  The policy of the Trial Management Group (TMG) 
is to be inclusive of minority ethnic groups at a level representative of population norms.  However the small 
numbers will inevitably mean that sub-group analysis by ethnicity is unlikely to be possible and will not be part of 
the statistical analysis plan. 
9.8. Policy related to women with reduced cognitive capacity 
One of the key reasons for undertaking this research is to ensure that all older women are given access to optimal 
treatment for their breast cancer which takes into account their age, health status, tumour characteristic and 
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personal preferences.  One of the major disease states that affects older people is cognitive impairment, which will 
affect a significant percentage of women in this age group.  Severe cognitive decline is a major determinant of life 
expectancy and therefore is a critical factor to take into account when assessing optimal treatments.  Moderate 
degrees of cognitive impairment may influence perceived ability to give informed consent to research but is still 
compatible with a reasonable life expectancy and therefore treatment optimisation is of great importance.  There 
has been very little research to study cancer of any sort in people with cognitive decline due to the perceived 
difficulty of obtaining consent.  This group of people are therefore excluded from research and we have little or no 
idea how they should be best treated. 
 
The study will try to ensure that older women with cognitive impairment are offered access to this research.  The 
2005 MCA
58
 sets out clear guidelines for when and how researchers should approach this issue.  There are 3 tests 
to apply to determine if it would be appropriate to include people lacking capacity in the research.   
The criterion relevant to this research is:  
 
‘That the research will serve to increase knowledge of the cause, treatment or care of people with the same or 
similar condition and that the risks to participants will be negligible, with no significant interference with their 
privacy of freedom of action’. 
 
For women in whom there is doubt about capacity, as mandated by the MCA, we will take steps to ensure that 
participants are given the opportunity to comprehend the study and if it is then established that they do not have 
capacity to do so we will identify a personal consultee (a family member or friend) who is prepared to act on their 
behalf.  This project will not use nominated consultees if there is no available personal consultee. 
 
These are defined as followed for the purpose of this study
58-59
: 
 
 Personal consultee: someone who knows the person who lacks capacity in a personal capacity who is able 
to advise the researcher about the person who lacks capacity’s wishes and feelings in relation to the 
project and whether they should join the research (section 32(2)).  They may be either of the following: 
 
o a family member, carer or friend  
o an attorney acting under a Lasting Power of Attorney (LPA)  
o a court appointed deputy, provided that they had a relationship with, or personal knowledge of, 
the person lacking capacity before their appointment as deputy (for example, a deputy could be 
a family member).  
 
The personal consultee must not be someone who is caring for the person who lacks capacity or is interested in 
their welfare in a professional capacity or for remuneration.  Remuneration does not cover family members 
receiving some of the person’s pension or other benefits as a payment towards their share of the household 
expenses.  
In accordance with the general principles of the Act, the researcher must make every effort to take into account 
the wishes of the person who lacks capacity about whom to consult (e.g. their partner, or a particular friend or 
carer) and to act in accordance with any relevant previous statement or wishes, however made, including non-
verbal forms of communication.  Depending on the nature of the research, it may be possible to establish a 
person’s general wishes and feelings, for example if they experience diminishing or fluctuating capacity.  
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A number of people may be capable of acting as a personal consultee, but they should be someone whom the 
person who lacks capacity would trust with important decisions about their welfare.  Usually it will be someone 
with a close personal relationship with the potential subject, for example their next of kin, spouse or partner 
(including same-sex partners), adult child or parent. Other relatives or a close friend or past carer may be 
considered.  If a potential consultee does not feel able to take on the role, they may suggest that someone else 
takes on the role.  
 
The personal consultee may withdraw the patient’s participation at any time and if, at any future date the 
participant expresses a wish or indicates by showing distress that they do not wish to be involved, their 
participation will be terminated. 
 
The study will involve the completion of a few simple questionnaires by women who are cognitively able to 
complete them but for women without such ability, the study will be purely an observational/data collection 
exercise which will expose them to no risks.  The treatment offered in the cohort study will be normal care.  It is 
likely that most of the women with severe cognitive decline will be offered PET and whilst this will be a source of 
bias, this group’s outcomes with PET have never been studied to determine whether this approach is satisfactory.  
We will be able to undertake a planned subgroup analysis of women with cognitive decline as a result of this data 
which will be a unique and very valuable resource. 
Given the low risk and burden of this study to participants, consultee agreement is reasonable in those who do not 
have the capacity to give consent. It is also necessary to include the non-statutory carers of these patient 
participants as carer participants.  Figure 2 shows the recruitment algorithm to be used depending upon the 
presence or absence of capacity to consent to the study, and the presence or absence of a carer. 
The researcher will have primary responsibility for assessing the capacity of the individual to participate in 
research, according to the 2005 MCA and under the direct supervision of the local investigators and the overall 
supervision of the Chief Investigator of the project. The researchers will have a health professional background and 
will be fully trained in assessing older people, and compliant with ICH Good Clinical Practice (GCP) 
recommendations. The researcher will be informed by the clinical teams of all necessary and appropriate issues 
and information regarding the participant.  
Patients who do not have capacity to give consent and have no consultee present will be excluded.  
All participants will be given study information material, including those recruited using the consultee procedures; 
copies will be provided to consultees or next of kin as appropriate. 
9.9 Loss of capacity during the research project 
Because of the age group under study for this project, it is possible that some study participants may lose capacity 
during the follow up period.  The following arrangements will be made once it becomes known that the person has 
lost capacity.   Schedule 2 of the Regulations (MCA: Loss of capacity during a research project, 2007) sets out the 
requirements to identify a consultee for the patient (as above). That person should be provided with information 
about the project and with information on the nature of the consent given by the participant when they consented 
to participate.  
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The role of the consultee is similar to that in normal research situations. They must advise on whether the research 
subject would want to allow samples or data collected before loss of capacity to continue to be used in the study. 
The fact that the person who lacks capacity had originally consented to join the research project, and the extent to 
which future incapacity was considered at that time, will be important aspects to draw to the attention of the 
consultee. However, the researcher must take due heed of any advice from the consultee that continued 
involvement in the study would be contrary to the wishes of the person who lost capacity.  
 
The versions of the PISs and consent forms are contained in appendices 8 and 10.  Differentiation between full and 
partial participation will be achieved by means of a tick box on the consent form agreeing to complete the 
questionnaires, which is clearly noted to be optional for all participants. 
9.10. Screening 
Prior to study entry, each patient’s inclusion and exclusion criteria must be checked.   
The ER status of the tumour must also be known before study entry is considered to ensure they meet the criteria 
for either the PET or the chemotherapy options.  Patients considered for the chemotherapy comparison may be 
considered after definitive surgery when full histology is available. 
Staging investigations are not required as part of the study protocol, but if indicated clinically, patients should not 
be considered for trial entry until staging investigations show them to be free of metastatic disease. 
9.11. Patient Invitation 
Patients will be invited to participate by the Consultant Breast Surgeon or Consultant Oncologist or an appropriate 
delegated individual.  A full verbal explanation of the trial and Patient Information Sheet will be provided by a 
Eligible for study 
participation 
Cognitively able 
Offer choice of full 
participation 
Patient  Information 
sheet and Consent 
form 1 
Offer choice of 
partial participation 
Patient  Information 
sheet and Consent 
form 1 
Mental incapacity 
as judged by trained 
clinical staff 
Personal consultee 
available  in clinic 
Proxy  Information 
sheet and Consent 
form  2 
No personal 
consultee available 
In-eligible 
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member of the trial team at site (medical staff and research nurses with up to date GCP training) for the patient to 
consider.  This will include detailed information about the rationale, design and personal implications of the study.   
In order to reduce the burden of visits for these older women, and in view of the low impact of the trial which 
involves no change of management and simple completion of optional questionnaires and follow up data 
collection, a minimum of 15 minutes (but longer if wished) is permissible for patients to decide if they wish to 
enter the trial.  In practice they will be given written information after a verbal explanation and if they are 
interested, offered a quiet room with a drink where they may chat with relatives, friends and/or a breast care 
nurse.  They will be given the opportunity to discuss the trial with their healthcare professional or research nurse 
before they are asked whether they would be willing to take part in the trial.   The rationale for this short time 
period is to remove the need for an additional visit for consenting for the frailer older women who are considering 
PET.  For these women a trip to hospital may involve a lengthy ambulance ride, a lot of waiting around in the 
ambulance bays and is very tiring.  In normal practice they would simply be given their PET tablets at their 
diagnostic visit and not seen again in clinic until their first follow up visit at 6-12 weeks.  The study does not wish to 
burden them with the additional requirement for an extra visit to discuss the trial. 
For patients who will be re-attending (those who want more time to consider treatment options or who are having 
surgery for example), re-discussion prior to consent will be after a longer interval if wished. 
9.12. Informed Consent 
Assenting patients will then be formally assessed for eligibility and invited to provide written informed consent if 
for full or partial participation.   Those who are considered for limited participation who are cognitively impaired 
will have participation agreed with their personal consultee who will assent to the study.  Formal assessment of 
eligibility and informed consent discussion will be undertaken by the Principal Investigator at each individual 
centre or by appropriate personnel who are authorised to do so by the Principal Investigator responsible for that 
site.  This may include appropriately qualified medical and nursing staff.  The consent process will be documented 
in the patient’s medical notes.  Written informed consent (or consultee assent) for entry into the trial must be 
obtained prior to participation.  All staff involved in the consent process will be trained in the assessment of 
mental capacity and in cases where this is lacking, efforts will be made to first assess the patient’s own wishes 
(both directly or via any documented advanced directives) before discussion with a personal consultee. 
The right of the patient to refuse consent without giving reasons will be respected.  Further, the patient will remain 
free to withdraw from the study at any time without giving reasons and without prejudicing any further treatment.  
A copy of the consent form will be given to the patient (or personal consultee), a further filed in the hospital notes 
and a third will be held in the site file. 
9.13 Safety endpoints 
There are no pre-defined safety end-points for this study.  However, any adverse events which occur as a result of 
normal care will be reported to the TMG.  
The bulk of the research will involve completion of simple and well validated questionnaires, so there will be no 
physical pain, discomfort or distress. Questionnaires, however, take time to complete and so can be perceived as 
an inconvenience. Some of the questions refer to personal care (IADL, ADL) and mental health (MMSE), so they can 
also be perceived as being intrusive and it is possible in some participants the mere asking of these questions could 
give rise to a sense of distress, or could unmask distress about these issues.  
Recruitment burdens will be minimised by the following approaches: 
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 The recruitment process has been designed to avoid being overly onerous or time consuming. 
 We have chosen assessments which are widely used and validated and have been found to be generally 
acceptable in use.  
 Experienced research nursing staff, used to dealing with patients with cancer, will be involved. 
 Women with cognitive incapacity or significant frailty will not be expected to undertake these 
questionnaires which will be administered by proxy (carer or relative) as much as possible, or omitted 
altogether. 
 In some cases women will be offered telephone/remote questionnaire completion to reduce time spent 
in clinics. 
9.14. Stopping rules and discontinuation 
There are no planned early stopping rules for this trial other than failure to recruit at a viable rate. 
9.15 Study Treatments 
The study is a pragmatic data collection only cohort study with no change to normal planned treatment for 
participating patients.   
9.15.a. Primary Endocrine Therapy versus Surgery plus Adjuvant Endocrine Therapy 
PET Alone 
The standard therapeutic dose of Anastrozole (1mg orally, once daily), Tamoxifen (20mg orally, once daily) or 
Letrozole (2.5mg orally, once daily) will be given until disease progression or side effects mandate a change of 
management or death occurs.  Treatment is continued indefinitely whilst there is evidence of continued clinical 
benefit.  Monitoring is undertaken at the discretion of the Unit according to their normal protocol but must be 
undertaken at least once every 6 months during the study follow up period.   
On the development of progressive disease management will be changed as per local protocol, patient preference 
and clinical indications and may include: surgery, change to an alternate anti-oestrogen or radiotherapy 
(chemotherapy is less unlikely in this cohort but will be documented if used).  Change of management, its 
indication, type and timing will be recorded by the study staff.  
New primary breast cancer or metastatic disease will be treated in accordance with the MDT decision and patient’s 
tolerances and wishes. 
9.15.b. Surgery plus adjuvant endocrine therapy (+/- radiotherapy) 
Surgery to the breast 
Women who are to be treated by surgery will be offered a choice of surgery appropriate to their preferences, the 
extent of their disease and their fitness for anaesthesia according to local Unit Protocols.  The post-surgical 
specimen will be examined by the local pathologist and the final pathology report copied for the study site file.   
Axillary surgery 
Axillary surgery should be offered according to local Unit protocols and patient tolerances and wishes.   
Radiotherapy (post-surgery) 
Post-operative radiotherapy should be offered to women according to local and national guidelines and tailored to 
the woman’s wishes and tolerances.   
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Adjuvant endocrine therapy following surgery 
The standard therapeutic dose of Anastrazole (1mg orally, once daily), Tamoxifen (20mg orally once daily) or 
Letrozole (2.5 mg orally once daily) will be offered to women with ER+ve cancers for 5 years post-operatively 
according to unit protocols and her wishes and tolerance or until local/regional disease recurrence, new primary 
breast cancer, metastatic disease or drug intolerance develops.   
Disease recurrence, new primary breast tumour and metastatic disease 
Second and subsequent endocrine therapy and radiotherapy for local or regional disease recurrence will be at 
MDT discretion and tailored to the wishes and tolerances of the individual patient. 
New primary breast cancer or metastatic disease will be treated in accordance with the MDT decision and patient’s 
tolerances and wishes. 
Concomitant Therapies 
The following concomitant medications are prohibited for both the PET and surgery arms:  Hormone replacement 
therapy (HRT) or therapy with any other oestrogen containing preparation.   
 
9.16. Withdrawal from Treatment 
There are 3 levels of patient withdrawal: 
 Patients withdrawing from the study treatment but still willing to be followed up according to the visit 
schedule. 
 Patients withdrawing from the study treatment and the visit schedule but still willing to be followed up at 
their standard visits. 
 Patients withdrawing consent for the study. In this case data up until the point of withdrawal for these 
patients will be used unless patients request removal of their data from the trial database under the 
provisions of the Data Protection Act 1998.  
9.17. Patients lost to follow-up 
One or two attempts will be made by the local clinician to contact the patient either in writing or by phone if a 
patient does not attend follow-up assessments in clinic.  If this proves unsuccessful patients who no longer attend 
follow-up assessments in clinic will be considered lost to follow-up and no more clinic appointment reminders will 
be sent.  However attempts will still be made by the local clinician to obtain survival data by contacting the 
patient’s GP or care home etc.  The only exception to this is patients who withdraw consent for the trial and 
collection of follow-up data. 
9.18. Visit Schedule. 
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Full Participation Baseline 6 
weeks 
6 
months 
12 
months 
18 months 24 months Long-term 
IADL *       
ADL *       
MMSE *       
ECOG perf. status *       
Subjective Global 
Assessment 
*       
Co-morbidity *       
EQ5D * * * * * *  
QoL * * * * * *  
Decision style *       
RECIST if PET * * * * * *  
Registry data access       * 
Tissue Access       * 
Tumour details *       
Treatment details  * * * * * *  
Adverse events * * * * * *  
 
Partial Participation Baseline 6 
weeks 
6 
months 
12 
months 
18 months 24 months Long-term 
IADL *       
ADL *       
MMSE *       
ECOG perf. status *       
Subjective Global 
Assessment 
*       
Co-morbidity *     *  
RECIST if PET * * * * * *  
Cancer Registry 
permission 
      * 
Tissue Access       * 
Tumour details *       
Treatment details  * * * * * *  
Adverse events * * * * * *  
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Data collection only Baseline 6 
weeks 
6 
months 
12 
months 
18 months 24 months Long-term 
IADL (proxy) *       
ADL (proxy) *       
MMSE (proxy) *       
ECOG perf. status 
(proxy) 
*       
Co-morbidity (proxy) *     *  
RECIST if PET * * * * * *  
Cancer Registry 
Access 
      * 
Tissue Access       * 
Tumour details *       
Treatment details  * * * * * *  
Adverse events 
(proxy) 
* * * * * *  
 
9.19.b. Follow-up Assessments 
The follow-up assessments detailed should be undertaken at the time-points specified in the visit schedule.  
Clinical Follow-up Assessments 
Patients on PET 
The Consultant Breast Surgeon, Consultant Oncologist or an appropriate delegated individual will measure the size 
of the primary tumour and the largest of the diseased axillary lymph nodes (if present) as detailed in appendix 4.  
The presence or absence of non-target lesions will also be recorded.  Response will be assessed based on the 
RECIST Response criteria 
56
 below.  Response will be graded as either complete response, partial response, static 
disease or progressive disease. 
RECIST Response Criteria 
Using the sum of the longest diameter of the target lesions 
(primary tumour and the largest diseased axillary lymph 
node, if present): 
Complete response (CR): Complete disappearance of 
disease. 
Partial response (PR): At least a 30% decrease in the size of 
the target lesions relative to baseline. 
Progressive disease (PD): At least a 20% increase in the size of the target lesions relative to the smallest 
measurement since start of treatment or an increase in the total number of palpable lesions or the development 
of metastatic disease. 
Static disease (SD): Neither sufficient shrinkage for PR, nor sufficient increase for PD. 
LeftRight
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All Patients 
Appropriate clinicians as delegated by the Principal Investigator will carry out the following assessments: 
 Failure-Free Survival 
Patients who attend follow up visits free of local or regional disease (or without progressive disease for 
patients on PET alone arm), and free of metastatic disease, will be classed as being failure free.  Patients 
with either local or regional disease recurrence (those who have had surgery), PD (patients on the PET arm), 
or metastatic disease at follow-up will be categorised as having an ‘event’.  
 Physical examination according to local practice 
 Treatment details e.g. radiotherapy, surgery, chemotherapy, trastuzumab, endocrine therapy 
 Treatment related adverse events 
 Management of local/regional recurrence, progressive disease, metastatic disease or new primary breast 
tumour (if applicable) 
Quality of Life Assessment 
The QoL questionnaires will be completed again at follow up visits every 6 months. 
Health Economics Assessment 
The EQ5D questionnaire will be completed again at each follow up visit. 
9.20 Statistical Considerations 
9.20.a. Statistical team members 
Statistical analysis is the responsibility of the study statistical team led by Professor Stephen Walters (Senior Study 
Statistician) with support from Dr Neil Shephard (Study Statistician).  The analysis plan outlined in this section will 
be reviewed and a final statistical analysis plan (SAP) written before any analysis is undertaken.  All analyses will be 
performed by the same statistician (Neil Shepard) under the supervision of Professor Walters.  
9.20.b. Trial Design 
The trial is a pragmatic cohort study designed to observe normal UK clinical practice.  Data will be reported and 
presented according to the revised CONSORT guidelines for pragmatic trials
60
.  
9.20.c. Sample size 
We propose to recruit and follow-up eligible women from at least 22 UK Breast Units.  Each Unit sees between 200 
and 700 breast cancers per year, of which 30% will be over age 70.  Assuming an uptake rate of 50% this will allow 
us to collect data on over 3 500 subjects over 3 years.  We expect a high uptake rate from this simple, 
questionnaire-based study.  With 2 years follow-up this integrated dataset will provide an evidence base for the 
medium term post primary treatment.  Longer-term follow-up via registry data will maximise the project’s long-
term value.  We will ask all women to consent for the study team to have access to their registry data and also to 
give consent for subsequent access to their stored tissue samples (which will form the basis of future research). 
9.20.d. Baseline Characteristic Data Analysis 
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Baseline sociodemographic (age, ethnicity) and individualised baseline scores (EORTC QoL scores, EQ-5D, ADL, 
IADL, MMSE, Charlson Index, ECOG performance status) will be summarised and assessed for comparability 
between the different treatment groups (surgery versus PET and chemotherapy versus no chemotherapy).  For 
continuous variables means and standard deviations or medians and interquartile ranges will be calculated 
depending on the distribution of the data.  The number of observations will be presented alongside the 
summaries.  For categorical variables such as age sub-group and ethnicity, the number and percentage of 
participants in each of the categories will be presented. 
All baseline summaries will be presented and reported for each treatment group (surgery; PET; chemotherapy; no 
chemotherapy) and in total.  Baseline imbalances in these characteristics will be descriptively reported and 
adjusted for in the statistical model.  
9.20.e. Interim Analysis and Data Monitoring and Ethics Committee. 
There are no statistical criteria for stopping the study early as the study is simply observing normal UK practice and 
therefore very low risk.  The study may be stopped after interim analysis after 12 months if the study is not 
meeting recruitment targets.  This decision will be made by the TMG on the basis of advice from the DMEC. 
9.20.f. Data Sources 
Data used in this study will come from data entered into the following sources: 
 The CRFs 
 Study Questionnaires 
 Cancer Registry Outcome Data (longer term outcomes and patients lost to follow-up. 
The data will be stored on a bespoke database, constructed by the Study Data Manager, (Dr Tim Chater).  Data will 
be monitored by the study data monitor periodically to check accuracy. 
9.20.g. Statistical Analyses 
Since the study is a cohort it is likely that the baseline demographic, clinical and QoL characteristics of the women 
on the different treatment regimens (surgery versus PET, and chemotherapy versus no chemotherapy) are 
different and this may influence future outcomes.  In order to make sure that we are comparing like with like and 
allow for differences in case-mix between the difference treatment regimens we shall use a variety of statistical 
methods.  The two main statistical approaches that will be used to adjust for baseline imbalances in patient 
characteristics will be:  
1. Propensity score methods and  
2. Analysis of covariance  
However with sufficiently large numbers of patients an analysis of covariance model alone is often sufficient.  
Analysis of covariance can produce biased estimates of treatment effect if there is extreme imbalance in baseline 
characteristics or if the treatment effect is not constant with respect to the baseline characteristics.  We will 
therefore also use propensity score methods which are based on determining an individual patient’s probability of 
being treated, with a particular therapy/regimen, conditional on their baseline characteristics (e.g. age, ethnicity, 
EORTC QoL scores, EQ-5D, ADL, IADL, MMSE, Charlson Index, ECOG performance status, treating centre).  A 
propensity score for each patient or the probability of having a particular treatment regimen (for example surgery 
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or PET) will be derived from a binary logistic regression model using baseline characteristics as covariates.  A 
second propensity score for each patient or probability of being treated with chemotherapy or no chemotherapy 
will also be derived from a binary logistic regression model. 
We will then use matching, stratification or analysis of covariance using the calculated propensity scores (for each 
individual patient) to balance patient characteristics between treatments and allow the estimation of an unbiased 
estimate of treatment effect of firstly PET versus. surgery and secondly chemotherapy versus no chemotherapy on 
QoL outcomes. 
9.20.i. Patient and Clinician Decision Making Preferences and Styles 
Patients are recognised to possess different preferences for involvement in healthcare decision-making.  Decision 
Making Preferences (DMP) and Decision Making Styles (DMS) are terms most commonly adopted regarding this.  
Three main categories are described in the literature; active, collaborative and passive; representing those wanting 
to take control, share decisions with others or defer decision making to others.  Most published international 
studies utilise a validated tool comprising a simple five-point scale, to capture patient’s DMP and DMS
64
.  This tool 
will be used in the study to determine the decision making preferences and styles of the patients.  This is shown in 
Appendix 12.1.  In addition, for each patient recruited the treating clinician (surgeon or oncologist with primary 
responsibility for care) will be asked to state whether each patient is best treated with either PET or surgery or 
chemotherapy or no chemotherapy, regardless of the final treatment choice.  This will give us some insight into the 
relative importance of patient and clinician opinion on ultimate treatment preference.  
9.20.K. Data Completeness 
Reporting data completeness is an integral part of trial reporting.  Hence a CONSORT style flow diagram will be 
used to display data completeness and patient throughput from eligibility screening, invitation, study acceptance 
and final follow-up visit.  This information will be made available to the TMG and DMEC on request and as regular 
reports.  The statistical team will also report the number of: 
 Patients screened per month 
 Patients recruited per month 
 The number and percentage of patients who complete each follow up or are lost to follow up 
 The number of patients who have complete data for each key variable.  
To allow time for data entry, items will only be considered incomplete if they have not been entered within 30 
days of the expected date. 
9.20.l. Primary Endpoint 
The study is unusual in that the primary outcome will be a statistical model of outcomes for older women and the 
determination of the complex and interacting set of characteristics that determine optimal treatment for older 
women.  It is fully expected that a direct comparison of the typical outcome measures such as overall and disease 
specific survival rates between women treated with both surgery or PET or chemotherapy or no chemotherapy will 
be different.  This is because clinicians will select frailer, older women for non-surgical treatment and for no 
chemotherapy.  These 2 groups will therefore be expected to have higher overall mortality rates and, as these 
treatment arms are less effective, they may also have higher rates of disease related mortality and disease 
recurrence.  It would therefore not be appropriate to directly compare these standard outcomes as if this were an 
RCT.  The following outcomes will however be described and reported for the study by treatment type: 
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 Overall survival    
 Breast cancer specific survival 
 Other cause mortality 
 Cause of death. 
Kaplan Meier curves will be derived for each treatment type, by age, disease characteristics, co-morbidity and 
frailty subgroup to illustrate how these factors interact with treatment type and disease stage. 
Overall survival (OS) curves will be calculated using the Kaplan Meier method.  Overall survival will primarily be 
compared between the treatment groups using multivariate modelling, Cox’s Proportional Hazards model if 
appropriate, to adjust for minimisation factors.  Overall survival will also be compared using multivariate modelling 
adjusting for the minimisation factors and other important prognostic factors.  Hazard ratios (HR) and 
corresponding 95% CIs will be presented.  The upper limit of the 95% CI around the HR for the treatment effect will 
be compared with the HR non-inferiority margin of 1.245.  Yearly OS, median survival, and corresponding 95% CIs 
will be presented for each treatment type 
9.20.m.  Secondary Endpoints 
As for the primary outcomes, it is expected that there will be systematic bias between the baseline characteristics 
of the different treatments groups which will impact on outcomes making direct, unadjusted statistical 
comparisons difficult.  However the following secondary outcome measures will be described for each of the 
following: 
 Failure free survival 
 Time to local recurrence (disease progression in PET) 
 Time to local recurrence 
 Time to metastatic recurrence 
 Date of change of management for PET patients (delayed surgery, change of anti-oestrogen or 
radiotherapy) 
 Time to change of management. 
Kaplan Meier curves for the above will be derived for women in different age, disease characteristic, co morbidity 
and frailty subgroups.   Failure Free Survival and cumulative incidence functions for local disease control will be 
calculated and compared using multivariate modelling, Cox’s Proportional Hazards model if appropriate, to adjust 
primarily for the minimisation factors only, and also to adjust for the minimisation factors and other important 
prognostic factors.  HRs and corresponding 95% CIs will be presented.  Yearly survival/local disease control, median 
survival/local disease control, and corresponding 95% CIs will be presented for each treatment group. 
Sensitivity analyses will be conducted to account for missing data for Failure Free Survival, breast cancer specific 
survival and local disease control. 
Time to local progression or recurrence  and its treatment will be summarised descriptively. 
Treatment related adverse events and reasons for stopped treatment will be summarised descriptively for each 
treatment group.  The maximum grade of toxicity (AEs) per patient and the overall rate of toxicities will be 
summarised (according to standard Common Terminology Criteria for Adverse Events, CTCAE) 
9.20.n. Subgroup analyses 
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Age subgroup analysis (75-79, 80-84, 85-89 and 90+ years), Barthel Index subgroup analysis (mild, moderate or 
severe), Charlson score and degree of dementia (mild, moderate or severe) will also be carried out on the primary 
and secondary outcome measures.  
9.20.o.  HES data analysis. 
HES data from the WMCIU will be collected for all patients in the cohort study and once the cohort study is 
complete the quality of the HES data will be compared with the actual comorbidity data, to assess whether its use 
as a proxy for comorbidity is valid or accurate.  Similarly the accuracy of the HES data derived Charlson index will 
be compared with the cohort study derived index.   
9.21. Data Management 
Trial data will be recorded by hospital staff (predominantly the NCRN funded locality research nurses) in the 
electronic or paper-based CRFs and signed off by appropriate trial personnel as detailed in the authorised 
signatories log completed for each participating site.  It is anticipated that the majority of CRF completions will be 
electronic using a specially designed electronic web-based CRF designed for the study by the study Data Manager, 
(Tim Chater) and Chris Murray (EpiGenesys).  The Study Manager, Study Monitor and Data Manager will collate all 
data from all study sites and will be responsible for verifying and checking the data. 
All data will be handled, computerised and stored in accordance with the Data Protection Act 1998.  Quality 
control will be maintained through adherence to departmental standard operating procedures (SOPs), and by 
following the principles of GCP according to the EU Directive 2005/28/EC (GCP Directive), which was implemented 
in The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006. 
Participating hospitals will be expected to maintain a file of essential trial documentation (Investigator Site File), 
which will be provided by the Study team.  It is the responsibility of each centre to retain copies of all completed 
CRFs for the trial and their study file on site or at their designated archive facility for a minimum of 15 years after 
study completion. 
All centres will be asked to complete a log of all patients who are screened for eligibility who do not subsequently 
take part and the reason for non-participation. 
9.22. Data Monitoring 
Data will be monitored for quality and completeness by the Study Team.  Missing data will be chased until it is 
received, confirmed as not available, or the trial is at analysis. 
The Study Team will conduct source data verification (SDV) on a minimum of 10% of patients. 
9.22.a. Data Monitoring and Ethics Committee (DMEC) 
An independent Data Monitoring and Ethics Committee (DMEC) will be established to review the safety and ethics 
of the trial.  Detailed reports will be prepared by the Study Manager for these committees on an annual basis, and 
for the interim and final analyses.  The committee will meet every 12 months and will produce a report on trial 
viability and safety. 
The DMEC will be composed of the following independent members: a geriatrician, a medical oncologist and a 
breast surgeon. 
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9.22.b. Trial Management Group (TMG) 
A TMG will be established to provide overall supervision of the trial, in particular: trial progress, adherence to 
protocol, patient safety and consideration of new information.  The committee will meet every 6 months during 
recruitment and annually thereafter for the duration of the trial. 
Membership of the TMG: 
Lynda Wyld: Chair 
Malcolm Reed: Co-Chair 
Sue Ward: Lead Modeller 
Stephen Walters: Senior Trial Statistician 
Rosie Cooper: Trial Manager 
Chantelle Morris:  Clerical officer and study monitor (will take minutes) 
A minimum of 2 Consumer representatives 
Jenna Morgan: Clinician variation project lead 
Karen Collins: Quality of life lead 
Paul Richards: Trial modeller 
Alistair Ring: Oncology Advisor 
Tom Robinson: Geriatrics advisor 
Gill Lawrence and Catherine Lagord: Representatives of the WMCIU 
9.23. Ethics and Good Clinical Practice 
The trial will be performed in accordance with the recommendations guiding physicians in biomedical research 
involving human subjects, adopted by the 18
th
 World Medical Association General Assembly, Helsinki, Finland, June 
1964, amended at the 48
th
 World Medical Association General Assembly, Somerset West, Republic of South Africa, 
October 1996.  Informed written consent (or consultee assent) will be obtained from the patients prior to 
participation in the study.  The right of a patient to refuse participation without giving reasons must be respected.  
The patient must remain free to withdraw at any time from the study without giving reasons and without 
prejudicing her further treatment.  The study will be submitted to and approved by a National Research Ethics 
Committee (MCA Approved) and the appropriate locality site specific R&D approval prior to entering patients into 
the study.  The Study will provide the main Research Ethics Committee with a copy of the final protocol, patient 
information sheets, consent forms and all other relevant study documentation.  The trial will be conducted in 
accordance with the principles of GCP according to the EU Directive 2005/28/EC (GCP Directive), which was 
implemented in The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006. 
9.24. Confidentiality 
The Study Team will collect patient data that includes some patient identifiers.  The latter are required to allow 
back-identification of patients for the purpose of data clarification and clinical safety monitoring.  The Study Team 
will comply with all aspects of the Data Protection Act, 1998.  Any information that would allow patients and 
clinicians to be identified will not be released into the public domain.  If a patient withdraws consent from further 
study participation but not from collection of data, their data will remain on file and will be included in the final 
study analysis.  
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9.25. Archiving 
At the end of the trial, data and the Trial Master File will be securely archived at the Academic Unit of Surgical 
Oncology and participating centres for a minimum of 15 years.  Following authorisation from the sponsors 
arrangements for confidential destruction will then be made.  If a patient withdraws consent for their data to be 
used, it will be confidentially destroyed. 
9.26 Indemnity 
This study is sponsored by the Sheffield Teaching Hospitals NHS Foundation Trust (STHNHSFT) which will be liable 
for negligent harm caused by the design of the study.  The NHS has a duty of care to patients treated, whether or 
not the patient is taking part in a clinical trial, and the NHS remains liable for clinical negligence and other 
negligent harm to patients under this duty of care. 
As this is a clinician-led study there are no arrangements for no-fault compensation. 
9.27. Trial Sponsorship 
The trial will be sponsored by the Sheffield Teaching Hospitals NHS Foundation Trust (STHNHSFT). This organisation 
will therefore be responsible for the initiation and management of the trial as defined in the principles of GCP 
according to the EU Directive 2005/28/EC (GCP Directive), which was implemented in The Medicines for Human 
Use (Clinical Trials) Amendment Regulations 2006. 
9.28. Study Organisational Structure 
9.28.a. Chief Investigator (CI) 
The Chief Investigator is involved in the design, conduct, co-ordination and management of the trial. 
9.28.b. Trial Management Group (TMG)  
The TMG (membership detailed above) will be assigned responsibility for the clinical set-up, on-going 
management, promotion of the trial, and for the interpretation of results. Specifically the TMG will be responsible 
for (i) protocol completion, (ii) CRF development, (iii) obtaining approval from the main REC and supporting 
applications for Site Specific Assessments, (v) appointing and facilitating the TSC and DMEC, (vi) reporting of 
serious adverse events, (vii) monitoring of screening, recruitment, treatment and follow-up procedures, (viii) 
auditing consent procedures, data collection, trial end-point validation and database development. 
9.28.c. Data Monitoring and Ethics Committee (DMEC)  
The DMEC will review the safety and ethics of the trial by reviewing interim data during recruitment.  The 
Committee will meet or communicate via teleconference 12-monthly. 
9.29. Funding 
The study is funded by a Programme Grant from the National Institute for Health Research. 
9.30. Publication Policy 
The success of the trial depends upon the collaboration of all participants.  For this reason, credit for the main 
results will be given to all those who have collaborated in the trial, through authorship and contributorship.  
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Uniform requirements for authorship for manuscripts submitted to medical journals will guide authorship 
decisions.  These state that authorship credit should be based only on substantial contribution to:  
 conception and design, or acquisition of data, or analysis and interpretation of data 
 drafting the article or revising it critically for important intellectual content 
 and final approval of the version to be published 
 and that all these conditions must be met (www.icmje.org ). 
In light of this, the Chief Investigators will be named as authors in any publication.  In addition, all collaborators will 
be listed as contributors for the main trial publications, giving details of roles in planning, conducting and reporting 
the trial. 
To maintain the scientific integrity of the trial, data will not be released prior to the end of the trial, either for trial 
publication or oral presentation purposes, without the permission of the Trial Steering Committee or the Chief 
Investigators.  In addition, individual collaborators must not publish data concerning their patients which is directly 
relevant to the questions posed in the trial until the main results of the trial have been published. 
Section 10.0. Revision and validation of model based on cohort study data 
The initial statistical model using merged retrospective data from the WMCIU and CFAS will be revised and refined 
using data from the cohort study. 
It is proposed that the data from the Cohort study will be used to test and revise the initial statistical model as 
follows:  
1. We will use the baseline integrated data set to analyse patterns of allocation to Surgery or PET or surgery 
alone versus surgery + chemotherapy and the relationship with breast cancer specific and co-morbidity covariates.  
2. We will repeat the time to event modelling from the initial statistical model using the (up to three years’ 
worth of) longitudinal data from the cohort study alone as the data source.  This will enable us to examine whether 
evidence is emerging of differences in model coefficients. 
3.   We will undertake comparison using the original statistical models to predict probabilities of early outcomes 
for the cohort and examine them against observed outcomes. 
4. Finally, we will develop Bayesian evidence synthesis approaches to provide a new set of statistical models for 
time to recurrence, time to breast cancer and non-breast cancer death linking the longer-term data from separate 
cancer registry and MRC CFAS data with the short to medium term outcomes data from the prospective cohort 
study. 
The end product will be a revised statistical model incorporating retrospective and prospective collected data.  Of 
note, the statistical model will be further updatable if the cohort is followed longer-term through the routine 
cancer registry data collection process.  
In addition to the development of a statistical model that can be used to predict individual outcomes, we are 
proposing to construct an economic model to inform National Guidelines on treatment choice for older women 
with breast cancer. 
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The economic model is likely to take an individual level modelling approach, incorporating the revised statistical 
model (using both retrospective and prospective data) that allows the impact of different strategies for treatment 
selection to be compared.   
We will use standard approaches to incorporate evidence on costs and QoL of health states including using routine 
sources, literature and the combined data from the retrospective sources and the cohort study. This will enable 
both healthcare costs and expected QALYs lived for different treatment options to be calculated for the individual 
and for subgroups.  Discounting of longer term costs and benefits will be undertaken in line with standard UK 
practice.  
Estimates from the model will be used to assess the comparative cost-effectiveness of different intervention 
strategies.  The effects of structural and parameter uncertainties on the model estimates will be assessed using 
sensitivity analyses as recommended in the NICE guide to the methods of technology appraisal.  Results of 
probabilistic sensitivity analyses will be plotted on the cost-effectiveness plane along with associated acceptability 
curves
67
. 
Section 11. Development of software to support interactive web pages for decision support 
The web-based treatment algorithm will be based on the computer model of predicted outcomes and the variance 
caused by patient and disease parameters.  The University of Sheffield web design service, EpiGenesys, will 
develop the ‘front end’ of the algorithm.  Using a similar format to Adjuvant On-Line
37
, with facility to specify 
patient parameters (age, health status, frailty, tumour characteristics), it will present the user with an output 
suggesting outcomes from either surgery or PET (survival, recurrence or progression free survival, death from non-
breast cancer causes, QoL) or surgery alone or surgery plus or minus chemotherapy.  These will be presented in a 
range of graphic formats depending on the expected user groups (clinicians or patients).   
Section 12.  Piloting of interactive web tool and refinement prior to National launch 
The web treatment decision algorithm will then be tested for ease of use, practicality and intention to use long-
term in the 22 participating centres using individual interviews, questionnaires and focus groups of 6 to 8 
professionals (Surgeons, Oncologists, Breast Care Nurses, Consumers). Feedback will be collated and built into the 
algorithm before a final version is made available for general use. This phase of the project is not detailed in the 
present protocol and will be developed for a separate ethics application in future. 
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Appendix 2: Research Ethics Committee approvals for Bridging the Age 
Gap in Breast Cancer study 
 
 
 
NRES Committee London - South East 
HRA Ground Floor 
Skipton House 
80 London Road 
London 
SE1 6LH 
30 November 2012 
Ms Lynda Wyld 
Senior Lecturer in Surgical Oncology and Honorary Consultant Surgeon 
University of Sheffield 
Room EU 36, Academic Unit of Surgical Oncology 
E Floor, Royal Hallamshire Hospital 
Beech Hill Road, Sheffield 
S10 2JF 
 
 
Dear Ms Wyld 
 
Study title: Bridging the Age Gap in Breast Cancer: Improving 
Outcomes for Older Women. 
REC reference: 12/LO/1808 
Protocol number: STH17086 
 
The Research Ethics Committee reviewed the above application at the meeting held on 14 
November 2012. Thank you for attending to discuss the study. 
 
We plan to publish your research summary wording for the above study on the NRES 
website, together with your contact details, unless you expressly withhold permission to do 
so. Publication will be no earlier than three months from the date of this favourable opinion 
letter. Should you wish to provide a substitute contact point, require further information, or 
wish to withhold permission to publish, please contact the Co-ordinator Mr Jay McGregor, 
nrescommittee.london-southeast@nhs.net. 
 
Ethical opinion 
 
Q) The Committee was concerned that a follow-up phone call to the home of a 
participant who has died could cause distress to the family. How will this be 
accounted for and what measures are in places to help/prevent distress? 
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A) Ms Wyld explained that her team see the participants regularly in clinic and she will be aware 
of who has or hasn’t died. The follow-up visits are linked with clinic appointments and if the 
participant doesn’t turn up, and doesn’t reply to correspondence, then she will contact the 
participant’s GP to find out further information. 
 
Q) The Committee wanted to know why the participants are recruited into the study on the day 
of their diagnosis. There was a concern that participants will be distressed by the news that they have 
breast cancer and will not want to take part in a research study. 
 
A) Ms Wyld explained that it would be burdensome to ask elderly women to come back to clinic more 
than once. Also, most of the women will have already been told that they may have cancer by their GP. 
For some of the patients, Ms Wyld argued, taking part in the study will be a 
welcome distraction from the distress of being diagnosed with breast cancer. 
 
Q) The Committee were keen to know what clinicians will say to potential participants to recruit them 
into the study. There was a concern that participants could feel coerced to take part in the study 
depending on what the clinician says to them. 
 
A) Ms Wyld acknowledged that this was a possibility. She agreed to create an information pack for 
recruiting clinicians. She said this will be as sensitive as possible and she agreed to share it with the 
Committee. 
She said this will be as sensitiveas possible and she agreed to share it with the Committee. 
 
The members of the Committee present gave a favourable ethical opinion of the above research on the 
basis described in the application form, protocol and supporting documentation, subject 
to the conditions specified below. 
 
Mental Capacity Act 2005 
 
I confirm that the committee has approved this research project for the purposes of the Mental 
Capacity Act 2005. The committee is satisfied that the requirements of section 31 of the Act will be met 
in relation to research carried out as part of this project on, or in relation to, a person who lacks 
capacity to consent to taking part in the project. 
 
Ethical review of research sites 
 
NHS Sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion” below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the study. 
 
Management permission or approval must be obtained from each host organisation prior to the  
start of the study at the site concerned. 
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Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at  http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought from the 
R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is responsibility of the sponsor to ensure that all the conditions are complied with before 
the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Covering Letter  22 October 2012 
Investigator CV   
Letter from Sponsor   
Other: Summary of PPI Feedback   
Other: Data protection register entry university of Sheffield   
Other: Section 251 approval request   
Other: Computer system security 2 21 October 2011 
Other: Computer system validation 1 21 October 2011 
Other: Computer system disaster mitigation and recovery 2 21 October 2011 
Other: HES data application outpatient   
Other: HES data application inpatient   
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Other: Funding agreement from NIHR   
Other: Permission from the trusts caldicott guardian   
Other: Thank you letter 1 20 October 2012 
Other: STH Data protection registration   
 
Other: Information security policy for the STH trust 5 15 August 2012 
Participant Consent Form: Patients 1 20 October 2012 
Participant Consent Form: Assent form, for relatives, carers and 
friends 
1 20 October 2012 
Participant Information Sheet: patient 1 20 October 2012 
Participant Information Sheet: carer 1 20 October 2012 
Protocol 1 20 October 2012 
REC application  25 October 2012 
Referees or other scientific critique report   
GP letter 1 20 October 2012 
Other: Dataset requirements 1 22 October 2012 
Other: Data protection register renewal:   STH Trust  15 January 2012 
 
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
 
There were no declarations of interest. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
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After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
Notifying substantial amendments 
Adding new sites and investigators 
Notification of serious breaches of the protocol 
Progress and safety reports 
 
 
Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure.  If you wish to make your views known please use the 
feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/LO/1808                                                 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
Professor David Caplin 
Chair 
 
Email: nrescommittee.london-southeast@nhs.net 
 
Enclosures:                  List of names and professions of members who were present at the 
meeting and those who submitted written comments 
“After ethical review – guidance for researchers” 
 
Copy to:                       Erica Wallis, Sheffield Teaching Hospitals NHS Foundation Trust Erica 
Wallis, Sheffield Teaching Hospitals NHS Foundation Trust NIGB 
Ethics & Confidentiality Committee Secretariat
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NRES Committee London - 
South East 
 
Attendance at Committee meeting on 14 
November 2012 
 
 
 
Committee Members: 
 
 Name  Profession  Present  Notes 
Dr Ashok Bhiman Consultant Psychiatrist No  
Professor David Caplin Physicist Yes  
Mr Ron Driver University 
Lecturer/Statistician 
Yes  
Professor John Eastwood Consultant Renal 
Physician 
Yes  
Dr Alan Fishtal GP Yes  
Dr Ann Gallagher Reader in Nursing Ethics 
(Nurse Member) 
Yes  
Mr Guy Gardener Retired Assistant Chief 
Constable 
Yes  
Mrs Vera Hughes Training Consultant Yes  
Dr Robin MacKenzie Director Medical Law & 
Ethics 
No  
Professor Liz Meerabeau University Professor 
(Nurse Member) 
Yes  
Professor Liz Meerabeau University Professor 
(Nurse Member) 
Yes  
Mr Roy Sinclair Pharmacist Yes  
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Confidentiality 
Advisory Group 
 
M s Lynda Wyld 
The Medical School       Skipton House 
University of Sheffield       80 London Road  
Beech Hill Road Sheffield      London SE1 6LH 
S10 2JF 
Tel: 020 797 22557 
Email: HRA.CAG@nhs.net 
 
 
Date: 12 April 2013 
 
Dear Ms Wyld 
 
Study title:                            Bridging the Age Gap in Breast Cancer: Improving 
Outcomes for 
Older Women 
Project CAG reference:       ECC 8-04 (g)/2013 
 
Thank you for your research application, submitted for approval under the Health 
Service (Control of Patient Information) Regulations 2002 to process patient 
identifiable information without consent. Approved applications enable the data 
controller to provide specified information to the applicant for the purposes of the 
relevant activity, without being in breach of the common law duty of confidentiality, 
although other relevant legislative provisions will still be applicable. 
 
The role of the Confidentiality Advisory Group (CAG) is to review applications 
submitted under these Regulations and to provide advice to the Health Research 
Authority on whether an application should be approved, and if so, any relevant 
conditions. This application was considered by the Confidentiality Advisory 
Group’s predecessor, the Ethics and Confidentiality Committee at its meeting on 
the 6 February 2013. 
 
Secretary of State approval decision 
 
The Secretary of State provided provisional approval for this amendment which 
was confirmed in the outcome letter dated 20 February 2013 and agreed that 
final approval could be given once the conditions had been met. 
 
As these conditions have been met, final approval can be confirmed. 
 
This letter should be read in conjunction with the outcome letter dated 20 February 2013. 
 
Context 
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This research application from the University of Sheffield detailed a study which 
aimed to determine the age, co-morbidity, frailty and disease characteristics of 
women over 70 with early breast cancer in order to provide guidance on 2 primary 
questions: 
 
1.        What are the personal and cancer characteristics of women who can 
be safely advised that surgery is unlikely to confer any advantage to them? 
2.        What are the personal and cancer characteristics 
of women who should be advised 
to have adjuvant chemotherapy after surgery? 
 
 
Support was requested in order to access linked HES and cancer registry data which 
included date of death. 
 
 
Specific conditions of support 
 
1.  Confirmation of a favourable REC opinion. Received 
 
2.  Confirmation of satisfactory security arrangements. Confirmed 11/04/2013 
 
3.  Reasonable efforts should be made to inform the cohort of the processing to ensure 
that the requirements of the DPA are met. 
 
 
 
As the above conditions have been accepted and/or met, this letter provides confirmation of 
final approval. I will arrange for the register of approved applications on the HRA website to 
be updated with this information. 
 
Annual review 
 
Please note that this approval is subject to submission of an annual review report to show 
how you have met the conditions or report plans, and action towards meeting them. It is also 
your responsibility to submit this report 6 weeks prior to the anniversary of your final 
approval and to report any changes such as to the purpose or design of the proposed 
activity, or to security and confidentiality arrangements. 
 
 
 
Please do not hesitate to contact me if you have any further queries in relation to this 
letter, I would be grateful if you could quote the above reference number in all future 
correspondence. 
 
Yours sincerely 
 
 
 
Claire Edgeworth 
Deputy Confidentiality Advice Manager 
 
 
 
Email:  HRA.CAG@nhs.net 
 
Enclosures:                             Standard conditions of approval 
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Copy to:                       London - South East, nrescommittee.london- 
southeast@nhs.net
Standard conditions of approval 
 
The approval provided by the Health Research Authority is subject to the following 
standard conditions. The applicant will ensure that: 
1.  The specified patient identifiable information is only used for the 
purpose(s) set out in the application. 
 
2.  Confidentiality is preserved and there are no disclosures of information in 
aggregate or patient level form that may inferentially identify a person, nor will 
any attempt be made to identify individuals, households or organisations in the 
data. 
 
3.  Requirements of the Statistics and Registration Services Act 2007 are 
adhered to regarding publication when relevant. 
 
4.  All staff with access to patient identifiable information have 
contractual obligations of confidentiality, enforceable through 
disciplinary procedures. 
 
5.  All staff with access to patient identifiable information have received appropriate 
ongoing training to ensure they are aware of their responsibilities. 
 
6.  Activities are consistent with the Data Protection Act 1998. 
 
7.  Audit of data processing by a designated agent is facilitated and supported. 
 
8.  The wishes of patients who have withheld or withdrawn their consent are respected. 
 
9.  The Confidentiality Advice Team is notified of any significant changes (purpose, 
data flows, data items, security arrangements) prior to the change occurring. 
 
10. An annual report is provided no later than 12 months from the date of your 
final confirmation letter. 
 
11. Any breaches of confidentiality / security around this particular flow of data should 
be reported to 
CAG within 10 working days, along with remedial actions taken / to be taken. 
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Appendix 3: Signed Funding Agreement 
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Appendix 4: Systematic review and Cochrane search strategies 
MEDLINE (Cochrane)  
# ▲ Searches 
1 randomised controlled trial.pt. 
2 randomized controlled trial.pt. 
3 controlled clinical trial.pt. 
4 randomized.ab. 
5 randomised.ab. 
6 placebo.ab. 
7 randomly.ab. 
8 trial.ab. 
9 groups.ab. 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11 early breast cancer.mp. 
12 early breast carcinoma.mp. 
13 early breast tumor.mp. 
14 early breast tumour.mp. 
15 early breast neoplasm.mp. 
16 locally advanced breast cancer.mp. 
17 locally advanced breast carcinoma.mp. 
18 locally advanced breast neoplasm.mp. 
19 locally advanced tumor.mp. 
20 locally advanced tumour.mp. 
21 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22 exp Mastectomy/ 
23 mastectom$.mp. 
24 surger$.mp. 
25 wide local excision.mp. 
26 axillary surger$.mp. 
27 22 or 23 or 24 or 25 or 26 
28 endocrine therapy.mp. 
29 primary endocrine therapy.mp. 
30 exp Tamoxifen/ 
31 tamoxifen.mp. 
32 29 or 30 or 31 
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33 10 and 21 and 27 
34 10 and 21 and 27 and 28 
35 10 and 21 and 32 
36 33 or 34 or 35 
37 limit 36 to (humans and yr="2008 -Current") 
EMBASE (Cochrane)  
#41:  #40 AND [humans]/lim AND [embase]/lim AND [2008-2013]/py 
#40:  #37 OR #38 OR #39 
#39:  #9 AND #27 AND #36 
#38:  #9 AND #27 AND #32 AND #33 
#37:  #9 AND #27 AND #32 
#36:  #34 OR #35 
#35:  'tamoxifen'/exp OR tamoxifen 
#34:  'primary endocrine therapy' 
#33:  'endocrine therapy'/exp OR 'endocrine therapy' 
#32:  #28 OR #29 OR #30 OR #31 
#31:  'axillary surgery' 
#30: 'wide local excision'/exp OR 'wide local excision' 
#29: 'surgery'/exp OR surgery 
#28: 'mastectomy'/exp OR mastectomy 
#27: #15 AND #26 
#26: #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 
#25: 'locally advanced breast tumor' 
#24: 'locally advanced breast tumour' 
#23: 'locally advanced breast carcinoma' 
#22: 'locally advanced breast neoplasm' 
#21: 'locally advanced breast cancer' 
#20: 'early breast tumor' 
#19: 'early breast tumour' 
#18: 'early breast carcinoma' 
#17: 'early breast cancer' 
#16: 'early breast neoplasm' 
#15: #10 OR #11 OR #12 OR #13 OR #14 
#14: 'breast tumor'/exp OR 'breast tumor' 
#13: 'breast tumour' 
#12: 'breast carcinoma'/exp OR 'breast carcinoma' 
#11: 'breast cancer'/exp OR 'breast cancer' 
#10: 'breast neoplasm' 
#9: #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 
#8: groups:ab 
#7: trial:ab 
#6: randomly:ab 
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#5: placebo:ab 
#4: randomi*ed:ab 
#3: controlled AND clinical AND trial 
#2: randomized AND controlled AND trial 
#1: randomised AND controlled AND trial 
 
WHO ICTRP (Cochrane)  
Basic Searches: 
1. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly 
women (70 years plus) 
2. (Surgery AND endocrine therapy) AND breast cancer 
3. (mastectomy AND endocrine therapy) AND breast cancer 
4. Primary endocrine therapy AND breast cancer 
Advanced Searches: 
1. Title: Surgery versus primary endocrine therapy for operable primary breast cancer in elderly 
women (70 years plus). Recruitment: All 
2. Condition: early breast cancer. Intervention: surgery AND endocrine therapy. Recruitment 
Status: All 
3. Condition: locally advanced breast cancer. Intervention: surgery AND endocrine therapy. 
Recruitment Status: All 
4. Condition: early breast cancer. Intervention: surgery OR endocrine therapy. Recruitment 
Status: All 
5. Condition: locally advanced breast cancer. Intervention: surgery OR endocrine therapy. 
Recruitment Status: All 
6. Condition: early breast cancer. Intervention: primary endocrine therapy OR Tamoxifen. 
Recruitment Status: All 
7. Condition: locally advanced breast cancer. Intervention: primary endocrine therapy OR 
Tamoxifen. Recruitment Status: All 
ClinicalTrials.gov (Cochrane)  
Basic Searches: 
1. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly 
women (70 years plus) 
2. (Surgery AND endocrine therapy) AND breast cancer 
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3. (mastectomy AND endocrine therapy) AND breast cancer 
4. Primary endocrine therapy AND breast cancer 
Advanced Searches: 
1. Title Acornym/Titles: Surgery versus primary endocrine therapy for operable primary breast 
cancer in elderly women (70 years plus). Recruitment: All Studies. Study Results: All Studies. 
Study Type: All Studies. Gender: All Studies 
2. Condition: early breast cancer OR locally advanced breast cancer. Intervention: surgery AND 
endocrine therapy. Recruitment: All Studies. Study Results: All Studies. Study Type: All Studies. 
Gender: All Studies 
3. Condition: early breast cancer OR locally advanced breast cancer. Intervention: surgery OR 
endocrine therapy. Recruitment: All Studies. Study Results: All Studies. Study Type: All Studies. 
Gender: All Studies 
4. Condition: early breast cancer OR locally advanced breast cancer. Intervention: primary 
endocrine therapy OR Tamoxifen. Recruitment: All Studies. Study Results: All Studies. Study 
Type: All Studies. Gender: All Studies 
CENTRAL (Cochrane)  
#1 MeSH descriptor: [Breast Neoplasms] explode all trees 
#2 early breast cancer* or early breast neoplas* or early breast tumour* or early breast tumor* 
#3 locally advanced breast cancer* or locally advanced breast neoplas* or locally advanced 
breast tumour* or locally advanced breast tumor* 
#4 #2 or #3 
#5 #1 and #4 
#6 MeSH descriptor: [Mastectomy] explode all trees 
#7 mastecom* or surger* or wide local excision or axillary surger* 
#8 #6 or #7 
#9 endocrine therap* 
#10 primary endocrine therapy or tamoxifen 
#11 MeSH descriptor: [Tamoxifen] explode all trees 
#12 #10 or #11 
#13 #5 and #8 
#14 #5 and #8 and #9 
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#15 #5 and #8 and #12 
#16 #13 or #14 or #15 
 
Re-run Search EMBASE, MEDLINE, PsycINFO, CINAHL (JM #1): 
1. "Primary endocrine therapy".ti,ab; 156 results.  
2. "breast cancer".ti,ab; 372631 results.  
3. tamoxifen.ti,ab; 39543 results.  
5. letrozole.ti,ab; 3840 results.  
6. anastrazole.ti,ab; 171 results.  
7. Exemestane.ti,ab; 1905 results.  
8. Arimidex.ti,ab; 586 results.  
9. Femara.ti,ab; 206 results.  
10. Aromasin.ti,ab; 80 results.  
12. "aromatase inhibitor".ti,ab; 5542 results.  
13. 1 OR 3 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 12; 45314 results.  
14. "breast carcinoma".ti,ab; 41713 results.  
15. 2 OR 14; 397757 results.  
16. ("elderly women" OR "older women" OR "over 70 years" OR "over 65 years" OR "over 80 
years").ti,ab; 53112 results.  
17. 13 AND 15 AND 16; 556 results.  
18. (adjuvant OR neoadjuvant).ti,ab; 218474 results.  
19. 17 NOT 18; 231 results.  
20. Duplicate filtered: [17 NOT 18]; 231 results.  
21. (cohort OR longitudinal OR population).ti,ab; 2635192 results.  
22. 17 AND 21; 149 results.  
23. Duplicate filtered: [17 AND 21]; 149 results.  
24. 19 OR 22; 321 results.  
25. ("randomised control trial" OR "RCT" OR "randomized control trial").ti,ab; 24301 results.  
26. 17 AND 25; 1 results.  
27. 24 OR 26; 299 results.  
28. Duplicate filtered: [24 OR 26]; 299 results.  
 
Re-run Search EMBASE, MEDLINE, PsycINFO, CINAHL (JM #2):  
1. breast.ti,ab; 620918 results.  
2. mammary.ti,ab; 116787 results.  
3. 1 OR 2; 703410 results.  
4. carcinoma.ti,ab; 865262 results.  
5. tumour.ti,ab; 327512 results.  
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6. tumor.ti,ab; 1534028 results.  
7. cancer.ti,ab; 2198338 results.  
8. malignant.ti,ab; 580370 results.  
9. malignancy.ti,ab; 191631 results.  
10. 4 OR 5 OR 6 OR 7 OR 8 OR 9; 4121836 results.  
11. elderly.ti,ab; 434690 results.  
12. older.ti,ab; 661946 results.  
13. (age AND 65).ti,ab; 207197 results.  
14. (over AND 65).ti,ab; 100427 results.  
15. (age AND 70).ti,ab; 193387 results.  
16. (over AND 70).ti,ab; 117974 results.  
17. (age AND 75).ti,ab; 177202 results.  
18. (over AND 75).ti,ab; 100641 results.  
19. (age AND 80).ti,ab; 179242 results.  
20. (over AND 80).ti,ab; 125010 results.  
21. 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20; 1754791 results.  
22. 3 AND 10 AND 21; 34122 results.  
23. "primary endocrine therapy".ti,ab; 156 results.  
24. 3 AND 10 AND 23; 137 results.  
25. Duplicate filtered: [3 AND 10 AND 23]; 137 results.   
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NIGB 
Ethics and Confidentiality Committee 
Appendix 5: NIGB approvals for registry study 
 
 
 
 
Ms Lynda Wyld      5
th
 Floor, Skipton House, 
The Medical School       80 London Road  
University of Sheffield       London 
Beech Hill Road       SE1 6LH 
Sheffield       Tel: (020) 7004 1539 
S10 2JF       Email: eccapplications@nhs.net 
 
 
 
 
20 February 2013 
 
 
 
Dear Ms Wyld 
 
ECC 8-04 (g)/2013 Bridging the Age Gap in Breast Cancer: Improving Outcomes for 
Older Women 
 
Thank you for your application for approval under the Health Service (Control of Patient 
Information) Regulations 2002 to process patient identifiable information without consent. 
Approved applications enable the data controller to provide specified information to the 
applicant for the purposes of the relevant activity, without being in breach of the common law 
duty of confidentiality. The role of the NIGB Ethics and Confidentiality Committee (ECC) is to 
review applications submitted under these Regulations and to provide advice to the Secretary 
of State for Health (SofS) on whether an application should be approved, and if so, any 
relevant conditions. This application was considered on 06 February 2013. 
 
Secretary of State decision 
 
Following consideration of the ECC advice, reproduced below, the Secretary of State has 
determined that the application should be provisionally approved. 
 
Context 
 
This research application from the University of Sheffield detailed a study which aimed to 
determine the age, co-morbidity, frailty and disease characteristics of women over 70 with 
early breast cancer in order to provide guidance on 2 primary questions: 
 
1.  What are the personal and cancer characteristics of women who can be safely 
advised that surgery is unlikely to confer any advantage to them? 
2.  What are the personal and cancer characteristics of women who should be advised to 
have adjuvant chemotherapy after surgery? 
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Support was requested in order to access linked HES and cancer registry data which 
included date of death. 
 
 
ECC advice 
 
Members considered the application at their meeting on the 06 February 2013, the advice 
provided to the SofS is reproduced below. 
 
Members discussed that the questions posed by the study were important and were 
supportive of the activity taking place. 
 
Practicable alternatives 
 
Members considered whether there was a practicable alternative to the use of identifiable 
data in this instance and noted that the argument for requiring full date of death had been 
discussed at length and approved in relation to previous cancer studies. 
 
Compliance with the DPA 
principles 
 
One of the requirements of the Regulations is that applications should not be inconsistent with 
the Data Protections Act 1998 (DPA), with this in mind members noted that the application did 
not detail any fair processing activities in relation to the activity. Members advised that 
reasonable efforts should be made to ensure that the cohort is informed about the processing 
of data for the specified purposes. 
 
ECC conclusion 
 
In line with the comments above, members agreed that the minimum requirements of the 
Regulations appeared to have been met and agreed to provide a recommendation of 
approval for this activity, subject to the following conditions. 
 
Conditions of support 
 
 
 
1.  Confirmation of a favourable REC opinion. Received 
 
2.  Confirmation of satisfactory security arrangements. Please note there has been a 
change to the security review process. Please review the following link 
(http://www.nigb.nhs.uk/s251/forms) which sets out the change, and please follow 
the guidance given. If you have any queries over this, please contact the Exeter 
Helpdesk. You can contact the Exeter helpdesk on 01392 251289 or 
exeter.helpdesk@nhs.net 
 
3.  Reasonable efforts should be made to inform the cohort of the processing to ensure 
that the requirements of the DPA are met.
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Further actions 
 
Once the conditions of approval have been accepted or met final confirmation of 
approval can be provided. 
 
Important changes 
 
Please note that the current administration of applications made under these 
Regulations by the NIGB Ethics and Confidentiality Committee is due to transfer to the 
Health Research Authority by 01 April 2013. Such arrangements will be communicated 
to applicants once confirmed. 
 
 
 
Please do not hesitate to contact me if you have any queries following this letter, I 
would be grateful if you could quote the above reference number in all future 
correspondence. 
 
 
 
Yours sincerely 
 
 
 
 
Claire Edgeworth 
NIGB Deputy Approvals Manager 
 
Cc. London - South East,  nrescommittee.london-southeast@nhs.net 
 
 
Standard conditions 
 
The approval provided by the Secretary of State for Health is subject to the 
following standard conditions. 
 
The applicant will ensure that: 
 
1.  The specified patient identifiable information is only used for the purpose(s) set 
out in the application. 
 
2.  Confidentiality is preserved and that there is no disclosure of information in 
aggregate or patient level form that may inferentially identify a person, nor will 
any attempt be made to identify individuals, households or organisations in the 
data. 
 
3.  Requirements of the Statistics and Registration Services Act 2007 are adhered 
to regarding publication when relevant. 
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4.  All staff with access to patient identifiable information have contractual 
obligations of confidentiality, enforceable through disciplinary procedures. 
 
5.  All staff with access to patient identifiable information have received 
appropriate ongoing training to ensure they are aware of their 
responsibilities. 
 
6.  Activities are consistent with the Data Protection Act 1998. 
 
7.  Audit of data processing by a designated agent of the Secretary of 
State is facilitated and supported. 
 
8.  The wishes of patients who have withheld or withdrawn their consent are 
respected. 
 
9.  The NIGB Office is notified of any significant changes (purpose, data flows, 
security arrangements) to the application. 
 
10. An annual report is provided no later than 12 months from the date of your 
final confirmation letter. Details are available on the NIGB website. 
 
11. Any breaches of security around this particular flow of data should be reported 
to the NIGB within 10 working days, along with remedial actions taken. 
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Appendix 6: Variation in Clinician Preference study protocol 
  
 
Variation in Clinician Preferences 
for Treatment in Older Women with 
Operable Breast Cancer. 
 
Protocol Version 1.0 
24th October 2012 
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Study Protocol version: 1.0 
Date:    24th October 2012 
Study Start Date:  1st October 2012 
Funder:    National Institute for Health Research 
Funding Type:   Programme Grant 
Award Number:  RP-PG-1209-10071 
Sponsoring Body:  Sheffield Teaching Hospitals NHS Foundation Trust 
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Executive Summary. 
 
Breast cancer is now the most common cancer in the UK, with 48,000 cases diagnosed in 
the UK each year [Cancer Research UK, 2009]. A third of these occur in women over the age 
of 70 years [Reed MWR, 2009]. Recent reports demonstrate that patients aged over 70 
years are the only group of cancer patients in the UK where the mortality from cancer is 
not falling and may even be rising [Bastiaannet E, 2011]. This is thought to be due, in part, 
to under-treatment.  
 
One area of practice where treatment in older women differs from that in younger women 
is the omission of surgery in women with oestrogen receptor positive cancer. Surgery is the 
mainstay of treatment for younger women, but in frailer, older women, surgery may be 
avoided and disease control achieved with anti-oestrogens alone. This is called primary 
endocrine therapy (PET). This may be a perfectly appropriate treatment option in frailer 
older women, for whom operative intervention may be associated with increased risks of 
complications because of pre-existing co-morbidities or frailty. However practice in the UK 
is highly varied with some health regions operating on almost 90% of older women, others 
on only 60%. This suggests that guidelines on best practice are urgently needed to 
standardise care.  Much of the data on the use of PET was derived from studies which are 
now 30 years old.  In this time life expectancy has risen, with many people still healthy and 
fully independent in their 70s and 80s. The resulting effect is that some older women may 
be under-treated, whilst others are over-treated. 
 
Currently, there are no treatment guidelines to determine which patients should be offered 
PET as opposed to surgery. The decision is a complex one with many factors that may 
influence how a particular patient is managed, for example: co-morbidities, cognitive 
function, frailty and dependence, patient preference and clinician preference. 
 
This proposed mixed methodology study has 3 stages: 
1. Systematic review of the current published literature on clinician preferences for 
surgery versus primary endocrine therapy in older women with operable breast 
cancer. 
2. Elicit the views and preferences of specialist health care professionals regarding the 
benefits and risks of surgery and primary endocrine therapy through semi-
structured, purposively selected interviews. 
3. Use of a bespoke questionnaire to quantify the strength of each theme identified in 
stages 1 and 2. This will permit the study team to determine levels of clinician 
practice variance and the key factors that underpin this. 
 
Background. 
An Ageing Population. 
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The population of the UK is aging and the average life expectancy has increased by 30 years 
during the last century, with most people now expected to live into their 80s [Christensen 
K, 2009]. The elderly are the most rapidly increasing population group [Olshansky SJ, 2001] 
and the overall health status of this group is also improving [Christenshen K, 2008; 
Christensen K, 2009]. Improved disease prevention with better control of chronic diseases, 
mean the elderly are living longer even in the presence of chronic health problems. Despite 
this, there is wide variation in the health status of this age group, with some 75 year olds 
who are fit and healthy, living an active lifestyle, whilst others are frail, with multiple co-
morbidities, necessitating assisted living. Determining best practice in this group is 
therefore complicated and treatment requires tailoring to individual patients, not to their 
chronological age. 
 
Breast Cancer in Older Women. 
A third of the 48,000 breast cancers diagnosed in the UK each year occur in women over 
the age of 70 years [Reed MWR, 2009]. Recent reports demonstrate that patients aged 
over 70 years are the only group of cancer patients in the UK where the mortality from 
cancer is not falling and may even be rising [Bastiaannet E, 2011]. This inequality is a major 
priority for the NHS [Department of Health, 2012].  
Breast cancer in older women tends to have a slightly difference disease biology than in 
younger women, with higher rates of oestrogen sensitivity [McCarty KS, 1983; Diab SG, 
2000], lower rates of HER-2 receptor expression [Diab SG, 2000] and a slower growth rate 
[Diab SG, 2000]. However, older women tend to present with more advanced breast cancer 
[Schonberg MA, 2010]. The size of the primary tumour is larger [Diabe SG, 2000; Golledge J, 
2000; Maidone MG, 2003; Monfardini S, 2009] and there are increased rates of locally 
advanced [Eaker S, 2006] and metastatic disease [Yancik R, 1989; Wyld L, 2004].  
Breast cancer outcomes have been shown to be inferior in older women compared to 
those in younger women [Bastiaannet E, 2009; Wishart GC, 2010; van de Water W, 2012]. 
Despite this, however, the clinical significance of breast cancer is proportionally less in 
older women as breast cancer specific mortality is overtaken by other cause mortality once 
a woman is in her early 80s. This translates to breast cancer causing only approximately 
23% of deaths in women with breast cancer in their mid-80s, compared to 73% of deaths in 
patients in their early 50s [Diab SG, 2000]. However the interactions of age, co-morbidity 
and frailty in older patients with breast cancer has a significant impact on disease outcomes 
and there is convincing evidence that women over the age of 80 have a higher risk of dying 
of their breast cancer than women in their 70s [van der Water W, 2012]. It is thought that 
this may be due, in part to sub-optimal treatment [Schonberg MA, 2010]. Clinician 
awareness of these interactions would enable treatment to be optimised to prevent over- 
or under-treatment. 
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Treatment of Breast Cancer in the Elderly: Surgery versus PET 
The mainstay of treatment for breast cancer in most women is surgery, and whilst fitter 
older women should ideally be offered the same treatments as younger women, less 
aggressive strategies may be justified for frailer patients where surgery may carry increased 
risks. Primary endocrine therapy (PET) is an example of a modified treatment strategy that 
is suitable for this group of patients, and uses only medical therapy in the form of anti-
oestrogen drugs, such as Tamoxifen. Up to 90% of breast cancers in older women express 
the oestrogen receptor (ER) [McCarty KS, 1983; Diab SG, 2000] which, when stimulated, 
promotes tumour growth. Anti-oestrogen therapies block the ER, causing tumour 
regression. PET is an effective means of breast cancer control in the short to medium term 
in frailer older women [Hind D, 2007] and has the advantage of avoiding anaesthesia with 
its risks of cardio-respiratory complications, as well as avoiding the physical and 
psychological morbidity of surgery. 
Primary Endocrine Therapy was first described in the late 70s and early 80s and rapidly 
became popular [Preece PE, 1982; Bradbeer JW, 1983], with early response rates of 75% or 
better [Preece PE, 1982; Bradbeer JW, 1983]. Whilst initially effective, well-tolerated and 
associated with a low complication rate, tumour re-growth occurs within a median of 
around 24 months [Fentiman IS, 2003; Mustacchi G, 2003] and second line therapy is 
required. 
Randomised controlled trials comparing PET with surgery have shown PET to have inferior 
local disease control rates [Robertson JF, 1988; Gazet JC, 1994; Mustacchi G, 1998; 
Fentiman IS, 2003; Mustacchi G, 2003]. Despite this, there is no mortality disadvantage on 
meta-analysis of all trials, although there is a trend in favour of surgery [Hind D, 2006]. In 
addition, since these trials were carried out, a new, more potent class of anti-oestrogen 
drugs (the aromatase inhibitors) have become available [Eiermann W, 2001; Ellis MJ, 2001; 
Mouridsen H, 2003; Howell A, 2005], meaning that PET may now be more efficacious if 
candidates are selected appropriately. 
Patients themselves have demonstrated a high degree of satisfaction with both surgery and 
PET [Husain LS, 2008]. Factors in favour of PET include: avoidance of hospitalisation and 
surgery, a desire to retain independence, fear of anaesthesia and a desire for minimal 
disruption to life and independence [Husain LS, 2008]. 
 
Variation in Practice. 
In the UK there is wide variation in practice relating to the treatment of older women with 
breast cancer, with some areas demonstrating a 40% rate of PET, whilst in other areas the 
rate is only 10% [BCCOM Audit, 2007]. The concern is that women in centres with low 
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surgery rates will be inappropriately denied operative intervention, with the long-term 
consequences of local recurrence, necessitating a change in management. Conversely, in 
regions with high rates of surgery, women may be inappropriately subjected to the 
morbidity or even mortality of surgery with no benefit. 
Regionally, variance may be explained in part by deprivation levels.  The low PET rate 
regions are in southern England (Oxford and Thames), where rates of deprivation are low.  
The higher PET rate areas are in northern England (Yorkshire and Humber, North East) 
where levels of deprivation are higher.  It is widely accepted that deprivation levels are 
linked to higher burdens of other diseases, rates of smoking, lower levels of educational 
attainment and lower screening uptake rates.  These factors may contribute to women 
presenting at a later stage in their disease and being less able to undergo safe surgery.  This 
is speculation as no study has looked at this issue and it is unlikely to account for a 4 fold 
variation in practice.   
 
Clinician preference may also form a substantial cause of practice variance.  Anecdotal 
evidence indicates that some surgeons have a very strong preference for surgery and 
others feel that PET is appropriate for the majority of older women.  The causes of this 
varying opinion are not known but may include person experience, interpretation of the 
literature or unit protocols.  It may also be affected by the anaesthetic staffs’ attitudes to 
anaesthesia in older women and the availability of regional and local anaesthesia 
techniques. 
 
This study will examine the variance in practice by two means. Initially, a series of 
interviews with health care professionals will be undertaken in units with high, 
intermediate and low rates of non-surgical treatment. This will establish the factors taken 
into account when assessing older women for treatment and the personal weights that 
clinicians place on these. Following this a bespoke questionnaire will be used to quantify 
these factors and correlate them with the different health regions. This will incorporate a 
number of scenarios relating to hypothetical older women with varying levels of health, 
fitness, cognition etc. This will enable us to explore the contribution of physician opinion in 
treatment decisions and how this varies by health region.  A separate study which is not 
included in this protocol (and is part of a separate ethics application) will study regional PET 
rates and case mix adjustment (for issues such as stage at diagnosis, deprivation levels, 
screening etc). 
 
 
Summary 
Consistently research has reported that older women (>70 years) have huge variation in 
their breast cancer treatment pathways compared to younger women and that this 
variance is, in part, determined by locality.  
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Given than most breast cancers occur in older age it is important that this group receive 
appropriate treatment options based on their personal health status and treatment 
preferences rather than their chronological age. There is a need for more standardised 
assessment of patient fitness, taking into account individual co-morbid status and frailty.  
This study will give an insight into the factors that are taken into account when clinicians 
are deciding on treatment plans for older women.  It is part of a larger programme of 
research which will also determine the factors the older women themselves take into 
account when they decide on how they wish to be treated and the outcomes of different 
treatments in this age group.  It is hoped that the research will enable the development of 
guidelines for optimised, individualised care of older women with breast cancer. 
 
Aims of the study. 
 
1. To explore the views of specialist healthcare professionals towards to management 
of older women (>70yrs) with operable breast cancer, particularly in terms of PET 
versus surgery. 
2. To determine the factors underlying treatment decision making in health care 
professionals relating to older women with breast cancer. 
3. By means of a bespoke questionnaire, to quantitatively assess the above factors on 
a wide group of healthcare professionals and correlate these findings with local 
social and demographic factors. 
 
Study Outcomes. 
Primary Outcome: 
To determine the factors underlying treatment decision making in health care 
professionals relating to older women with breast cancer.  
  
Secondary Outcome: 
To determine the level of variance in decision making practice amongst health care 
professionals.  
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Research Methods. 
Study Design: 
 
Detailed Methodology. 
 
Stage 1: Literature Review. 
Search Strategy. 
A systematic search of studies, both published and unpublished, focusing on the risks and 
benefits of PET versus surgery in older women (>70 years) with operable breast cancer will 
Systematic Literature Review 
Qualitative 
Interviews 
with Breast 
Surgeons 
Develop and 
pilot discrete 
choice 
instrument 
Framework 
Analysis to 
identify key 
themes 
Qualitative 
Interviews 
with 
Oncologists 
Qualitative 
Interviews 
with Breast 
Care nurses 
Develop and 
pilot a bespoke 
questionnaire 
to quantify 
importance of 
themes 
Application of 
questionnaire 
to UK breast 
care teams 
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be performed. Studies focusing on decision making and risk perception relating to health 
care professionals when treating older women, will also be reviewed. Additionally, cohort 
studies looking at the treatment of this group of patients will be sought to try and further 
clarify current practice.  
The following electronic databases will be searched from as primary resources. The 
Cochrane Library, CRD databases (DARE, NEED, HTA), Medline, Embase, Psychinfo, CINAHL, 
Specialist databases (Cancer lit in PubMed, Oncolink and Scopus). Searching of key 
websites, for example The Royal College of Surgeons, will also be undertaken. Hand-
searching of papers, grey literature (using the British Library's Integrated Catalogue), 
current research projects (NIHR Clinical Research Network Portfolio database, HTA 
database) and reference lists of relevant papers will also be reviewed.  
 
Stage 2: Qualitative interviews with health care professionals 
This study will establish the views and preferences of a range of health care professionals 
with expertise in breast care regarding the breast cancer treatment options; surgery (+ 
adjuvant endocrine therapy) and PET, and the factors influencing these. Data will be 
collected via semi-structured qualitative interviews. Maximal variation sampling will be 
used to include different types of HCP (surgeons, oncologists, and breast care nursing) and 
HCP from breast units with different rates of surgery or PET usage. Interview data analysis 
using the Framework Approach will occur alongside recruitment, and recruitment will 
cease on achievement of data saturation. From previous work in the field it is anticipated 
approximately 35 interviews will be required. 
Regulatory Approvals. 
Research and Development approval will be obtained for the project. All study researchers 
will have undergone full GCP training and hold valid NHS research passports.  
Sites. 
The study will recruit health care professionals from breast units across the UK. Units will 
be identified by examination of published rates of PET versus surgery for a particular region 
which is freely available via national cancer dataset such as the BCCOM audit [BCCOM 
Audit, 2007]. Within regions identified as having high, low or intermediate rates of PET, 
contact will be made with a local principle investigator who will be asked to identify 
surgeons, oncologists, and breast care nurses for contact. Data will be requested on rates 
of non-surgical treatment for each unit to validate registry and national audit data. 
Units identified include: 
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PET rates Units Identified PI 
High Derby KL Cheung  
Nottingham Ms Ellie Gutteridge 
Newcastle Mr Richard Bliss, Mr Andy Griffiths and 
Professor Tom Lennard 
Intermediate Sheffield Lynda Wyld 
Leicester Anne Stotter 
Cardiff Professor Robert Mansel and 
Professor Helen Sweetland 
Low Oxford Charlie Chan  
Whiston Riccardo Audisio  
London, Guys Michael Douek 
 
Recruitment. 
A local principle investigator (PI) will be identified at each site by direct contact from a 
member of the study team. The PI will be asked to provide a list of names of suitable health 
care professionals working within the unit who may be happy to be contacted by the study 
team. Individuals will then be sent a study pack by post which will contain the following: a 
letter of invitation, a participant information sheet (PIS), a study reply slip and a freepost 
envelope. A sample letter of invitation/PIS is contained in Appendix I. This will invite the 
HCP to complete a reply slip to agree to be contacted about taking part. A sample reply slip 
is in Appendix II. On receipt of a reply slip indicating agreement to participate, the research 
team will contact the interview candidate and arrange a time and place to meet. This will 
be agreed verbally and confirmed in writing before the scheduled date. A consent form will 
be signed before the interviews commence (Appendix III). 
Conduct of the Interviews. 
Participants will be contacted again the day before their interviews to ensure they still wish 
to proceed. They will be given an opportunity to decline if they so wish. All interviewees 
will be reassured that they may terminate or pause the interview at any point without 
stating a reason for doing so and that their participation is entirely voluntary. If wished, 
telephone interviews may be offered. All interviews will be digitally recorded and 
transcribed verbatim. All data collected will be pseudo-anonymous and databases 
password protected in accordance with the Data Protection Act. Feedback from the 
research will be offered to all study participants. 
Interview Schedule and Content. 
An interview schedule has been developed by the study team. This will enable the 
interviews to explore key issues but also give opportunity for free expression of views with 
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open questions. The areas for discussion are based on previous interviews with health care 
professionals [Hussain LS, 2007; Walters S, 2011] where similar issues were explored and 
which will serve as pilot projects for the present study.  
The interviews will explore the following areas: 
What treatment options would you normally consider for an older woman (over 70) with 
operable primary breast cancer? 
Prompts: Would surgery form part of your potential management plan in all 
patients? 
 Is PET an option for all patients in this group? 
What do you feel are the risks and benefits of surgery and PET for this age group? 
Prompts: Morbidity and mortality of surgery 
 Local recurrence risks, local control 
 Compliance 
What factors influence your choice of management for a particular patient with primary 
operable breast cancer? 
Prompts: Age of patient at diagnosis 
 Frailty of patient 
 Co-morbidities, including dementia 
 Anaesthetic considerations 
 Optimisation of other health issues 
 Patient choice 
 Carer preferences 
 Guidelines 
 Stage/operability of cancer 
 Cancer biology (e.g. ER and HER2 status, mucinous subtype) 
 Pre-operative assessment: anaesthetic assessment, formal geriatric 
assessment, “end of the bed” assessment 
Are there any other factors that influence your overall practice in this patient group? 
Prompts: Influence of cancer targets 
 Influence of costs 
If in such patients there is the potential for choice of either surgery or primary endocrine 
therapy, what level of involvement does the patient play in the management decision?  
What factors have influenced your personal strategy for dealing with these patients? 
Prompts: Literature evidence 
 Patient preference 
 Experience of cases over the years 
 Unit policy 
 Training and mentoring 
 Breast care nurse input 
What affects the amount of information you relay to a patient following a diagnosis of 
breast cancer? 
Prompts: Patient wishes 
 Patient cognitive status 
 Relative and carers information needs 
What do you think elderly women feel about primary endocrine therapy? 
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Prompts: Easier than having surgery 
 Safer than having surgery 
 Less certainty of a cure 
 Less hassle 
What do you think elderly women feel about having surgery? 
Prompts: Fear of death 
 Disfigurement or loss of breast 
 Fear of hospitalisation 
 Burden on others 
 Loss of independence 
 Complications (e.g. arm swelling) 
Any additional comments the participant would like to add 
 
Data Analysis. 
Qualitative interview transcript analysis will follow the National Centre for Social Research 
Framework” approach, to identify recurrent themes [Richie J, 2003]. The Framework 
approach permits the systematic analysis of large volumes of textual data and permits 
within and across case and theme comparison. Analysis will be undertaken by Jenna 
Morgan with oversight/supervision from three experienced qualitative researchers (Dr 
Collins and Ms Wyld). A thematic index will be drawn up and applied to the data. Data will 
be distilled, summarised and entered into thematic charts to allow examination and 
interpretation of the data and to identify any relationships between themes. 
 
Stage 3: Questionnaire Study. 
In order to quantify the findings of earlier phases of the study and link them to participant 
and locality characteristics, a bespoke questionnaire will be developed based on the themes 
and findings of the qualitative interviews.  
An initial pilot questionnaire will be developed and will be reviewed by means of several 
focus groups by health care professional members of the study team and the extended 
‘bridging the Age Gap in breast cancer study team (LW, MWR, LC, RAA, AS, REC) and 
members of the surgical and breast care nursing team locally in Sheffield, to ensure it has 
content and face validity, is comprehensible and useable. The survey will be piloted to 
examine the length, acquiescent response set, flow, salience, ease of administration and 
response and acceptability to respondents [Boynton PM, 2004]. Respondents will also be 
asked to indicate how long it took them to complete the questionnaire and will be invited to 
comment on any questions which were difficult to interpret or to answer. Appropriate 
modifications will be made to the design and content of the questionnaire before it is sent 
out to the wider population of UK healthcare professionals. 
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The questionnaire will contain questions themed around risks, benefits and preferences for 
PET and surgery in older women with a variety of clinical characteristics and presentations. 
Age, sex, locality and professional status (trainee, consultant) and professional type (BCN, 
Surgeon, Oncologist) will provide baseline demographics. A preliminary version of the 
questionnaire to show the integral participant information sheet, format and probable 
content is attached to this document (Appendix IV) but will be modified by phases 1 and 2.  
The questionnaires will be sent to relevant healthcare professionals via post and/or e-mail, 
along with a covering letter (Appendix VI and individual participants will identify themselves 
to the research team by returning the completed questionnaire, thus ensuring participant 
confidentiality, and providing implied consent.  
Recruitment. 
The questionnaire will be sent to all members of the Association of Breast Surgeons, both 
surgeon and BCN members. It will also be sent to the Association of Cancer Physicians. 
Respondents will be asked to tick a box to state what UK health region they work in and 
whether their area is rural or urban, affluent, intermediate or deprived to allow estimation 
of whether they are in a high, low or intermediate PET rate region and will also be asked to 
estimate what percentage of their older breast cancer cases they treat with PET or surgery 
(tick box categories). Responses will thereby remain anonymous. The questionnaires will be 
prepared and made up into packs together with a prepaid envelope and sent to the 
association who will undertake the mailing to maintain confidentiality. Return of a 
completed questionnaire will be taken as indicative of consent. 
A record of the number of packs sent out will be kept and correlated with the number 
returned to give the response rate. Based on our previous similar study we expect a 
response rate of 40%. No reminders will be sent. 
Statistical Analysis Plan and Sample Size Calculation. 
The first part of the questionnaire is essentially descriptive and will be analysed by 
calculation of median response and range to the Likert style questions. Correlation of 
response medians with HCP characteristics such as age subgroup and professional subtype 
will be performed using Chi squared test.  
The discrete choice questionnaire wherein scenarios are described and treatment 
preferences for PET or surgery or undecided will be analysed. Discrete choice scenarios 
provide information on the relative weights individual professionals attach to the various 
dimensions (variables) involved in the decision making process and how willing they are to 
trade these off against each other in reaching a decision. Respondents will be provided 
with pair wise choices between hypothetical scenarios and asked to choose their preferred 
scenario from each pair. These choices can then be used to infer the trade-offs people are 
willing to make with respect to changes in the levels of the attributes. 
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This part of the survey will be developed in conjunction with Professor Stephen Walters. 
Scenarios will be evaluated by Professor Tom Robinson to determine whether all are 
realistic representations of real life older women and also to estimate whether individual 
scenarios would be associated with a predicted life expectation of less than 2 year, 2-5 
years or greater than 5 years.  These time periods have been selected as women with 
predicted life expectancies of less than 2 years will be likely to gain no benefit from surgery 
whereas those likely to survive for over 5 years are likely to develop disease progression 
without surgery, based on a median effect duration of PET from published literature of 24 
months. 
For pragmatic reasons (survey length and acceptability), a limited number of variables can 
be incorporated into the study design. The key variables included in this survey will be 
patient age, health status, cognitive function, functional status and breast cancer ER status. 
Scenario descriptions will then be generated by ‘Orthoplan’ software from SPSS, converting 
an orthogonal array of dimensions and their levels into an additive model, generating all 
possible combinations of levels of the key variables. The hypothetical combinations will be 
presented in the form of a survey, as scenarios composed of the different levels of the 
variables. 
Respondents will be asked to make a choice between the different models proposed for 
each scenario. At this stage of the design it is not possible to specify the factors and levels 
to be included in the hypothetical scenarios for the discrete choice scenarios. However, 
previous work with health care professionals in the breast cancer area (Walters et al, 2010, 
Caldon et al 2007) has suggested that respondents can look at up to 25 scenarios with 5 
factors (with up to five levels for some of the factors). For sample size purposes, with 100 
responders to the DCE then for any hypothetical scenario, assuming say 50% of health care 
professionals would choose a woman with these characteristics to have PET, then we 
should be able to estimate this proportion within +/- 10% (i.e. 95% CI: 40 to 60%). With 60 
responders to the DCE then for any hypothetical scenario, assuming say 50% of health care 
professionals would choose a women with these characteristics to have PET, then we 
should be able to estimate this proportion within +/- 12% (i.e. 95% CI: 38 to 62%). 
Training of the Research Student in Qualitative Research Methods. 
 
The student will be formally mentored by Ms Wyld and Dr Collins throughout her research 
attachment and will be entered into a qualitative research lecture module run by ScHARR 
at the University of Sheffield. She will also attend a 1 day training course on interviewing 
techniques run by Dr Michelle Winslow of the University of Sheffield (a specialist in oral 
history and qualitative interviewing techniques). The student will also be accompanied by 
Dr Collins or Ms Wyld during her first few interviews and quality control applied 
subsequently by means of review of audio recordings. 
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Project Gantt Chart and Time Lines. 
 
Action (Months) 3 6 9 12 15 18 21 24 
Literature Review         
Write-up literature 
review for 
publication 
        
Recruitment and 
interviewing 
        
Transcribe and 
analyse interviews 
        
Develop and send out 
questionnaire 
        
Data analysis         
Report, write up and 
publication 
        
 
Data Management. 
All data will be handled, computerised and stored in accordance with the Data Protection 
Act 1998. A Site File of study documentation will be retained for a minimum of 15 years 
after study completion. All data collected will be pseudo-anonymised and databases will be 
password protected in accordance with the Data Protection Act. Data will be stored in a 
locked room at the Royal Hallamshire Hospital, Sheffield, for 15 years before being 
confidentially destroyed. 
 
Ethics. 
The study will be performed in accordance with the recommendations guiding 
physicians in biomedical research involving human subjects, adopted by the 18th 
World Medical Association General Assembly, Helsinki, Finland, June 1964, 
amended at the World Medical Association General Assembly, Seoul, Korea, 
October 2008. Informed written consent will be obtained from the older women 
and clinicians prior to entry into the study. The right of a participant to refuse 
participation without giving reasons will be respected. The participant will remain 
free to withdraw at any time from the study without giving reasons and without 
prejudicing further treatment. The study will be conducted in accordance with the 
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principles of GCP according to the EU Directive 2005/28/EC [Commision of the 
European Communities, 2005]. The study does not require specific ethics approval 
as it is recruiting health care professionals rather than patients. 
 
Confidentiality. 
The study will collect healthcare professional data that may include some 
participant identifiers. All data collected will be pseudo-anonymised and databases 
will be password protected in accordance with the Data Protection Act. A list of 
participant names will be stored separately from participant details. The study will 
comply with all aspects of the Data Protection Act 1998. Any information that 
would allow clinicians to be identified will not be released into the public domain. If 
a participant withdraws consent for their data to be used then it will be 
confidentially destroyed.  
 
Archiving. 
At the end of the study, data and the Study Site File will be securely archived for a 
minimum of 15 years. Following authorisation from the sponsors arrangements for 
confidential destruction will then be made. If a participant withdraws consent for 
their data to be used, it will be confidentially destroyed.  
 
Indemnity. 
This study will be sponsored by Sheffield Teaching Hospitals NHS Foundation Trust 
who therefore will be liable for negligent harm caused by the design of the study. 
There are no patients involved in this study and therefore the risks to patients 
associated with this study are minimal. 
 
Study Sponsorship. 
This study will be sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. 
 
Responsibilities and Operational Structure. 
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Ms Lynda Wyld (Senior Lecturer and Consultant Surgeon at STH) will be the research 
student's primary supervisor and project lead. Qualitative and mixed methodological 
expertise will be provided by Dr Karen Collins. Statistical advice will be provided for analysis 
of the questionnaire data by Professor Walters and Dr Shepherd. 
 
Trial Management Group 
The TMG will meet regularly to review progress. This will include the following team 
members: 
Ms L Wyld, Dr K Collins, Prof MW Reed, Miss J Morgan, Dr N Shepherd. 
 
 
Funding. 
The day to day conduct of the study will be undertaken by the research fellow 
(during a 24 month research placement). Miss Morgan will be employed by 
Sheffield Teaching Hospitals NHS Trust for the duration of the project as a Clinical 
Research Fellow. Salary funding is provided by the STH Trust from the NIHR funded 
‘Bridging the Age Gap’ programme grant. The necessary digital transcription 
machines are already available in the Department. Interview transcription will be 
provided by the Age Gap study administrative officer, Charlene Martin. Stationary, 
postage and printing costs for the study will be supported by the Age Gap study 
consumables budget.  
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Appendix 7: University Ethics Approval Letter for Clinician 
Variation Study 
The  
Medical  
School. 
 
 
Miss Jenna  Morgan     Medical School Office 
Clinical Research Fellow    Sara Watkinson 
Academic Unit of Surgical Oncology  Research Ethics Administrator 
University of Sheffield     University of Sheffield 
Medical School      Beech Hill Road 
Sheffield, S10 2RX     Sheffield  S10 2RX 
23 November 2013     Telephone: +44 (0) 114  226 1458 
REF: SMBRER243     Email: 
s.watkinson@sheffield.ac.uk 
 
Dear Jenna 
 
Variation in Clinician Preference for Treatment of Older Women with  
Operable Breast Cancer 
 
I  am  pleased to inform   you  that   on  22
nd   
November 2012 the  School’s  
Ethics  Reviewers approved the  above-named project on ethics grounds, 
on the  basis  that  you will adhere to and use the following documents that 
you submitted for ethics review. 
 
i)         Ethics form, version  1, 05/11/12 [approved – 22/11/12] 
ii)        Variation in Clinician Preferences Protocol [approved – 22/11/12] 
 
 
However,  one  small  suggested amendment is that  on  page  17 it suggests 
analysis  will be undertaken by  Jenna  Morgan  and  three  experienced 
researchers, however, only  two  are listed.  Is there to be two or three and 
if the latter please could you provide a name. 
 
Please  find attached the final versions of the 
documents you should  use. 
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If during  the course of the project you need to deviate  from the  above-
approved documents, please inform  me.  The written approval of the 
School’s Ethics Review Panel will be required for  significant  deviations 
from or significant  changes to  the  above-approved  documents.  If you 
decide to terminate the project prematurely, please inform me. 
 
Yours  sincerely 
 
Sara Watkinson 
School Research 
Ethics Administrator 
 
 
Enc 
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Appendix 8: IRAS Application for Variation in Clinician 
Preference Study 
Welcome to the Integrated Research Application System 
IRAS Project Filter 
The integrated dataset required for your project will be created from the answers you give to the 
following questions. The system will generate only those questions and sections which (a) apply to your 
study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the 
questions before proceeding with your applications. 
Please enter a short title for this project (maximum 70 characters)  
Variation in Treatment of Older Women with Operable Breast Cancer 
 
1. Is your project research? 
  Yes     No 
 
2. Select one category from the list below: 
  Clinical trial of an investigational medicinal product 
  Clinical investigation or other study of a medical device 
  Combined trial of an investigational medicinal product and an investigational medical device 
  Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in 
clinical practice 
  Basic science study involving procedures with human participants 
  Study administering questionnaires/interviews for quantitative analysis, or using mixed 
quantitative/qualitative methodology 
  Study involving qualitative methods only 
  Study limited to working with human tissue samples (or other human biological samples) and data 
(specific project only) 
  Study limited to working with data (specific project only)   Research tissue bank 
  Research database 
If your work does not fit any of these categories, select the option below: 
  Other study 
 
2a. Please answer the following question(s): 
a) Does the study involve the use of any ionising radiation?                                                            No  
b) Will you be taking new human tissue samples (or other human biological samples)?        No  
c) Will you be using existing human tissue samples (or other human biological samples)?      No 
 
3. In which countries of the UK will the research sites be located?(Tick all that apply) 
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England Scotland Wales 
Northern Ireland 
 
3a. In which country of the UK will the lead NHS R&D office be located: 
England 
 
4. Which review bodies are you applying to? 
NHS/HSC Research and Development offices  
Social Care Research Ethics Committee  
Research Ethics Committee 
National Information Governance Board for Health and Social Care (NIGB)  
Ministry of Justice (MoJ) 
National Offender Management Service (NOMS) (Prisons & Probation) 
For NHS/HSC R&D offices, the CI must create Site-Specific Information Forms for each site, in addition to 
the study-wide forms, and transfer them to the PIs or local collaborators. 
 
It looks like your project is research requiring NHS R&D approval but does not require review by a REC 
within the UK Health Departments Research Ethics Service – is that right? 
  Yes      No 
 
4b. Please confirm the reason(s) why the project does not require review by a REC within the UK Health 
Departments Research Ethics Service: 
  Projects limited to the use of samples/data samples provided by a Research Tissue Bank (RTB) with 
generic ethical approval from a REC, in accordance with the conditions of approval. 
  Projects limited to the use of data provided by a Research Database with generic ethical approval from a 
REC, in accordance with the conditions of approval. 
  Research limited to use of previously collected, non-identifiable information 
  Research limited to use of previously collected, non-identifiable tissue samples within terms of donor 
consent 
  Research limited to use of acellular material 
  Research limited to use of the premises or facilities of care organisations (no involvement of 
patients/service users as participants) 
  Research limited to involvement of staff as participants (no involvement of patients/service users as 
participants) 
5. Will any research sites in this study be NHS organisations? 
  Yes      No 
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5a. Are all the research costs and infrastructure costs for this study provided by an NIHR Biomedical 
Research Centre, NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in Health Research 
and Care (CLAHRC) or NIHR Research Centre for Patient Safety & Service Quality in all study sites? 
  Yes      No 
If yes, NHS permission for your study will be processed through the NIHR Coordinated System for gaining 
NHS Permission (NIHR CSP). 
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research 
Network (CRN) support and inclusion in the NIHR Clinical Research Network (CRN) Portfolio? Please see 
information button for further details. 
  Yes      No 
If yes, NHS permission for your study will be processed through the NIHR Coordinated System for gaining 
NHS Permission (NIHR CSP) and you must complete a NIHR Clinical Research Network (CRN) Portfolio 
Application Form immediately after completing this project filter and before completing and submitting 
other applications. 
6. Do you plan to include any participants who are children? 
  Yes       No 
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking 
capacity to consent for themselves? 
  Yes       No 
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in 
the study following loss of capacity. Intrusive research means any research with the living requiring 
consent in law. This includes use of identifiable tissue samples or personal information, except where 
application is being made to the NIGB Ethics and Confidentiality Committee to set aside the common law 
duty of confidentiality in England and Wales. Please consult the guidance notes for further information on 
the legal frameworks for research involving adults lacking capacity in the UK. 
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM 
Prison Service or who are offenders supervised by the probation service in England or Wales? 
  Yes       No 
9. Is the study or any part of it being undertaken as an educational project? 
  Yes      No 
Please describe briefly the involvement of the student(s):  
The study will be part of an MD and the student is the Chief Investigator 
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate? 
  Yes      No 
10. Will this research be financially supported by the United States Department of Health and Human 
Services or any of its divisions, agencies or programs? 
  Yes       No 
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage 
of the project (including identification of potential participants)? 
  Yes       No 
Integrated Research Application System 
Application Form for Research administering questionnaires/interviews for quantitative analysis or 
mixed methodology study 
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NHS/HSC R&D Form (project information) 
Please refer to the Submission and Checklist tabs for instructions on submitting R&D applications. 
The Chief Investigator should complete this form. Guidance on the questions is available wherever you 
see this symbol  displayed. We recommend reading the guidance first. The complete guidance and a 
glossary are available by selecting  Help. 
Please define any terms or acronyms that might not be familar to lay reviewers of the application. 
Short title and version number: (maximum 70 characters - this will be inserted as header on all forms) 
Variation in Treatment of Older Women with Operable Breast Cancer 
 
PART A: Core study information 
1. ADMINISTRATIVE DETAILS 
A1. Full title of the research: 
Variation in Clinician Preference for Treatment in Older Women with Operable Breast Cancer 
 
A2-1. Educational projects 
Name and contact details of student(s): 
Title  Forename/Initials Surname Miss Jenna Morgan 
Address  3 Copperfield Close Sherburn-in-Elmet Leeds.  LS25 6NP 
E-mail                    jenna.morgan@doctors.org.uk 
Telephone             07738257127 
 
Give details of the educational course or degree for which this research is being undertaken: Name and 
level of course/ degree: 
MD 
 
Name of educational establishment: University of Sheffield 
 
Name and contact details of academic supervisor(s): 
Title Forename/Initials Surname Ms   Lynda   Wyld 
Address EU36 Academic Unit of Surgical Oncology, University of Sheffield Medical School, Beech Hill 
Road, Sheffield,  S10 2JF 
E-mail                    l.wyld@sheffield.ac.uk. Telephone             0114 2268640 
Fax                         01142713314 
 
Title Forename/Initials Surname Dr    Karen                    Collins 
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Address                 Reader in Health Services Research, Sheffield Hallam University, Sheffield, S10 2BP 
E-mail                    k.collins@shu.ac.uk 
Telephone             0114 2255732 
Please state which academic supervisor(s) has responsibility for which student(s): 
Please click "Save now" before completing this table. This will ensure that all of the student and academic 
supervisor details are shown correctly. 
Student(s)                                             Academic supervisor(s) 
Student 1 Miss Jenna Morgan                Ms Lynda Wyld.  Dr Karen Collins 
A copy of a current CV for the student and the academic supervisor (maximum 2 pages of A4) must be 
submitted with the application. 
 
A2-2. Who will act as Chief Investigator for this study? 
  Student 
  Academic supervisor 
  Other 
 
A3-1. Chief Investigator: 
Title  Forename/Initials Surname Miss Jenna   Morgan 
Post              Clinical Research Fellow in Breast Surgery  
Qualifications                          MB ChB, MRCS(Ed), PGDipMedEd  
Employer                                 Sheffield Teaching Hospitals NHS Trust 
Work Address                         EU25 Academic Department of Clinical Oncology, University of Sheffield, 
Beech Hill Road, Sheffield,  S10 2JF 
Work E-mail                            j.morgan@sheffield.ac.uk 
* Personal E-mail                   jenna.morgan@doctors.org.uk 
* Personal Telephone/Mobile 07738257127 
* This information is optional. It will not be placed in the public domain or disclosed to any other third 
party without prior consent. 
A copy of a current CV (maximum 2 pages of A4) for the Chief Investigator must be submitted with the 
application. 
 
 
A4. Who is the contact on behalf of the sponsor for all correspondence relating to applications for this 
project? 
This contact will receive copies of all correspondence from REC and R&D reviewers that is sent to the CI. 
Title Forename/Initials Surname Ms   Erica  Wallis 
Address                 Clinical Research Office, 11 Broomfield Road, Sheffield, S10 2SE 
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E-mail                    Erica.Wallis@sth.nhs.uk 
Telephone             0114 2265931   Fax                         01142265937 
 
A5-1. Research reference numbers. Please give any relevant references for your study: 
 
Applicant's/organisation's own reference number, e.g. R & D (if 
available):                                                                                                   STH 17054 
Sponsor's/protocol number:                                                                      1.0 
Protocol Version:                                                                                        1.0 
Protocol Date:                                                                                             24/10/2012 
Funder's reference number:                                                                      RP-PG-1209-10071 
Registration of research studies is encouraged wherever possible. You may be able to register your study 
through your NHS organisation or a register run by a medical research charity, or publish your protocol 
through an open access publisher. If you have registered your study please give details in the "Additional 
reference number(s)" section. 
 
A5-2. Is this application linked to a previous study or another current application? 
  Yes      No 
Please give brief details and reference numbers. 
This study is part of the Bridging the Age Gap Stuy which is an NIHR funded programme of research 
looking at different aspects of how breast cancer is treated in older women.   Various component projects 
are currently or recently undergoing review. 
 
2. OVERVIEW OF THE RESEARCH 
To provide all the information required by review bodies and research information systems, we ask a 
number of specific questions. This section invites you to give an overview using language comprehensible 
to lay reviewers and members of the public. Please read the guidance notes for advice on this section. 
A6-1. Summary of the study.  Please provide a brief summary of the research (maximum 300 words) 
using language easily understood by lay reviewers and members of the public. Where the research is 
reviewed by a REC within the UK Health Departments Research Ethics Service, this summary will be 
published on the website of the National Research Ethics Service following the ethical review. 
Breast cancer is common, with 48,000 cases diagnosed in the UK each year. A third of these occur in 
women over the age of 70 years (Breakthrough Breast Cancer, 2010). Recent reports demonstrate that 
patients aged over 70 years are the only group of cancer patients in the UK where the mortality from 
cancer is not falling and may even be rising. This is thought to be due, in part, to under-treatment. 
Of particular concern is the widespread use of primary endocrine therapy (PET) where patients do not 
undergo surgery for their cancer and anti-oestrogen therapy is the only treatment. Whilst a valid 
treatment option in frailer older women, where operative intervention may be detrimental because of 
existing co-morbidities, frailty or patient preference, practice in the UK is highly varied. Additionally, with 
the aging population in the UK, life expectancy has risen, with many people still healthy and fully 
independent in their 70s and 80s. The resulting effect is that some older women may be under-treated, 
whilst others are over-treated. 
We propose to elicit the views and preferences of specialist health care professionals regarding the 
benefits and risks of surgery and primary endocrine therapy through semi-structured, purposively 
selected interviews. 
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We will then use a bespoke questionnaire to quantify the strength of each theme identified in the 
interviews and will be supplemented by expert opinion of the research team.   An initial pilot 
questionnaire will be developed and will be reviewed and piloted by a group of clinicians collaborating on 
the project.   Amendments will then be made in response to feedback before it is sent out to all members 
of the Association of Breast Surgeons. This will permit the study team to determine levels of clinician 
practice variance. 
 
A6-2. Summary of main issues. Please summarise the main ethical, legal, or management issues arising 
from your study and say how you have addressed them. 
Not all studies raise significant issues. Some studies may have straightforward ethical or other issues that 
can be identified and managed routinely. Others may present significant issues requiring further 
consideration by a REC, R&D office or other review body (as appropriate to the issue). Studies that present 
a minimal risk to participants may raise complex organisational or legal issues. You should try to consider 
all the types of issues that the different reviewers may need to consider. 
This study raises no significant ethical issues.   The study participants are clinicians and the study seeks 
their opinions about how to treat older women with cancer.   There is no risk to participants who will 
either consent to be interviewed or to complete an anonymised questionnaire.   The only inconvenience 
will be in the time these take (up to an hour for the interviews and 20 minutes for the questionnaire).   
Informed written consent will be obtained from clinicians prior to entry into the study for the interviews 
and presumed consent by their completion of the questionnaire. The right of a participant to refuse 
participation without giving reasons will be respected. The participant will remain free to withdraw at any 
time from the study without giving reasons. 
The study does not require specific ethics approval as it is recruiting health care professionals rather than 
patients. 
 
3. PURPOSE AND DESIGN OF THE RESEARCH 
A7. Select the appropriate methodology description for this research. Please tick all that apply: 
  Case series/ case note review 
  Case control 
  Cohort observation 
  Controlled trial without randomisation 
  Cross-sectional study 
  Database analysis 
  Epidemiology 
  Feasibility/ pilot study 
  Laboratory study 
  Metanalysis 
  Qualitative research 
  Questionnaire, interview or observation study 
  Randomised controlled trial 
  Other (please specify) 
 
A10. What is the principal research question/objective? Please put this in language comprehensible to a 
lay person. 
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To determine the factors underlying treatment decision making in health care professionals relating to 
older women with breast cancer. 
 
A11. What are the secondary research questions/objectives if applicable? Please put this in language 
comprehensible to a lay person. 
To explore the views of specialist healthcare professionals towards to management of older women 
(>70yrs) with operable breast cancer, particularly in terms of PET versus surgery. 
To determine whether there is a link between the maanagement of older women with operable breast 
cancer and the local social and demographic factors. 
 
A12. What is the scientific justification for the research? Please put this in language comprehensible to 
a lay person. 
In the UK there is wide variation in practice relating to the treatment of older women with breast cancer, 
with some areas demonstrating a 40% rate of PET, whilst in other areas the rate is only 10%. 
The concern is that women in centres with low surgery rates will be inappropriately denied operative 
intervention, with the long-term consequences of local recurrence, necessitating a change in 
management. Conversely, in regions with high rates of surgery, women may be inappropriately subjected 
to the morbidity or even mortality of surgery with no benefit. 
Regionally, variance may be explained, in part by deprivation levels as patient co-morbidities, frailty and 
preference are all potential causes. However, it is believed that clinician preference may also form a 
substantial cause of variance. 
A13. Please summarise your design and methodology. It should be clear exactly what will happen to the 
research participant, how many times and in what order. Please complete this section in language 
comprehensible to the lay person. Do not simply reproduce or refer to the protocol. Further guidance is 
available in the guidance notes. 
The study will recruit participants from breast units across the country. Using published national audit 
data we will identify sites with high, medium or low Primary Endocrine Therapy (PET) rates. 
A local principle investigator (PI) will be identified at each site by direct contact from a member of the 
study team.   The PI will be asked to provide a list of names of suitable health care professionals working 
within the unit who may be happy to be contacted by the study team.   Individuals will then be sent a 
study pack by post which will contain the following: a letter of invitation, a participant information sheet 
(PIS), a study reply slip and a freepost envelope. 
The study pack will invite the health care professional to complete a study reply slip to agree to be 
contacted about taking part. On receipt of a reply slip agreeing to participate, the research team will 
contact the interview candidate and arrange a time and place to meet.   This will be agreed verbally and 
confirmed in writing before the scheduled date.   A consent form will be signed before the interviews 
commence. 
Participants will be contacted again the day before their interviews to ensure they still wish to proceed. 
They will be given an opportunity to decline if they so wish.   All interviewees will be reassured that they 
may terminate or pause the interview at any point without stating a reason for doing so and that their 
participation is entirely voluntary. If wished,telephone interviews may be offered. All interviews will be 
digitally recorded and transcribed verbatim. All data collected will be pseudo-anonymous and databases 
password protected in accordance with the Data Protection Act. 
The interviews will enable us to explore key issues but also give opportunity for free expression of views 
with open questions.   The interviews will specifically explore the following areas: 
Treatment options for older women with ER positive breast cancer 
Methods for selection 
Patient engagement in selection of treatment Role and importance of clinician preferences Role and 
importance of the BCN 
Role and importance of the family and friends 
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Influence of co-morbidity Influence of frailty Influence of dementia 
Influence of disease biology and stage/operability 
Influence of HCP past experiences 
Influence of costs 
Influence of cancer targets 
Interviews will continue until saturation of "themes" is reached - from previous research, we anticipate 
that we will require approximately 35 interviews to achieve this. Qualitative interview transcript analysis 
will follow the Framework’ approach, to identify recurrent themes. Data will be entered into thematic 
charts and examined to allow interpretation of the data and to identify any relationships between 
themes. 
In order to quantify the findings of earlier phases of the study and link them to patient characteristics, a 
bespoke questionnaire will be developed based on the themes and findings of the qualitative interviews. 
An initial pilot questionnaire will be developed and will be reviewed by means of several focus groups of 
health care professional members of the study team and the extended ‘bridging the Age Gap in breast 
cancer study team (LW, MWR, LC, RAA, AS, REC, and members of the surgical and breast care nursing 
team locally in sheffield) to ensure it has content and face validiy, is comprehensible and useable. 
The questionnaire will be piloted to examine the length, acquiescent response set, flow, salience, ease of 
administration and response and acceptability to respondents (Boynton & Greenhalgh, 2004). 
Appropriate modifications will be made to the design and content of the questionnaire before it is sent 
out to the wider population of UK HCP. 
The finalised questionnaire will then be sent out to members of the Association of Breast Surgeons (ABS) 
and the Association of Cancer Physicians. The questionnaires will be prepared and made up into packs 
together with a prepaid envelope and sent to the associations who will undertake the mailing to maintain 
confidentiality.   Return of a completed questionnaire will be taken as indicative of consent. 
From previous studies, we anticipate a response rate of approximately 40%. No reminders will be sent. 
There will be an initial section asking for respondent demographics and locallity. Quantitative analysis of 
the questions will be undertaken and correlation between answers given to establish any relationships. 
 
A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, 
service users, and/or their carers, or members of the public? 
 
  Design of the research 
  Management of the research 
  Undertaking the research 
  Analysis of results 
  Dissemination of findings 
  None of the above 
Give details of involvement, or if none please justify the absence of involvement. 
We will not be involving patients, service users, and/or their carers, or members of the public as this 
study involves only NHS health care professionals.   The wider age gap programme of research has 
extensive user involvement for all aspects related to patient contact but this is not relevant to this sub 
project of the larger programme of research. 
 
4. RISKS AND ETHICAL ISSUES 
RESEARCH PARTICIPANTS 
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A15. What is the sample group or cohort to be studied in this research? 
Select all that apply:   
 Blood 
  Cancer 
  Cardiovascular 
  Congenital Disorders 
  Dementias and Neurodegenerative Diseases 
  Diabetes 
  Ear 
  Eye 
  Generic Health Relevance 
  Infection 
  Inflammatory and Immune System 
  Injuries and Accidents 
  Mental Health 
  Metabolic and Endocrine 
  Musculoskeletal 
  Neurological 
  Oral and Gastrointestinal 
  Paediatrics 
  Renal and Urogenital 
  Reproductive Health and Childbirth 
  Respiratory 
  Skin 
  Stroke 
 
Gender:                                                        Male and female participants 
Lower age limit:  18                                     Years 
Upper age limit:                                            No upper age limit 
 
A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters). 
NHS Health Care Professionals working in breast cancer units in the UK. 
 
A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters). 
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None 
 
RESEARCH PROCEDURES, RISKS AND BENEFITS 
A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants 
as part of the research protocol. These include seeking consent, interviews, non-clinical observations 
and use of questionnaires. 
Please complete the columns for each intervention/procedure as follows: 
1. Total number of interventions/procedures to be received by each participant as part of the research 
protocol. 
2. If this intervention/procedure would be routinely given to participants as part of their care outside the 
research, how many of the total would be routine? 
3. Average time taken per intervention/procedure (minutes, hours or days) 
4. Details of who will conduct the intervention/procedure, and where it will take place. 
Intervention or procedure                                                           1   2     3                     4 
Study Interview Information Pack                                              1   no   10minutes     Sent via post 
Telephone contact with study team to arrange interview     1   no   10 minutes    Telephone, Chief 
Investigator. Informed, written consent                                    1   no   5 minutes      In person, Chief 
Investigator. Qualitative interview                                              1   no   30 minutes    In person, Chief 
Investigator. Questionnaire                                                          1   no   20 minutes    Sent via post 
 
A21. How long do you expect each participant to be in the study in total? 
We will not technically be "following-up" participants so their involvement in the study will be at discrete 
intervals. However, for those participants who take part in interviews and are members of the Association 
of Breast Surgeons (ABS) - there will be a period of approximately 12 months where they may be 
contacted about the study - i.e. that can expect to receive the questionnaire in the post. 
For participants who are only sent the questionnaire this will be a one-off event and on receipt of their 
completed questionnaire they will not be contacted again. 
 
A22. What are the potential risks and burdens for research participants and how will you minimise 
them? 
For all studies, describe any potential adverse effects, pain, discomfort, distress, intrusion, inconvenience 
or changes to lifestyle. Only describe risks or burdens that could occur as a result of participation in the 
research. Say what steps would be taken to minimise risks and burdens as far as possible. 
We have not identified any potential risks to participants however, it will be made clear that no one has 
to participant if they do not wish and they may withdraw at any time without providing a reason. 
Participants may suffer some burden in respect to their time as the interviews will take approximately 30 
minutes to contact and the questionnaire will also require time to complete, although we estimate this 
will be only approximately 15 minutes. 
 
A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, 
embarrassing or upsetting, or is it possible that criminal or other disclosures requiring action could 
occur during the study? 
  Yes       No 
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A24. What is the potential for benefit to research participants? 
There will be no direct benefit to the research participants. 
 
A26. What are the potential risks for the researchers themselves? (if any) 
We have not identified any potential risks to the researchers. 
 
RECRUITMENT AND INFORMED CONSENT 
In this section we ask you to describe the recruitment procedures for the study. Please give separate 
details for different study groups where appropriate. 
 
A27-1. How will potential participants, records or samples be identified? Who will carry this out and 
what resources will be used?For example, identification may involve a disease register, computerised 
search of GP records, or review of medical records. Indicate whether this will be done by the direct 
healthcare team or by researchers acting under arrangements with the responsible care 
organisation(s). 
For the interviews, we will recruit participants from breast units across the country. Using published 
national audit data we will identify sites with high, medium or low Primary Endocrine Therapy (PET) rates. 
A local principle investigator (PI) will be identified at each site by direct contact from a member of the 
study team.   The PI will be asked to provide a list of names of suitable health care professionals working 
within the unit who may be happy to be contacted by the study team.   Individuals will then be contacted 
by post and invited to participate. 
For the questionnaire, we will recruit participants through their membership to the Association of Breast 
Surgeons (ABS) and the Association of Cancer Physicians. This will be done via the association. 
 
A27-2. Will the identification of potential participants involve reviewing or screening the identifiable 
personal information of patients, service users or any other person? 
  Yes       No 
Please give details below: 
 
A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites? 
  Yes       No 
 
A29. How and by whom will potential participants first be approached? 
With respect to the interviews, the potential principal investigators at different sites will be contacted 
directly by a member of the study team, usually be e-mail. Direct contact with the interview participants 
will initially be via the study pack which will be sent via post. 
With respect to the questionnaires, the potential participants will simply be sent a postal questionnaire 
via the Association of Breast Surgeons or Association of Cancer Physicians. 
 
A30-1. Will you obtain informed consent from or on behalf of research participants? 
 
   Yes      No 
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If you will be obtaining consent from adult participants, please give details of who will take consent and 
how it will be done, with details of any steps to provide information (a written information sheet, videos, 
or interactive material). Arrangements for adults unable to consent for themselves should be described 
separately in Part B Section 6, and for children in Part B Section 7. 
If you plan to seek informed consent from vulnerable groups, say how you will ensure that consent is 
voluntary and fully informed. 
For the interviews, all participants will be sent a written information sheet with the invitation to 
participate. Full, written, informed consent will then be obtained from each participant in person, prior to 
the interview. 
For the questionnaire, all participants will be sent a written information sheet with the questionnaire. 
Return of a completed questionnaire will be taken as consent to participate. 
If you are not obtaining consent, please explain why not. 
Please enclose a copy of the information sheet(s) and consent form(s). 
 
A30-2. Will you record informed consent (or advice from consultees) in writing? 
  Yes      No 
 
A31. How long will you allow potential participants to decide whether or not to take part? 
For both the interviews and the questionnaire studies, we will be sending the invitation to participate via 
post. Potential participants will not be contacted again as part of the questionnaire study and they will 
only be contacted again for the interviews if they return the study reply slip - there is no maximum time 
for them to do this, therefore allowing potential participants as long as they require to decide whether to 
participate. Clearly the study period will only be a finite amount of time and as such if potential 
participants haven't responded within six months it will be assumed that they do not wish to take part. 
 
A33-1. What arrangements have been made for persons who might not adequately understand verbal 
explanations or written information given in English, or who have special communication needs?(e.g. 
translation, use of interpreters) 
None. By the nature of being health care professionals working within the NHS, there is an assumption 
that all potential participants will have the understanding, verbal and written English language skills in 
order to comprehend the information given. Should they require further information we have provided 
contact information on the participant information sheets. 
 
A33-2. What arrangements will you make to comply with the principles of the Welsh Language Act in 
the provision of information to participants in Wales? 
None. Again, by nature of being health care professionals working within the NHS, there is an assumption 
that Welsh participants will have adequate English language skills to understand and participate in the 
study. 
 
A35. What steps would you take if a participant, who has given informed consent, loses capacity to 
consent during the study? Tick one option only. 
The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or 
tissue which is not identifiable to the research team may be retained. 
The participant would be withdrawn from the study. Identifiable data or tissue already collected with 
consent would be retained and used in the study. No further data or tissue would be collected or any 
other research procedures carried out on or in relation to the participant. 
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  The participant would continue to be included in the study. 
  Not applicable – informed consent will not be sought from any participants in this research. 
  Not applicable – it is not practicable for the research team to monitor capacity and continued capacity 
will be assumed. 
 
Further details: 
As we are not recruiting patients and there is no follow-up period this is not applicable. Only participants 
able to provide informed consent at the time of their interview will be interviewed. Informed consent will 
not be taken for the questionnaire study as this will be implied by return of a completed questionnaire. 
 
CONFIDENTIALITY 
In this section, personal data means any data relating to a participant who could potentially be identified. 
It includes pseudonymised data capable of being linked to a participant through a unique code number. 
Storage and use of personal data during the study 
A36. Will you be undertaking any of the following activities at any stage (including in the identification 
of potential participants)?(Tick as appropriate) 
  Access to medical records by those outside the direct healthcare team 
  Electronic transfer by magnetic or optical media, email or computer networks 
  Sharing of personal data with other organisations 
  Export of personal data outside the EEA 
  Use of personal addresses, postcodes, faxes, emails or telephone numbers 
 Publication of direct quotations from respondents 
  Publication of data that might allow identification of individuals 
 Use of audio/visual recording devices 
  Storage of personal data on any of the following: 
  Manual files including X−rays 
  NHS computers 
  Home or other personal computers 
   University computers 
  Private company computers 
  Laptop computers 
 
Further details: 
Participants may be contacted initially via e-mail/telephone/postal address. Interviews will be digitally 
recorded and transcribed verbatim. 
Data will be stored in a pseudo-anonymised fashion on an electronic database on a university computer 
that is password protected and kept in a locked room in the Hallamshire Hospital Sheffield. 
 446 
 
 
 
 
 
Consent forms and participant response forms will be kept in paper form in a locked drawer in a locked 
room in the hallamshire hospital, sheffield. 
Publication of direct quotations from respondents may be used but these will be completely anonymous 
and no participant will be indentified in any way. 
 
A37. Please describe the physical security arrangements for storage of personal data during the study? 
All data will be handled, computerised and stored in accordance with the Data Protection Act 1998.   All 
data collected will be pseudo-anonymised and databases will be password protected in accordance with 
the Data Protection Act. Data will be stored in a locked room at the Royal Hallamshire Hospital, Sheffield, 
for 15 years before being confidentially destroyed. 
 
A38. How will you ensure the confidentiality of personal data?Please provide a general statement of 
the policy and procedures for ensuring confidentiality, e.g. anonymisation or pseudonymisation of 
data. 
All data collected will be pseudo-anonymised and databases will be password protected in accordance 
with the Data Protection Act 1998. 
 
A40. Who will have access to participants' personal data during the study? Where access is by 
individuals outside the direct care team, please justify and say whether consent will be sought. 
The chief investigator and supervisors only. 
 
Storage and use of data after the end of the study 
A41. Where will the data generated by the study be analysed and by whom? 
Data generated by the study will be pseudo-anonymised by the Chief investigator. It will be analysed in 
combination with the supervisors and statisticians from the university of sheffield. 
 
A42. Who will have control of and act as the custodian for the data generated by the study? 
Title Forename/Initials Surname  Ms   Lynda  Wyld 
Post                       Lecturer in Clinical Oncology and Honarary Consultant Surgeon 
Qualifications        MB.ChB. B.Med.Sci. PhD. FRCS. 
Work Address        EU36 Academic Unit of Surgical Oncology University of Sheffield Medical School Beech 
Hill Road, Sheffield, S10 2JF 
Work Email            l.wyld@sheffield.ac.uk 
Work Telephone    0114 2268640 
 
A43. How long will personal data be stored or accessed after the study has ended? 
  Less than 3 months 
  3 – 6 months 
  6 – 12 months 
  12 months – 3 years 
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  Over 3 years 
If longer than 12 months, please justify: 
Pseudo-anonymised data will be kept in a site file for 15 years before being confidentially destroyed. 
 
A44. For how long will you store research data generated by the study? 
Years:   15 
 
A45. Please give details of the long term arrangements for storage of research data after the study has 
ended.Say where data will be stored, who will have access and the arrangements to ensure security. 
The data will be password protected and stored in a locked room in the Hallamshire Hospital, Sheffield, 
under the care of LW, all in accordance withe the Data Protection Act 1998. 
 
INCENTIVES AND PAYMENTS 
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits 
or incentives for taking part in this research? 
  Yes       No 
 
A47. Will individual researchers receive any personal payment over and above normal salary, or any 
other benefits or incentives, for taking part in this research? 
  Yes       No 
 
A48. Does the Chief Investigator or any other investigator/collaborator have any direct personal 
involvement (e.g. financial, share holding, personal relationship etc.) in the organisations sponsoring or 
funding the research that may give rise to a possible conflict of interest? 
  Yes      No 
 
NOTIFICATION OF OTHER PROFESSIONALS 
A49­1. Will you inform the participants ’ General Practitioners (and/or any other health or care 
professional responsible for their care) that they are taking part in the study? 
  Yes       No 
If Yes, please enclose a copy of the information sheet/letter for the GP/health professional with a version 
number and date. 
 
PUBLICATION AND DISSEMINATION 
A50. Will the research be registered on a public database? 
  Yes      No 
Please give details, or justify if not registering the research. 
The project will be adopted into the NIHR portfolio and as such will be available on the NIHR website. 
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Registration of research studies is encouraged wherever possible. 
You may be able to register your study through your NHS organisation or a register run by a medical 
research charity, or publish your protocol through an open access publisher. If you are aware of a suitable 
register or other method of publication, please give details. If not, you may indicate that no suitable 
register exists. Please ensure that you have entered registry reference number(s) in question A5-1. 
 
A51. How do you intend to report and disseminate the results of the study?Tick as appropriate: 
  Peer reviewed scientific journals 
  Internal report 
  Conference presentation    
Publication on website    
Other publication 
  Submission to regulatory authorities 
  Access to raw data and right to publish freely by all investigators in study or by Independent Steering 
Committee on behalf of all investigators 
  No plans to report or disseminate the results 
  Other (please specify) 
 
A52. If you will be using identifiable personal data, how will you ensure that anonymity will be 
maintained when publishing the results? 
We will not be using identifiable personal data in any published results. 
 
A53. Will you inform participants of the results? 
  Yes      No 
Please give details of how you will inform participants or justify if not doing so. 
Participants will be asked if they wish to receive details of the study results. Participant will be informed in 
writing of the results if they wish. Most participants, by nature of their healthcare professional status will 
have access to the published material. 
 
5. Scientific and Statistical Review 
A54. How has the scientific quality of the research been assessed? Tick as appropriate: 
  Independent external review 
  Review within a company 
  Review within a multi−centre research group 
  Review within the Chief Investigator's institution or host organisation 
  Review within the research team    
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Review by educational supervisor    
Other 
Justify and describe the review process and outcome. If the review has been undertaken but not seen by 
the researcher, give details of the body which has undertaken the review: 
The project has been extensively peer reviewed by the grant review board of the NIHR programme grant 
scheme. Extensive feedback and project modification was undertaken as a result. 
For all studies except non-doctoral student research, please enclose a copy of any available scientific 
critique reports, together with any related correspondence. 
For non-doctoral student research, please enclose a copy of the assessment from your educational 
supervisor/ institution. 
 
A56. How have the statistical aspects of the research been reviewed?Tick as appropriate: 
  Review by independent statistician commissioned by funder or sponsor 
  Other review by independent statistician 
  Review by company statistician 
   Review by a statistician within the Chief Investigator’s institution 
  Review by a statistician within the research team or multi−centre group 
  Review by educational supervisor 
  Other review by individual with relevant statistical expertise 
  No review necessary as only frequencies and associations will be assessed – details of statistical input 
not required 
In all cases please give details below of the individual responsible for reviewing the statistical aspects. If 
advice has been provided in confidence, give details of the department and institution concerned. 
Title           Forename/Initials Surname Professor Stephen  Walters 
Department           Clinical Trials Research Unit 
Institution               ScHARR (School of Health and Related Research), University of Sheffield 
Work Address        Regent Court, 30 Regent Street, Sheffield, S1 4DA  
Telephone              0114 222 0730 
E-mail                    S.J.Walters@sheffield.ac.uk 
Please enclose a copy of any available comments or reports from a statistician. 
 
A57. What is the primary outcome measure for the study? 
To determine the factors underlying treatment decision making in health care professionals relating to 
older women with breast cancer. 
 
A58. What are the secondary outcome measures? (if any) 
To determine the level of variance in decision making practice amongst health care professionals. 
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A59. What is the sample size for the research?  How many participants/samples/data records do you 
plan to study in total? If there is more than one group, please give further details below. 
Total UK sample size:                                        150 
Total international sample size (including UK): 150 
Total in European Economic Area:                     150 
Further details: 
As with all projects where qualitative interviews are undertaken, we will base our sample size on the 
attainment of saturation of themes. This is usually achieved after 20-25 interviews but as we intend to 
interview several different professional group (nurses, geriatricians, surgeons and oncologists) we may 
need to interview more. It is therefore not possible to put a precise limit on this at this stage. 
For the questionnaire, our previous discrete choice experiment questionnaire required us to send out 250 
questionnaires with a response rate of 40% to achieve the required sample size of 100 for meaningfull 
analysis. We have based our present sample size on the same estimates, following statistical input from 
Professor Stephen Walters (professor of Medical stataistics at ScHARR). These calculations are outlined in 
the study protocol. 
 
A60. How was the sample size decided upon? If a formal sample size calculation was used, indicate how 
this was done, giving sufficient information to justify and reproduce the calculation. 
The interview sample size will be decided according to qualitative methods of "saturation of themes". 
Based on previous research undertaken by the study team, it is estimated that this may achieved after 
20-25 interviews but as we intend to interview several different professional group (nurses, geriatricians, 
surgeons and oncologists) we may need to interview more. It is therefore not possible to put a precise 
limit on this at this stage. 
Again, for the questionnaire, the study size is based on previous work undertaken by the study group. A 
previous discrete choice experiment questionnaire required us to send out 250 questionnaires with a 
response rate of 40% to achieve the required numbers for meaningfull analysis (approximately 100). We 
have based our present sample size on the same estimates, following statistical input from Professor 
Stephen Walters (professor of Medical stataistics at ScHARR). These calculations are outlined in the study 
protocol. 
 
A61. Will participants be allocated to groups at random? 
  Yes      No 
 
A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for 
qualitative research) by which the data will be evaluated to meet the study objectives. 
For the interview section: 
Qualitative interview transcript analysis will follow the Framework approach, to identify recurrent 
themes.   The Framework approach permits the systematic analysis of large volumes of textual data and 
permits within- and across- case and theme comparison.   Analysis will be undertaken by the chief 
investigator with supervision from experienced qualitative researchers (KC and LW - student supervisors). 
A thematic index will be drawn up and applied to the data. Data will be distilled, summarised and entered 
into thematic charts before being examined to allow interpretation of the data and to identify any 
relationships between themes. 
For the Questionnaire section: 
The first part of the questionnaire will be descriptive and will be analysed by calculation of median 
response and range to Likert-style questions.   Correlation of response medians with HCP characteristics 
such as age subgroup and professional subtype will be performed using Chi squared test. 
The discrete choice questionnaire wherein scenarios are described and treatment preferences for PET or 
surgery or either will be developed in conjunction with Professor Stephen Walters. Discrete choice 
 451 
 
 
 
 
 
scenarios provide information on the relative weights individual professionals attach to the various 
dimensions (variables) involved in the decision making process and how willing they are to trade these off 
against each other in reaching a decision. Respondents will be provided with pair wise choices between 
hypothetical scenarios and asked to choose their preferred scenario from each pair. These choices can 
then be used to infer the trade-offs people are willing to make with respect to changes in the levels of the 
attributes. 
Scenarios will be evaluated by Professor Tom Robinson to determine whether all are realistic 
representations of real life older women and also to estimate whether individual scenarios would be 
associated with a predicted life expectation of less than 2 year, 2-5 years or greater than 5 years. 
Correlations will be assessed between clinician choices and region/age/sex/healthcare role to see if there 
are any associations. 
 
6. MANAGEMENT OF THE RESEARCH 
A63. Other key investigators/collaborators. Please include all grant co−applicants, protocol co−authors 
and other key members of the Chief Investigator’s team, including non­doctoral student researchers. 
Title           Forename/Initials Surname Professor Thomson Robinson 
Post                       Professor in Ageing and Stroke Medicine / Honorary Consultant Physician 
Qualifications        B.Med.Sci, BM.BS, MRCP, MD, FRCP Employer               University of Leicester 
Work Address        Department of Caardiovascular Services, University of Leicester, Level 5 (room 539), 
Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW  
Telephone             01162523183  Work Email            tgr2@le.ac.ik 
 
Title Forename/Initials Surname Mr    Neil Shephard 
Post                       Medical Statistician 
Employer               Clinical Trials Research Unit, ScHARR  
Work Address        Regent Court, 30 Regent Street, Sheffield, S1 4DA  
Telephone              0114 222 5203  Work Email            n.shephard@sheffield.ac.uk 
 
Title Forename/Initials Surname Dr    Erica   Wallis  
Post                       Senior Research Coordinator  Qualifications        MBChB 
Employer               Sheffield Teaching Hospitals NHS Foundation Trust 
Work Address        Clinical Research Office, 11 Broomfield Road, Sheffield , S10 2SE  
Telephone              0114 2265931  Fax                         01142265937 
Work Email            Erica.Wallis@sth.nhs.uk 
 
Title           Forename/Initials Surname Professor Malcolm   Reed 
Post                       Professor of surgical oncology, consultant breast surgeon 
Qualifications        MB.ChB, B.Med.Sci, MD, FRCS  
Employer               Sheffield University 
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Work Address        FU20 Academic Unit of Surgical Oncology University of Sheffield Medical School Beech 
Hill Road, Sheffield S10 2JF  
Telephone             0114 2713326 Work Email            m.w.reed@sheffield.ac.uk 
 
Title           Forename/Initials Surname Professor Stephen  Walters 
Post                       Professor of Statistics 
Qualifications        BSc. PCGE, MSc, PhD, CStat 
Employer               ScHARR (School of Health and Related Research), University of Sheffield 
Work Address        Regent Court, 30 Regent Street, Sheffield,  S1 4DA  
Telephone              0114 222 0730 Work Email            S.J.Walters@sheffield.ac.uk 
 
A64. Details of research sponsor(s) 
A64-1. Sponsor 
Lead Sponsor 
Status:    NHS or HSC care organisation                                                     
Commercial status:     Non-Academic       Commercial 
  Pharmaceutical industry   Medical device industry   Local Authority 
  Other social care provider (including voluntary sector or private organisation) 
  Other 
If Other, please specify: 
 
Contact person 
Name of organisation Sheffield Teaching Hospitals NHS Foundation Trust 
Given name                 Simon 
Family name               Heller 
Address                       Clinical Research Office , 11 Broomfield Road,  S10 2SE 
Country                          UNITED KINGDOM  
Telephone                   0114 2265938  Fax                               01142265937 
E-mail                          s.heller@sheffield.ac.uk 
Is the sponsor based outside the UK? 
Yes          No 
Under the Research Governance Framework for Health and Social Care, a sponsor outside the UK must 
appoint a legal representative established in the UK. Please consult the guidance notes. 
 
A65. Has external funding for the research been secured? 
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Funding secured from one or more funders 
External funding application to one or more funders in progress 
No application for external funding will be made 
 
What type of research project is this? 
Standalone project 
Project that is part of a programme grant 
Project that is part of a Centre grant 
Project that is part of a fellowship/ personal award/ research training award 
Other 
Other – please state: 
 
Please give details of funding applications. 
Organisation         National Institute of Health Research 
Address                 Room 132, Richmond House, 79 Whitehall, London  
Post Code             SW1A 2NS Telephone             02033286700 
Fax                         02076265128 
Email                     enquiries@nihr.ac.uk 
Funding Application Status:                         Secured       In progress 
Amount:           £1.7M 
Duration 
Years:              5 
Months:            0 
If applicable, please specify the programme/ funding stream: 
What is the funding stream/ programme for this research project?  
NIHR Programme Grants for Applied Research 
A66. Has responsibility for any specific research activities or procedures been delegated to a 
subcontractor (other than a co-sponsor listed in A64-1) ? Please give details of subcontractors if 
applicable. 
  Yes      No 
 
A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK 
or another country? 
  Yes      No 
Please provide a copy of the unfavourable opinion letter(s). You should explain in your answer to question 
A6-2 how the reasons for the unfavourable opinion have been addressed in this application. 
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A68. Give details of the lead NHS R&D contact for this research: 
Title Forename/Initials Surname Dr    Erica                      Wallis 
Organisation         Sheffield Teaching Hospitals NHS Foundation Trust 
Address                 Clinical Research Office, 11 Broomfield Road, Sheffield,      S10 2SE 
Work Email            Erica.Wallis@sth.nhs.uk 
Telephone             0114 2265931  Fax                         01142265937 
Details can be obtained from the NHS R&D Forum website:  http://www.rdforum.nhs.uk 
 
A69-1. How long do you expect the study to last in the UK? 
Planned start date: 03/12/2012 
Planned end date:  03/10/2014 
Total duration: 
Years: 1  Months: 10  Days: 0 
 
A71-1. Is this study? 
  Single centre 
  Multicentre 
 
A71-2. Where will the research take place? (Tick as appropriate) 
   England    Scotland    Wales  Northern Ireland 
   Other countries in European Economic Area 
Total UK sites in study 20 
 
Does this trial involve countries outside the EU? 
  Yes      No 
 
A72. What host organisations (NHS or other) in the UK will be responsible for the research sites? Please 
indicate the type of organisation by ticking the box and give approximate numbers of planned research 
sites: 
  NHS organisations in England                             19 
  NHS organisations in Wales                                1 
  NHS organisations in Scotland 
  HSC organisations in Northern Ireland 
  GP practices in England   GP practices in Wales   GP practices in Scotland 
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  GP practices in Northern Ireland 
  Social care organisations 
  Phase 1 trial units 
  Prison establishments 
  Probation areas 
  Independent hospitals 
  Educational establishments   Independent research units   Other (give details) 
Total UK sites in study:                                               20 
 
A73-1. Will potential participants be identified through any organisations other than the research sites 
listed above? 
  Yes      No 
 
A73-2. If yes, will any of these organisations be NHS organisations? 
  Yes       No 
If yes, details should be given in Part C. 
 
A74. What arrangements are in place for monitoring and auditing the conduct of the research? 
The study is a low risk study involving health care professionals giving interviews and completing 
questionnaires. As such there is no requirement for safety monitoring. Study progress will be monitored 
by a trial management group which will meet once every 6 months to discuss progress and milestones. 
 
A76. Insurance/ indemnity to meet potential legal liabilities 
Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and 
Social Care (HSC) in Northern Ireland 
 
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal 
liability of the sponsor(s) for harm to participants arising from the management of the research? Please 
tick box(es) as applicable. 
Note: Where a NHS organisation has agreed to act as sponsor or co-sponsor, indemnity is provided 
through NHS schemes. Indicate if this applies (there is no need to provide documentary evidence). For all 
other sponsors, please describe the arrangements and provide evidence. 
  NHS indemnity scheme will apply (NHS sponsors only) 
  Other insurance or indemnity arrangements will apply (give details below) 
Please enclose a copy of relevant documents. 
 
A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal 
liability of the sponsor(s) or employer(s) for harm to participants arising from the design of the 
research? Please tick box(es) as applicable. 
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Note: Where researchers with substantive NHS employment contracts have designed the research, 
indemnity is provided through NHS schemes. Indicate if this applies (there is no need to provide 
documentary evidence). For other protocol authors (e.g. company employees, university members), please 
describe the arrangements and provide evidence. 
  NHS indemnity scheme will apply (protocol authors with NHS contracts only)    
Other insurance or indemnity arrangements will apply (give details below) 
Please enclose a copy of relevant documents. 
 
A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal 
liability of investigators/collaborators arising from harm to participants in the conduct of the research? 
Note: Where the participants are NHS patients, indemnity is provided through the NHS schemes or 
through professional indemnity. Indicate if this applies to the whole study (there is no need to provide 
documentary evidence). Where non-NHS sites are to be included in the research, including private 
practices, please describe the arrangements which will be made at these sites and provide evidence. 
  NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only) 
  Research includes non-NHS sites (give details of insurance/ indemnity arrangements for these sites 
below) 
Please enclose a copy of relevant documents. 
 
A78. Could the research lead to the development of a new product/process or the generation of 
intellectual property? 
  Yes   No   Not sure 
 
PART C: Overview of research sites 
Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be 
responsible for the research sites.  For NHS sites, the host organisation is the Trust or Health Board. 
Where the research site is a primary care site, e.g. GP practice, please insert the host organisation (PCT or 
Health Board) in the Institution row and insert the research site (e.g. GP practice) in the Department row. 
IN1 
 NHS site Non-NHS site                                                    
Forename Lynda   Family name Wyld 
Country:   England                                                  Email                     l.wyld@sheffield.ac.uk 
Qualification                     MB.ChB. B.Med.Sci. PhD. FRCS 
Country                    UNITED KINGDOM  
Organisation name          SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST 
Address NORTHERN GENERAL HOSPITAL, HERRIES ROAD SHEFFIELD SOUTH YORKSHIRE, S5 7AU 
 
IN2 
  NHS site Non-NHS site                                                    
Forename      Kwok Leung  Family name Cheung 
Country:   England                                                  Email             Kwok_Leung.Cheung@nottingham.ac.uk 
Qualification (MD...)            MBBS, DM, FRCS, FACS 
Organisation          DERBY HOSPITALS NHS FOUNDATION TRUST UNITED KINGDOM 
Address DERBY CITY GENERAL HOSPITAL UTTOXETER ROAD DERBY DERBYSHIRE DE22 3NE 
 
IN3 
NHS site Non-NHS site                                                    
Forename              Eleanor  Family name         Gutteridge 
Country:   England 
Organisation name NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST 
 Email                     Eleanor.Gutteridge@nuh.nhs.uk Qualification (MD...)                    FRCS  
Address TRUST HEADQUARTERS QMC CAMPUS, DERBY ROAD NOTTINGHAM NG7 2UH 
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IN4 
 NHS site Non-NHS site 
Country:   England 
Forename              Andrew  Family name         Griffiths 
Email                     andrew.griffiths@ncl.ac.uk   Qualification (MD...) FRCS  
Organisation name THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST 
Address FREEMAN HOSPITAL FREEMAN ROAD HIGH HEATON, NEWCASTLE-UPON-TYNE, NE7 7DN 
 
IN5 
NHS site  Non-NHS site 
Country:   England 
Organisation name UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST 
 Forename              Anne        Family name Stotter 
Email                     anne.stotter@uhl-tr.nhs.uk Qualification (MD...)                    MA, MBBS, PhD, FRCS 
Country                    UNITED KINGDOM  
Address GWENDOLEN HOUSE GWENDOLEN ROAD LEICESTER LEICESTERSHIRE  LE5 4QF  
 
 IN6 
  NHS site Non-NHS site 
Country:   England 
Organisation name UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST 
 Forename              Zenon  Family name         Rayter 
Email                     Zenon.Rayter@UHBristol.nhs.uk Qualification (MD...)                    MBBS, MS, FRCS 
Country                    UNITED KINGDOM  
Address                 MARLBOROUGH STREET BRISTOL AVON    BS1 3NU 
  
IN7 
NHS site Non-NHS site 
Country:   England 
Organisation name ST HELENS AND KNOWSLEY HOSPITALS NHS TRUST 
 Forename              Riccardo  Family name         Audisio 
Email                     raudisio@doctors.org.uk  Qualification (MD...)                    FRCS 
Country                    UNITED KINGDOM  
Address WHISTON HOSPITAL WARRINGTON ROAD PRESCOT MERSEYSIDE  L35 5DR 
 
IN8 
 NHS site Non-NHS site 
Country:   England 
Organisation name: GUY'S AND ST THOMAS' NHS FOUNDATION TRUST 
Forename              Michael  Family name         Douek 
Email                     michael.douek@kcl.ac.uk Qualification (MD...)                    MD, FRCS 
Country                    UNITED KINGDOM  
Address TRUST OFFICES GUY'S HOSPITAL GREAT MAZE POND LONDON GREATER LONDON   SE1 9RT  
 
IN9 
 NHS site Non-NHS site 
Country:   England 
Organisation name: DARTFORD AND GRAVESHAM NHS TRUST 
 Forename              Seema  Family name         Seetharam 
Email                     seemaseetharam@nhs.net Qualification (MD...)                    FRCS 
Country                    UNITED KINGDOM  
Address DARENT VALLEY HOSPITAL DARENTH WOOD ROAD DARTFORD KENT  DA2 8DA 
  
IN10 
NHS site Non-NHS site 
Country:   England 
Organisation name: ROYAL BERKSHIRE NHS FOUNDATION TRUST 
Forename      Stephen Family name  Courtney 
Email             stephen.courtney@royalberkshire.nhs.uk Qualification (MD...)            MCh. FRCS 
Country            UNITED KINGDOM  
Address ROYAL BERKSHIRE HOSPITAL LONDON ROAD READING BERKSHIRE  RG1 5AN 
 
IN11 
NHS site Non-NHS site 
Country:   Wales 
Institution name    UNIVERSITY HOSPITAL OF WALES 
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Forename              Helen  Family name         Sweetland 
Email                     Sweetland@cardiff.ac.uk Qualification (MD...)                    MB.ChB. MD. FRCS 
Country                    UNITED KINGDOM  
Street address      HEATH PARK Town/city    CARDIFF Post Code             CF14 4XW 
  
IN12 
NHS site Non-NHS site                                                    
Forename              Martin Family name         Lee  
Country:   England 
Organisation name  UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST 
 Email                     martin.lee@uhcw.nhs.uk Qualification (MD...)                    MB.ChB, MA, MSc. 
FRCS 
Country                    UNITED KINGDOM  
Address WALSGRAVE GENERAL HOSPITAL CLIFFORD BRIDGE ROAD COVENTRY WEST MIDLANDS CV2 2DX 
 
IN14 
NHS site Non-NHS site 
Country:   England 
Organisation name: PLYMOUTH HOSPITALS NHS TRUST 
 Forename              Roger Family name         Watkins 
Email                     roger.watkins@phnt.swest.nhs.uk Qualification (MD...)                    MB BChir, 
FRCS 
Country                    UNITED KINGDOM  
Address DERRIFORD HOSPITAL DERRIFORD ROAD PLYMOUTH DEVON  PL6 8DH 
 
IN15 
NHS site Non-NHS site 
Country:   England 
Organisation name: DONCASTER AND BASSETLAW HOSPITALS NHS FOUNDATION TRUST 
Forename              Clare Family name         Rogers 
Email                     clare.rogers@dbh.nhs.uk Qualification (MD...)                    MBChB MD FRCSEd 
(Gen.Surg.) 
Country                    UNITED KINGDOM  
Address DONCASTER ROYAL INFIRMARY ARMTHORPE ROAD DONCASTER SOUTH YORKSHIRE DN2 5LT  
  
IN16 
 NHS site Non-NHS site 
Country:   England 
Organisation name: CHESTERFIELD ROYAL HOSPITAL NHS FOUNDATION TRUST 
Forename              Steve Family name         Holt 
Email                     Steve.Holt@chesterfieldroyal.nhs.uk Qualification (MD...)                    MB.ChB, FRCS 
Country                    UNITED KINGDOM  
Address                 CALOW CHESTERFIELD DERBYSHIRE S44 5BL 
 
IN17 
NHS site Non-NHS site 
Country:   England 
Organisation name: YORK TEACHING HOSPITAL NHS FOUNDATION TRUST 
Forename              Rana Family name         Nasr 
Email                     rana.nasr@york.nhs.uk Qualification (MD...)                    FRCS 
Country                    UNITED KINGDOM  
Address YORK HOSPITAL WIGGINTON ROAD YORK NORTH YORKSHIRE YO31 8HE 
 
IN18 
NHS site Non-NHS site 
Country:   England 
Organisation name: THE ROTHERHAM NHS FOUNDATION TRUST 
Forename              Inder Family name         Kumar 
Email                     Inder.Kumar@rothgen.nhs.uk Qualification (MD...)                    FRCS, 
General Surgery 
Country                    UNITED KINGDOM  
Address                 MOORGATE ROAD ROTHERHAM SOUTH YORKSHIRE S60 2UD  
  
IN19 
 NHS site Non-NHS site 
Country:   England 
Organisation name: BARNSLEY HOSPITAL NHS FOUNDATION TRUST 
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Forename              Julia Family name         Dicks 
Email                     jdicks@nhs.net Qualification (MD...)                    MBChB, FRCS Gen, MRCS 
Country                    UNITED KINGDOM  
Address                 GAWBER ROAD BARNSLEY SOUTH YORKSHIRE S75 2EP 
 
IN20 
NHS site Non-NHS site 
Country:   England 
Organisation name: NORTHERN LINCOLNSHIRE AND GOOLE HOSPITALS NHS FOUNDATION TRUST 
 Forename              Rajesh  Family name         Vijh 
Email                     rvijh@nhs.net Qualification (MD...)                    MS, FRCS(ed) 
Country                    UNITED KINGDOM  
Address DIANA PRINCESS OF WALES HOSPITAL SCARTHO ROAD GRIMSBY NORTH EAST LINCOLNSHIRE 
DN33 2BA  
 
PART D: Declarations 
D1. Declaration by Chief Investigator 
1.   The information in this form is accurate to the best of my knowledge and belief and I take full 
responsibility for it. 
2.   I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice 
guidelines on the proper conduct of research. 
3.   If the research is approved I undertake to adhere to the study protocol, the terms of the full 
application as approved and any conditions set out by review bodies in giving approval. 
4.   I undertake to notify review bodies of substantial amendments to the protocol or the terms of the 
approved application, and to seek a favourable opinion from the main REC before implementing the 
amendment. 
5.   I undertake to submit annual progress reports setting out the progress of the research, as required by 
review bodies. 
6.   I am aware of my responsibility to be up to date and comply with the requirements of the law and 
relevant guidelines relating to security and confidentiality of patient or other personal data, including the 
need to register when necessary with the appropriate Data Protection Officer. I understand that I am not 
permitted to disclose identifiable data to third parties unless the disclosure has the consent of the data 
subject or, in the case of patient data in England and Wales, the disclosure is covered by the terms of an 
approval under Section 251 of the NHS Act 2006. 
7.   I understand that research records/data may be subject to inspection by review bodies for audit 
purposes if required. 
8.   I understand that any personal data in this application will be held by review bodies and their 
operational managers and that this will be managed according to the principles established in the Data 
Protection Act 1998. 
9.   I understand that the information contained in this application, any supporting documentation and all 
correspondence with review bodies or their operational managers relating to the application: 
l Will be held by the REC (where applicable) until at least 3 years after the end of the study; and by NHS 
R&D offices (where the research requires NHS management permission) in accordance with the NHS Code 
of Practice on Records Management. 
l May be disclosed to the operational managers of review bodies, or the appointing authority for the REC 
(where applicable), in order to check that the application has been processed correctly or to investigate 
any complaint. 
l May be seen by auditors appointed to undertake accreditation of RECs (where applicable). 
l Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response to 
requests made under the Acts except where statutory exemptions apply. 
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10.   I understand that information relating to this research, including the contact details on this 
application, may be held on national research information systems, and that this will be managed 
according to the principles established in the Data Protection Act 1998. 
11.   Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, 
I understand that the summary of this study will be published on the website of the National Research 
Ethics Service (NRES), together with the contact point for enquiries named below. Publication will take 
place no earlier than 3 months after issue of the ethics committee’s final opinion or the withdrawal of the 
application. 
Contact point for publication(Not applicable for R&D Forms) 
NRES would like to include a contact point with the published summary of the study for those wishing to 
seek further information. We would be grateful if you would indicate one of the contact points below. 
Chief Investigator 
Sponsor  
Study co-ordinator 
Student 
Other – please give details 
None 
Access to application for training purposes (Not applicable for R&D Forms) Optional – please tick as 
appropriate: 
I would be content for members of other RECs to have access to the information in the application in 
confidence for training purposes. All personal identifiers and references to sponsors, funders and 
research units would be removed. 
 
This section was signed electronically by Miss Jenna Morgan on 16/11/2012 12:52. 
 
Job Title/Post:                Clinical Research Fellow 
Organisation:                 University of Sheffield 
Email:                            jenna.morgan@doctors.org.uk 
Signature:                    ..................................................... Print Name:                 Jenna Morgan 
Date:                            13/11/2012                   (dd/mm/yyyy)  
 
D2. Declaration by the sponsor's representative 
If there is more than one sponsor, this declaration should be signed on behalf of the co−sponsors by a 
representative of the lead sponsor named at A64-1. 
 
I confirm that: 
1.   This research proposal has been discussed with the Chief Investigator and agreement in principle to 
sponsor the research is in place. 
2.   An appropriate process of scientific critique has demonstrated that this research proposal is 
worthwhile and of high scientific quality. 
 461 
 
 
 
 
 
3.   Any necessary indemnity or insurance arrangements, as described in question A76, will be in place 
before this research starts. Insurance or indemnity policies will be renewed for the duration of the study 
where necessary. 
4.   Arrangements will be in place before the study starts for the research team to access resources and 
support to deliver the research as proposed. 
5.   Arrangements to allocate responsibilities for the management, monitoring and reporting of the 
research will be in place before the research starts. 
6.   The duties of sponsors set out in the Research Governance Framework for Health and Social Care will 
be undertaken in relation to this research. 
7.   Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I 
understand that the summary of this study will be published on the website of the National Research 
Ethics Service (NRES), together with the contact point for enquiries named in this application. Publication 
will take place no earlier than 3 months after issue of the ethics committee's final opinion or the 
withdrawal of the application. 
 
This section was signed electronically by Dr Dipak Patel on 16/11/2012 12:39. 
Job Title/Post:                Research Manager 
Organisation:                 Sheffield Teaching Hospitals NHS Foundation Trust 
Email:                            dipak.patel@sth.nhs.uk  
 
D3. Declaration for student projects by academic supervisor(s) 
1. I have read and approved both the research proposal and this application. I am satisfied that the 
scientific content of the research is satisfactory for an educational qualification at this level. 
2. I undertake to fulfil the responsibilities of the supervisor for this study as set out in the Research 
Governance Framework for Health and Social Care. 
3. I take responsibility for ensuring that this study is conducted in accordance with the ethical principles 
underlying the Declaration of Helsinki and good practice guidelines on the proper conduct of research, in 
conjunction with clinical supervisors as appropriate. 
4. I take responsibility for ensuring that the applicant is up to date and complies with the requirements of 
the law and relevant guidelines relating to security and confidentiality of patient and other personal data, 
in conjunction with clinical supervisors as appropriate. 
Academic supervisor 1 
This section was signed electronically by lynda wyld on 19/11/2012 14:31. 
Job Title/Post:               consultant Organisation:                University of sheffield Email:                            
l.wyld@sheffield.ac.uk 
Academic supervisor 2 
This section was signed electronically by Dr Karen Collins on 16/11/2012 16:15. 
Job Title/Post:               Reader in Health Care Research Organisation:                Sheffield Hallam University 
Email:                            k.collins@shu.ac.uk 
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Appendix 9: NHS R&D approvals 
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Dear Miss Morgan, 
   RJ113/n041 
  
Variation in Clinician 
preference for treatment in 
older women with operable 
breast cancer 
no ethics required 
 Thank you for submitting your research project to the R&D Department. The project 
has now been approved by the Trust and has been allocated the 
Trust R&D registration number RJ113/N041. The project has been registered on the 
Trust's research database. 
 
Please quote the R&D registration number in any communications with 
the R&D Department regarding your project. 
 
Conditions of Approval: 
 The principal investigator must notify R&D of the actual end date of the 
project. 
 The Principal Investigator is responsible for ensuring that Data Protection 
procedures are observed throughout the course of the project. 
 The agreed protocol must be followed. R&D must be notified of any changes 
to the protocol prior to implementation. 
In line with the Research Governance Framework, your project may be randomly 
selected for monitoring for compliance against the standards set out in the 
Framework. For information, the Trust's process for the monitoring of projects and 
the associated guidance is available from the Trust's intranet or on request from 
the R&D Department. You will be notified by the R&D Department if and when 
your project has been selected as part of the monitoring process. No action is needed 
until that time. 
Please ensure the recruitment figures for GSTFT sites are uploaded to the UKCRN 
monthly. GSTFT will need to inform the lead site as the lead site will need to upload 
the figures to the UKCRN. 
Many thanks for registering your research project 
 With best wishes 
 Elizabeth 
Elizabeth Bruna 
Research & Development Governance Specialist 
NIHR GSTFT/KCL Biomedical Research Centre 
T: +44 (0)20 7188 7188 Ext: 51682|  F: 0207 188 8330 | 
T: elizabeth.bruna@gstt.nhs.uk | W: www.guysandstthomas.nhs.uk/ 
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Title: Variation in Treatment of Older Women with Operable Breast Cancer      
CI: Jenna Morgan    
IRAS number: 117503        
REC number: N/A    
R&D Reference:  3042 
  
I am pleased to confirm North Bristol NHS Trust (NBT) NHS permission for the 
above study. 
  
FULL R&D APPROVAL 
  
You have permission to begin recruitment 
  
Please forward a copy of the updated R&D form – listing NBT as a research site by 
01 July 2013.  
  
I understand that Sheffield Teaching Hospitals NHS Foundation Trust will act as 
sponsor for this study. 
  
We acknowledge that this project does not require ethical review by a NHS Research 
Ethics Committee under the UK Health Departments’ Governance Arrangements for 
Research Ethics Committees (GAfREC), however it may be necessary to contact the 
University Research Ethics Committee (UREC). 
  
If your study is an interventional clinical trial, there is a new target to enter your first 
patient into the study within 70 days of submitting a full & valid R&I application. 
Please notify us of the date of the first patient first visit. If you experience any 
problems recruiting, please contact the R&I office for advice and support. 
  
We wish you every success with your study. We are keen to support good research at 
North Bristol NHS Trust and are pleased that you have decided to conduct your 
project here. 
  
The lead Research Governance Officer for this study is Stephanie Macpherson, who 
will remain your ongoing main point of contact. They can be reached at the 
following email address: research@nbt.nhs.uk. 
  
Approval is given on the understanding that this project be carried out according to 
Good Clinical Practice and UK Statutory Instrument, and within the guidelines of 
the NHS Research Governance Framework for Health and Social Care, and NHS 
Trust policies, procedures, and SOPs which are available online at 
http://www.nbt.nhs.uk/research. 
 In particular you have responsibility for: 
  
-  Ensuring that, all participants sign informed consent (whenever applicable). 
-  Adhering to the protocol and ensuring your co-workers do the same. 
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-  Ensuring all recruitment figures are uploaded to the Edge database on a weekly 
basis. 
-  Providing us with information about any amendments to the protocol, changes in 
funding, personnel or end date. 
-  Informing us of any research-related adverse events. 
-  Ensuring that any staff working on this study at this site have been issued with a 
contract with NBT (honorary, substantive or bank) or a letter of access before they 
commence work on the study at this site. 
-  Maintenance of an Investigator Site File and/or Trial Master Files. 
  
Researchers who hold substantive or honorary contracts with North Bristol NHS 
Trust (NBT) will be covered against claims of negligence by patients of NBT under 
the Clinical Negligence Scheme for Trusts (CNST). This scheme does not cover ‘no 
fault’ compensation and the Trust is precluded from taking out separate insurance to 
cover this. Any patient or volunteer taking part in the study is entitled to know that if 
they suffered injury as a result of participating in the study they would first have to 
prove negligence in a court of law before they could gain compensation. If the study 
involves patients of any other Trust or healthcare organisation, you will need to 
confirm the indemnity arrangements with that organisation. 
  
In addition, other information may be requested from time to time and lay summary 
of the results will be requested from you at the end of the study. 
  
This full R&D approval document will need to be filed in your Investigator Site File 
and/or Trial Master Files. 
  
In accordance with the NBT Research Monitoring and Audit policy, this study is 
subject to audit by the R&I Office. We will contact the Principal Investigator to 
make appropriate arrangements for this. 
  
Many thanks 
  
Nicola Williams 
Deputy Director 
Research & Innovation 
North Bristol NHS Trust 
  
Tel: 0117 323 6468 
Fax: 0117 323 6192 
http://www.nbt.nhs.uk/research 
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DIRECTORATE OF RESEARCH & DEVELOPMENT 
Director: Professor D Rowbotham 
Assistant Director: Dr David Hetmanski  
R&D Manager:Carolyn Maloney 
Direct Dial: (0116) 258 8351 
Fax No: (0116) 258 4226 
08-04-2013 
 
Miss Anne Stotter Consultant Breast Surgeon 
University Hospitals of Leicester Glenfield Hospital 
Groby Road Leicester LE5 4PW 
Dear Miss Anne Stotter 
Research & Development Office Leicester General Hospital 
Gwendolen Road 
Leicester LE5 4PW 
 
 
Ref: UHL CSP: 117503 
Title:  Variation in Clinician Preference for Treatment in 
Older Women with Operable Breast Cancer 
Project 
Status: Approved End Date: 03/10/2014 
I am pleased to confirm that with effect from the date of this letter, the above study 
has Trust Research & Development permission to commence at University 
Hospitals of Leicester NHS Trust. The research must be conducted in line with 
the Protocol and fulfil any contractual obligations agreed with the Sponsor. If you 
identify any issues during the course of your research that are likely to affect these 
obligations you must contact the R&D Office. 
 
In order for the UHL Trust to comply with targets set by the Department of Health 
through the ‘Plan for Growth’, there is an expectation that the first patient will be 
recruited within 30 days of the date of this letter. If there is likely to be a problem 
achieving this target, please contact the office as soon as possible. You will be asked 
to provide the date of the first patient recruited in due course. In addition, the Title, 
REC Reference number, local target recruitment and actual recruitment for this 
study will be published on a quarterly basis on the UHL Trust external website. 
 
All documents received by this office have been reviewed and form part of the 
approval. The documents received and approved are as follows: 
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Document Title Version Date REC 
Approval Protocol 1 24-10-2012 N/  
Clinical Preference Questionnaire 1.0 24-10-2012 N/A 
Health care Professional 
Information Sheet (Interview) 
1.0 24-10-2012 N/A 
Clinician Preferences Study HCP 
Consent 
1.0 24-10-2012 N/A 
li ician Preferences Study Reply 
Form 
1.0 24-10-2012 N/A 
 
Health Care Professional Cover Letter 1.0 24-10-2012 N/A 
Clinician Preference Study HCP Prompt Sheet 1.0 24-10-2012 N/A 
Please be aware that any changes to these documents after approval may 
constitute an amendment. The process of approval for amendments 
should be followed. Failure to do so may invalidate the approval of the 
study at this trust. 
Undertaking research in the NHS comes with a range of regulatory responsibilities. 
Please ensure that you and your research team are familiar with, and understand the 
roles and responsibilities both collectively and individually. 
 
Documents listing the roles and responsibilities for all individuals involved in research 
can be found on the R&D pages of the Public Website. It is important that you familiarise 
yourself with the Standard Operating Procedures, Policies and all other relevant 
documents which can be located by visiting 
www.leicestershospitals.nhs.uk/aboutus/education-and-research 
 
The R&D Office is keen to support and facilitate research where ever possible. If you have 
any questions regarding this or other research you wish to undertake in the Trust, 
please contact this office.  Our contact details are provided on the attached sheet. 
 
This study has been reviewed and processed by the Leicestershire, Northamptonshire  & 
Rutland Comprehensive Local Research Network (LNR CLRN) using the Coordinated 
System for gaining Trust Permission (CSP). If you require any further information on the 
approval of this study please contact the LNR CLRN office on 0116 258 6185 making 
reference to the CSP number which is located at the top of this letter. 
 
We wish you every success with your research. 
Yours sincerely 
 
Carolyn Maloney 
R&D Manager 
Encs: .R&D Office Contact Information 
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Appendix 10: Interview Consent Form 
Variation in Clinician Preference for Treatment of Older 
Women with Operable Breast Cancer.    
Health Care Professional Consent Form (Interview)                
Please initial each statement in the boxes provided and sign at the bottom of the page. 
Name of Participant               Date Signature 
 
Name of Person taking consent             Date Signature 
 
When completed, 1 for participant, 1 for researcher site file 
  
I confirm that I have read and understood the information leaflet dated 24
th
 October 2012 
(version 1.0) for the above study. I have had the opportunity to consider the information 
and ask questions and have had these answered satisfactorily. 
 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights  being 
affected. 
 
 
I give permission for the interview to be audio recorded. 
 
I understand that quotes from my interview may be used within written reports or 
publications and that any quotes would be completely anonymous and could not 
be linked to me in any way. 
 
I understand that relevant interview data collected during the study may be looked at by 
individuals from the Sheffield Teaching Hospitals NHS Foundation Trust or from 
regulatory authorities, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to these records’. 
 
 
I agree to take part in the above study  . 
 
 
I give permission to be contacted in the future about participating in a follow-up interview. 
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Appendix 11: List of principal investigators at each site for 
interview component 
Trust Local PI Local R&D number 
(if applicable) 
Date of 
R&D 
approval 
Sheffield Teaching Hospitals NHS 
Foundation Trust 
Miss L Wyld STH17054 17/01/2013 
St Helen’s & Knowsley Teaching 
Hospitals NHS Trust 
Mr R Audisio RBN 836 31/01/2013 
Guys & St Thomas Foundation Trust Mr M Douek RJ113/n041 15/02/2013 
Barnsley Hospital NHS Foundation 
Trust 
Miss J Dicks BHNFT539 26/02/2013 
University Hospitals Coventry and 
Warwickshire NHS Trust 
Mr H Khan HK114212 04/02/2013 
Chesterfield Royal Hospital NHS 
Foundation Trust 
Mr S Holt CSP: 117503 13/02/2013 
Northern Lincolnshire & Goole 
Hospitals NHS Foundation Trust 
Mr R Vijh CSP: 117503 19/03/2013 
Derby Hospitals NHS Foundation 
Trust 
Mr KL Cheung DHRD/2013/029 10/04/2013 
University Hospitals of Leicester NHS 
Trust 
Miss A Stotter UHL CSP: 117503 08/04/2013 
Dartford & Gravesham NHS Trust Ms S 
Seetharam 
DVH190 15/05/2013 
Doncaster & Bassetlaw Hospitals NHS 
Foundation Trust 
Miss C Rogers 0514/2012/NCT 03/06/2013 
North Bristol NHS Trust Mr M Shere 3042 18/06/2013 
Nottingham University Hospitals NHS 
Trust 
Miss E 
Gutteridge 
12BS002 08/08/2013 
Oxford University Hospital NHS Trust Miss PG Roy 10512 01/10/2013 
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Appendix 12: Participant information sheet (PIS) for interviews 
 
Variation in Clinician Preferences for Treatment in Older Women 
with Operable Breast Cancer. 
Health Care Professional Information Sheet (Interview) 
 
Invitation to participate in the study 
We would like to invite you to take part in a research study being organised 
by the University of Sheffield and Sheffield Hallam University. Please take 
time to read the following information carefully and feel free to contact us for 
further information.  
 
What is the purpose of the study? 
In the UK there is wide variation in practice relating to the treatment of older 
women with breast cancer, particularly with reference to rates of Primary 
Endocrine Therapy (PET). Whilst some of this variance may be explained by 
variance in patient characteristics such as health and fitness, education, 
deprivation and disease stage, clinician preference may also play a part.  We 
would like to interview a number of specialist health care professionals who 
are involved in either the management of breast cancer or care of the elderly 
about their views regarding the management of older women with operable 
breast cancer to give us a better understanding of why this variance exists.  
 
Do you have to take part?  
Your taking part in this study is entirely voluntary. If you do not want to take part, 
you do not have to give a reason and you will not be contacted again about this 
study. If you decide to take part but later change your mind, you can withdraw from 
the study at any time and do not have to give a reason.  
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What will happen if you take part? 
If you wish to take part in the study, follow the instructions below and a member of 
the study team will then contact you to arrange an interview at a time and place 
most convenient to you. Interviews will take between 20-30 minutes to conduct. 
The interview will be recorded with your consent. Recordings will be stored 
electronically and anonymously, and will only be available to the study team.  
 
Contact for further information 
If you would like any further information, or have any questions concerning this 
study, please contact Miss Lynda Wyld (Senior Lecturer and Consultant Surgeon), 
EU36, University of Sheffield Medical School, Beech Hill Road, Sheffield, Royal 
Hallamshire Hospital, Sheffield. Telephone: 0114 2268640.  
 
What do I need to do now? 
Whether you decide to take part in this study or not, we would be grateful if you 
would complete the Study Reply Form accompanying this information leaflet and 
return it to us in the FREEPOST envelope provided. You do not need a stamp.  
If you decide not to take part, please tick the box beside ‘No, I do not wish to take 
part in this study’ and return the form to us. You do not need to fill in any other 
details on the form.  
If you wish to take part in the study, please tick ‘Yes, I would like to take part in 
this study’, fill in the contact details section on the Study Reply Form and the 
consent form provided and return them.  
 
Please keep this information leaflet for future reference. 
Thank you for reading this information sheet and for taking an interest in the 
research study. 
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Appendix 13: Outline of interview topics for participants 
At start: 
Issues that may be raised during interview:  
What treatment options would you normally consider for an older woman (over 70) with 
operable primary breast cancer? 
Prompts: Would surgery form part of your potential management plan in all 
patients? 
 Is PET an option for all patients in this group? 
 
What do you feel are the risks and benefits of surgery and PET for this age group? 
Prompts: Morbidity and mortality of surgery 
 Local recurrence risks, local control 
 Compliance 
 
What factors influence your choice of management for a particular patient with primary 
operable breast cancer? 
Prompts: Age of patient at diagnosis 
 Frailty of patient 
 Co-morbidities, including dementia 
 Anaesthetic considerations 
 Optimisation of other health issues 
 Patient choice 
 Carer preferences 
 Guidelines 
 Stage/operability of cancer 
 Cancer biology (e.g. ER and HER2 status, mucinous subtype) 
 Pre-operative assessment: anaesthetic assessment, formal geriatric 
assessment, “end of the bed” assessment 
 
Are there any other factors that influence your overall practice in this patient group? 
Prompts: Influence of cancer targets 
 Influence of costs 
 
If in such patients there is the potential for choice of either surgery or primary endocrine 
therapy, what level of involvement does the patient play in the management decision?  
 
What factors have influenced your personal strategy for dealing with these patients? 
Prompts: Literature evidence 
 Patient preference 
 Experience of cases over the years 
 Unit policy 
 Training and mentoring 
 Breast care nurse input 
 
What affects the amount of information you relay to a patient following a diagnosis of 
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breast cancer? 
Prompts: Patient wishes 
 Patient cognitive status 
 Relative and carers information needs 
 
What do you think elderly women feel about primary endocrine therapy? 
Prompts: Easier than having surgery 
 Safer than having surgery 
 Less certainty of a cure 
 Less hassle 
 
What do you think elderly women feel about having surgery? 
Prompts: Fear of death 
 Disfigurement or loss of breast 
 Fear of hospitalisation 
 Burden on others 
 Loss of independence 
 Complications (e.g. arm swelling) 
 
Any additional comments the participant would like to add 
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Appendix 14: Relationship between interview codes and 
themes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Idea of standard treatment 
 Usual treatment of over 70s 
 Idea of equality 
 Treatment considered as 
standard 
 
 Importance of age 
 Importance of patient fitness 
 Importance of comorbidities 
 Importance of frailty 
 Importance of social 
circumstances 
 Importance of functional 
status 
 Impact of dementia on 
treatment offered 
 Importance of life expectancy 
 Tumour factors affecting 
treatment 
 Importance of patient 
preference 
 Other factors 
 Ability to tolerate treatment 
 Idea of equality 
 Importance of age 
 Variation of treatment with 
age 
 Reasons for regional variation 
 Idea of over treatment 
 Ability to tolerate treatment 
 Variability of older patients 
 Assessments used 
 End of the bed assessment 
 Use of CGA 
 Optimisation 
 Regular anaesthetist 
 
Usual treatment 
strategy for over 70s 
Factors influencing 
treatment 
Variation in treatment 
of older patients 
Assessment of older 
patients 
Theme 
1 
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 Overall opinion of surgery 
 Surgery is more common in the 
elderly 
 How surgery is tolerated in the 
elderly 
 Benefits of surgical treatment 
 Opinion of local anaesthetic 
surgery 
 Use of local anaesthetic surgery 
 Use of regional blocks 
 
Use of surgery in the 
elderly 
Refusal to undergo 
surgery 
 Negatives of surgical treatment 
 Patients feelings about surgical 
treatment 
 How surgery is tolerated in the 
elderly 
Older women’s views 
of surgical treatment 
 Reasons patients refuse 
surgery 
 Response to refusal 
 Patients refusing standard Rx 
 Why patients refuse standard 
treatment 
 Reaction to refusal of 
standard treatment 
Local anaesthetic 
surgery 
Theme 
2 
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 Overall opinion of PET 
 When PET offered 
 Type of PET used 
 Use of neo-adjuvant  
 Benefits of PET 
 Type of PET used 
 Method of assessment 
 F/U process 
 Average length of response 
 Response to failure 
 
Use of PET in the elderly 
Practicalities of PET 
 Negatives of PET 
 Patients feelings about PET 
 Aware it’s not a cure 
 Impact of palpable lump 
 Impact of intensity of F/U 
Older women’s views of 
PET 
Theme 
3 
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 Patients’ refusal to choose 
 Role of clinician and pt in DM 
 DM in older women 
 Patients’ view of their age 
 Patients’ idea of diagnosis 
 
DM in older women 
 Reasons patients refuse surgery 
 Why patients refuse standard 
treatment 
 Patients’ view of their age 
 Patients’ idea of diagnosis 
 
Patients’ prior 
knowledge/ 
perceptions 
 Factors affecting information 
giving 
 Information content 
 Role of BCN 
Information giving 
 Recommending treatment 
 Reaction to refusal to choose 
 Reaction to refusal of standard 
Rx 
 Role of clinician and pt in DM 
 Influence of HCP on DM 
 Role of BCN 
 Importance of clinician’s 
judgement 
 
Influence of HCP on 
DM 
 Factors that have influenced 
their opinion 
 Role of MDT 
 Usefulness of guidelines 
 Available evidence 
 Usefullness of decision aids 
 
Factors influencing 
HCP opinon 
Theme 
4 
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 Offering choice 
Patients’ refusal to 
choose 
 Making recommendations 
 Patients’ refusal to choose 
 Why patients may defer choice 
 Reaction to refusal to choose 
 Giving time to think 
Theme 
5 
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Appendix 15: Interview Framework Matrix 
Theme 1: Attitudes towards treating older women with breast cancer 
 
 
1.1 Impact of age on treatment of breast 
cancer 
1.2 Factors influencing treatment 1.3 Assessment of older patients 1.4 Variation in the treatment of older women 
S01 
Female 
High 
PET 
As you would treat a woman of any age. 
Normal Rx as per the protocol for a woman 
of any age. Mentions Mx, ANC, chemo. 
Ideally like to treat... in the most aggressive 
way that you possibly can. Someone who is 
clearly fit... should offer them an operation. 
I do consider it (PET) for women in this age 
group. Treats pts as individuals, tailors 
accordingly, consider her ability to tolerate 
the Rx. 
Take into account fitness. Not fit for a haircut = 
PET. Should be based on biological fitness. Not 
doing her any favours by treating her with that 
degree of aggression if has life-limiting co-
morbidities. Mentions: lung cancer, COPD, cardiac 
problems, AF. Very frail lady... probably better off 
with tablets. Slightly demented... better off with 
tablets...may have a preference... have to respect 
that. ER & HER2 status. Take into account her 
preferences. Pt views obviously have the primacy. 
Views of relatives. Ability to tolerate the Rx. 
Anaesthetic assessment useful in "borderline" 
group. No geriatricians involved. Might want... 
anaesthetic assessment... let’s put the actual 
risk of an anaesthetic into the mix. End of bed 
assess leads to full anaesthetic assessment. 
Everything’s based on the... opinion of the 
surgeon as to their fitness... everyone’s got 
different thresholds... means that people 
haven’t got a clue what they’re doing. Doesn't 
use CGA. Comorb... Refer them... optimisation. 
Different anaesthetists have different 
thresholds for who's fit for a GA. Team effort. 
Anaesthetist calculates risk. 
Used to an over 70s policy- one of my 
colleagues used to put everyone on PET if they 
were over 70. When I was a newly qualified 
doctor, there was generally the view that 
anyone over 70 was too old to have anything. 
Definition of old is changing... “70 is old” is now 
become “80 is old”. Nowadays 70 is not 
regarded as old. At the moment everything’s 
based on the preference or the opinion of the 
surgeon...there’s no guidance and everyone’s 
got different thresholds. May be more Rx than 
she actually needs. You're not doing her any 
favours by treating her with that degree of 
aggression. Consider her ability to tolerate the 
treatment. It's a very heterogeneous 
population. 
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S02 
Male 
High 
PET 
Considers surgery for every pt. Uses PET 
probably in three situations. I would want 
to comply with standard guidelines... 
unless there’s a reason not to. If it’s easy to 
treat (breast cancer in the elderly) then why 
wouldn’t you? 
Regardless of age. Contradicts: Everyone does take 
age into account... you can’t help it. biological age. 
ability to withstand certain Rx's. Pivot age... into 
the 80s... more likely to die of something else than 
BC. If F&W recommend op. Rare that someone is 
so unwell that they couldn’t have an op. Tries not 
to let dementia or being in a wheelchair influence. 
IADL important in Rx DM. Life expectancy 
important in Rx DM: predicted survival of <2-3 yr 
there’s no... benefit from surgery.... > 5 yr... 
definite role for surgery...  between... 2-5 yr... 
choice to be made. Other than strongly (ER) 
positive... would be recommending surgery. Try 
not to go on 1st impressions. 
Anaesthetic opinion to make a more rational 
judgement. No formal Charlson/questionnaires. 
It’s largely having a background knowledge of 
the important factors but not accurately and 
confidently measuring them. Don’t do a CGA at 
the moment and don’t have access to that. 
Thinks CGA should be done if the pt has any 
degree of frailty. 
I would want to comply with standard 
guidelines... unless there’s a reason not to. 
Everyone does take age into account, and you 
can’t help it. "pivot age"... somewhere into the 
80s, where you’re more likely to die of 
something else than BC. The thing that’s 
resilient is that around 40% of older people are 
not getting operations. I would like to see... a 
narrowing in the variation in Rx. Thinks the fact 
that older women get all info from HCP is 
perpetuating the variation in Rx. It’s about 
narrowing the variation in practice which is due 
to the HCP preference. Lack of benefit: surgery 
is not going to be of significant benefit. 
Predicted survival of <2-3 yr there’s no 
additional benefit from surgery. If you’re 90 
and it’s only 20-25% of people die of BC, it’s still 
a significant cause of death. Thinks size or Rx 
effect was misrepresented, resulting in a 
collective under-Rx. 
S03 
Male 
Low 
PET 
Consider... surgical option... or I would 
consider a non-surgical option if the lesion 
is ER+. I’ve not ever made up my mind a 
priori - I want to offer the best Rx to every 
single individual pt. 
Crucially important is pt’s fitness. Frailty is the only 
parameter. Considers lack of mobility because of 
risk of VTE with Tam. These pts (dementia) need 
double consenting and surgery. Cope better with 
half an hour surgical procedure rather than with a 
full life of PET. Two Rxs are not entirely 
superimposable, unless she is going to die before 
the cancer comes back. ER positivity. Pt’s 
preference... crucially important. Several older pts 
cannot comply with Rx (PET). 
Uses “Timed Up and Go,” “Groningen Frailty 
Index” and “VES13” to assess fitness. 
Mandatory to have frailty assessments 
otherwise you are biased in an ageist decision 
which is not evidence-based. Routinely 
performs frailty assessments on all patients 70 
and above. Talk to the geriatrician... 
cardiological assessment when they’ve got 
swollen legs. Not even a CGA is entirely 100% 
reliable. 
I want to offer the best Rx to every single 
individual pt. Thinks reason for variation in Rx is 
because of the Dundee report in the 80s that 
presented... PET as the panacea, that surgery 
was not needed and lazy surgeons buy this 
without any critical mass. The question is, is 
this beneficial for the pt? Is the pt going to take 
advantage of the surgery or is she going to die 
before? 
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S04 
Male 
Low 
PET 
Offer the same options as… a lady who’s 
under 70 yr old. Standard Rx is surgery. It's 
difficult to avoid offering surgery to pts... of 
any age. Offers both BCS and Mx if 
appropriate. 
Age doesn't impact on Rx offered. Difficult to avoid 
offering surgery to pts... of any age. If they’re fit 
for an op then I would operate on them. Significant 
co-morbidity such as significant other cancer might 
make a pt not suitable for surgery Contradiction: 
offer the same surgical options even with 
significant co-morbidities. Frailty doesn't impact 
Rx. Significant dementia may not be suitable for 
surgery. ER positivity.  Pt who declines surgery. 
Routine anaesthetic assessment, doesn't 
influence decision: happens after I’ve made a 
decision to operate. Decision re: fitness for 
operation made by the clinician/nurse who 
sees the pt. Don't have a regular anaesthetist - 
we're lucky if we see the same person every 
week. 
I would offer the same options as I would offer 
to a lady who’s under 70 years old. I try to 
avoid falling into the trap of let’s give them a 
more radical operation with more risk of 
lymphoedema just because we don’t want to 
operate again. I don’t like, or I don’t agree with 
the notion that because they are old you’ve got 
to offer them Mx and ANC to avoid the second 
anaesthetic. That doesn’t make sense to me. 
Benefit of surgery is small, particularly in older, 
frailer women. 
S05 
Male 
Low 
PET 
All the options that I would a fit 30 y.o, as I 
would a fit 70 y.o. In terms of... quality... or 
the nature of surgery it wouldn’t change. 
Cautious with chemo. Rx needs to be 
individualised, it needs to be tailored, it's 
bespoke Rx. Rx that the cancer deserves 
and not an age deserves. Never 
differentiate on age because I wouldn't 
want that to be done to me. Done a 
reconstruction on an 85 y.o. Pt's best 
interest. 
Don’t differentiate... on age. 70+... same Rx as 
would anyone else. Rx that the cancer deserves 
and not an age deserves. Fitness influences. 
Severe co-morbidity you're not going to take her 
breast off. Wouldn't normally operate on a very 
frail old lady. Considers dementia but would 
always aim to get optimal Rx. ER status. Pt choice 
biggest factor but if you tell them what's best for 
them they would eventually come around to your 
POV. Pt-driven decision, rather than a surgeon-
driven. Important can withstand surgery. Loss of 
independence post-op so may benefit from 
masterly inactivity & PET. 
Full assessments performed by elderly care 
team - they would tell us “Yes, there’s no 
reason why this pt can’t have a GA”. Decides in 
clinic whether a pt needs further assessments 
and refers her to elderly care team. Use PET 
whilst optimising them and leave on PET if can't 
optimise. 
Give all the options that I would a fit 30 year 
old, as I would a fit 70 year old. So a 70-year 
old, or 70+, would get the same treatment, as 
would anyone else in our unit. I don’t think 
anyone should treat anyone purely because 
she’s 70. I would never differentiate on age 
because i wouldn't want that to be done to me 
and so why would I do it to someone else? 
Done a reconstruction on an 85 yo. You give 
the pt Rx that the cancer deserves and not an 
age deserves. Clinicians bias, particularly of the 
older generation of surgeons. Surgeon-driven 
decisions - dysfunctional MDT means surgeons 
dictate what is happening. Spare her the 
mastectomy, when we know that her COPD 
may kill her before her breast cancer does. The 
co-morbidities will kill them before their 
cancer. We can’t just generalise and say I’m 
going to do this for everyone over the age of 
70. You would individualise the treatment. 
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N06 
Female 
Low 
PET 
Don’t think they’re limited. Offered all 
ranges that are appropriate to the pt. Look 
at the pt as an individual. Example of 
offering a 72 y.o. chemo. 
Age is a number, doesn't determine Rx. Not 
physically fit may only be offered PET. Only if the 
anaesthetist says "this lady cannot go under 
anaesthetic" - is it the anaesthetists that ultimately 
decide Rx then? Chronic morbidities, e.g. heart 
disease, may prevent pts being fit. Depends how 
frail they are. NH + dementia: there's no way we 
would be able to do surgery on her. Dementia may 
prevent pts being fit for surgery. 
Assessed by specialist older person's team and 
anaesthetic opinion - even if they look like 
they're unfit: we would always send 
someone...for an assessment... even if they 
look like they’re not physically fit, we would 
always get that second recommendation and 
only if the anaesthetist says “this lady cannot 
go under an anaesthetic”. 
Example of offering a 72 y.o. chemotherapy - I 
think they’re offered all ranges that are 
appropriate to the patient. I think we look at 
the patient as an individual. Age is a number - it 
doesn't determine a treatment. Less variation 
between surgeons now in terms of treatment 
options - thinks because of strict MDM 
recommendations. Although occasionally 
surgeons deviate from the recommendation - 
which has been known to happen, surgeons 
just say “well actually, I think this way". 
Becoming more aggressive with all Rx now 
compared to previously. You can have a very fit 
80 y.o. Inherent bias, stresses "even" with older 
ladies - even at that age. Body image is so 
varied, even with older ladies. 
S07 
Female 
High 
PET 
Treat any pt surgically first. Most women at 
70 are perfectly fit for an anaesthetic. 
Standard Rx unless a reason not to. I’m sure 
there are those who come, looking frail, 
with carers and they’re 86 and we just go 
have this nice tablet. 
With 70 y.o's, I wouldn’t be having this 
conversation (about PET)... it’s mostly over 80s. 
More about co-morbs than age. Biological age. If 
somebody’s fit for surgery. Multiple meds, MIs, 
CVAs, diabetes... may not benefit from op. I’m sure 
there are those who come, looking frail... and we 
just go have this nice tablet. Daily activities 
influence. Dementia: discuss PET, depends how 
they'd cope with hospitalisation. If... going live >5 
yrs... probably going to come to the end their E... T. 
ER positivity. Would offer a choice of PET if they 
look appalled at the thought of an op. Anaesthetist 
opinion important. 
Anaesthetic assessment. Hard to put a finger 
on exactly what point do you look at somebody 
and think we’ll talk about ET. Doesn't use CGA. 
Regular anaesthetist, so my pts would be 
discussed with her. Helps to have someone you 
work with regularly: she knows what the op 
involves... potential morbidity. 
Some clinician bias - I’m sure there are those 
who come, looking frail, with carers and they’re 
86 and we just go have this nice table. I 
wouldn’t generally with 70 year olds, I wouldn’t 
be having this conversation... it’s mostly over 
80s. Most women at 70 are perfectly fit for an 
anaesthetic but there are some who aren't. 
Older pts vary - describes a very unfit 86 y.o. 
who wanted an operation vs 84 y.o. who's fit as 
a fiddle and PET not really working but won't 
entertain an operation. 
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S08 
Male 
High 
PET 
Between 70-80... we’d really want them to 
be having surgery. 80+ would be happy to 
discuss PET but if fit will still be pushing 
surgery. Once they get to 85 and above, 
then I would be certainly talking to patients 
about PET in equal terms as surgery. 
From 70 to 80... I would certainly not consider PET 
in that group. 80+ PET a concept that I would be 
happy to discuss. 85+ certainly talking to pts about 
PET in equal terms as surgery. If not fit very happy 
to consider PET. Serious co-morbs would prevent 
surgery. Would be pushing the primary surgery if I 
feel that they have very few morbidities. Rx 
decision influenced by: co-morbs, multiple meds, 
immobility, recent cardiac/resp probs. Frailty not 
best marker unless so frail they can't survive 
surgery. Doesn't look at NH status. Immobility 
influences Rx decision. 1st impressions: if she 
comes storming in. Dementia doesn't influence Rx 
decision. Rx must be geared towards the pt 
lifespan. Locally advanced should get surgery. 
Really want them to be having surgery unless they 
absolutely say... they don’t want it. Whether they 
can withstand surgery important deciding factor. 
If there are any queries then I would refer on to 
the anaesthetist, for an anaesthetic opinion. 
Told by the anaesthetist that she would 
probably be unlikely to survive surgery. If you 
or they are not sure then a referral to 
anaesthetic department for a much more 
intensive review. Uses anaesthetic r/v to back 
up decision not to operate. It is purely bedside 
history-taking and a frank discussion with the 
pt. Doesn't use CGA. Regular anaesthetists in 
some lists but not others. 
70 to 80 I don’t consider elderly. Age dictates 
Rx options offered. Talks about no survival 
advantage for either Rx after 85 yo. When 
you’re 80-82 y.o. & you’ve got BC, whether you 
do a lumpectomy or you do PET, I don’t think 
they’re going to live any longer and I don’t 
think the local control is that much of an issue 
that we ought to take everyone down for 
surgery. So why do surgery & RTx & everything 
when these pts- they’re not going to live any 
longer than their natural lifespan. There is a 
significant group that will not tolerate surgery 
& therefore it’s worth...give them tablets, see 
how it does. Although there are some patients 
who are in their mid-70s who are clearly not for 
surgery. 
N09 
Female 
High 
PET 
If fit & healthy - surgery. I think I’m of the 
opinion that surgery is the gold standard. 
Would like to think age doesn't play a factor in Rx 
decision. Thinks Rx decision is based on fitness. 
PMH discussed at MDT and helps form provision 
Rx plan. Medical conditions that might impact on 
their anaesthetic risk - e.g. very high BP, chest 
problems, repeated MIs, cardiac problems, 
wheelchair-bound, arthritic, very disable - those 
kind of things might come into all of the equations 
about making decisions. Dementia comes into DM 
- discuss with family what they feel would be 
beneficial for their loved one - doesn’t mean to say 
we don’t do surgery on patients with dementia, 
but we don’t want to put patients under 
unnecessary distress. Mentions issue of 
compliance with PET. 
Anaesthetic assessment to assess surgical risk. 
May be fit on paper but then clinician sees 
them and feels they're not then there may be a 
change in Rx plan. 
Would like to think age doesn't play a factor in 
Rx decision. 70 is not old these days, so you're 
looking at you're 80s and 90s now. Rx varies 
between clinicians - some will offer a choice of 
either option and others won't - some surgeons 
will do that, others don't, so it's very clinician 
dependent. Talks about some pts being very 
worried about surgery, others just want to get 
on with things. 
 505 
 
 
 
 
 
S10 
Male 
High 
PET 
We usually do sentinel node for them, so 
we tried to avoid axillary clearance to stop 
them from having lymphedema. We don’t 
discriminate pts on age, so whether she's 
young or 70 or even 80, if the cancer is 
operable, I would offer them surgery. Either 
WLE +SNB or Mx + SNB. 
Don’t discriminate on age. Majority pts 85+ would 
be for PET: at that age, they are not very keen to 
go for surgery, or the family... are not very keen, 
especially if they are very frail. 70-85 if they are fit 
we usually offer them surgery. If fit, go ahead with 
surgery. If high risk will operate if the anaesthetist 
is happy/pt accepts risk. Mentions DM, asthma, 
stroke, angina, heavy smoker. Severity important: 
not every co-morb means I should... go for HT. You 
don’t like to lose your pt, if she has got a lot of 
comorbidities, to put her under anaesthesia, 
especially if you have an alternative... it’s better to 
be safe. If they are very frail... & the relatives are 
happy to go with HT, we try...not to enforce the Rx 
on them. Mobility not a contraindication. 
Dementia: go for surgery if the pt/relatives happy. 
ERPR status. Cancer type doesn't matter. If pt is 
happy. Targets/cost don't influence. 
Seems to leave decision to anaesthetist - will 
operate unless the anaesthetist says they are 
not happy. Anaesthetic pre-assessment clinic - 
they will tell us fit or not fit for surgery. Doesn't 
use CGA. Usually write to physician about co-
morbidities in terms of severity and fitness for 
surgery or optimisation. Has a regularly 
anaesthetist but his pts may not be seen by his 
anaesthetist. 
We don’t discriminate patients on age. Majority 
of pts 85+ would be for PET. Reason for 85 as 
cut off: at that age, they are not very keen to go 
for surgery, or the family, the relatives, they are 
not very keen, especially if they are very frail. 
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N11 
Female 
Low 
PET 
Surgery would be the main Rx that would be 
discussed in the first instance. People 
shouldn’t be prejudiced against because of 
an age. We've operated on a lot of older 
pts, 80+, 90. It would be unfair not to offer 
it (surgery). 
Age seems more important to pts than HCP: age is 
an important factor because when people say “am 
I too old”... people shouldn’t be prejudiced against 
because of an age. Take fitness into account. If 
unfit for surgery would discuss that surgery not the 
best option. Co-morbs influencing fitness for 
surgery include heart problems, warfarin, lots of 
medication - these would make somebody think "is 
this (surgery) the best thing?" Take frailty into 
account. Physical frailty more important than 
mental health. Size of tumour may affect Rx - e.g. 
neo-adjuvant to downsize. Most important for 
deciding Rx is the pts opinion - they come 
thinking... "I won't be able to do this" but they 
leave thinking "I'm quite happy to go for this" - is 
this really pt preference or is it reassuring and 
persuading them that surgery is the best? 
Use PACE questionnaire to assess how fit 
someone is. Get anaesthetic assessment of 
fitness before discussing surgery not being the 
best option. Anaesthetic opinion as second 
opinion. Pre-op assessment reassures pts. Take 
into account anaesthetic r/v. Uses other 
assessments combined with a few simple 
questions to decide whether a pt is able to 
have surgery. Questionnaire used in clinic, 
looks at the whole person - mental capacity, 
depression, family support, ADLs, eyesight, 
hearing, mobility - holistic look at the person. 
Also timed stand-up and go. Combine this with 
the anaesthetic review to decide if the pt is 
able to have surgery. 
People shouldn’t be prejudiced against because 
of an age. Age seems more important to pts 
than HCP in DM. 70 is young. Take into account 
a person and the word "old" can't be used 
about a lot of people.  
N12 
Female 
High 
PET 
Let's assess her... and take the surgical 
option forward. 
Consider PET if ladies can't withstand a GA. If a 
lady has a lot of co-morbidities... it would be more 
focussed towards PE(T). PET a good option for pts 
who are not mobile, come into clinic in a 
wheelchair. PET would be an option for pt with 
complete senile dementia with poor QoL. 
Importance of quality of life - I think you have got 
to address certain QoL issues. 
Pre-op assessment - allows us to reassure pts 
that surgery is safe. Always have general pre-
op, incl: ECG, PFT, CXR, bloods + anaesthetic 
assessment to ensure not going to do more 
harm than good. Get anaesthetic assessment to 
check ok to offer surgery. Getting more 
thorough about assessing pts for surgical 
options. 
I always try to give the same information out, 
whether a patient’s in their 20s or their 90s. 
Surgery for elderly more common in recent 
years than it used to be - you don’t sort of see 
primary endocrine as the only choice now for 
the elderly lady. I think doctors generally are 
getting better at steering patients towards the 
surgical options more so than perhaps 8 years 
ago. 
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N13 
Female 
High 
PET 
Primarily surgery + then the add-on Rxs as 
per surgery results. I think if you asked sort 
of almost all of us that worked in the unit 
“what would you offer someone as a first 
line treatment” it would always be surgery if 
they were fit for it. Choice of WLE/Mx. 
Usually axillary surgery - but some pts 
where we're willing to compromise - does 
this suggest less aggressive with extremes 
of age?? Offer chemo if fit and would 
benefit. Offered immediate recon to a 76 
y.o. - there was no reason not to. 
Used to be about age but not anymore. We’re so 
not ageist now. Irrespective of age, don't really 
offer PET to fit pts. You're trying to work out are 
they fit enough: Nothing we won’t do if someone’s 
fit. Look at all co-morbs when deciding suitability 
for surgery. Usually health issues that steers Rx 
decision. Dementia doesn't exempt them from 
surgery but Usually family that sways us into PET - 
last thing they want is to put their - parents usually 
- through surgery. Talks about life-expectancy may 
be shortened by something else but will still 
operate: if we can then let's get rid of it. Hormone 
sensitivity. Very much personal choice. About what 
they want... it’s about not judging that and just 
doing what they want you to do. Look at whether 
could withstand GA. Look very carefully at can we 
afford to give them an anaesthetic or would PE(T) 
be far safer for them. 
If sceptical about how well they'd tolerate a GA 
would get an anaesthetic consultant to assess 
them for level of risk. Anaesthetic assessment 
is a risk stratification. Do a basic performance 
status and co-morbidity score - helps 
determine fitness level, what they could 
withstand and what could we recommend for 
them. Occasionally anaesthetist will refuse to 
put a pt to sleep - they’ll say someone’s risky 
for an anaesthetic, it’s not often they’ll say you 
know “we really can’t do this”. Generally work 
with a similar anaesthetist. We've got one 
who's extremely cautious. 
It used to be about age but not anymore.  You 
assume that in an older lady they’ve used their 
breasts for what they work for and they don’t 
actually have a use... so I think we assume that 
they're not going to be bothered (about 
disfigurement). I think we’re so not ageist now 
compared to how we used to be. More often 
than not we’re wanting to Rx something that 
probably won’t actually end their life. Talks 
about decision re: Rx impacted by what Rx 
would benefit the pt - therefore Rx may not be 
of benefit. You learn what’s acceptable for 
some is not acceptable for everybody else. 
More open-minded now. I’ve seen us operate 
on people... in more recent times that in the 
olden times... we’d have thought “do you know 
what? That’s too risky!” I think we’re so not 
ageist now compared to how we used to be. 
S14 
Male 
High 
PET 
Primarily surgery, BCS if possible, & Mx with 
whatever axillary assessment is required. 
Also are given the option of PET. 
PET mainly used for pts 77-90, there are very few 
70-77 who are treated with PET. Wherever they 
are fit for anaesthesia they would go for surgery. 
Co-morbs determine suitability for surgery - pts 
with severe COPD, CCF or CVAs would be more 
unsuitable for surgery as they're high risk for GA - 
would still be offered LA surgery. Frailty 
contributes to life-expectancy. If in NH need info 
from carers on things like compliance. Dementia... 
they would probably be recommended PET.  
Compliance can be an issue for dementia pts which 
would influence decision - surgery an option if 
won't take tablets. Pt choice an influence. Not 
targets or costs. 
Anaesthetic assessment for high risk pts to 
quantify surgical risks before we decide on 
surgical Rx. I occasionally get them to see a 
geriatrician for their life-expectancy. If in my 
view they are high risk then I would send them 
to the anaesthetist for their assessment.  No 
regular anaesthetist - used to at last hospital. 
Mainly used for pts 77-90, there are very few 
70-77 who are treated with PET.  
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S15 
Female 
High 
PET 
Boils down to...is this woman fit for 
standard Rx?  Choice of Mx and WLE, SNB if 
no evidence of axillary disease, ANC if they 
have, adjuvant ET if ER+, RTx with same 
indications as for younger women. 
Acceptance of chemo for women >70 has 
been quite slow. 
Boils down to is this woman fit for standard Rx. 
Certain co-morbs have a significant chance of 
death if you operate on them. Recent serious 
illness (MI, PE, acute pancreatitis) - we use ET until 
they're well and then operate. Very frail elderly pts 
generally don't want an operation and lose their 
natural defence against cancer. Severe dementia is 
associated with short life-expectancy so Rx with 
PET if ER+ vs. Poor mental function not associated 
with short life-expectancy (e.g. brain damage) we 
need to get them through surgery. Rx decision 
mostly about life expectancy: A woman who is 
likely to live >2 yr, & certainly anyone who is likely 
to live >5 yr, will be talking about the limited 
efficacy of ET if it’s used on its own. Life 
expectancy is key. ER status. 
Assessment of pt's BC, PMH, mental & physical 
function, fitness for GA (ASA). Anaesthetic and 
geriatric assessments. 3 assessments key to 
assessing life-expectancy: MMSE, Bartel, ASA: 
anyone who scores poorly on 1+ = short life 
expectancy, 3 = very likely to die. Referred to 
specialist clinic based on an eyeball. Not very 
accurate -a lot of the pts when they’ve come 
through the assessment, are actually fit. Have a 
geriatrician in specialist elderly clinic and assess 
multiple factors. Geriatrician's opinion of life-
expectancy important. “you wouldn’t hesitate 
to refer someone to an oncologist... if they’ve 
got cancer ... so why don’t you involve a 
geriatrician in management?”. Not always the 
same anaesthetist but generally have a regular 
one - I will talk to him about particularly 
difficult cases ahead of time. Regular 
anaesthetist hugely helpful. 
We’re all biased and we’re not supposed to be 
biased but we all are... older people are 
unattractive - tries to visualise them as they 
used to be, ask about thier job/past. How can it 
be uniform when there’s no evidence base to 
base it on? Now we can’t do that anymore 
(make it up as we go along) because we now 
have some evidence which we’ve been 
presenting but mostly nobody knows about it, 
it’s quite difficult to get the whole surgical 
community aware of stuff.  Talks about working 
out whether someone has a good chance of 
surviving long enough to benefit - i.e. some will 
not benefit from surgery as will die before. 
People say that you can get any pt through BC 
surgery, though why would you want to if 
she’s not likely to benefit. Far, far more 
variable than younger people.  
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G16 
Male 
High 
PET 
Mentions some pts who surgeons felt 
uncomfortable offering standard Rx to. 
Co-morbs limiting life-expectancy impact on Rx 
decision. Co-morbs are not just present or absent, 
there are stages of severity. Most important factor 
is functional assessment - gives an idea about what 
limitations their co-morbs have on their ability to 
live. Important to assessment cognition because 
impairment more common when formally 
assessed, need to know capacity before deciding, 
& severe impairment results in significant 
reduction in life-expectancy. Impaired cognition is 
a very important predictor of not just total life 
expectancy but disability-free life expectancy. Life-
expectancy impacts on Rx decision. Past 
experience - If your last 80 y.o. died, then actually 
you’re going to remember “I knew it was wrong, I 
knew I was right not to have operated on 
somebody who was 80, because all 80 y.o.'s do 
badly". 
Questionnaires: Personal Activities of Daily 
Living, Domestic Activities of Daily Living,  
Cognitive Impairment, co-morb assessment 
(amalgam of Satariano, Charlson and MRC C-
FAS.Also Geriatric Depression Score: screening 
tool and doesn't really influence DM. Use 
assessments when there's uncertainty about 
best Rx to get more info. Clinic uses CGA 
applied by a non-geriatrician as well as resident 
geriatrician in the clinic. Use it as a decision-
informing tool. You often find that people are 
not best Rx'd, when they see somebody who 
knows what they are doing, then actually you 
can make Rx changes that actually improve 
their underlying comorbidity. Few pts you 
diagnose something new, a few with 
established co-morbs who have worsened or 
not on current best Rx, a few need preventative 
Rx - in total maybe 15% need optimisation. 
Ability to optimise or not does help with 
making a final decision in about half. 
I think it became clear that in most centres, 
certainly in the UK, there seemed to be a very 
different % of pts having surgery and % of pts 
having PET once they got to a certain age...  Rx 
appeared to be being influenced by the fact of 
their age rather than how they were. You've 
got that teaching... over years where there's a 
certain age where you're always taught people 
get complications. Previously decisions were 
based on age, now based on whether pt is F&W 
(in Leicester due to clinic). Mentions that for 
someone with lots of other medical problems 
the BC's actually not the major problem. 
Important issues vary from person to person as 
we're all individuals. I think people have seen 
that, I think the amount of surgery in the over 
70s has increased and there is less reliance on 
PET.  
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N17 
Female 
High 
PET 
Older pts, are treated equitably. You’ve got 
to be able to say that “we will consider that 
we are going to treat this 80 y.o. lady the 
same as we would a 50 y.o. lady”. Discuss all 
Rx available - including surgery, RTx, chemo, 
ET. 
Don't preclude by age now. “it’s not about your 
chronological age, it’s about your biological age”.  I 
think they (surgeons) can be... looking at 
somebody and saying “they’re too old”. 10-12 
years ago Rx used to be based on age. If not at all 
fit to have surgery... you go down the route of 
talking about ET. Obviously look at any comorbs. 
People look at some pts and think "she looks too 
frail, we shouldn't be thinking about Rx'ing her". 
Look at what they do on a day-to-day basis, where 
they live. Severe dementia impacts on life 
expectancy so perhaps should think about PET but 
if fit and family agrees then surgery. This lady is 
going to be around for another 10 yr or more, so 
we should be Rx'ing the cancer thoroughly, and 
that would include surgery vs. This lady is probably 
only going to survive another couple of yr then we 
should be thinking about not operating and 
perhaps giving ET. Take into account cultural 
issues. 
Full assessment allows pts to make an informed 
decision. Full assessment gives the pts 
confidence about surgery. After assessments 
may be apparent that they're not at all fit to 
have surgery. Pts referred to specialist clinic all 
have staging - bloods, CXR, ECG +/- CT. 
Functional assessments limited - for instance, 
‘can you walk upstairs?’, and they say “no, I 
live in a bungalow”... you can very easily take 
their independence away from them. 
Older pts, are treated equitably. You ’ve got to 
be able to say that “we are going to Rx this 80 
y.o. lady the same as we would a 50 y.o. lady”. 
We don't preclude by age now - even offer 
chemo. They (some surgeons) can be... looking 
at somebody and saying “they’re too old”. 10-
12 years ago Rx used to be based on age. 
Somebody that’s 80 can be biologically 60. And 
then you get somebody that’s 60 that can be, 
they’ve got the body of an 80 year old. Age 
changes its meaning as well as you get older. 
20yrs ago would have been guilty of saying 
she's too frail for surgery but now realises that 
Rx should be equal despite age. 10-12 years ago 
there were more pts on PET because people 
said they were "too old" for surgery. 
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S18 
Female 
High 
PET 
May just offer them surgery. May discuss 
PET. May discuss neo-adjuvant PET + WLE 
under LA +/- RTx. May not stage axilla if USS 
negative. Treating them exactly the same as 
we would with any normal patient - 
"normal" pt - are the >70s not normal? 
If a pt is completely fit... I might only offer surgical 
Rx. In pts who are very fit, I do feel uneasy about 
using PET. Some pts where it's clear there's no way 
they'll be fit so puts on PET. Rx options depend on 
PMH & medication. Even pts with quite significant 
PMH do often live a substantial amount of time. Rx 
options depend on how the pt looks and behaves. I 
might ask them how far they can walk, whether 
they can do stairs, how many pillows they sleep on, 
that sort of thing. I always take into account how 
they arrive as well, if they’ve walked in. Pts with 
dementia assess how they would cope with 
admission. Pt’s life expectancy is quite important 
though... pts often do better than their life 
expectancy because medical Rx is getting better. 
Discuss PET if ER+. Rx options depend on pt's 
wishes & desires. If pt enquires about PET would 
discuss it. 
Anaesthetic assessment - her opinion of pts 
fitness determines whether they are referred 
for formal anaesthetic assessment. Some pts 
it's clear (end of bed) they're not fit and getting 
an anaesthetic assessment would be wasting 
everybody's time so advises PET. Asks PMH, 
med list, how they get to clinic, to build up a 
picture of their health. The majority of pts now 
I’ve got a feel, just because I’ve been a 
consultant for long enough, where an 
anaesthetic might be an issue. Has a regular 
anaesthetist which makes a big difference. 
Treating them exactly the same as we would 
with any normal patient - "normal" pt. I have 
no idea why there is regional variation. Thinks 
she did much of her training in a region that 
was keen on PET. Talks about a surgeon in their 
trust who has a very high surgical rate ~95% 
including elderly pts and then talks about 
another surgeon who was quite keen on PET - 
so surgeon as a cause? Surgeons not doing 
their own F/U don't see the consequences of Rx 
- if you only see the failures of PET that would 
give you a negative view. I sometimes talk 
about... cancers that pts might die from and 
cancers that pts would die with. We increased 
our surgery rate - in response to data released 
showing that older women had poorer survival 
due to inadequate Rx. 
 512 
 
 
 
 
 
N19 
Female 
Low 
PET 
Options usually would be a wide excision or 
Mx... limited use of recon...and sometimes, 
even if it's deemed to be operable, HT 
would be considered as an option instead of 
surgery. 
Age cut-offs for things like recon - being over 70, 
she was well out of the league then (for recon). But 
I guess for some people in their 70s, that should 
still be an option. Existing health problems impact 
on Rx options. You think "she looks quite frail; is 
she going to be strong enough to withstand 
hospitalisation, anaesthetic, the going home, the 
recovery. Social circumstances, health of family 
members influence Rx DM from pt's perspective. 
Pt who's a carer tendency to think would recover 
quicker from Mx cos no RTx. Can be influenced by 
the circumstances. Mobility/activity impacts on 
suitability for surgery. Rx depends on degree of 
dementia.  Severe dementia greatly influences DM, 
would Rx with PET. ER status. Pt choice: if it 
becomes evident that surgery is not... what she 
wants then it would be narrowed down to one of 
the other options like HT. 
No comments. Thinks there are age cut-offs for things like 
reconstruction - being over 70, she was well out 
of the league then (for recon). But I guess for 
some people in their 70s, that should still be an 
option. Thinks age cut-offs are changing 
because of increasing the screening age. Thinks 
variation in Rx it could be to do with the health 
variation of different populations. Variability of 
pts - some people in their 70s who have only 
recently finished work, are still very active &  
independent, travel, do all their own 
housework, cooking, cleaning, whereas some 
people in their 50s are already immobile, see 
themselves as disabled, don’t see themselves 
as independent. Variability in outlook too - 
somebody is very +ve they will have a more 
swift recovery as opposed to somebody that's 
very -ve in their life. 
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S20 
Male 
High 
PET 
Normal Rx would be surgery. 3 groups: 1) 
definitely surgery (70s, minimal co-morbs); 
2) definitely PET (significant co-morbs, 
would kill her by doing surgery); 3) choice of 
both (oldish, some co-morbs, life 
expectancy >2-3yr, ER rich tumour).If we're 
not careful, it'll be lopsided in the sense 
we'll just Rx them like younger people. If we 
don’t Rx them like younger people, we’ll be 
accused of being ageist, which in my view is 
wrong, because as I told you, they have the 
geriatric needs and their tumours are 
different biologically, therefore it would be 
a dis-service to them. 
Age important due to life exp. Don’t assess them 
based on their chronological age, but biological 
age... but you have to admit that as the age 
increases they have more problems. Considers 
fitness for surgery: whether a pt can actually 
withstand an op. Uncommon that someone is 
unfit. Pts with co-morbs may be fit enough for 
surgery but life expectancy may be shorter. Cardio- 
& cerebro-vascular disease more relevant as 
competing causes of death than chronic 
conditions. Mentions frailty. Degree of dementia: 
dementia itself should not be just a label that they 
should be having PET. Compliance issues. Life-exp: 
PET doesn't give enough duration of benefit for 
someone to survive another 10, 20 yrs. Biology of 
tumour. Considers pt choice: I don’t see any reason 
why she can’t have that choice if she understands 
the consequences. 
Anaesthetic assessments vary between 
anaesthetists: have one anaesthetist who, I 
won’t say he’s courageous, but he’s someone 
who would be quite prepared to take on 
difficult cases. For some, which we feel that 
routine anaesthetic assessment may not be 
sufficient, we send them to him and he’s very 
prepared to see them. Thinks we should be 
assessing tumour biology & geriatric elements 
more thoroughly. Most people eye-ball the pt. 
Formal assessments make it more objective but 
whether that's better than eye-balling or not 
we don't know. If we think the pt would benefit 
from anaesthetic assessment we arrange that 
accordingly. Don't use CGA or tools to assess 
co-morbs or fitness. Sends some pts to a 
geriatrician for their input.  
There's a bit of ageism... which I'm quite 
against. It's been highlighted that we need to 
pay attention to their care but if we're not 
careful, it'll be lopsided in the sense we'll just 
Rx them like younger people. If we don’t Rx 
them like younger people, we’ll be accused of 
being ageist. Rx of older women seems to be 
changing. Some variation in Rx due to ageism of 
HCPs incl BCNs, generalist vs specialists. There 
is the attitude that older pts doen't view 
survival as important. You have a surgeon who 
always operates... and you have someone who 
would always... puts them on medication - I've 
got a feeling that we should blame the HCPs 
more rather than pts. “>70” means a wide 
range, it could be >90 or >100. Tend to push a 
bit more for surgery now... people tend to think 
surgery is the best otherwise you’re ageist. 
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S21 
Female 
High 
PET 
Much the same irrespective of age. I think age does not matter, it’s the fitness of the 
pt to cope with an anaesthetic. If they are fit, 
anaesthetically fit to have surgery, they will be 
offered the option of having surgery. Even if pt not 
fit for GA would do it under LA if pt wanted 
surgery. Comorbs would prompt anaesthetist 
assessment - only put them on PET if they write 
back and say “the risk is very high”. With pts who 
lack capacity will discuss with carers the best 
management plan and come to a decision as a 
group, not my decision... I'm not there, I don't 
know. You would probably think “do no harm” 
don’t operate on them... having said that we’ve 
had ER negative pts and you have to operate on 
them. If they feel that they do not want to have 
the operation then I will accept their decision and 
put them on hormone therapy. Women who want 
surgery I will make every effort - I never say no - 
seems to place greatest importance on this. 
Anaesthetic assessment. Only if they say the 
risk is very high does it influence her. If 
anaesthetist says not fit for GA there are other 
ways of doing surgery. If I feel that the pt has a 
number of comorbidities I will not list the pt for 
surgery, but instead I would refer her to my 
anaesthetic colleague for a full medical 
assessment. 
I think age does not matter. Personal choice of 
the clinician. I think that a lot of clinicians have 
their own personal views - compares hospital 
she trained in with one now, says [Place] they 
were seen in a different clinic and didn't get 
any imaging and were only seen by certain 
people if they were Rx'ed with PET, here they 
get exactly the same as if they were 35. Pts 
aren't being offered choice - they don't even 
know... "I wasn't given a choice, I was just told 
this is the operation I was going to have". 
Most... adults having a GA will take at least a 
fortnight to just recover from that trauma of 
surgery. The elderly will take a little longer. 
N22 
Female 
High 
PET 
They’re given the same options as any pt 
that comes through the door really. Ideally 
we’d like to start with surgery. There are 
other potential Rxs if surgery is deemed 
inappropriate. 
We don't look at DOB really. You can have fit 80/90 
y.o., 100 y.o. pts and an unfit 40 y.o. Surgery is the 
preferred choice if they’re fit for an anaesthetic 
and the procedure. Based on co-morbs: A few 
aren't offered a choice of Rxs because of their co-
morbs. ER status. Very much guided by the pt's 
feelings towards Rx. Some of them look really quite 
keen when you talk about surgery, some will say 
"is there another way?" 
If any concerns about a pts fitness will do an 
anaesthetic assessment to assess suitability for 
surgery. All pts attend pre-op assessment so 
things are picked up and addressed, e.g. 
murmurs HTN. We don't rule them out... we let 
somebody who is the right person decide if 
they're fit for an anaesthetic or not. Can assess 
as they’re coming through the door really, so 
they turn up out of breath before they’ve even 
sat down to start the process, you can glean a 
lot from that. So really it’s inspection, so you 
look at the pt, you get a sense whether they’re 
going to be ideal candidates straight off. If they 
turn up looking cyanosed, breathless, you know 
potentially that they’re not going to be fit.   
They’re given the same options as any pt that 
comes through the door really. You can have fit 
80/90 y.o., 100 y.o. pts and an unfit 40 y.o. We 
know a lot of it is clinician-led. We know the 
units with high mastectomy rates were given 
choices, we know the ones with the low they 
weren’t even- had a hint of mastectomy. So I 
think a lot of it is clinician-led because they’re 
not given true choices. In my opinion. If they’re 
given a choice, I think they’d be higher surgery 
rates. WhenIi first started... you saw a date of 
birth and though "oh well she'll be tablets" but 
very much you don't go on that at all now... I 
think that has changed. Think pts know more 
about Rx options. We're not scared to talk 
about cancer anymore. 
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N23 
Female 
Low 
PET 
The same as anybody else of any other age. 
If they’re fit when they walk through the 
door we’re thinking about surgery first. 
Contradicts herself: Says: They all get 
offered recon; everybody that has a Mx gets 
offered recon - Then says: because of your 
heart disease I’m afraid we won’t be able to 
offer you that” or “well we could do an 
implant, as a quick operation"... if they're 
well into their 80s and frail we don't 
mention it. Oldest lady that's had recon 
after Mx is 75. Talks about one 70 y.o. who's 
having chemo. 
Age isn’t really a factor. Not about their age, it’s 
about what they are like with their age.70... would 
really be trying to move that person away from 
thinking about ET.  Well into their 80s doesn't 
mention recon. Rx DM based on general health. If 
they’re fit when they walk through the door we’re 
thinking about surgery first. Lots of co-morbs then 
Rx becomes a conversation. Fitness for surgery was 
in doubt would offer them PET. Mentions 
breathlessness, heart disease. Start mentioning 
PET if somebody was really generally crumbly. 
Would give them (very frail pts) the offer of 
surgery as well as (P)ET. Dementia: mentions PET. 
Cancer biology. Talk to them about... surgery first... 
if they seem... not that keen, we would say “there 
is this alternative”. Deprivation affects pt 
expectations: people from deprived areas... they’re 
not treated quite the same in life... so... sometimes 
it’s like “well why is he giving me a choice?” 
Have an anaesthetic assessment. We do a 
social needs assessment as they’re coming in, 
so we identify if they’re going to need any help 
- in the 6yrs been doing it less than a handful 
have required social services input. Majority 
have an anaesthetic opinion because a day case 
would just get the nurse doing it. Might refer 
back to specialist if known to them for an 
opinion, e.g. cardiology. Not often that 
anaesthetist says can't have on operation 
because most have been screened out for LA or 
PET. We’re going for the op unless the 
anaesthetist tells us otherwise”. Decide re: 
fitness for surgery based on GP referral letter, 
PMH, first impressions - it's a judgement I think 
when then walk in. Don't go for a geriatric 
opinion. Have a regular anaesthetist. 
A 70 y.o. is not old...80 if you've not got 
medical conditions and 90 is neither. Also not 
having cut-off points of ages, it’s not an ageism. 
Age has shifted - 70 no longer "old" - thinks 
should be mid-80s. I think attitudes towards 
the elderly have changed. The elderly have 
changed as well.  Thinks there could be a 
north/south divide - people up north are a bit 
more stioc. A lot more people are going for 
surgery nowadays. I'm 100% confident that far 
more people go for surgery nowadays... 
whereas that was in the minority 10 years ago. I 
think attitudes towards the elderly have 
changed. 
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S24 
Male 
Low 
PET 
Up until 3 yrs ago, all of my pts over the age 
of 70 as soon as I got to [Place], we offered 
them hormone treatment or an operation. 
Now we still offer them a drug option, 
although we say to them the best Rx is 
surgery. The majority of my elderly pts will 
have their WLE under local. 
70’s not really my cut off now, it’s more like 80. 
Either they’re fit or they’re not fit for a GA... that’s 
the... game-changer. Rx & life expectancy depends 
on comorbidities. Pts that I’m thinking are fit for an 
op... have probably only got 1 comorb. Mentions 
COPD, cardiac failure, cardiac disease limiting 
function & LTOT. In a wheelchair... pretty much a 
no-goer... frailty is a very clear decision that 
they’re not fit. Associates wheelchair-bound with 
frailty? Then: Some people are in a wheelchair for 
other reasons. NH residence doesn't impact Rx.Co-
morbs limiting function (can't climb stairs) makes 
them unfit. Try really hard to not operate on 
people who are demented. Dementia is the one 
indication for PET in my book. Life expectancy of 
>15 yr = surgery.ER status. Tumour size: likely to 
recommend surgery if WLE but may not give RTx. 
Pt choice most important, it's the pt's decision: I 
wouldn’t turn anyone down. 
Everyone goes through pre-assessment and 
those that are at high risk will see an 
anaesthetist. The pre-assessment filters those 
out. Probably some pts who don't go for pre-
assessment because they're obviously not fit - 
But they will have expressed an interest in not 
having an operation probably. Well I think 
that’s a very important end-of-the-bed 
assessment, frailty. No CGA. Used to have a 
regular anaesthetist but not now. 
I would say 70’s not really my cut off now, it’s 
more like 80. This kind of drive to do more 
surgery for elderly patients has actually raised 
the definition of ‘elderly’ from 70 to 80. I think 
we’re now dealing with the same questions 
but with a population of 10 years older. 
Practice changed from offering everyone 70+ 
straight choice because evidence came out that 
we have worst survival for older pts. 
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S25 
Female 
Low 
PET 
If they are F&W, we offer them surgery. I’m 
quite aggressive with managing these pts 
with surgery. Thinks elderly pts are better 
with Mx than WLE- one definitive operation, 
one recovery, no RTx, F/U is easier, saving 
the breast is less important. Does a lot of LA 
surgery but doesn't stage the axilla. In these 
pts again, you don’t really set out to do a 
totally curative operation. Talks about a 70 
y.o. who demanded recon and did it cos 
looked 50. I offer them surgery, that’s what 
I would do with my younger pts. I wouldn’t 
tell my 40 year old patients “I’ll put you on 
tablets”. 
Immaterial of the age... dependent on their 
general health. Not their chronological age, it's 
their physiological age. More likely to do Mx in 
older pts. If... F&W and can withstand anaesthetic 
and an op we offer them surgery. Apart from the 
very severe comorb... we do offer surgery to all our 
pts. Talk pts out of surgery if significant co-morbs 
e.g. MI/CVA: risks of surgery are far too high to 
justify it. If no co-morbs would operate even if in 
90s as life-expectancy is 5-10yrs. Wheelchair 
bound pts tend to have comorbs. Severely 
demented, putting them through a major op... very 
difficult to justify... when... PET may work equally 
well.  Pt choice... some... older women... choose 
not to have an op. Suitability for surgery about 
ability to recover. Independence... very 
important... If... you leave them with a very poor 
QoL... older pts... would rather die... than lose that 
independence and end up in a home: if likely will 
choose PET.  
If lots of co-morb and concern re: fitness for GA 
get an anaesthetic assessment pre-op by cons 
anaesthetist to see if they're suitable we leave 
it to the anaesthetists to decide. Still operates 
on high-risk pts if pt willing to accept the risk. 
Pick out the ones who are high risk and get an 
anaesthetic assessment. BCNs do social history 
and assessment. No CGA - because most of our 
pts are generally off the couch the next 
morning. Regular anaesthetist most of the 
time. 
Live in a world where most of our pts are older 
and older so using a particular cut-off doesn’t 
seem to work anymore. Having more elderly 
pts come through. Lean towards Mx in older 
pts, saving the breast less important to older 
pts & risks go up. Socioeconomic status... level 
of education amongst pts... stage at which they 
are presenting to you... so surgeon preference 
is probably one of many factors. Surgeons have 
attitudes and preferences but I doubt very 
much if that is the single most important factor. 
Risks of... op far outweighs any benefit. Rarely 
die from these cancers, something else gets 
them.  They will die of something else much 
before the BC kills them. They would rather die 
of the cancer than lose that independence and 
end up in a home. Rx tailored to that pt - one 
size does not fit all. Pts are living longer and 
getting older... a lot of them self-refer to 
screening even beyond the screening age. 
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S26 
Male 
Low 
PET 
My primary choice would be to do surgical 
intervention. I do WLE... & SNB on them... 
sometime if you have to re-do the margins, 
sometimes they’re close, they still have the 
second operation to have the margin 
sufficient rather than jumping in to have full 
Mx & if RTx is indicated they go for RTx. So 
age is not a cut-off. 
Age is not a big thing for me. Primary aim is to see 
whether the pt is fit enough to surgery. Look at the 
ASA status. If they are fit at that time then I am 
going to offer surgery. Severe cardiac comorbidity 
or severe respiratory problems such that can't do 
GA would go for PET. Prev DVT, PV bleed: bit jittery 
to start on certain things. Talks about using PET - 
these are clearly the ones who are wheelchair 
bound. By and large in those type of pts who can’t 
even stand up... we tend to do PET. Demented pt 
in a NH - clear cut not fit for anaesthetic. I mean 
it’s very rare we end up doing surgery... I can’t 
think of where I’ve subjected somebody who’s 
totally demented, signed a form 4 and took them 
to surgery, no. The other argument is whether pts 
will succumb to something else in the interim 
period. ER status. Skin tethering/puckering/ 
involvement would talk to them about ?neoadj 
PET. Pt choice. Provided pt is happy to undergo 
surgery. 
If the anaesthetists are happy. We do get the 
anaesthetic opinion sometimes. All three, we 
all have a regular anaesthetist. 
There is no big consensus, if you read the 
literature there is no didactic thing to say. 
That’s why different people have different... 
people varied in their opinions. The other 
argument is whether pts will succumb to 
something else in the interim period. I’ve seen 
change in the management of these patients of 
a period of years- used to do more ANC, now 
SNLB/OSNA - used to do more Mx, now more 
WLE. Seeing more pts in 6th/7th/8th rounds of 
screening. 
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N27 
Female 
Low 
PET 
 
If fit, surgery - including WLE if suitable and 
SNLB/OSNA.I would say we don’t treat them 
any different to a woman in her 40s, 50s or 
60s. WLE + SNLB/OSNA + ET + RTx. 
We don’t tend to be ageist. Look at their level of 
fitness to see whether they were fit for 
anaesthetic. If they were fit  you would probably 
discuss surgery. Depending on their comorbidities 
would look at ET. CVAs, heart problems, DM, 
COPD, asthma - might stop them offering surgery. 
If had CVA Tam might not be suitable. Arthritis 
means Arimidex not used. It very much depends on 
their mobility. We would never not treat them 
because they’ve got dementia. If we feel that that 
was in their best interest... we’d want to offer 
them optimum treatment the same as anybody 
else. Some people don't want to have surgery. 
Ultimately, it’s patient choice. It’s all down to 
patient choice and information. Talks about ER/PR 
status. 
They would potentially then have an 
anaesthetic assessment with all that 
encompasses, looking at ECG, heart. They 
would have a holistic assessment as well to see 
who was at home and things as well to get a 
comprehensive idea of what sort of support 
would need to be put in. It’s down to the 
anaesthetist to see whether they would 
consider or think it’s viable to put them under 
anaesthetic - if so we would offer them surgery.  
I would say we don’t treat them any different 
to a woman in her 40s, 50s or 60s.  We don’t 
tend to be ageist.  
S28 
Female 
Low 
PET 
We tend to offer them surgery. We have 
lower thresholds... we are relaxed enough 
to offer them (P)ET. I don’t follow a 
dogmatic scheme. We don’t talk about any 
fancy breast surgery, it’s always straight-
forward and simple unless somebody’s very 
fit, 70-looking-50 then it’s different and I’ve 
done reconstruction on 70+ but very few 
pts who are incredible fit. 
Not the chronological age it’s the fitness age... 
which is important. 80 above... lower threshold to 
offer them ET, between 70 and 80 most people go 
through the knife. First focus is surgery. Unit's 
policy: if fit for GA = surgery. Co-morbs prompting 
full assessment: Heart, lungs, vascularpath with 
MI/CVAs, breathless when walk. Impacts choice of 
surgery: bad lungs + left BC = rather do Mx than 
WLE to avoid RTx. More often pt physiology. Pts 
from NH: tend to stick them on ET. Can go up a 
flight of steps they can walk from the entrance to 
your clinic, you know they’ll be ok for a GA. 
Somebody who’s stopped 3 times walking 200m 
you know they’re not the best candidates. Memory 
loss, dementia, tends not to offer surgery. Do I see 
this pt still independent in 5 yrs. Nodal disease:  
less comfortable about leaving about them on ET. 
If they refuse surgery... relaxed enough to offer 
them ET. Pt preference. Targets are never an issue. 
If the fitness is an issue... subject them to the 
full testing rather than giving them high risk GA. 
Get the assessments because what you don’t 
want them to do is to render them dependent 
because of the problems of recovering. 
Anaesthetist/physician decide whether pt is fit 
for GA. Pre-assessed by regular anaesthetist. 
She organises tests before referring to 
physicians for optimisation to speed up the 
process. I don’t follow a dogmatic scheme, I 
think it’s a bit of eye-balling the pt in the clinic. 
There’s a lot of pts you can eyeball, if they can 
go up a flight of steps they can walk from the 
entrance to your clinic, you know they’ll be ok 
for a GA. Eye-balls them to guestimate their 
life-expectancy > or < than 5 years. Don't use 
CGA. These pts (elderly) are put on a list where 
there’s a regular anaesthetist, although that’s 
often easier said than done.  
80 above is where we have a lower threshold to 
offer them endocrine therapy, between 70 and 
80 most people go through the knife. Pts of this 
age group, particularly if they have significant 
comorbidities... the low grade cancer... is 
unlikely to kill them and they are more likely to 
succumb to the other comorbidities. 
Investigating pt more aggressively now and 
therefore we know the extent of the disease 
and know what the pt needs.  
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S29 
Female 
Low 
PET 
If she had operable breast cancer and she 
was fit enough for surgery then that would 
be my first recommendation to her. I think 
the guidelines that every pt having a Mx 
should be offered breast recon is nonsense 
and I really feel quite strongly about that, I 
think it’s reasonable to discuss what a Mx 
will look like, but to actually start offering 
89 year olds a TRAM flap or a breast implant 
when one breast is down here and an 
implant would be up here, I think it is 
guidelines gone mad. 
More likely to stage elderly pts. Depend on her 
general fitness. Illness which are going to 
compromise their life-expectancy (recent MI, other 
cancers)... make a difference to what I 
recommend. Lt BC with active cardiac disease 
might recommend Mx to avoid RTx. Frailty... 
difficult thing to quantify... gut feeling... if you 
blow on them they would fall over. Wizened... not 
got much strength... they are a difficult group to 
know how they are going to respond to 
anaesthesia. Dementia: Cannot understand what 
you’re planning... have to have a very strong 
indication to operate (e.g. ulceration, bleeding). 
Important... you’re not swayed unduly...by their 
carers or the family. Limited life-expectancy... will 
make a difference to what I recommend. ER status. 
Many pts... prefer not to go down that route 
(surgery).Unusual... not to survive anaesthetics... 
might not necessarily mean that it has no impact 
on... their QoL. 
Normally get a pre-operative assessment and 
see whether the anaesthetist felt she was 
suitable for surgery.  There are obviously some 
pts who, even to surgeons, it’s obvious they’re 
not going to be suitable for anaesthesia. It’s 
really cardiac function, respiratory function 
that I’d be thinking about, when I was trying to 
assess end-of-the-bed-wise they were fit 
enough for surgery. Doesn't use CGA but thinks 
they are in the pipeline - I suspect there is a 
role for that. I work with a, my anaesthetist 
happens to also be an intensivist and it’s 
actually really unusual that he will say someone 
is really not fit for surgery. 
70s, I don’t really regard as old. It’s often put 
down to... pt choice, I suspect that it’s part of 
the issue and I suspect the way it’s put to pts is 
probably bigger part of differences. There’s a 
misconception that BC in the elderly is a 
relatively benign disease.  Relatively unusual for 
a pt actually not to survive anaesthetics these 
days - not necessarily mean that it has no 
impact on their next few months and their QoL. 
Difficult to predict which pts an operation will 
affect their QoL. Much fewer now (pts Rx'd 
with PET) than I would have done perhaps 5 yr 
ago. Some yrs ago you’d just say “oh, this 84 yr 
old with, I’ll just pop her on Tam”... (now) 
you're more likely to be challenged and 
therefore have to justify your decision. I would 
hope that that change in practice, has not only 
been peer-pressure, but it’s been evidence-
based as well.  
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N30 
Female 
Low 
PET 
Generally they are offered surgical options. 
But they can also be offered PET. 
If... fit enough... they are always offered surgery. 
Important to be mindful of comorbs: whether they 
would be safer on HT. Also be offered PET if... pt 
feels that home circumstances are such that they 
can’t cope with surgery. NH isn’t really a barrier to 
having surgery... if it’s a RH... they’re probably 
even more suitable... because you know when 
they're discharged they've got somebody looking 
after them & supporting them. If their dementia is 
such that it’s going to upset them... generally 
people with dementia can cope just as well with 
surgery... depends on their family. ER status. 
Tumour size: might try neo-adjuvant to downsize. 
Some pts have an initial preference that they say 
‘actually, I’d prefer not to have surgery if I didn’t 
need to’ and so I think that’s something that has to 
be taken into consideration. Some people have 
very strong views on what’s right for them. 
One would hope that in the thorough, robust 
assessment process, you would ensure that risk 
is not inordinate but as low as you can and 
you’d optimise the pt as much as possible.  
No comments. 
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N31 
Female 
High 
PET 
Exactly the same, apart from- I’d say if you 
were 90... couldn’t have recon of course 
because of all the complications that come 
with that. But we have had a lady had- was 
she 78, or 76?- she went for a DIEP 
reconstruction that she wanted. So the 
choices are the same unless we feel it is 
unsafe or the length of the anaesthetic 
would be a problem. Mentions 
chemotherapy for women in their 70s. 
Age is irrelevant really... it’s the individual person 
themselves. PET would start to be offered as a 
choice in 86 plus. Would always want to do surgery 
if it was fit. Anything that would affect a GA - 
mentions obesity, heavy smokers, alcoholics, 
breathlessness - at the end of the day is it going to 
be unsafe to do that procedure on the lady. We 
don’t want to do more harm. She was so frail. 
You’d have to look at that definitely. If someone 
was in a NH with dementia, we’d include the 
family... we'd still look at that (surgery).A lot of 
ladies are living to their late 90s and if they’re 80 
that’s a long time isn’t it so it’s more likely or 
possibly that they’re going to be offered surgery.ER 
status: as long as they’re ER positive of course. But 
also it’s choice: some women would rather take 
the risk of PET. One of only reasons not to operate 
is if lady absolutely doesn't want a GA. 
We would look at the medical history, if they 
had a lot of problems, if they were on a lot of 
medication that would affect the anaesthetic... 
we’d send them for anaesthetic assessment. 
Only reason we won't operate is if the 
consultant anaesthetist says we can't do a GA. 
Try not to go on first impressions: We’d ask 
first, we wouldn’t just judge. We’d look at her 
notes and ask her medical history.  
Exactly the same. Ladies in their 70s are like my 
ladies that were yrs ago in their 50s or 60s... I 
would class now 70 is young, is like the 60 y.o.s 
from years ago. Age is irrelevant really isn’t it, it 
should be. And you can have a fit 84 year old 
who’s fitter than someone who’s 54. Would 
start to be offered as a choice in 86 plus. So I 
think although it looks on paper that people are 
treating older women differently, sometimes 
it’s a lot of pt choice. I mean we do treat 
differently throughout the UK don’t we 
because it’s people’s opinions as well. 
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S32 
Female 
High 
PET 
My preferred option, if at all possible, 
would be surgery. 
Biological age rather than chronological age. Pts 
who are considered high-risk for surgery... pt 
suitability for GA. Mainly co-morbs: recent MI, 
CVA, anti-coagulant. If they (radiologist) feel... the 
pt is very frail they... feed them into that non-
surgical... clinic. If they’re very frail... obviously PET 
would be more ideal. Looking at the new referral 
proforma... and it says 83, NH resident, wheel-
chair bound... you're already thinking "I wonder if 
she's ER+?" If lack capacity: can only impose 
surgery upon them if you feel that it is in their best 
interests... you’ve got to be in a situation where 
there isn’t an alternative. How can you be sure 
that the pt’s taking the PET. Weigh that up against 
what their life expectancy would be from other 
things. More likely to die of the consequences of 
her underlying disorder than she is of this tiny 
incidental cancer that’s been found. ER status. Pt 
preference... a pt who genuinely doesn’t want to 
have surgery. 
Anaesthetic assessment - The consultant 
anaesthetist will then feed back to us whether 
they feel that they’re a high risk for a GA or not. 
We see and assess the pts, if we have any 
concerns about their fitness for GA then they 
go for a formal anaesthetic assessment. They’re 
first of all assessed by us, any problems flagged 
up. Don’t have access to a geriatrician 
routinely, but (recently)... everybody over 70 
had to have a frailty score done and so the 
frailty score was an eye-ball by the clinician 
that saw the pt and then the pt’s own 
assessment of their own ability to do the 
activities of daily living, etc. We have a list... 
where the high-risk pts tend to go because we 
have a critical care anaesthetist that is the 
consultant on that particular list. So if we have 
very high risk ladies, that tends to be where 
they’re best managed, he does lots of 
paravertebral blocks and bits and pieces. 
It’s going to be pt factors, it’s going to be 
clinician factors isn’t it... I suppose you would 
infer... that it was socio-economic, class & 
education of pts... perhaps a more well-
educated pt is more able to weigh up the 
choices and make an informed decision... 
there’s no denying that it’s clinician preference 
as well and sometimes it is driven by things like 
research projects... I think that it would be very 
difficult to try to produce a standardised way of 
managing these pts. Important to have a 
unified approach within a unit otherwise like 
throwing pts into a lottery. You’ve got your 
tennis playing 75, 78, 80 year olds and you’ve 
got your decrepit 71 year olds. We’ve got a big 
history of PET in this unit and with the 
academic department moving away to Derby 
there’s been a sea-change more towards 
surgery. Definitely we operate on more than 
we used to here. 
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S33 
Female 
High 
PET 
Predominately surgery, and a choice 
between wide local and Mx, and sometimes 
more complex surgery, breast reductions 
and reconstruction if they’re very fit. My 
focus was always to offer surgery first. 
Age impacts decision: life expectancy is obviously 
different. Not their calendar age, but their 
physiological function. Discuss more complex 
surgery if they're very fit. If not fit for GA and need 
an axillary procedure we’d discuss the endocrine 
option. Pts with complex comorbidities it (surgery) 
would not be my preferred choice. Cardiac or 
respiratory problems... make me think we should 
be discussing endocrine as an option here. Frailty 
important in DM - because I think it’s really 
important not to affect their long-term QoL. We 
still operate on ladies from NHs but it is more 
complex to organise. Wouldn't operate if can’t 
consent to surgery. I think they do get comparable 
outcomes if their life expectancy’s probably less 
than 10 years. ER status. Some pts say “I definitely 
don’t want a GA” - that’s easy. Previous exposure 
to endocrine agents. QoL after Rx is 
underestimated... or... not really considered. 
If we think they're fit they just get routine pre-
op assessment, if think unfit then we'd request 
a specific anaesthetic assessment with a 
consultant anaesthetist and we have got access 
to one of the geriatricians is running a rapid 
access system as well for us. Some ladies where 
they come back and say after we’ve arranged 
some investigations and we wouldn’t consider 
them suitable for a GA, in which case, obviously 
we’d discuss LA options and endocrine. There 
are some ladies where they say “umm, they’re 
risky but we feel you could safely get them 
through an anaesthetic...” in which case we’d 
talk to the ladies. Sometimes after that 
complex discussion they no longer want the 
risks of an anaesthetic. All have regular 
anaesthetists. 
If you’re 80...or if you’re 95 and F&W your long-
term life expectancy is obviously different. I 
think there’s several reasons, I think locally 
here in Nottingham there was a big interest in 
PET as a research and any unit that’s doing 
research into anything will generally use more 
of that Rx as an option. And then I think that 
once ladies in the community know that their 
friends have been on tablets for five years 
they’ll sometimes say “actually well, my 
friend’s had tablets, can’t I just do that?”.  Most 
of the cancers are not going to be what would 
kill them if it went untreated, let alone with ET. 
The general approach in the west midlands was 
for surgery first and I think that’s generally 
being promoted a lot more at all meetings in 
the last few years for surgery whenever 
possible. 
N34 
Female 
High 
PET 
I think any lady who’s fit for surgery is 
initially offered surgery. They can be offered 
a variety but generally if they’re fit for 
surgery, that’s what they’re offered. We 
even have 70 year olds who have 
reconstruction believe it or not- 
subconscious bias. 
We look at age more medically than actually years. 
If they’re fit for surgery, that’s what they’re 
offered. If they’re not well enough, you’re going to 
kill them on the table, then there’s no benefit 
giving them surgery. Talks about a pt with 
dementia that couldn't get to clinic so just 
recommended the GP start on Letrozole. Gives an 
example of a pt with mild memory impairment 
who wanted surgery so had it. If they really, really 
don’t want it and they’re saying “I really don’t 
want this surgery” there’s another option. 
Anaesthetic assessment. Ultimately I would say it comes down to 
choice... perhaps ladies are not given the 
choice I would have to argue. Or it’s not given 
in a way, in a non-biased way possibly. It 
depends how many of those ladies are coming 
for screening... and if your uptake for screening 
at that age is not as good... perhaps the bigger 
lumps are not so operable. 
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Theme 2: Experience of surgical treatment in older women with breast cancer 
 
 
2.1 Opinions on surgery 
2.2 Pros and cons of surgical 
treatment 
2.3 Older women's views of surgery 2.4 Refusal to undergo surgery 2.5 Local anaesthetic surgery 
S01 
Female 
High 
PET 
Should offer surgery if fit. It's the best 
thing for them and you shouldn't 
really be messing around with 
anything less than that. 
Pros: Better way of getting 
symptomatic control. what the 
surgery gives you is enhanced local 
control. Metastatic control the same. 
Enhanced local control. Well 
tolerated. 
Cons: Complications and the risks of 
surgery may be higher. Risks include: 
not surviving the anaesthetic, pain, 
discomfort, hospitalisation, loss of 
function, confusion, disfigurement, 
lymphoedema, mutilation, 
haematoma, bleeding. 
Most of them are pleasantly 
surprised by breast surgery... it’s 
better than they thought it was going 
to be. Few who have significant SEs... 
“well if I’d known this was going to 
happen I wouldn’t have let you do 
the operation”. Pt's have a good 
opinion where it goes well. 
You might get someone... who says 
“oh, I don’t want an op"… you can't 
ignore those views even if you think 
that that's perhaps not the right thing 
for them. 
You should offer an op and that 
doesn't necessarily just mean... under 
GA. Depends on whether WLE or Mx - 
trying to do a Mx under local... is not 
a nice thing to do. Epidurals... intra-
pleural blocks... those kind of regional 
techniques... permit you to do full 
surgery in an awake patient. Varies 
according to anaesthetist. 
S02 
Male 
High 
PET 
Definite role for surgery if predicted 
survival >5yrs. Having an op has no 
impact on 1 yr survival at all. 
Pros: Under 80, surgery probably 
does have a (survival) benefit as long 
as you haven’t got severe co-morbs. 
Cons: May be no additional benefit 
from surgery. Surgery probably 
doesn’t have much, if any impact on 
survival in people over 90. 
Everyone worries about surgery. No Comments. No comments. 
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S07 
Female 
High 
PET 
Surgery is the standard Rx: the first 
option I would discuss. If somebody’s 
fit... I would tend to favour surgery. 
Most women at 70 are perfectly fit 
for an anaesthetic. Had a 90 y.o. 
recently have a Mx and she did very 
well. 
Pros: Minimise future morbidity. 
Surgery is getting rid of it... then it’s 
gone. Had a 90 y.o. recently have a 
Mx and she did very well. 
Cons: Coming into hospital is a risk 
for losing their independence. Implies 
about recurrence. 
Some of them worry about losing any 
independence. 
Less fit women perhaps don’t want 
an op. I don’t want any more 
messing, just leave me alone. 
Certainly a number of pts who refuse. 
Personal experiences. Bizarre 
reasons: donating body to university. 
Present pros and cons. Have the right 
to make their own decisions. Respect 
their reasons even if thinks strange: 
wasn't the most logical reason but it 
was her reason. Put on PET but keep 
saying to her “this isn’t working very 
well - it’s going to end up growing". 
You can do a WL(E) under LA... it 
doesn't seem to be something we do. 
Can't do axilla under LA. Sometimes 
use LA, not often. Women either... 
happy with a short anaesthetic... or 
they... don't want an operation... so 
it's (LA) not an option that seems 
readily taken up. 
S08 
Male 
High 
PET 
Better for pts with fungating 
tumours. Important to offer surgery 
in younger pts with life expectancies 
of 5+ yrs. Offers less aggressive 
surgical options in the elderly, 
quicker, only one operation. Surgery 
is the best Rx. 
Pros: Better for local recurrence. 
Better local control. WLE - quick, less 
morbidity and easier recovery. You're 
not truly worried about the cosmesis 
in elderly: bias/stereotype? 
Cons: Whether they can withstand 
surgery. 
The group that chooses surgery feels 
that it will get rid of the cancer. The 
ones that choose to have surgery are 
delighted by surgery and they don’t 
seem to regret that at all. 
We’d really want them to be having 
surgery unless they absolutely say to 
me that they don’t want it.  The pt 
didn’t want surgery so we put her on 
tablets. If the pt is adamant... then I 
wouldn’t, that’s illegal to do so. 
If they’re not fit for GA, we really do 
question your rationale for why 
you’re doing them (under LA). I do 
about one or two a year. So if not fit 
for GA get PET rather than LA surgery. 
S10 
Male 
High 
PET 
Surgery is the best option. Pros: Get ET afterwards anyway to 
reduce risk of recurrence. Low 
morbidity. Example of a high-risk pt 
doing well: I did it and she is OK.  
Cons: Mentions surgical and 
anaesthetic risk - including death. 
Specifically mentions lymphoedema, 
infection. 
I think 85... at that age, they are not 
very keen to go for surgery. 
At that age, they are not very keen to 
go for surgery. 
Can't ensure a clear margin under 
local. Likes LA. Use if doesn't respond 
on PET. Used to use LA a lot but less 
now as AIs are effective so try to push 
them to PET, also heavier case load - 
we don't have enough time to do this 
under local. 
S14 
Male 
High 
PET 
Primarily the Rx that is mostly advised 
is surgery. Surgery is the first line. 
Things are safe now, anaesthesia's 
better.  
Pros: It's more curative. Surgery 
allows you to get hold of the disease 
much earlier. Generally doesn't 
restrict their independence after 
surgery.  
About 70% are happy to go ahead 
with surgery. 
Usually I find that they just don’t 
want to have surgery - that is the 
main driving force behind their 
decision. I certainly tell them which is 
the preferable option. 
Just take out the primary tumour 
under LA, that would be offered to 
them. Offer LA for high risk pts who 
still want surgery. Used to regularly 
give thoracic epidurals to pts and 
here we don’t have anybody who’s 
giving thoracic epidurals. 
 527 
 
 
 
 
 
S15 
Female 
High 
PET 
Surgery is best Rx: pt says "I want the 
best Rx" then it would be 
incongruous to be talking about... 
(P)ET. About 2/3 pts  have surgery.  
Pros: Get rid of the lump. Like not to 
have to come and see us.  
Cons: A few pts...if you operated on 
them there was a significant chance 
that they would die. Mentions risk of 
stroke... bleed... chest infection... 
heart attack. Loss of independence, 
end up in residential care. Some 
surgical pts don't F/U anymore. 
Seromas after Mx. 
Example of a depressed pt who 
wanted surgery as she thought it 
would kill her. They know if you come 
into hospital, something bad could 
happen. Not worried about dying, 
they're concerned about loss of 
independence. An urban myth that... 
surgery cures you... still a lot of 
people who think that. They think it's 
going to hurt more than it does. Pts 
who have Mx don't like getting 
seromas. Mostly not afraid of 
anaesthetics. 
Picking up on uncertainty is really an 
important component of why older 
women say no. They’d rather die 
than lose their independence... their 
priorities are very different... It’s not 
about survival. 
Not geared up for LA surgery in UK - if 
you say to somebody “we could do 
your operation under LA”, they are 
potentially more distressed by that 
than they would be by having a GA. 
Have to decide, is it going to be safer 
to have them asleep and pain free... 
or anxiety, what’s more likely to put 
the blood pressure up, down, 
whatever. If she’s not fit for a GA, she 
can have a LA. Doesn't often operate 
under LA. 
S18 
Female 
High 
PET 
Surgery under GA is the gold 
standard. We increased our surgery 
rate in response to data released 
showing that older women had 
poorer survival due to inadequate Rx. 
Pros: Better chance of doing well. 
Cons: SEs from... surgery & RTx. 
Mentions short-term limitation in 
movement, pain and swelling, 
travelling for RTx. 
Some women want to avoid surgery, 
despite poorer survival. Most of them 
hate the idea of having to come into 
hospital. 
Historical ideas. Many pts are quite 
clear they don't want complications, 
would rather just take a tablet. 
Maintenance of independence. 
Previous experience of surgery. Don't 
like being in hospital. Educate them. 
They want to prioritise QoL over 
quantity of life.  
Uses LA about once a month (~1/10 
pts) - by offering it as a third option 
Been able to persuade a few pts who 
were quite resistant to the idea of 
surgery to having surgery. Good 
option for pts with dementia because 
it avoids admission. Will put anybody 
under LA... I would literally operate 
on anybody. Anaesthetist does 
intercostal blocks... may open up the 
possibility of Mx under LA if needed 
for disease control. 
S20 
Male 
High 
PET 
Surgeons take a dichotomous 
approach: fit = surgery; not fit = ET. 
Pts in their 70s, minimal co-morbs 
should definitely have surgery as PET 
cannot beat surgery. Overall... we 
tend to recommend surgery. Tend to 
push a bit more for surgery now than 
before... people tend to think surgery 
is the best otherwise you’re ageist. 
Pros: Better... local control. Doubt is 
to whether surgery offers a survival 
benefit. If someone cannot live with 
having a tumour there then surgery is 
better. Surgery is very safe. 
Depending on their circumstances, 
surgery can make them worry less. 
Cons: Losing a breast. Surgery can 
make them worry more. Also SEs of 
ET - it's not either or. 
They’re worried about caring for their 
spouse, or being on their own. Could 
bring their worries worse or could be 
less depending on their individual 
circumstances. 
Survival may not be the most 
important thing to older pts. I don’t 
see any reason why she can’t have 
that choice if she understands the 
consequences. I would not make a 
derogatory comment on PET if she 
asks the question. “oh I don’t want to 
go through this”. 
I know some people have done Mx & 
things under paravertebral block, 
local - I have not personally done that 
but I think it’s possible. 
 528 
 
 
 
 
 
S21 
Female 
High 
PET 
Considers the two Rxs equally - no 
preference either way. There is this 
hormone therapy or there is surgery 
and I play it equally. I never say no 
(to doing surgery). 
Pros: You've removed the disease. 
Trips to the hospital less frequent. 
You're done and dusted. Most 
recover well.  
Cons: RTx means too-ing and fro-ing 
and being dragged around the 
countryside. Put their heart under 
strain - don't know how they'll come 
through it. Take longer to recover. 
You don’t just operate and that’s it, 
next day you’re hunky dory. 
The majority... who do have the 
surgery say “I’m amazed how well I 
feel”. Single widows think surgery will 
cause inconvenience to their family. 
Don't want to inconvenience their 
family. If they... do not want to have 
the op then I will accept their 
decision & put them on HT & I do also 
tell them if at any stage you change 
your mind... it’s not a big problem. 
Warns them might run out of medical 
Rx.  
If not fit for GA but adamant want 
surgery will bend over to find an 
anaesthetist to give her some form of 
anaesthesia so I can undertake the 
procedure. I have anaesthetic 
colleagues who would do vertebral 
blocks and I will put the LA and he will 
sedate them and we’ve done Mxs and 
WLEs under local so surgery is an 
option. I have done a Mx on a 96 y.o, 
under LA... & sedation, but it’s been 
done so it’s not impossible. 
S32 
Female 
High 
PET 
I would always present surgery... as 
the first option. My preference would 
really always be surgery. I feel that 
the best chance of a cure is surgery. It 
isn’t surgery vs tablets, it’s surgery 
and further tablets vs further tablets. 
Been a sea-change more towards 
surgery. Now very pro-surgery here. 
Operate on more than we used to 
here.  
Pros: Done and dusted, you’re not 
bringing people back...  easier on the 
pts and... clinic numbers. Up an about 
the next day...  they’re managing 
really quite well.  
Cons: Often these ladies are teetering 
on the edge of managing... having an 
op, having a GA, is actually going to 
impair them so much that they won’t 
be able to manage. Mentions 
seromas. 
Frightened of being admitted into 
hospital. Frightened of losing their 
independence. Worries about the 
GA... perception that a Mx is a very 
painful procedure. Generally they are 
very pleased. Haven’t had anybody 
that’s said to me “I wish I hadn’t done 
that”. They’re surprised by how 
reasonably easy the surgery is. 
“I don’t want an op”. They over-
estimate how frail they are. 
Remember people being in hospital 
for a week. Surgery’s moved on a lot 
but their perception perhaps of it 
hasn’t. Bad experience. Frightened of 
losing their independence. I’ll say 
“well, what is it that bothers you?” 
Happy to put them on to PET. Doesn't 
try and push them towards surgery as 
long as they understand. 
I don’t like doing wide locals and 
sentinel nodes under LA. He 
(anaesthetist) does lots of 
paravertebral blocks and bits and 
pieces. So we do have regional 
anaesthesia techniques that we can 
use as well... It’s not common. Did a 
wide local and sentinel node under a 
regional block and local and it wasn’t 
the most fun. 
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S33 
Female 
High 
PET 
We try and offer surgery wherever 
possible. That’s generally being 
promoted a lot more at all meetings 
in the last few yrs for surgery 
whenever possible.  
Pros: Older population report less 
problems than younger. Doesn't 
mean they don't have problems, they 
just don't report them. More resilient 
to the cosmetic effects and the pain 
effects. 
Cons: In the elderly... we’ve... got a 
high haematoma risk, and high 
complication risk. Complication rates 
are generally higher. Complication... 
causes a much bigger set-back and a 
much bigger impact on their QoL the 
older ladies. 
Much more stoical if they get some 
breast oedema or some breast pain 
post-treatment. They find RTx much 
more inconvenient. Modern surgery’s 
maybe not what they perceive. Most 
of them are pleasantly surprised... 
that they’ve got through it so well. 
Has a bigger impact than they maybe 
perceived to lose their breast. 
Pleased to have just got rid of the 
disease. 
Independence is what’s most 
important to them. Previous 
experience of surgery. 
Inconveniencing their family... worry 
that they’ll never… be able to look 
after themselves... might end up in a 
NH or lose their independence. “I 
definitely don’t want a GA” - that’s 
easy. Stress... they wouldn’t be cured. 
If they've got concerns about... the 
anaesthetic, arrange for them to 
meet an anaesthetist. 
For axillary surgery, I much prefer to 
do that with a GA. Can do wide locals 
with LA plus or minus sedation. Rarely 
(uses LA), because I think it’s much 
more difficult to do the axilla. If 
they’re not fit for a GA then we will 
often still offer resection of the 
primary with LA. One of our 
consultants does paravertebral 
blocks, but generally if he feels 
they’re too frail for a GA he’d be 
reluctant to risk the complications of 
a paravertebral block and often it 
means they can’t position ideally on 
their side for the paravertebral block. 
G16 
Male 
High 
PET 
Surgery is best. I think people have 
seen that, I think the amount of 
surgery in the over 70s has increased.  
Cons: Mentions that people die of 
surgery. 
No comments. “I’m not having an op whatever you 
say”. Give them the confidence 
they're fitter than they thought.  If 
you can get to the reason & you 
address that you can actually try to 
persuade them. People... are entitled 
to make decisions that don’t make 
sense.  Definitely people who will 
come in and do not want surgery. An 
experience that they... family or close 
friend has had. If they’re a main 
carer. Read something in the paper. 
No comments. 
N09 
Female 
High 
PET 
I’m of the opinion that surgery is the 
gold standard. 
Cons: Takes them out of their own 
environment, frightening. 
Think operation and anaesthetic is 
something they put themselves & 
families through - cause worry. Might 
feel like a burden. Some just get on 
with it. 
Pt indicates some sort of uncertainty, 
or they’re frightened of surgery, or 
something that makes them feel very 
uncomfortable with having an op, 
then I would certainly flag it up (PET 
as an option). 
No comments. 
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N12 
Female 
High 
PET 
Surgery is the best Rx - repeats this 
statement multiple times throughout. 
Surgery is the best option for these 
ladies. Surgery for elderly more 
common in recent years. Doctors  
getting better at steering pts towards 
the surgical options. Ladies in their 
late 90s and early 100s that have had 
GAs and have survived that and... are 
still F&W. 
Pros: Remove the cancer. Very safe. 
Ladies in their 90s/100s have had GAs 
and survived and are still F&W. 
Cons: Mentions disfigurement, 
anxieties. 
Pts worry about surgery. Historically... 
the elderly have been quite fearful of 
anaesthetics. Always a lot better than 
they anticipated. Think surgery is a 
serious thing and you have to stay in 
hospital for weeks. Pleasantly 
surprised... how they feel post-op. 
They don't want to be bothered with 
it... want the easiest option. Don't 
have many pts refuse because they 
explain it's safe. Sometimes pts have 
such fearful pre-conceived ideas that 
they make that decision not to have 
surgery. Important to inform those 
ladies that its actually very safe and 
surgery is the best option.  
Seeing more and more surgeons 
doing surgery to the breast under LA 
which again isn't optimal because we 
can't do surgery in the axilla to stage 
the disease. 
N13 
Female 
High 
PET 
Surgery is the better option. All 3 
consultants are pretty keen on 
surgery as a first instance. Very pro-
surgery. Outer surface surgery so 
doesn't impact on older pts 
independence. Pro-surgery... whether 
that's right or wrong.  Operate on 
people that... in the olden times... 
we’d have thought... that’s too risky!” 
Pros: Remove the cancer. They'll be in 
just one night with Mx. Recover very 
quickly. Better disease control. 
Cons: Harder to get over for an older 
person. Bleeding, infection, problems 
with the anaesthetic. It's quite 
disfiguring surgery. Mentions 
potential risks and complications. 
Some ladies... are absolutely 
distraught after surgery... it’s gone... 
it's not them anymore. 
Some pts think if they have surgery 
then they don't need tablets. Not 
everyone who's older wants 
something like a Mx. Some pts want 
to avoid RTx/travelling so opt for Mx. 
They're surprised at how F&W they 
are after it. 
If they want to decline surgery... we 
could treat it with an ET. Explain 
effectiveness of PET is sometimes 
short-lived & we'd sooner catch them 
while there F&W... rather than... 
when their health might have 
deteriorated. It’s about not judging 
that & just doing what they want 
you to do. We just support them 
doing it. 
GA is far superior... we'll do a very 
straightforward lumpectomy with lots 
of LA but it's not our preference. 
Mentions can't do axilla. 
N17 
Female 
High 
PET 
Want to treat it thoroughly, and 
‘thoroughly’ is offering surgery. If 
surgery is safe then that’s the route 
we will... go down. 20yrs ago would 
have said she's too frail for surgery 
but now realises that Rx should be 
equal despite age. 
Pros: Not a major op in terms of 
we're interfering with any clockwork 
inside the body. 
They just think about their age and 
would maybe, they’re tired, they’ve 
lost some of their reserve in life, they 
just feel that they wouldn’t be able to 
cope with an op. Feel they may be 
incapacitated after surgery. Think it 
might upset their QoL balance. 
I'm too old. If I have an anaesthetic 
I'm going to die. Feel that they 
wouldn’t be able to cope. Previous 
experience. Body image issues... turn 
around and say "no". Alternative Rx 
easier. Don’t want to upset the 
balance... it’s about QoL not quantity. 
Assessment so can make informed 
decision. Explain that it's not major 
surgery. Find out why they are 
refusing. She’s saying she doesn’t 
want to have surgery. Worry about 
the anaesthetic. 
No comments. 
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N19 
Female 
High 
PET 
The options usually would be a wide 
excision or mastectomy, sometimes 
reconstruction. Doesn't seem to 
personally have strong preferences 
for either Rx - choice seems most 
important. 
Pros: Mx: it's all gone... done and 
dusted, they don't need any more 
surgery. WLE:  keep breast which is 
very important regardless of age. 
Cons: May need further surgery. Pts 
are fearful of surgery and the 
recovery. Mx: small number... 
despite their age, still would feel a 
great sadness at losing their breast 
and having an altered body image. 
WLE: RTx and the journey. 
Pts are fearful of surgery and 
recovery, feel that surgery will knock 
them back: I’ve heard people say they 
fear that they may never recover fully 
the level of activity.  
Pre-fixed idea of what can be done or 
can’t be done... “what’s the point of 
doing anything?”. Past experience. 
"I'm of a certain age... is it worth 
doing anything?" I'm looking after my 
sick husband I don’t want to leave 
him.  Fear of hospitals/ cancer/ 
surgery/ losing the breast. 
Understand why they're refusing: 
Informing pts correctly then hopefully 
you can influence or give them the 
info that would empower them.  
Has limitations with axillary surgery. 
Is offered by all surgeons in the unit 
but don't do many. Offered mainly for 
local control. 
N22 
Female 
High 
PET 
One or two (of the surgeons) will say 
‘we appreciate that surgery probably 
is ideal’.  
Pros: The cancer’s gone. Knowing 
psychologically it's gone. Reduces 
having to come up to the hospital. 
Get rid and they can move forward. 
Less uncertainty. Most will be doing 
things that they’re doing, you know, 4 
to 6 weeks afterwards really.  
Cons: Some pts think it will avoid 
another tablet - have to stress, 
‘you’re not going to avoid the tablets. 
Have to factor a period of 
recuperation. Loss of breasts. 
They are pleasantly surprised about 
how well they are afterwards. Feel 
that it’s... going to stop them doing 
what they’re doing now and limit 
what they can do. It's not to be 
feared now. You do get a bit of that, ‘I 
don’t need them (breasts) anymore’. 
People still think the only way to Rx 
BC is surgery. 
Don’t want to be bothered... elderly 
relative at home. They just feel... it’s 
going to stop them doing what 
they’re doing now and limit what 
they can do. E.g. of a pt who didn't 
want anyone to know she had cancer 
so was convenient to have PET. ‘Is 
there any other way?’. Not many will 
try and avoid surgery. They've heard 
you can just take a tablet.  
Techniques like SLNB are limited with 
LA. They do LA surgery. More of a 
palliative tool, but have been done 
where we need local control. 
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N31 
Female 
High 
PET 
Encourage surgery on all women... 
Surgery is the main and this is what 
we would rather do’. When they’re in 
their 80s... as surgeons, all they’re 
thinking is the quick fix, ‘let’s do this 
(Mx) and then they’re sorted’.  
Cons: Some people are traumatised 
by having their breast off. Travelling 
for RTx. Mentions a F&W 84 y.o. who 
ended up in a NH following surgery - I 
had no concerns about her having an 
op but she's in the NH now. Pts can 
deteriorate after surgery. 
I’ve come across ladies who have had 
the surgery and some have regretted 
it. I had a lady... she said ‘I wish I’d 
gone to the grave with two breasts’. 
Some people are traumatised by 
having their breast off. 
Absolutely fed up. Some women you 
are not going to change. ‘I’ve got to 
die of something, duck’. Wanted to 
leave her body to medical science. 
They’ve got a husband... they’re 
nursing. Thought she’d be a burden. 
Misunderstanding or what their 
mates told them. Fear of GA. Tells 
them it might not work for very long. 
Surgeon encouraged her to have 
surgery... tell her the risks. They’ve 
got a right to choose. "I want to 
understand why... whatever you 
choose, I will support you". 
Can’t do axillary surgery. If they can't 
have a general... she doesn't do it 
that often but she does (use LA). 
Ladies with major heart problems 
that are desperate to have surgery. I 
had a lady...really obese, got 
horrendous COPD...  when she met 
the consultant anaesthetist she was 
like ‘under no circumstances I can put 
you under a general’, so she’s had a 
local. 
N34 
Female 
High 
PET 
Majority... offered surgery... seen as 
being the best care, you know, the 
optimum care as it were.  
Pros: Mastectomies as day cases. 
Better local control. They cope very 
well. 
Cons: There’s some ladies where 
having the cancer isn’t the issue, it’s 
having a Mx because there’s some 
very glamorous 75 y.o's. SEs and 
potential effects of anaesthetic. 
There’s obviously a risk of not being... 
as well as they were before. 
Most of our ladies are very surprised 
by how well they do cope.  
Fear of dying on the table.  Bad 
experience. It’s too big a thing. 
They’re not bothered about treating 
it. Fear of being flat. I don’t want 
surgery. Fear of the unknown. When 
you... give them the info... they can 
view things very differently... 
“actually that’s not that bad, I could 
cope with that”. What are the 
issues... what’s right for you. I’m not 
here to change anybody’s mind. 
No comments. 
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S03 
Male 
Low 
PET 
Considers surgical option for over 
70s. There is no BC pt who is not 
operable. May not be beneficial. Not 
really much disadvantages in that it’s 
a quick procedure like a haircut; plays 
down risks - infection rate is minimal, 
I don’t leave a drain and it’s entirely 
pain free and I’ve never had an 
operative death. 
Pros: Day case procedure, quick, 
home the next day so not apart from 
their partners, home environment, 
pets. You take the cancer and you bin 
it. Quotes less than 1% complication 
rate. Better local recurrence and QoL. 
Cons: Not really much disadvantages. 
Mentions infection rate, drain, pain 
and death but only to say they don't 
happen. Pts don’t like going to 
theatre.  
They don’t like going to theatre, and 
nobody really does.  
No comments. I’ve done Mx under local or nerve 
block, it can be easily handled, if 
needed. 
S24 
Male. 
Low 
PET 
Best Rx is surgery. Surgery was the 
gold standard. Drive to do more 
surgery for elderly pts. 
Pros: Reassurance... the cancer’s not 
there... don’t have to keep worrying 
about it... don’t have to keep coming 
to the clinic. Less pts in F/U clinic! 
Don’t think there’s an anaesthetic 
risk. In and out as a day case. 
Cons: Shakes them out of that 
comfort zone of being in denial. 
Coming into hospital & catching... 
MRSA. General deterioration... of the 
health of the pt having been in a 
hospital. 
No comments. People who don’t really want an op 
that are saying “I’m not really fit 
enough”. Wouldn't try and change 
their mind - I would say “Ok, let’s put 
you on hormone tablets...” Get the 
BCN to... understand what it is about 
this lady that she’s frightened about... 
and bring them into a place where 
they’re more comfortable and 
relaxed about it. Doesn't happen very 
often. 
E.g. of frail 90 y.o. I may have to do it 
but if I do it, I’ll do it under local 
anaesthetic. Performs LA WLE surgery 
all the time, including SLNB, Mx not 
so often - the majority of my elderly 
pts will have their WLE under local. 
N11 
Female 
Low 
PET 
Most people would want to have 
surgery. We're a unit that would 
promote surgery. It would be unfair 
not to offer it. Surgery is the primary 
way to get rid of a BC. In your best 
interest. We’ve operated on... 
centenarians. A joy to see older pts 
come through surgery - they've 
obviously got a lot from it.  
Pros: Get rid of the cancer. Can be a 
day case. Joy to see older pts come 
through surgery: they've obviously 
got a lot from it. Older people... are 
very able and capable of getting 
through this. 
Cons: Body image being important no 
matter how old they are. Just part of 
the Rx plan, adjuvant Rx sometimes 
hits people harder, incl travel for RTx. 
Most people would want to have 
surgery if they could have it. Am I too 
old to have surgery? Oh, I could do 
this. Will it impact on their lives. Relax 
when know it's day case. Worry 
about RTx but  don’t think people 
would stop themselves from having it 
because of where they’ve got to be. 
GA worries people of any age. 
Don't get many refusing surgery as 
reassure them, give them confidence, 
they know they can change their 
mind, they've been fully assessed.  
If they felt that this surgery is 
something they wanted to do, but a 
LA is the only way to have this done, 
it would be done that way. Important 
for some people to stay awake. Not 
common but has been done. 
Mentions use of nerve blocks to say 
they have been done. 
 534 
 
 
 
 
 
N23 
Female 
Low 
PET 
Preferable option. We’re thinking 
about surgery first.  Only pts who are 
extremely unwell or coming to the 
end of their natural life who would 
not be offered surgery. Far more 
people go for surgery nowadays. 
Pros: Majority go home on the day, 
it's day case surgery. Not needing to 
come back for so many 
appointments. 
Cons: Mentions arm stiffness, 
lymphoedema. Mobility can be 
impaired due to arm stiffness if they 
walk with aids. Anaesthetic can make 
them feel their age, it can knock 
them. Can take you a little bit longer 
to get over an anaesthetic, the 
recovery of activity. Worry of surgery. 
Body image with Mx can be quite 
devastating. 
They worry about “will I get through 
an anaesthetic?”. See it as a huge 
operation, worry about permanent 
changes, worry about surviving. Most 
say that it's (breasts) done its job, 
body image isn't so important but get 
some women where Mx is 
devastating for their body image.  
They’re already old and they fear that 
it might just be the thing that tips the 
balance for them. 
How would they recover when 
they've got absolutely nobody. They 
fear that it might just be the thing 
that tips the balance for them. 
Worried they'll become dependent. 
Reiterate they're fit, got a lot of 
natural life years ahead, it'll start to 
grow.  So that I feel they’re fully 
informed... “as long as you’re aware 
then that’s your decision, we will 
respect that decision”. In a way it is 
about persuading and it goes against 
pt choice. 
Suboptimal because if you can’t get 
into the axilla, so that’s not always 
the best way. We have done LN 
biopsies to the axilla but we knew 
that’s not the best because it can be 
painful. Even if not fit for surgery we 
would offer LA surgery. The frailer 
ones, they feel comfortable with 
having a LA & S24 does LA more than 
most.  
S04 
Male  
Low 
PET 
Standard Rx is surgery. Risks are very 
low. Difficult to avoid offering 
surgery. If they can be put to sleep 
they get an op. Indefensible not to 
offer surgery if fit for it. 
Pros: The benefit of surgery is there 
but it’s not huge. Low risk. I haven't 
had a mortality to date. 
Cons: The risks of surgery are very 
low but the pts’ perceptions about 
the risks are completely different 
from the actual risk. 
They’re obviously concerned about 
the risks... but the pt's perceptions 
about the risks are completely 
different from the actual risk. 
A pt who declines surgery, a lot of 
women in that age group have their 
own opinions and they can't be 
changed. 
In general doesn't operate under LA. 
Only one anaesthetist who uses 
regional blocks as well as GA so not 
used often, positive about their use in 
this way. Their anaesthetist uses 
regional techniques with heavy 
sedation without GA. 
S05 
Male  
Low 
PET 
Overall in favour of treating all 
women with surgery. Has to be 
surgery at some point. Result would 
always be to facilitate surgery as 
opposed to avoid surgery. Best 
practice and best for cure. 85 y.o. 
with recon: she's fine... she  was up 
the next day and she was running 
around. 
Pros: Best practice and best in terms 
of cure. Well tolerated: she was up 
the next day and she was running 
around. 
Cons: We don’t want it to make you 
unwell or give you prolonged hospital 
stay, HDU admission because of an 
anaesthetic. Loss of their 
independence. One pt said "the worst 
thing that can happen is that I have a 
flat chest".  
Gives an example of a recon on an 85 
y.o. - she loves it, she’s is really 
extremely pleased, she’s very happy. 
You do have some people with strong 
opinions, who don’t want to have 
anything done. As a physician, if you 
tell them what’s best for them they 
would eventually come around to 
your point of view. Uses PET for pts 
who don’t want to have surgery but 
then says: I have yet to see a pt who 
has refused surgery.  
LA surgery not an optimal thing to do. 
Mx under LA really uncomfortable for 
pts... they start jerking... the smell of 
cautery... bleeds more; not pleasant. 
Use of LA depends on how much local 
control is a problem or if progresses 
on PET. Offer LA if can't optimise for 
GA. One anaesthetist who does 
blocks, incl paravertebral and 
pectoral for pain control. 
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S25 
Female 
Low 
PET 
I’m quite aggressive with managing 
these pts with surgery. Wouldn't 
deny them. By far the superior 
option. Definitive curative option 
than PET. Elderly pts are better with 
Mx - one definitive operation, one 
recovery, no RTx, F/U is easier. Not 
visceral surgery, it’s superficial 
surgery so most of these pts actually 
do very well.  
Pros: Can be curative. Not visceral 
surgery, it’s superficial surgery so 
most of these pts actually do very 
well. Does not hinder their mobility, 
their GI function, does not hinder 
their ability to get up and go to the 
toilet... it’s a breeze really.  
Cons: Complications happen... some 
of them end up going back to theatre. 
Mentions local recurrence. 
A lot are reluctant to have surgery as 
don't understand the implications. 
They're afraid of surgery. Less 
concerned about disfigurement. 
Apprehension about post-op care and 
recovery. They’re quite surprised how 
well they feel.  
Who's going to look after the 
cat/house/drive me to appointments. 
Apprehensive about risk of 
complications. Made up their minds 
beforehand. Don't want to burden 
family. Prev experience. Don't 
understand implications of refusing. I 
say... there are tablets... but it’s not 
as guaranteed... and let them choose. 
If you really think you might ever 
have surgery, have it now... before it 
advances and your health 
deteriorates. Duty to inform them but 
don't force them. Try talk them into 
it. “I’m not interested in an op at my 
age”.  
I do mastectomies under LA. Most are 
salvage procedures, wouldn't offer as 
a primary procedure because not 
curative. It’s a sub-optimal Rx 
because you’re not staging the axilla. 
Elderly pts tend to be small breasted 
so it's quite an easy operation to do, 
20-30 min. If skin breach is an issue 
would do it under LA. We have one 
consultant who’s started... to do a 
few... pectoral block. 
S26 
Male   
Low 
PET 
Change in the management of these 
pts of a period of years- used to do 
more ANC, now SNLB/OSNA - used to 
do more Mx, now more WLE. My 
primary choice would be to do 
surgical intervention. 
Pros: Know that margins are clear - 
you know it is all gone. 
Cons: Mentions complications under 
anaesthesia. 
Pts  don't want to stay in hospital. 
They think it’s very mutilating 
surgery... they can’t E&D & they’re 
going to lie down in bed for many 
days... they are surprised after you do 
the surgery they sit up and have a cup 
of tea by the time you’ve finished the 
last pt.  
It’s the fear and... misunderstanding. 
I’m not going to twist that ladies arm. 
We just put it across the best 
scenario, the worst scenario... If ET 
doesn’t work and that’s how we put it 
across. I don’t twist their arm but as 
much as possible. Some pts merely 
say “no, I don’t want that”.  
Does Mx and lumpectomy under LA. 
It’s not a question of if you can do the 
surgery it’s a question of is this a 
realistic way to approach the whole 
thing. Mx in a real frail lady... can do 
that under LA. Not many anaesthetist 
of ours do regional blocks. Problem 
is... to do the axillary.  
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S28 
Female 
Low 
PET 
My first choice is usually surgery. 
Surgery is considered as an aggressive 
Rx.  
Pros: If you remove the cancer, then 
a pt knows the cancer’s gone. Don't 
have to drag pts back to clinic. 
Cons: You don’t want... to render 
them dependent. 
surgery’s viewed as a big thing. Pts 
worry surgery may tip the balance of 
their life - lose independence. 
Surgery’s viewed as a big thing. What 
are they going to gain by chopping 
parts of the body. "I don’t want to be 
in a NH where I have a Mx scar and 
somebody else is dressing me, 
looking at my deformed body.  They 
are the ones I would like to persuade 
towards surgery. If it becomes locally 
advanced how would you manage... 
most people come on board. We 
have a lower threshold to offer them 
endocrine. 
Some pts you feel... they’d be best off 
having that area taken off under LA... 
because it’ll be a problem for them to 
deal with the wounds. I haven’t done 
very many (LA) in the last couple of 
years but I am not averse to it. Have a 
very active anaesthetist who will do 
pectoral blocks and things. 
S29 
Female 
Low 
PET 
Primary surgery is better. Pts will get 
ET anyway. Uncommon actually that I 
wouldn’t offer pts an op. Hope that 
that change in practice, has not only 
been peer-pressure, but it’s been 
evidence-based as well.  
Pros: Relatively unusual for a pt 
actually not to survive anaesthetics. 
Better local control. 
Cons: Whether or not they survive. 
Longer-term effects of bringing 
somebody into hospital and giving 
them an operation affecting memory 
and mobility. Sailed through the 
anaesthetic but it’s really knocked her 
for 6. Impact their QoL. More 
elderly... longer they will take to 
recover... physically and cognitively. 
More likely to have co-morbs 
associated with problems post-op 
(e.g. warfarin/bleeding). RTx  - 
travelling for 3/52. Significant 
minority... sexually active, for whom 
how they look is still terribly 
important. 
"Oh, I thought I didn’t have to have 
the tablets because I had the 
operation". Majority of the pts will 
use a phrase like “nobody’s going to 
see me” or “it’s done its job”. 
Sometimes prefer not to go down 
that route. Fear... elderly spouse and 
they're the primary carer. Don’t feel 
they’re worth treating. GP may have 
said... “they’ll just give you a tablet”. 
Bad experiences. Talk to them about 
why I’m recommending surgery. 
“ok... you’re not very keen on 
surgery... why we don’t we put you 
on a trial of HT. Would try and 
persuade younger pts.  Encourage 
them to realise that they have 
potentially a long-term future. 
Although if they weren’t fit enough 
for a GA we may consider a LA as 
well. Not used often - mainly for pts 
with borderline fitness for GA, esp if 
they are ER -ve or imminent 
ulceration. 
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N06 
Female 
Low 
PET 
Surgeons will operate on pts if they 
can so most people have surgery. So 
if you’re going to do the right 
operation, do it up front. Unit's policy 
is surgery is the best Rx. Almost 
everyone get surgery - only if the 
anaesthetist says this lady cannot 
undergo an anaesthetic.  
Pros: Only a day case. 
Cons: Having surgery is scary. May 
"knock them" (i): lose some 
independence. 
Having surgery is scary. Worry 
whether they will come round from 
the anaesthetic. See Mx as a big op. 
Older pts prefer to stay in hospital 
longer after an op. Worry about post-
op recovery/ support. Surprised by 
quick recovery. They're not doing 
anything... take it off. 
No comments. Have used LA in the past although 
very rarely now because of 
anaesthetic advances. 
N27 
Female 
Low 
PET 
We would always... say... surgery 
would be the optimum Rx. 
Cons: Alludes to risk of surgery: there 
have been a few pts we've been 
relatively concerned about and 
actually have come through the 
anaesthetic... incredibly well. 
Frightening. Mentions wound break 
down. 
Their feeling is: are they going to 
survive an anaesthetic? They are 
absolutely terrified....  what the 
implications will be, how will they 
manage at home if they live at home. 
If it goes well... they’re relieved... If... 
they have problems, then I don’t 
think they regret it, I think they just 
accept that.  
Decline Rx based on that they’re the 
main carer for another person. Tell 
them it may initially work but then it 
starts to regrow and might lose the 
window of opportunity to operate. 
They’re unwilling to, then obviously 
then ET. We had a couple the other 
day, really didn’t want to have 
surgery. 
Surgery under LA is sub-optimum 
because wouldn't go into the axilla: 
would be intolerable under a local. 
Have done in the past. Couple of 
ladies who need to have a Mx and 
that has been done under LA. 
Especially if it's going to fungate or 
break through the skin. 
N30 
Female 
Low 
PET 
Surgery is usually the first thing 
they’re offered. The majority are 
treated with surgery.  
Pros: Removes the area... can be 
curative. Greater information. Lump’s 
not there... emotional benefits. 
People recover physically quite well. 
Recovery and length of stay generally 
quite short. 
Cons: Mx can be quite a devastating 
thought... it does disrupt their routine 
and it’s an emotional and 
psychological hurdle to get over. Risk 
to anaesthesia. 
Feel that it will knock their routine 
and they don’t want surgery. Pts 
often perceive it to be a greater 
trauma than it necessarily is. People 
are often quite positive about it. They 
are a little bit anxious about 
anaesthetics. 
Some pts... prefer not to have 
surgery... that has to be taken into 
consideration. They can’t cope with 
surgery... feel that it will knock their 
routine. If they’re looking after an 
elderly husband. It is their decision... 
as long as we’ve given good quality 
info and we feel that the pt has 
understood... it’s important that 
that’s respected. Explore their 
rationale... make sure that they know 
that if they change their mind... it’s 
still an option. 
It is done but it’s not done on a 
regular basis. Might choose LA 
instead if the pt is not fit... for a GA.  
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Theme 3: Experience of Primary Endocrine Therapy as a treatment for older women with breast cancer 
 3.1 Opinoins of PET 3.2 Pros and cons of PET 3.3 Older women's views of PET 3.4 Practicalities of PET 
S01 
Female 
High 
PET 
OPINION: Reserved for people who will struggle 
to get through standard Rx. Do consider it (PET) 
for women in this age group. Inferior option. 
Equivalent mortality, inferior local control but 
not much. 
WHEN OFFERED: Won't tolerate or refuse 
surgery. Clearly not fit for a haircut. Choice in 
borderline women. Pretty frail... never get 
through an op in a million years.  
NEO: Start off as neo-adjuvant, give time to 
think: no harm... in starting them on the tablets 
and giving them some time to think. Trial of ET 
and if it’s not really working... go down the road 
of anaesthetic assessment. 
Pros: No Rx-related mortality. Give time to 
think. Reassured by tumour shrinking. 
Metastatic control the same. Shouldn't be any 
difference in mortality. No surgical risks. Well 
tolerated. 
Cons: May outlive response: you put them on 
PET and then they don't die of something else. 
Static response... might freak them out. Failed 
local control. Limited response. May not 
respond. Disturbed by palpable tumour. 
Inferior local control. 1/3 need change of 
management. Operate when older and frailer. 
Can just delay problems. Run out of Rx. 
They all think that PET is great because it’s the 
no risk scenario. Opinion is good when it goes 
well. 
Might freak them out if the lump doesn't 
disappear. Some women might find that a little 
disturbing... most women actually if the tumour 
is shrinking, found that very reassuring. 
PET TYPE: Letrozole. 
TUMOUR ASSESSMENT: Clinical. 
F/U: Bring them back in 3-6m and reassess. Will 
control BC for an average of 2-3 years.  
RESPONSE: Variable response (1-10 years). 
REACTION: Change management. If it’s not 
really working very well... go down the road of 
anaesthetic assessment. As soon as the disease 
starts to progress, you cut-and-run. 1/3 of them 
will need a change of management. Operate if 
fails, ?LA. If can't operate then palliative Rx.  
S02 
Male 
High 
PET 
OPINION:  I try not to set off with PET without 
having defined exactly why we’re doing it. 
Needs to justify it's use? It’s easy to sell it.  
WHEN OFFERED: I use it... in 3 situations... 
where the pt is clearly in a state of health 
where surgery is not going to be of significant 
benefit, 2nd... neo-adjuvant setting... and... 
where there is uncertainty about fitness for 
surgery to bide time while we make an 
assessment. Predicted life exp is 2 or 3 y. 
NEO: To downstage, just as we might use 
primary chemo in younger pts. 
No Comments. Pt opinion depends on how you put it: 
Majority... will say “Oh, well if I only need 
tablets, then that’s great" vs. "we can just give 
you tablets because you’re not well enough for 
an op, which would be best for you” then they 
have a different view. 
PET TYPE: Letrozole 
TUMOUR ASSESSMENT: clinical 
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S07 
Female 
High 
PET 
OPINION: Unpredictable. Always be the right 
decision for people who really don't want an 
op. Hope it works. 
WHEN OFFERED: People who don't want an op. 
Offer choice to pts with medical issues. These 
conversations (about PET) are generally over 
80. Those who come, looking frail, with carers 
and they’re 86 and we just go have this nice 
table. 
NEO: Recent MI: should be waiting 6/12, we'll 
put you on ET and then re-evaluate. 
Pros: They’ve missed out on an op. No 
admission, no GA. Some have prolonged good 
response.  
Cons: Limited response, may be worse off 2y 
down the line. May fungate and require 
dressings. F/U may be upsetting. 
Happy to take a tablet. Seen as less hassle. Like 
that it avoids an op. A lot of those frailer older 
pts are accepting of the fact that you’re not 
curing their disease. Lump generally not a 
factor: as it’s not bothering them... they’re not 
too fussed. F/U not an issue: Most pts I think 
don’t mind coming up to hospital every 3 or 4 
m. 
PET TYPE: Mentions Tamoxifen. 
RESPONSE: You see women who are on 
Tamoxifen for 10 years without a single sign of 
the tumour re-growing. Unpredictable 
response. If somebody’s going live >5 yrs then 
they’re probably going to come to the end their 
endocrine... Rx.  
REACTION: If fit should have surgery: I keep 
saying to her “this isn’t working very well - it’s 
going to end up growing, you are well you 
should have" (an op).  
F/U: Home visit instead of hospital appt. 
S08 
Male 
High 
PET 
OPINION: Inferior Rx if pts <80. Don't use it 
much ~5% or 3 per month - although actually in 
a high PET region. 
WHEN OFFERED: Generally wouldn't consider 
PET <80. Would discuss it 80-85 and would tell 
pts he considers PET equal with surgery if 85+. 
Won't tolerate surgery. Big fungating ca PET 
not in their best interest unless so frail can't 
survive surgery. Would push for PET in very 
high risk elderly pt. 
Pros: No surgery. Lack of other Rx like RTx, not 
coming into hospital, blood tests. 
Cons: May not work, suck it and see. SEs: joint 
pains, aches, risk of # (Letrozole). F/U can be 
difficult. Local control not as good. 20-30% will 
need surgery due to PD. 
I have actually seen pts looking very gloomy, 
very depressed & soon as you’ve said “we don’t 
need to do surgery, we can do tablets”, they 
look like themselves and they’re really happy. 
Accept SEs fairly well. Like that they don't need 
surgery, doesn't alter their lifestyle. Lack of 
cure isn't an issue: don't think it's a concept 
they understand. Not had pt bothered by lump. 
Like it when lump shrinks, feel like success - she 
was very happy... that I can’t feel the lump 
anymore... they know that it’s working. Most 
have relative/carer to bring them to 
appointment. seeing us is their social event. 
PET TYPE: Letrozole then Tam. 
RESPONSE: Between 3m to death. A lot of 
progression occurs within the 1st year. 20-30% 
will run out of ETs. 
REACTION: If it doesn’t work, we can then 
consider surgery. Swap ET from Letrozole to 
Tam, then surgery. 
S10 
Male 
High 
PET 
OPINION: Variable response. Thinks a low % of 
pts Rx'ed with PET. 
WHEN OFFERED: Prefers PET if anaesthetist not 
happy with risk. Usually 85+. If recent MI. 
Pros: Most of them they tolerate it very well. 
Few SEs. 
Cons: Hormone Therapy doesn’t work all the 
time. SEs: joint pains, menopausal symptoms, 
osteoporosis. 
They don’t ask about cured. I think they just 
understand that we are controlling it. 
Reassured by response, not bothered about 
residual lump - They are reassured that it’s not 
progressing. But they don’t care whether it is 
disappearing or staying put. 
F/U: Assess after 6m-1y, if no response would 
operate. If responding, see them in another yr 
& then we D/C them.  
RESPONSE: Starts working in 6m so have to 
wait 3-6m to see response. Variability of 
response: If PET does the job, carry on, if not 
then surgery. Believes it either works or 
doesn't: they don't work and then they stop.  
REACTION: Either changing tablets or offer 
them surgery (can be LA). Explain about very 
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high surgical risk and, if happy, will operate. 
S14 
Male 
High 
PET 
OPINION: Likely give control. It's not a cure - 
control is the operative word. 
WHEN OFFERED: Mentions PET to all older pts 
even if F&W. Mainly used for pts 77-90. Thinks 
about 30% older pts. 
NEO: Use PET as neo-adjuvant if not fit and 
reassess after a few months (i.e. recent MI). 
Pros: Likely to give control. Can change it if not 
tolerates. SEs easily controllable. 
Cons: Don't know how long response will be. If 
PET fails. 30-40% chance they'll progress after 
5-7yrs. May not respond. Compliance can be an 
issue. Risk of VTE, may need calcium 
replacement with. Might not tolerate. Not a 
cure. 
Just want to avoid surgery. Some bothered by 
the lump but not all. Explain lump will get 
smaller but it will be there, modify pt 
expectations. Reassured when shrinks. Some  
find it difficult to travel but not much of an 
issue. 
PET TYPE: Tend to start on Letrozole. 
TUMOUR ASSESSMENT: USS. 
F/U: F/U at 3m then 6m and then yrly for as 
long as they're on Rx. 
RESPONSE: Likely to give control over 5-6 years 
if they respond, 30-40% chance of progression 
after that. PET usually successful for 6,7 yrs. 
REACTION: You need to change or things. 
S15 
Female 
High 
PET 
OPINION: Only 1/3 have PET. Survival can be 
comparable. Limited efficacy. Safely Rx BC with 
PET if life-expectancy 1-2yrs. Lack of cure not 
relevant as surgery will not cure BC either. 
WHEN OFFERED: If life expectancy <2-3 yrs. Pts 
with severe dementia. 
NEO: Pts who have had some recent serious 
illness... we use ET until they’re well and then 
operate. 
Pros: Most pts notice no SEs whatsoever. 
Avoids them coming into hospital, having an 
op, avoids RTx. 
Cons: Limited efficacy: whether ET alone would 
be likely to work for long enough. Issues with 
compliance but pretty uncommon. Bad thing 
about ET is that they have to come to the clinic. 
Avoiding hospitalisation is a massive thing, they 
know if you come into hospital, something bad 
could happen. Some bothered by lump but a lot 
may not have noticed it themselves in the first 
place. Most people don't worry about the 
lump. They may ask is it getting smaller? Quite 
a lot of people like to be rid of the lump. I don’t 
think that’s as important as you might guess... 
Now I would have thought that that would be... 
quite a difficult thing to cope with but it doesn’t 
seem to be. 
TUMOUR ASSESSMENT: Calliper 
measurements, although not particularly 
accurate. 
F/U: Start off coming back every 3m. 3m, 4m, 
6m. Much more active F/U than surgery.  F/U 
for duration of Rx. Sometimes the GP says 
"really its so difficult for her, she's getting really 
upset". 
RESPONSE: Works for 2-3 years. 
S18 
Female 
High 
PET 
OPINION: Feels uneasy about Rxing fit women 
with PET. PET alone probably long-term is not 
as good an option. Not serving pts well by using 
PET. 
WHEN OFFERED: If ER+ and pt enquires about 
PET would discuss it. In pts whose fitness is 
uncertain. NEO: Larger tumours or skin/chest 
wall involvement prior to WLE under LA. Lots of 
pts even when the tumour shrinks don't want 
LA surgery. 
Cons: Resistance to AIs and the tumour grows. 
The cancer does sometimes come back and 
cause problems. 
A lot of the pts... once you give them the tablet 
option, they’re not interested in anything else. 
No they don’t want the surgery, they’ll just 
carry on with the tablets, thank you very much. 
Never found any pt worried about the lump, 
which amazes me. Feel quite reassured if they 
can feel it that it’s not enlarging. 
PET TYPE: AIs - Letrozole. 
TUMOUR ASSESSMENT: How they're doing in 
general, clinical exam, estimate size (don't 
always formally measure it), formal 
measurement with calipers/USS if enlarging. 
F/U: for duration unless pt refuses then GP. 
Interval depends on how they're doing, initially 
6wk to ensure tolerance & compliance, then 
3m then 6m or yearly. 
RESPONSE: Effects of AIs last longer than Tam. 
5 yrs easily, but some way longer than that. 
We’ve still got some pts with good responses at 
10 or 15 yrs. 
REACTION: Revisit GA surgery, offer LA. D/W 
oncologist re: switching AI. 
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S20 
Male 
High 
PET 
OPINION: Previously in 40% of >70s, less now. 
Extremely ER rich tumour that person's 
outcome is extremely good with PET so if quite 
old can be offered a choice. Wouldn't make a 
derogatory comment about PET. Unsure which 
Rx is more cost-effective. Strong supporter of 
PET... but I don’t indiscriminately use it - I want 
to use it in the right context.  
WHEN OFFERED: Good option if pt has a 
minimal chance of surviving >4yrs, if H score 
approaching 300 then even if life expectancy is 
10 yrs it might still be a choice. Pts w significant 
comorbs limiting their life expectancy to only a 
few ys or if you’re going to kill her by doing 
surgery.  
Pros: If properly selected, gives pretty good 
outcome. ET is quite easy.  
Cons: Issues with compliance. Mentions SEs 
(but get ET with surgery too). May be a bit 
more burden to the healthcare system in terms 
of F/U.  
No comments. TUMOUR ASSESSMENT: USS and clinical 
assessment every time: got a consultant 
radiographer who's very keen to do US. Unsure 
whether US has added value, more expensive. 
F/U: Burden on healthcare system in terms of 
F/U. Should F/U them up for duration of Rx.  
RESPONSE: Tumours with an ER H score >50 
their average time to progression is 49m (4 yrs). 
Longest time to progression is 103m (8-9 years) 
with H score approaching 300. Maximum you'd 
probably get 10 yrs.  
REACTION: Pts who progress on PET could still 
have a salvage op. 
S21 
Female 
High 
PET 
OPINION: Thinks >50% are Rx'ed with PET - I 
would probably say there are more in favour of 
hormone therapy than surgery. I do believe 
that the hormone therapy works.  
Pros: Least disruption to their life. It's a little 
tablet to take. Doesn't have any dramatic 
morbidity.              Cons: Might run out of 
medical Rx and the disease may progress. 
“oh, I’m on a hoard of them (tablets), one more 
won’t make a difference!”. If they know that 
there are tablets then they feel “good, I don’t 
have to have that op, there is another option”. 
Lump doesn't tend to worry them because 
explains to them that if the tumour remains the 
same of reduces in size it's a positive repsonse. 
PET TYPE: Anastrozole 1st line. 
TUMOUR ASSESSMENT: USS or MMG if not 
longer visible on US. 
F/U: Designated PET clinic: seen in one room by 
radiologist and consultant. First appointment at 
8-12wk, then 3m until good response then 6m 
until it disappears then yearly. On clinical 
judgement on how frequently. F/U until they 
don't want to come back or if goes to NH - then 
writes to GP to F/U. 
RESPONSE: If you see a response you'll see it 
within 1 yr.  
REACTION: “we have to think of other ways of 
treating this cancer”. Advise surgery, doesn't 
have to be GA, could be blocks/LA. Try 2nd/3rd 
line HT and takes it back to MDT for discussion. 
Would have to run out of HT or imminently 
likely to ulcerate before operates. 
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S32 
Female 
High 
PET 
OPINION: Can be very effective... always a finite 
limit. Not against PET... got a foot in both 
camps. If well-informed and genuinely don't 
want surgery then I don’t have any issue with 
that. 
OFFERED WHEN: Not fit or they expressed a 
desire to not to have surgery. High-risk for 
surgery. Recent MI or CVA.  
NEO: If undecided will put on PET and give time 
to decide whether want to proceed to surgery. 
Pros: Can be very effective. Avoidance of 
surgery: avoid disfigurement and RTx. 
Cons: Finite limit (control). At that point (Rx 
failure)... you may well be less well and less 
able to tolerate surgery. SEs. Compliance is not 
particularly good. Uncontrolled local disease 
and getting into a situation where you convert 
a perfectly easily operable tumour into a 
fungating mass lesion. 
Reassuring that they can see the lump shrinking 
so they know the Rx’s working. Others are very 
anxious and whittle continuously about it. 
Surgery easier on the pt because you're not 
bringing them back every 3-6m. 
PET TYPE: Letrozole 1st line. 
TUMOUR ASSESSMENT: Bi-dimensional caliper 
measurement, don’t routinely use US. 
F/U: Same clinician sees the pt, easier to pick 
up progression. 6-8wk to assess SEs then 4m 
later to assess response. Then 6m and D/C to 
GP. 
RESPONSE: Pts on Faslodex for 12y. May work 
for 2y, 5y.  Extremely variable. 2y, 2.5y period 
of control, I think that would be pretty 
medium-ish. 
REACTION: Expect to sequentially have to 
change Rx and we can have this discussion (re: 
surgery) again. 
S33 
Female 
High 
PET 
OPINION: Very rarely here, I think we’re using it 
less. 
NEO: start ET and get assessment (work-up 
takes a couple of months) and if anaesthetist 
think fit enough we'll proceed with surgery. 
Pros: They just carry on with their life. Don’t 
seem to have significant SEs. 
Cons: SEs: aches and pains (tend to ignore); hair 
loss with Letrozole, don’t think about it... and 
actually they do worry about those things. 
Happy not having had to have surgery. Love the 
fact that they can just carry on. Thinks pts are 
aware it's not a cure. Don't seem to be 
bothered about lump. Some of them say they 
get anxious a few days before the clinic 
appointment but most of them seem to be able 
to get on with their life. 
PET TYPE: 1st line is Letrozole. 
TUMOUR ASSESSMENT: clinical measurement 
(calipers) or US if not palpable. 
F/U: Initially 4m then 4/6m, D/C with open-
access if stable for a yr. 
RESPONSE: Variable, and I think that’s the 
difficulty. Average, 4-5 yrs... my perception is 
they either fail within a couple of yrs or they 
seem to go on for a long time. 
REACTION: Switch to Tam or Exe. 
G16 M: 
High  
No comments. Cons: Failed endocrine Rx when they're frailer 
and everything's more difficult. 
No comments. No comments. 
N09 
Female 
High 
PET 
OPINION: Inferior options so doesn't mention it 
unless asked. Really low in their unit - 
uncommon. 
WHEN OFFERED: Frightened or uncomfortable 
with having op then would flag up PET as an 
option. 
Pros: Don't see many progress. 
Cons: Issue of compliance. Don't see the PET 
pts as frequently in the initial period, not as 
supported. Mentions SEs - the idea of SEs can 
worry pts. 
Easier. Idea of PET is more comfortable to 
them. Lump bothers some: "it's not gone, it's 
sitting in my breast still", Feel their lump all the 
time... touching it, checking it. BC remaining in 
the breast feels very uncomfortable for some 
pts. Is this her feeling, because she then says: 
But they would then probably plump for 
surgery - also never had a pt say "I'll have 
tablets" then say they "don't like the lump" 
ASSESSMENT: Clinical exam. 
F/U: Initially 3-6 wks clinical r/v, check no SEs, 
taking the tablet. Then every 3m for 1yr then 
D/C. Not as frequently as surgical pts initially. 
Advise pt & GP to re-refer if progression. 
Doesn't know if GP regularly examines. 
Suspects only get flagged up as progression. 
RESPONSE: Doesn't take effect for at least 3/12. 
Don't see many progress. 
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N12 
Female 
High 
PET 
OPINION: Not optimal Rx. Number decreased 
over the years. Considers ET an adjuvant 
therapy. Very few only offered PET. Need to try 
to avoid giving PET as the only option for these 
ladies. 
WHEN OFFERED: Lots of co-morbs or senile. 
One pt because so anxious couldn't be 
admitted.          NEO: Put on PET if they have a 
holiday booked but then surgery would be 
booked after that. 
Pros: Where QoL most important. Avoid 
surgery. 
Cons: Seen a lot fail, they're 5/6 yrs on, more 
comorbs and surgery is the only option. Only 
keeps cancer at bay for a number of months. 
Seen as the easier option. Happy to have 
steered clear of surgery. Not bothered by 
lump: majority will say "I don't usually touch it". 
Often don't even know if it's responding. 
TUMOUR ASSESSMENT: Clinical assessment, 
usually calipers (varies between clinicians). 
F/U: Only seen by BCN for 1st 6m then just by 
phone if pt needs them, F/U done by medical 
staff every 4-6m. 
RESPONSE: Seen lots of women go through the 
ETs, fail, they’re 5/6 ys on. Mentions a pt who's 
been on PET a yr but not responded despite 
changing ET. Variable - some go a long time, 
others don't even get a first response. Only 
keeps cancer at bay for a number of months. 
REACTION: Swap ET. If still fail, surgery is the 
only option. 
N13 
Female 
High 
PET 
OPINION: Small % on PET. Kept aside for people 
that are not fit. Minute you say “you don’t need 
an op” they switch off. Fairly long-term good 
Rx, it’s a good alternative sometimes. Fabulous 
Rx, however not for everybody and not forever. 
WHEN OFFERED: PET is only... a first choice for 
someone who isn't fit for surgery or they've 
come knowing what they want. Don't offer it to 
people who are fit irrespective of age. 
NEO: Use ET as Rx while pts think about surgery 
- a bit like neo-adjuvant. Used while see if fit. 
Pros: Safer than surgery. Whilst making 
decision. 
Cons: Effectiveness sometimes short-lived, 
health may have deteriorated, no longer fit for 
surgery. Not a forever Rx. Run out of options. 
Relying on them to take it. Cancer's still there: 
while ever it's in your body you don't know 
what it's doing to you. Doesn't work over night. 
Not guaranteed effective for the rest of your 
life. 
Easier option. Relieved they don't need an op. 
Pts think it's this magic thing that disappears 
overnight. Don't like the idea that they still 
have a cancer within the body. Mixed 
emotions. Majority aware it's not a cure. 
Become over anxious & over obsessed... 
“before I never use to bother feeling but now 
I’m feeling every day & it’s still there”... it’s a 
big worry for a lot of ladies. F/U: quite 
distressing, particularly older ladies with 
dementia... they don’t want to come... families 
don’t want to bring them. 
PET TYPE: Letrozole as first option. 
TUMOUR ASSESSMENT: Don’t scan unless 
concerned; clinical measurement. 
F/U: Periodically for duration, open access 
telephone clinic. Sometimes their GPs will take 
over.   
RESPONSE: Varies greatly... potential to work 
for yrs... See people at maybe at 4 or 5 yrs that 
all of a sudden this particular Rx now is not 
effective. At 3/12 may be no change at all... it 
may take much longer. 
REACTION: Change therapies, sometimes you 
run out of options. 
N17 
Female 
High 
PET 
WHEN OFFERED: If not at all fit to have surgery. 
Short life expectancy, e.g. 2yrs. Severe 
dementia. If pt say surgery is not for me. 
Offered to all but emphasis on surgery.   
NEO: Some pts started on ET before going to 
clinic for assessment. Many ladies that are 
treated with PET... to reduce the size not 
because of their comorbs. Use PET to give time 
to think about choices. 
Cons: Maybe a yr or so down the line, that ET 
is going to stop working, and they’re going to 
be a couple of yrs older, maybe not fit for 
surgery at that point. 
“I’ll take tablets because that’s going to be 
easier for me to cope with”. Tell them PET 
might only work for short time, they’ll say “well 
I don’t mind if I just get another couple of yrs”. 
Very aware the cancer is still there. Initially 
might find the lump disturbing but after a few 
weeks they will notice the difference... so from 
that POV. then they are confident. Majority 
reassured by F/U. 
F/U: F/U in specialist clinic. NH residents who 
may be really too frail to come ask the GP to 
F/U and refer back if there is a problem. 
RESPONSE: Maybe a yr or so down the line ET is 
going to stop working. Probably a couple of yrs, 
sometimes less. May only work for 2 yrs. 
 544 
 
 
 
 
 
N19 
Female 
High 
PET 
WHEN OFFERED: Even if it’s deemed to be 
operable, HT would be considered an option, 
instead of surgery. 
Pros: Avoids surgery. Easier. 
Cons: Mentions SEs but generally wouldn't be 
too unbearable. It's living with the fact that 
they've got something in their breast - cancer's 
still there. Can feel guilty, like they're letting 
themselves or their family down by not being 
brave enough to have surgery. 
Some feel disappointed if they weren't having 
surgery, others are pleasantly surprised, they're 
relieved. Think taking a tablet is so much easier. 
Can feel guilty, like they're letting themselves 
or their family down by not being brave enough 
to have surgery. Aware it's not a cure. It’s 
almost as though “can’t I just keep taking this 
tablet? Why do I have to keep coming back?... 
Other people I think feel a measure of relief by 
coming back. 
RESPONSE: Variable: number of yrs, some 
>5yrs, others <1yr. 
N22 
Female 
High 
PET 
OPINION: Not many Rx'ed with PET. 
Contradiction: We do see quite a few on the 
Primary Endocrine now. 
NEO: Use ET while pts make a decision about 
whether to have surgery. 
Pros: Suit their lifestyle better. Haven’t got to 
worry... if they’ve got people at home, elderly 
partners, ‘who’s going to look after the dog?’, 
the cat. Convenience... just carry on and no one 
needs to know. 
Cons: Potential SEs. Worry of having to come 
back every few months to get it scanned and 
checked and if it does grow. Inconvenience of 
F/U: wait for hospital transport. 
Taking so much medication that they want to 
avoid another tablet. Lump bothers them until 
their first visit. Ones who would worry opt for 
the surgery, I think they’re comfortable that 
they’re having a tablet and it seems OK and ‘I’m 
being checked out’. Some like F/U: it’s a little 
trip out... look forward... to getting out and 
having a bit of company.  
PET TYPE: Either Arimidex or Letrozole. 
TUMOUR ASSESSMENT: Clinical exam + USS. 
F/U: Every 3 to 4 months. Get to a point where 
it's stable so let the GP F/U, refer back if 
concerned. 
RESPONSE: Could be many years.... doesn’t 
appear that we get many back who require 
surgery under locals. Longer now we use AIs. 
REACTION: If they don’t work then there are 
other tablets, but then if they don’t work then 
we may be visiting surgery at some point. 
N31 
Female 
High 
PET 
WHEN OFFERED: Start introducing PET as a 
choice in 86+. Had a lady who was 101, but 
really actually endocrine was the main choice. 
80% is pt choice, rest is because they're frail or 
unfit. 
NEO: We could look at starting her on 
endocrine for a while- if she had a chest 
infection...until they’ve got that sorted. 
Sometimes it’s too big, so they’re going to try 
and shrink it first. If it's shrinking they quite like 
the idea of staying on the ET. 
Cons: Women are living longer so if you do 
endocrine, you’re more likely to get them back 
when they’re a lot older and frailer and surgery 
may not then be an option and you’ve only got 
RTx. Can never get rid of it with just endocrine 
alone.  
They can be more anxious than the ladies 
who’ve had surgery. ‘I don’t like that in my 
breast anymore, it’s making me worry all the 
time’. They quite like that (regular F/U)... 
they’re being looked after and watched. 
TUMOUR ASSESSMENT: Clinical and US every 
time they come. Subjective measurements. 
F/U: Regular basis. Initially at 3m. 
RESPONSE: ‘It could work for 6m, 2 yrs, or for 
the rest of your life’. Might only work for 6m or 
she might... die from something completely 
different... very hard to predict. Some ladies it’s 
carried on growing, but not many. Lot of the 
time it’s yrs.  
REACTION: Surgery may not then be an option 
and you’ve only got RTx... you can switch your 
endocrine I suppose but there’s only usually 
RTx. 
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N34 
Female 
High 
PET 
OPINION: Never take it away but it could keep 
it under control for as long as they need. 
Minority treated with PET. 
WHEN OFFERED: “I really don’t want this 
surgery”. Gives you another option when they 
can’t always comply or understand. NEO: They 
can go on it initially to give them time to maybe 
have an anaesthetic assessment, or time to find 
out the info they need to decide what they 
want to do.  
Pros: Could keep it under control for as long as 
they need. Well tolerated. Most... get on with it 
pretty well. 
Cons: if they don’t get a good response... best 
option now is surgery but you could be a lot 
older. End up with an ulcerated, quite 
unpleasant malodorous wound. SEs:- flushes, 
arthritic pain, joint stiffness. Will never take it 
away. 
Really struggling because they can’t have 
surgery because they can’t trust in the tablets. 
For some ladies it’s very important that actually 
they’re rid of it. Those who are bothered re: 
lump would probably opt to have surgery. 
Seeing it respond...is... quite reassuring. It’s a 
bit of reassurance sometimes coming for clinic. 
F/U: Initially and again at 6m, then a yr, the D/C 
to GP.  
RESPONSE: Varies, I’ve got one lady who’s 
actually come off it after 20 yrs and had surgery 
because she got so fed up of taking it. Could 
last for life. Ladies that have been on it for 10 
yrs but realistically you’re looking at maybe 3-5 
yrs before you need to change. 
REACTION: If they don’t get a good response, 
then we might be saying “well, our best option 
now is surgery but you could be a lot older. 
Change ET. 
S03 
Male 
Low 
PET 
OPINION: Considers for all over 70s. Sub-
standard in terms of local recurrence and QoL. 
It is a good choice. Lazy surgeons use it without 
questioning the evidence. 
WHEN OFFERED: I offer both Rxs to all pts. If 
there's a bit of anxiety... I'm happy to keep 
them on the PE(T). 
NEO: Start them all on PET in view of bringing 
them to surgery to allow time for assessments. 
Pros: Most likely to have good control. Pretty 
well tolerated. 
Cons: Sub-standard in terms of local recurrence 
and QoL. SEs well-known but minute, incl 
endometrial ca. Limited period of efficacy - 
then the cancer comes back. 
No comments. RESPONSE: We expect these tablets to work, on 
average 3 yrs and then the cancer comes back. 
S24 
Male 
Low 
PET 
OPINION: Less now than used to <15%. Thinks 
survival is equivalent, main issue is QoL.  
WHEN OFFERED: Up until 3yrs ago was offering 
PET to all pts over the age of 70. Still offers pts 
PET but tells them surgery is best. Dementia is 
the one indication for PET in my book. 
NEO: Uses neo-adjuvant ET to shrink tumours 
to make them easier to operate on under LA. 
Pros: Happy that they haven’t had an op. 
Allows them to stay in the comfort zone of 
denial - don't have to face up to the fact that 
they've got something serious. 
Cons: Uncontrolled local disease. If I operate on 
her now, she probably will die. Continually 
watched. F/U reminds them they have cancer.  
“I’m glad I didn’t have an operation”. They’re 
not under the impression that it’s going to cure 
it. Haven't told me they're worried about it (the 
lump). Feel comfortable it's not getting bigger. 
Can forget about it. Inconvenience of coming to 
clinic. Reminded they've got cancer. Most of 
them want to come. 
TUMOUR ASSESSMENT: US the pts himself.  
F/U: Scan them every 6m. One-stop clinic, start 
with 3/12 F/U until knows they're responding 
then 6/12 if they're static or annual if they're in 
complete remission. Sometimes they say “can I 
not come?” and I say fine.  
RESPONSE: E.g. of a woman on PET for 9 years 
and now on Faslodex (had all the other drugs) 
with uncontrolled local disease. Works in about 
80%, average response of ~10 yrs. 
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N11 
Female 
Low 
PET 
OPINION: Surprised if they jump straight into 
PET. Very few have PET - low % - maybe 10%. 
WHEN OFFERED: Would be discussed in a broad 
sense as in these are the options available. 
NEO: Tends to be started as neo-adjuvant to 
downstage with a view to surgery after 3-6/12 
and pts leave knowing that. Some stay on PET 
with consent of surgeon if they think that's 
best. 
Cons: If comes back in a few years, you'll be a 
few yrs older, perhaps with more co-
morbidities. Not going to get rid of it.  
Quite happy knowing they're leaving the 
hospital on Rx. Become anxious if the cancer 
grows. Know it won't get rid of it. Thinks it 
bothers pts: every day they know... they have 
got cancer on board. Can be reassuring when it 
shrinks. Reassured knowing they're being 
assessed and checked... I can't say it's really 
going to make them feel worse. Awkward if 
they’re in a wheelchair or not very well - some 
say they don't want to come. 
ASSESSMENT: US at 3-6m. 
F/U: Told to come back sooner if the cancer 
grows. 3m to start the 6m or yr. Won't see 
much difference before 4m. Another surgeon 
see them every month. F/U for quite a while 
and if health deteriorates ask GP to monitor. 
RESPONSE: 2-3 years you're seeing a 
regression, then tumour recurrence.  
REACTION: Surgery might be advocated. 
N23 
Female 
Low 
PET 
OPINION: We know we’d anticipate it to work. 
WHEN OFFERED: If fitness for surgery was in 
doubt. Pts who are very immobile, bound to 
their own home, breathless. If... they don’t 
particularly want surgery... So it might be 
coming from the pt. If extremely unwell. Pts 
coming to the end of their natural life. 
Pros: Not having to go through an op.  
Cons: Not 100% effective in younger pts as 
going to be on it longer. Worrying about the 
cancer still being there - is it going to grow, it 
might stop working. May not be as fit for 
surgery when fail PET. F/U: an effort to bring 
them here, because sometimes we’ve had 
them practically brought in on beds and it’s so 
unfair for the pt. 
Generally happy being Rx'ed that way. Some 
worry and are forever touching it, thinking ‘is it 
going down, is it going down?’ See it as an alien 
and they don’t really want it in them. First 
appointment in particular gives them 
confidence and reassurance that it's working. 
PET TYPE: Used to start on Tam but now 
Letrozole. 
TUMOUR ASSESSMENT: US, all team trained. 
F/U: Starts at 3m then 6m unless pts are 
confused/demented or really unwell them F/U 
by GP and re-refer. 
RESPONSE: Not common to have to change 
therapies at 6m, more like a year, could have 
pts static for yrs. Variable: They were coming 
back 10 yrs later... and it's still shrinking, and 
then you have some that in a very short period 
of time relapse. Some go through all of them 
within a yr or 2. 
REACTION: We put you on to another tablet or 
we might have to go for surgery. 
S04 
Male  
Low 
PET 
OPINION: Only if there is a reason to consider 
it. Inferior Rx. Doesn't offer it: I don’t see them 
as 2 different options... I don’t see it as a 
standalone Rx. Thinks only offering PET is not 
defensible in court if a pt is fit for surgery. 
WHEN OFFERED: Uses PET by default, when 
they're not suitable for surgery. Pts with other 
cancer, significant dementia or declines op.  
NEO: Would offer it to pts who are not 
currently suitable for breast conservation, and 
who would become suitable. 
Pros: Keeps things at bay. Prevents the need for 
an op. 
Cons: Might not work. 
Mixed views.  Majority relieved they don’t need 
an op but significant minority who are not 
happy with the fact they are not getting an op, 
they feel uneasy about the fact they are on a 
medical Rx and haven’t had the tumour 
removed. 
No comments - doesn't really use it. 
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S05 
Male  
Low 
PET 
OPINION: Not recommended Rx if can have an 
op. Not optimal Rx. Doesn't consider ET as 
primary Rx:  has to be surgery at some point. 
Offering PET a slippery slope. Negative attitude: 
stick her on Letrozole and forget about her. 
Fine for very frail old pts. Some benefit from 
masterly activity. 
WHEN OFFERED: can't have surgery, don't want 
surgery, time to get used to or optimise for 
surgery. If can't optimise.  
NEO: Uses more as neo-adj. Result would be to 
facilitate surgery as opposed to avoid surgery. 
Pros: Avoid surgery. Normally good response, 
have options if progress. Spare them the blade 
of surgery and the morbidity. Few progress.  
Cons: May stop responding. Local control may 
become a problem. SEs: bony pains, 
osteoporosis, DVT.  Extra medication, e.g. 
adcal, bisphosphonates. Postponing surgery by 
4-5 yrs then you’ve postponed and you’ve got a 
frailer, older woman.  
Pts see advantage of PET that they avoid 
surgery. 
PET TYPE: Letrozole. 
F/U: Keep on very close surveillance so know if 
progresses. 
RESPONSE: 4-5 yrs. 
REACTION: Swap ET, go from Let to Tam. If she 
progresses then we would go in.  
S25 
Female 
Low 
PET 
OPINION: Not as guaranteed an outcome. In 
some situations (eg dementia) may work 
equally well. About 7-10% of pts on PET. Does 
work very well. Not as definitive. Uncertain Rx. 
WHEN OFFERED: Not fit for surgery. Heart 
attacks in last 6m. Pts who refuse op, pts with 
dementia. 
Pros: Works very well: few... come back for 
volume assessments and they’ve got no 
residual cancer. 
Cons: Failure of control, local problems: skin 
breach, fungating, ulceration. Don't think we 
have major problems with the SEs or 
compliance. Might stop working... general 
health is that much poorer and surgery may not 
be an option then. Longer you wait, the more 
unlikely you are going to operate on them. F/U 
disruptive. 
Most of them are quite happy. Most not 
worried about lump. It’s... a big deal bringing 
the up to hospital, disruptive. 
PET TYPE: Letrozole (Tam if osteoarthiritis) + 
Adcal D3, bisphosphonates in >75s. 
TUMOUR ASSESSMENT: Clinical + US. 
F/U:  If they're F&W: keep an eye on it because 
there may be a time to change the decision. In 
1st yr might do 3-4 monthly scans, when happy 
leave it 6m and some F/U by GP. F/U F&W pts 
for duration. May stop US if complete response 
and just clinical. 
RESPONSE: About a couple of yrs. Average 
time... is about 8 or 9 m before you see any 
benefit. About a yr or 2... where you do see 
them under control... about a 25% group who 
come back with the increasing size and then we 
do switch them to something else. One on PET 
for 11 yrs (now has inoperable disease). 
REACTION: Salvage operation. 
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S26 
Male  
Low 
PET 
NEO: Sometime people do start as a neo-
adjuvant hormonal manipulation... at that point 
in time you may not be able to make a decision 
to say are you doing it as a “neo-adjuvant” 
setting or that’s going to be a definitive 
endocrine treatment. Use it to buy time - they 
gain confidence... nothing is lost... or 
sometimes somebody has had a MI only 2m 
ago, or a mild stroke. 
Pros: Responds sometimes very well. No 
surgery, no admission. 
Cons: Two years down the line, other 
catastrophic events may happen and although 
we start the PET, not always the tumour 
responds to the level you want to respond. 
They love it. They think no knife. They say 
“look, what I did was right”. Accept they're not 
being cured. The reassurances when you do the 
ultrasound scan and tell them the volume loss... 
that gives them the happiness. There’s another 
group of people “I got a tumour, I don’t like it, 
take it out doctor”. 
PET TYPE: If had thromboembolic events... we 
put them on Letrozole. If not Tamoxifen. 
TUMOUR ASSESSMENT: US + MMG. Extreme 
cases (wheelchair bound) just clinical. 
F/U: Initially every 3m, depending on the trend; 
if decreasing in size less frequent. F/U for as 
long as possible. 
RESPONSE: May live for yrs. Softening is the 
first thing to happen and then it shrinks. 
Variable response. Don't come across many pts 
where you run out of ETs. 
REACTION: Switch the ET. It starts fungating... 
then we look at RTx. If small could use LA. 
S28 
Female 
Low 
PET 
OPINION: Feels uncomfortable putting pts on 
PET. PET is writing somebody off. 
WHEN OFFERED: If they refuse surgery or they 
don’t have that kind of support, on the social 
side... we are relaxed enough to off them ET. 
80+ lower threshold to offer them ET, 70-80 
most people go through the knife. 
NEO: Give neo-adj ET while they go through 
assessment and optimisation, gives them 
chance to see if it's responded - not delaying Rx 
whilst you get the assessments. You can leave 
them for 4-6 wks on ET and come back... by 
that time they’ve usually made up their mind.  
Pros: If more likely to succumb to comorbs you 
don’t necessarily want to subject them to 
surgery. Don't need hospital F/U, can be 
managed by GP. 
Cons: Non-responders... problematic, fungating 
cancers. Dragging pts back every 3-6m. Less fit 
in 5 yrs’ time, less likely to be candidates for 
surgery. If it becomes locally advanced. 
Don't seem to be bothered by the lump they 
don’t look at their breast, they don’t examine 
their breast, they don’t feel their breast.  
PET TYPE: Letrozole, but used Arimidex in other 
centres. 
TUMOUR ASSESSMENT: Varies according to 
surgeon, don't generally US unless neo-
adjuvant. 
F/U: Just see them for 3-6m and make sure 
they’re not obviously getting worse on Rx and 
then just leave it to the GPs. 
RESPONSE: Often after 5 yrs they start to fail. 
Don’t know the proportion, you don’t know the 
denominator. If they fail, they tend to fail 
within 3-5 yrs. 
S29 
Female 
Low 
PET 
OPINION: Uses it much less now than 5yr ago.  
WHEN OFFERED: If pt is reluctant to have 
surgery. 
NEO: Why don’t we put you on a trial of HT and 
see how you get on and see you again in 3 or 
4m time and see if your tumour’s responding. 
Pros: Avoiding surgery, I think that’s the only 
advantage, just trying to avoid the trauma of it. 
Cons: No disadvantages as pts will get ET if they 
have surgery anyway. Failure of local control 
can be quite a difficult clinical scenario to deal 
with, quite unpleasant. Mentions cognitive 
impairment that’s reported with Tamoxifen. 
It’s something you have to explore with them 
because it is a disadvantage, if they’re going to 
be feeling their lump twice a day. 
PET: AI, Letrozole. 
TUMOUR ASSESSMENT: Clinical +/- US, doesn't 
use calipers, I measure it by eye. 
F/U: Initially 3 or 4m. I might arrange to see 
them again once more... and if they continue to 
have stable disease, I’d usually discharge them 
back to the GP. 
RESPONSE: Probably a year or so. 
REACTION: I would try a second line. 
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N06 
Female 
Low 
PET 
OPINION: In the minority. 
WHEN OFFERED: If not fit for surgery.  
NEO: Trying to avoid Mx by giving ET. May be 
used when close to breach date - particularly if 
needs assessment. 
Pros: Can avoid Mx. Fairly easy Rx for an older 
pt. Quite an effective Rx. Good option without 
having too much impact on their life really. 
Cons: SEs. 
If it's well tolerated pts like it. They deem it 
effective. It doesn't impact on their life, it's an 
easy Rx. When lump physically shrinks can be a 
positive thing. 
TUMOUR ASSESSMENT: US + clinical 
assessment.  
F/U: Monitor them quite closely. Initially see 
after a month, 1st US @ 3m, if tolerating it see 
them at 6 months. Try and keep them on it for 
at least 6 m before doing surgery.  
RESPONSE: Usually wait 3-6 m for response 
before moving on to surgery. 
REACTION: It's not really working... let’s move 
on to surgery. 
N27 
Female 
Low 
PET 
OPINION: Maybe 20-25% treated with PET. Cons: If PET doesn't work can lose the window 
of opportunity to operate. 
They breathe a sigh of relief and think ‘actually 
I don’t need to go under anaesthetic’. Might 
feel that they're maybe abandoned: don't get 
as much contact time as surgical pts. If they can 
feel that it’s resolving... they seem ok with the 
decision. 
PET TYPE: Tamoxifen, Arimidex, Letrozole, 
Exemestane. 
TUMOUR ASSESSMENT: Clinical exam, if any 
discrepancy then repeat the US. 
F/U: See them within 3m, see if they’re either 
recessing or responding to Rx and then go from 
there. Have BCN number: ‘if you have SEs or 
anything, ring in’... tend to lose a little bit of 
contact with them but... it’s an open-door 
policy. 
RESPONSE: 9m window of opportunity for 
surgery. 
REACTION: If they’re non-responders... would 
re-explore the surgical option. Go onto a 
different ET to try and maintain response... so 
we would switch.  
N30 
Female 
Low 
PET 
OPINION: Low percentage... isn't uncommon. 
WHEN OFFERED: Pt feels that home 
circumstances are such that they can’t cope 
with surgery.. feel that it will knock their 
routine and they don’t want surgery. Will offer 
PET if felt it's in the patient's best interest.  
NEO: If there were comorbs or the tumour was 
sizeable might try neo-adjuvant to downsize 
and make surgery easier. 
Pros: They’ve not had to go through surgery; 
for some people, it’s the right thing. 
Cons: Run into problems later if they get 
resistance to it. Progress on ET, and if their 
health deteriorates, then that becomes far 
more challenging in treating the person 
optimally. 
Older people cope with it being there, as long 
as they see it shrinking or they know it’s not 
getting bigger.  
PET TYPE: Generally Letrozole.  
TUMOUR ASSESSMENT: Use US to... compare 
the sizes. 
F/U: Review in 2-3m... see what response is. 
Usually kept in F/U. If getting to hospital is 
difficult often ask GPs to F/U.  
RESPONSE: Settled on it for at least 2-3 yrs, 
some people can go on it for a lot longer... but 
that’s the point that I feel often they have to 
change Rx.  
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REACTION: May need to be changed onto a 
different one. Change Rxs or they come back 
for surgery at that point.  
 
Theme 4: Views on the decision-making process in older women 
  
4.1 Patients preconceptions 4.2 Information giving 4.3 Decision making in older women 4.4 Refusal to choose 
S01 
Female 
High 
PET 
No comments. As much as they want, you obviously have to be 
guided by them. 
Some women really don't want to make that 
decision, they think it's the sort of thing that a 
doctor should do... they're quite passive. “no 
doctor, you decide what’s best for me, I don’t 
know, I’m not the expert”. Encourage them to 
choose by giving info and time but will decide 
for them. 
Some women really don't want to make that 
decision, they think it's the sort of thing that a 
doctor should do. Defer decision to relatives or 
carers. Quite passive. Happens often - “no 
doctor, you decide what’s best for me, I don’t 
know, I’m not the expert” I mean I’ve had that 
said to me many times. 
Encourage them to choose by giving info and 
time but will decide for them -in that situation 
you say “Well I’ll tell you a little bit and let you 
have a little think about it and then if you 
want me to decide then I’ll decide for you.” 
S02 
Male 
High 
PET 
No comments. Informs pts about Rx plan, I’ll tell the pts in 
each of these situations exactly what we’re 
doing. No useful written info or media-based 
info for pts. Surgeons frame what the options 
are, CNS does majority of communication. 
Getting all info from HCP is perpetuating the 
variation in Rx. Amount of info based on what 
you can give to a pt in a clinical setting. Thinks 
older women like their info from the HCP. 
Tries not to stereotype older pts decision 
making styles. Stereotype that older people are 
passive info seekers who want to be advised 
what to do and would like to avoid operations if 
possible. Older people are perhaps more 
concerned about maintaining independence 
and autonomy than they are about months and 
years survival.  
Patients who say "you decide" are low 
information seekers and passive decision 
makers. 
Happy to decide but tries to elicit preference - I 
usually say "I’m quite happy to decide for you 
but before I do, I’d like you to spend some time 
talking to your nurse specialist because with a 
bit more time and a bit more info, and a bit of 
time to get over the upset of being told what 
the diagnosis is, you may find that you actually 
do prefer one or the other". 
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S07 
Female 
High 
PET 
It will be personal experiences. Some... more 
prepared than others. If pts already suspect 
diagnosis conversation can be short if they just 
say "I don't want an operation". 
Glazing of the eyes... only so much info that 
you can take in. Some more prepared than 
others. Sometimes conversation is brief if pt 
knows what you're going to say & they go "no I 
don't want an operation" so you don't get 
much chance. 
Infers that pts influenced by what they think 
surgeons think is best but they get it wrong: 
they think you want them to have an operation 
- not really! Pts have their own reasons by 
choosing Rxs: wasn't the most logical reason 
but it was her reason... it was how she felt 
about it. Most women in Barnsley I think make 
up their own minds. 
No comments. 
S08 
Male 
High 
PET 
No comments. Much less than younger women...that group of 
pts do not want to much info, can't cope with 
too much info. Discusses type of surgery, how 
long for PET, when see again, what to expect. 
It's purely dependent on the pt. Most Q&As 
from relatives rather than pts. 
I would be pushing for PET and I suspect she 
will more than happiliy agree with that - infers 
they are easy to lead? ‘Doctor knows best’. 
Elderly pts don't ask loads of questions, can’t 
cope with too much info. Quite passive: Just say 
"do what's best for me". Contradicts this with: 
they'll know whether they want PET or surgery. 
No comments. 
S10 
Male 
High 
PET 
No comments. I don't hide any facts from the pts. Mentions 
tablet SEs, failure, risks of surgery and 
anaesthesia, prognostic info. How the pt is 
accepting or digesting the info. Some of them 
are happy to accept everything, so I tell them 
everything. Some of them... they like just 
‘cancer’ or ‘not cancer’.  
No comments - seems to be HCP-centred Rx 
decision. Mentions: QoL is important in this 
type of woman. 
I’m happy to make a choice for them. 
S14 
Male 
High 
PET 
Most elderly ladies accept the diagnosis much 
more easily than younger ones. 
Tend to give the info to the pts and let them 
decide. Give them basic info, facts and figures. 
As much info as the pt wants. Some switch off 
and not listen to any more. Others will take 
more and so you give them more. Who comes 
with the pt, whether pt forgets. 
BCNs... reinforce what is being told. 
There are pts who ask him to decide. Defer 
choice to family member: “let her decide, you 
talk to her because I forget”. Some pts are quite 
happy to go along with whatever you 
recommend. I just find that the elderly ones 
accept things much more easily. Well not all of 
them like making their own decision, but a 
large proportion do. 
Yes there are pts who ask him to decide. Some 
pts defer choice to family member - some of 
them will just say “let her decide, you talk to 
her because I forget”. 
I think you take an objective decision as to 
what would give them more benefit. So that’s 
what you decide for them. 
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S15 
Female 
High 
PET 
No comments. Huge amount of info... info overload is a real 
issue. Incongruous to talk about everything if pt 
says doesn't want it. Depends a lot on what 
they're saying to me... don't talk about 
everything to everyone... need to be talking to 
each individual woman as an individual.  
Commoner for older pts than younger to ask Dr 
to decide for them. The older woman who lives 
independently, they’d rather die than lose their 
independence... their priorities are very 
different... it’s not about survival. 
Commoner for older pts than younger to ask Dr 
to decide for them. 
Say “well, what is right in the way of Rx for you 
depends to some extent on what’s important 
for you and what you would be most 
comfortable with. And since I’m not you, I can’t 
tell what that is, I need you to tell me”. Give 
time and usually will make a decision. 
S18 
Female 
High 
PET 
They know of people who were in hospital with 
a Mx and then had horrible emphysema. 
Previous experience of surgery. Experience of 
friends/relatives. A lot of pts when they come 
already know what they’ve got. Elderly pts are 
usually quite switched on. Often already made 
up their mind.  
Verbal info by her & BCN, also written info. 
Give them all the same info. As much as 
possible because I’d prefer them to be fully 
prepared. Pts need to be well informed to 
make a choice. Written info easier to 
understand and absorb than on a screen. BCN 
will then meet with them, usually at home, to 
go through everything again. BCN explains Rxs. 
Some women actually do want choice and they 
accept that they might actually have poorer 
survival. They want to prioritise QoL over 
quantity of life. Usually quite switched on. 
They’ve often already made up their mind. Not 
well informed but still a decision. Difficult to 
change their mind once they’ve got a set 
opinion. 
I weigh up all the info and then I feel it’s my 
duty to, that if they ask me to decide, to most 
strongly recommend the Rx which gives them 
the best survival, so if they’re fit for surgery, 
that would be surgery. Sometimes you're left 
with no choice because they insist that you 
make the choice - so fully inform them and 
document. 
S20. 
Male. 
High 
PET 
No comments. Gives verbal info, draws pictures, tailor 
according to their needs. Have to provide them 
with the info to allow them to make a decision. 
Face to face discussion is probably better than 
several booklets. Older pts require less info 
than younger pts. Depends which Rx: approach 
would be a bit different in terms of talking to 
them. BCNs give out written info. 
Require guidance... trust us... but once they’ve 
got the info, making a decision is not too 
difficult for them. QoL important, older pts 
don't view survival as important as younger pts. 
Some studies... indicate that older people... are 
more likely to listen to HCPs. They’re not that 
anxious, they’re realistic, so there is another 
myth out there that they can’t make their own 
judgement. Require less info, they are able to 
make a decision and stick to it, still require 
guidance. 
There is another myth out there that they can’t 
make their own judgement so therefore you 
make the decision for them. Sometimes 
happens. 
Talks about other people - if they believe that 
older pts can't make decisions then you get 
extreme situations where some people always 
operate and some always use PET. Depends on 
which Rx group they're in, 2 groups he has 
already decided so group in the middle - If 
there is a clear choice... I would try my best to 
stick with the concept of a choice. Would try 
and explore why she can't make the decision, 
what is important to her, that would probably 
tell me which decision is better for her. 
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S21 
Female 
High 
PET 
Majority make Rx decision before they come to 
clinic. Worried they have cancer before they've 
even had the biopsy. 
Re-caps important points: 1) lump is cancer, 2) 
these are the two Rx options. Lot of written 
info too. Gives everyone the same info. 
Depends how much they take in: after she 
heard the word cancer she never heard 
anything. Elderly pts: how much they retain is 
debateable. Play it by ear. Inconsistent. 
Majority made the decision before they come. 
Make up their minds quickly - Majority would 
be just say “yeah, give me the tablets or let me 
have the operation and let me get out of here”. 
If they ask me well what do I think, I will tell 
them... “You choose what is right for you, not 
what is right for me... or for anybody... It’s not 
about us it’s about you & what you want. This 
is the 1 time it is your decision.” Even if they 
say “Well what would you choose” I would say 
“I’m not sitting in that chair, & the tables are 
not turned, & I don’t know how I will choose if 
I was sitting where you’re sitting so it really is 
your choice”. Won't choose for dementia pts 
(unless ER-): we'll come to a decision as a 
group, not my decision. Gives them time. Tell 
pts they're not doing harm by choosing either 
Rx. 
S32 
Female 
High 
PET 
Over-estimate how frail they are. They 
remember people being in hospital for a week 
with Mx's. Surgery’s moved on but their 
perception hasn’t. Known somebody who’s had 
a bad experience. Previous experience if they 
have family members who’ve had surgery. 
It’s a little bit about starting to chat to the pt 
and get an idea of what I feel their... capacity to 
absorb info. 
Few pts who will say “well you decide for me 
Dr, you just tell me what to do”. “if it was your 
mum, what would you ask her to do or what 
would you tell her to do?”. 
You get... the few pts who will say “well you 
decide for me doctor, you just tell me what to 
do”. “if it was your mum, what would you ask 
her to do or what would you tell her to do?”. 
I find that very difficult... somebody who is 
clearly a high GA risk... I would say “well I feel 
that you have a good option in PET”, if they’re 
absolutely fine and well... I think you have to 
say to them, you know, “it’s a very personal 
choice and the standard thing to do would be 
to do surgery in somebody of your age… but it's 
really something that you need to think about". 
The other thing that we’ll sometimes do is you 
know, “why don’t we just put you on some PET, 
give you a little bit of time to think about what 
you want to do”. 
 554 
 
 
 
 
 
S33 
Female 
High 
PET 
Pt’s who’ve had other surgery it influences 
their decision. “Ooh I’ve not got too long to 
live”. 
Minimum you’ve got to discuss the diagnosis 
and the options available. Amount of info 
depends on partly how much they ask. “Do you 
want to have a drink instead” and take that, if 
they say “yes..." that’s the place to stop... non-
confrontation way of saying “have you had 
enough?”. 
Independence is what’s most important. Pt’s 
who’ve had other surgery it influences their 
decision. 
I think deciding for them is uncomfortable for 
me. I would normally sit with them and try and 
go through why they’re not keen on surgery 
and what the risks and benefits for them might 
be and try and bring them back with a 
member… someone else to support them, 
family or friend to talk it through and suggest 
that they meet some of our other ladies as well. 
if they’re not keen  (on surgery) at the start I 
would initially start them on endocrine therapy 
and keep discussing surgery with them because 
I think you’re not going to cause complications 
with PET. 
G16 
Male 
High 
PET 
“I’m not having an operation whatever you 
say”... they get the confidence that... they’re a 
bit fitter than they thought....  When people 
hold such strong, seemingly irrational, views it’s 
usually because of an experience. May have 
read something in the paper. Alternative 
sources to predict what dr is going to say, come 
with a view about what their diagnosis is and 
what the best Rx is. 
Benefits and the risks of each of those choices 
in a way that allows them to make an informed 
decision.  Talk you through the benefits and the 
risks of that and what else we could do. 
It always worries me when people say “Yes I’ll  
do anything you say, Doctor...”. Most pts have 
an expectation that their dr will suggest to 
them what the best Rx is. Look to professionals 
to help them make what is the best decision. 
Life experience or family experience... will 
impact on their DM. Lot of older people who 
will not question the dr, “you don’t ask the 
dr”... “you do what you’re told”. 
It always worries me when people say “Yes I’ll  
do anything you say, Doctor, I don’t want any 
explanation”. 
My approach is always “I hear what you’re 
saying; I will talk you through the options. Yes I 
will tell you what I think the most appropriate 
option will be, but I’m going to talk you through 
the benefits and the risks of that and what else 
we could do”. They probably don’t listen, I 
don’t know, they’re probably going to do what 
you say anyway.  
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N09 
Female 
High 
PET 
No comments. Risks and benefits of both Rx options. 
Overwhelm them. Check how pts feel with info 
and if they understand. What are you going to 
do with that info? Is it going to be a burden to 
you? Info on SEs. Amount dependent on 
clinician. Cloud people's judgement with too 
many options. Some say "I don't want a lot" but 
they're just frightened, others want everything 
& it scares them. 
Some women... actually want direction from 
the clinician. Didn't expect to be given Rx 
options... they are doctor-pt led and... do not 
want to be involved in the decision process. 
Some women may indicate that they actually 
don’t know how to make that decision. Some 
pts don't want a Rx but don't always voice it. 
Put pressure on themselves to make decision as 
don't want to burden their families. 
Some women that actually want direction, from 
the clinician. Didn't expect to have a choice, 
feel uncomfortable having to choose - do not 
want to be involved in the decision process. 
Some women may indicate that they actually 
don’t know how to make that decision. They 
are "doctor-patient led" - they are passive DM, 
prefer Dr to have a paternalistic style. 
Some clinicians will say “well, we’ll make that 
decision for you”. If don't want to be involved 
in DM: we accept that, and respect it too. Old 
school consultants more comfortable making 
decision for pts. 
N12 
Female 
High 
PET 
Sometimes pts have such fearful pre-conceived 
ideas about surgery that they make that 
decision not to have surgery. See themselves at 
the latter end of their lives... pre-conceived 
ideas about... women in their 80s shouldn't be 
having surgery. 
Important to inform pts that surgery is safe and 
the best option. Try to give the same info out 
whether a pts in their 20s or their 90s. 
Empower them with info. If not having surgery 
give them limited info. Older population I feel, 
don’t want info because don't want to make 
the decision. They don’t want to be 
empowered with info like the younger 
population. Give all the options and info for 
each.  
Older population, if a doctor says jump, the 
patient will respond and say how high? They 
want the surgeon... to tell them what is the 
best option, they don’t want to make 
decisions about their care. They will go with 
what the doctor says. They want the doctor to 
tell them what is best for them. The elderly... 
struggle with options for their Rx. 
No comments. 
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N13 
Female 
High 
PET 
The diagnosis is devastating irrespective of the 
fact that often they came with a lump and they 
almost assumed that it was (cancer). 
Written info about Rx and common SEs. Use 
info prescriptions:  routinely the same things 
for sort of surgery or primary endocrine. Go 
through potential major problems with that Rx, 
that sometimes has to do if that's all they want. 
Tell pts PET's not guaranteed effective. Time 
affects amount of info given by doctors, BCN go 
through more. Patient-dependent: give them 
what they want, when they want. 
Want you to make the decision for them. I’ll do 
what you think’s best. A lot of people want to 
please their families... with their decision. The 
older generation generally don’t want to put 
people out so that has a big impact on the DM. 
Inconsistent: Not many older people come 
knowing what Rx they want then: Some ladies 
know what they want... and they will only go 
with their own choice... sometimes you have to 
compromise and I think that's what we do a lot 
of the time. 
They almost want you to make the decision for 
them. We have quite a few... that say I’ll do 
what you think’s best. 
It’s hard because no matter what we feel is the 
best for someone, that’s our opinion. We 
always say “we can’t tell you what we thinks 
best... it’s whichever’s right for you” & we don’t 
know what’s right for them... you would hate 
to...  coerce them into something and then 
them come back & say “you told me I needed 
that” so you’ve got to be so careful, you can 
only give them the information you’ve got and 
say “based on what we know so far these are 
the genuinely choices”. 
N17 
Female 
High 
PET 
If I have an anaesthetic I'm going to die. Feel 
that they wouldn’t be able to cope with an op. 
Previous experience of major surgery. 
Philosophy of life as well, how they feel about 
their life. “I’m too old to have an op”. 
So much info they feel confident to make a 
decision.  Everybody gets the same. Take into 
account what they can understand and read. 
Involve family/ carers/ learning disabilities 
team. Info for different languages. Dementia 
pts have to assess what they can understand & 
remember. 
There are pts that can’t make a decision, don’t 
want to make a decision. Some have very fixed 
ideas: they still say “no, I don’t want to have an 
op”. Pts ask "what would you recommend?", 
"what would you do?". They don’t want to 
upset the balance... it’s about QoL not quantity. 
There are pts that can’t make a decision, don’t 
want to make a decision no matter how much, 
so you don’t want them to run away and not 
have any Rx. Quite often it can be about they’re 
just really unsure about what’s being said. 
You’ll say “there’s no ‘best’, it’s what’s safest” 
and that’s the route that we tend to go down. 
Talk about the pluses and minuses. You have to 
go back over it again and explore those issues. 
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N19 
Female 
High 
PET 
Pre-fixed idea of what can be done or can’t be 
done... “what’s the point of doing anything?”. 
Bad past experiences of somebody they've 
known. Think it's not worth Rx'ing because of 
their age. "I’m of a certain age, maybe there’s 
not a lot of point in doing something for 
me”...“is it worth doing anything?” because of 
the age I am. 
We (BCNs) go over the info and elaborate... 
explain more of the detail. 
For some people it is such a very difficult 
decision. They’re asking for guidance... as to 
really which one should they choose in view of 
the info that we know. It's quite difficult when 
people face that choice. “what would you do if 
it were me?”. Some take a tablet because it's 
easier but sometimes there's a sense of guilt, 
not being brave enough, feel they're letting 
themselves or their family down. Some people 
may come with a pre-fixed idea of what can be 
done or can’t be done, or might even think 
“what’s the point of doing anything?”.  
If somebody asks, as many people do, “what 
would you do if it were me?”, or “if it were your 
mum or grandma, what would you do?”. 
I feel, when somebody is given a diagnosis and 
given the options, for some people it is such a 
very difficult decision. I think when people ask 
that question, really they’re asking for 
guidance... as to really which one should they 
choose in view of the info that we know. I guess 
it's quite difficult when people face that choice 
(surgery vs. PET). 
I have known some people who say it’s difficult 
to know unless you’re in that position. I’ve 
known other people, perhaps even more 
helpful answer and actually answer it taking 
into consideration that person’s circumstances, 
which might then influence a decision. Thinks 
it's ok to advise "if I was in your situation" - if 
it's done in a measured way and with 
consideration of that person's circumstances. 
N22 
Female 
High 
PET 
Plant some seeds... so when they come back for 
the results, not many are totally knocked off 
their feet. Most have prepared themselves for 
the Dx. A lot of people have got internet access 
now... so they’re not surprised when we talk 
about surgery. Often they've heard you can just 
take a tablet. 
Written info: pack of info. Depends who's 
talking: Surgeons are pretty much... sing from 
the same hymn sheet regards the verbal info. 
Try not to flood them too much... can be 
overwhelmed.  
It’s QoL at the end of the day, and you see 
more of the importance of that really, quality 
rather than quantity sometimes. We do have 
occasionally ladies who go off to other 
countries for the odd spiritual need and 
sabbatical and they say ‘I’ll contact you when I 
get back’. 
If they're not sure they're given written info 
and BCN will be in touch and we'll discuss it. 
 558 
 
 
 
 
 
N31 
Female 
High 
PET 
They believe they’re not going to live, or a lot of 
them will say ‘I’ve got to die of something, 
duck’. Could just be a misunderstanding or 
what their mates told them.  
Give it them in bits... what is relevant at that 
time. Ask if they want leaflets: don’t just 
bombard them. Some ladies don’t want any 
(but husbands/sister will read them). Can't give 
the same info to all pts: Could offend 
somebody... just go with my intuition and 
asking the woman herself. 
What a Dr says is like God aren’t they, to a lot 
of older people. Get women saying ‘I can’t 
make a decision’ inconsistent: some are 
choosing surgery, some you cannot change. The 
surgeon encouraged her to have surgery... she 
went ‘I am not having-‘... some women you are 
not going to change.  
You still get women saying ‘I can’t make a 
decision’. 
They would say ‘I would rather do surgery’. If 
they were fit enough. We would rather take 
away the tumour and then treat with endocrine 
after. I’ll say ‘well, these are your options’. It’s a 
personal choice, we don’t know women well 
enough to help them make that decision. I’ll say 
‘all I can do is give you the facts and then for us 
to discuss it more’. 
N34 
Female 
High 
PET 
"I haven’t got much longer to live anyway” so 
of course the tablet will be fine. Perceive it as a 
big open wound that they’re going to be in for a 
week. Bad experience of a relative. Think it’s 
too big a thing to have done. They’re that old 
they’re not bothered about treating it at all... & 
feel too frail for it, the thought of having an 
op... is quite an enormity. 
Sometimes we will stagger that or it will be 
followed up. Need info about basic stuff. It’s 
too much to do it on the day, they’re too 
upset... so we would bring them back. It’s 
titrated to them. Our role is... info giving, 
understanding the info they’ve been given. 
Laying out the facts... this is the pathway of this 
option, this is the pathway of that way. 
Pts will regularly ask me what I would do. 
Perception that there’s a lesser choice. 
Generation that think the doctors know best... 
that’s a real struggle when you’re talking about 
a choice. People make decisions on their past 
experiences. Lonely place to make that 
decision. These ladies have been making 
decisions all their lives & actually their DMing 
skills are actually pretty good & you give the 
info & time & take the crisis element out of it & 
actually they’re very good at making decisions 
because they know what they want. They're 
pretty savvy. 
Pts will regularly ask me what I would do. 
Happens quite commonly. When you’re given 
choices, people have the perception that 
there’s a lesser choice. It’s a lifestyle choice at 
the end of the day it’s not a medical choice. 
We’ve done the medical choice. you’re still 
looking at a generation that think the doctors 
know best and sometimes that’s a real struggle 
when you’re talking about a choice.I quite 
honestly say I don’t know what I’d do until I 
was sat in that chair. It’s about laying out the 
facts. these are the pathways and we will 
support you to do whatever one’s right for you. 
It’s about... “tell me what the issue is for you 
here, what is it you’re feeling, what is it your 
concerned about?”. "You need to talk it 
through with the BCN but it’s important that 
you make the decision for you". Explains: 
you’ve got two very good options. Tell me what 
you want out of this Rx... one of these options 
will fit that very nicely. 
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S03 
Male  
Low 
PET 
No comments. Enough info to make informed decision. Need 
to be told that non-surgical management is 
sub-standard.  Advantages and the 
disadvantages, the risks and the benefits. 
Spend a good three quarters of an hour for 
every single such pt. Give full understanding of 
the clinical situation, progression of the 
disease, life-expectancy, the risks and benefits 
of each Rx. 
No comments. No comments. 
S24 
Male 
Low 
PET 
GPs still tell their pts if they’re elderly that they 
might just have tablets. Usually people who 
don’t really want an op that are saying “I’m not 
really fit enough”. 
Gives them the diagnosis, tells them what the 
options are and hands over the BCN. BCN gives 
all info: She's with me at the consultation so 
she goes through it in more detail. 
I could tell you the best way to treat your 
ingrowing toenail is to chop your head off and 
you know, if you’re an elderly lady you’d say 
fine - infers that elderly are passive DMers. QoL 
is very important. 
Never decides for pts (repeats this 3 times, 
feels very strongly) - I would say to them “go 
and talk to the Breast Care Nurse and have a 
think about it”. I never tell pts what I think they 
should have, because I could tell you the best 
way to treat your ingrowing toenail is to chop 
your head off and you know, if you’re an elderly 
lady you’d say fine.  
N11 
Female 
Low 
PET 
A lot of older women think BC is a disease of 
younger women. “am I too old to have 
surgery?”.  
Talk through practicalities. Asks if they like info. 
Tailor it, everybody's unique. Pts job can 
influence info-giving (teachers like info). “put 
their head in a sandpit”.  
Make sure understands, I often jump in with... 
and explanation of what's been said. 
Pts obviously listen to their Dr. Being a carer or 
animals or grandchildren at home can have a 
bearing on Rx decision. Elderly pts less likely to 
question as much as younger, do less of their 
own research. 
No comments. 
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N23 
Female 
Low 
PET 
They’re already old and they fear that it might 
just be the thing that tips the balance for them. 
The way people perceive themselves to be old 
is changed. “I thought I was too old to get 
cancer”. 
Prepare pts for surgery. Dr will say so much to 
the pt and then “[name] will go into a bit more 
detail about that”, “[name] will cover that”, so 
he sort of passes it on to me.  
“what do you think, Dr?”. A lot of people 
struggle when they’re being given a choice...  
they say "what do you think I should do?". 
Want the advice... to be told what to do, but 
they still want the info to know that they’re 
being given the choices. “you’re the expert, you 
should be telling me what I should have done”. 
Used to be 100% in elderly because they 
revered drs but that's gone now. Want to feel 
involved, but they don’t want that decision... 
because they’re too frightened of making the 
wrong decision. There’s the DMers in life that 
want to gather info... and there’s people that 
will never make a decision no matter what info 
you give them. 
Still high numbers of pts that say “what do you 
think, Doctor?”. I see a lot of people struggle 
when they’re being given a choice... and that's 
when at the end of the day they say "what do 
you think I should do?". You also get... people 
that want all the info but they still want the 
advice, they still want to be told what to do, 
but they still want the info to know that they’re 
being given the choices. I think it’s a lot of 
confidence in people now saying “you’re the 
expert, you should be telling me what I should 
have done”. Used to be 100% in elderly 
because they revered doctors but that's gone 
now. 
I always put it back to them... “it’s your 
decision, at the end of the day... by giving you a 
choice, one Rx is as good as the other”... then 
at least they know that they’re not going to 
make a wrong decision. I emphasise... there’s 
no right or wrong answer. So it’s what you 
think is best for you.  
S04 
Male  
Low 
PET 
A lot of women in that age group have their 
own opinions and they can't be changed. 
Enough info so that I’m satisfied that they have 
the minimum amount of info, and beyond that 
as much info as they want. Clinician's 
judgement how much info pt needs. I don’t feel 
the need to offload my info onto the pt.  
Doesn't really comment as he selects the Rx 
and doesn't offer choice. 
Doesn't offer a choice so no comments. 
S05 
Male  
Low 
PET 
You do have some people with strong opinions.  Give info about what the surgery entails, 
importance of optimisation, risks of Rx, or what 
PET entails. 
Pts will go with what the surgeon advises: if I 
want to take them down the endocrine route 
only then they'd go with it or if I said you need 
to have surgery, then they'd go with that. Sees 
them as passive DMers, easy to lead. 
Doesn't offer a choice of the two treatments so 
no comments. 
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S25 
Female 
Low 
PET 
I think they’ve made up their minds 
beforehand. Previous experience, them or 
family - don't want to go through all of that.  
Can’t give everyone the same standard info. 
Pt's intellect, how much they're absorbing. If 
they want info we always give it to them, if 
they don't want info we still give it to them but 
might cut it back a little bit... you can't force it 
on them. 
Go with the clinician’s recommendation. Pts 
can accept Rx risk (may go against advice): as 
long as the pt says "...I’ll take the risk...”. You 
tell them “well I think this is the best thing for 
you” they will do it. “oh, you’re the expert, I 
trust you, I put myself in your hands, you do 
what you think is best”. Independence is 
important to older pts.  A lot of these older pts 
they would rather die of the cancer than lose 
that independence & end up in a home. 
Is happy to decide in a borderline case e.g. Mx 
vs. WLE will choose Mx. 
S26 
Male  
Low 
PET 
The ones who make up their mind the same 
day tend to be the ones who know it's cancer. 
People out there they think that surgery’s evil, 
there are people isn’t it who say “don’t go to 
surgeons”.  
Surgeon can only do so much info-giving. 
Specialist nurse then gives info and explains a 
bit more. 
“what would you do Dr, what is your advice?”. 
The ones who make up their mind the same 
day tend to be the ones who know it's cancer, 
their decisions are a bit more easier. Some pts 
merely say “no, I don’t want that”. They take 
the choice and say “doctor, would you mind if I 
just take on to this and I don’t want surgery”. 
They kind of ask you that question don’t they 
“what would you do doctor, what is your 
advice?”. 
If I honestly feel that surgery’s the right thing, 
and if it is my mother and that’s what I want for 
my mum, I tell them , I don’t hesitate.  
S28 
Female 
Low 
PET 
Surgery’s viewed as a big thing.  This is a group where we do weigh and give the 
info because often they don’t have enough 
social support or access to the internet or the 
ability to read the info.  
They know if they’re not fit, that it doesn’t 
make sense to tip the balance of their life. They 
feel that they are at that part of life where 
what are they going to gain by chopping parts 
of the body.  
Generally speaking I tend to make the pts 
decide... encourage them to discuss it with the 
family members... BCN… they can often tease 
their worries and their issues that is stopping 
them making the decision. Give them time. I 
don’t tend to decide for them. 
S29 
Female 
Low 
PET 
Think they're too old to be offered surgery, as if 
they don’t feel they’re worth treating. GP may 
have said “I think this is cancer, but don’t 
worry, they’ll just give you a tablet”. Bad 
experiences of RTx... some elderly pts have very 
very strong views that they don’t want RTx. 
Widespread perception amongst the elderly 
that because we stop breast screening, it 
means they are no longer at risk. 
Have written standard info. Have to make a 
pretty immediate judgement really, there and 
then in the clinic as to whether you feel it’s 
appropriate for them to have that info or 
whether you think it might be scary. 
If they can’t make up their mind. This age group 
will be more likely to take on board what a 
consultant says simply because they’re a 
consultant... less likely to be influenced by the 
media and by the internet... more influenced by 
what their relatives feel and wanting to do 
what they think their family wants them to do.  
I think I’ve already told them what I think is the 
optimal Rx, which is surgery... I think if they 
can’t make up their mind then I think then they 
should have time to think about it...  I would 
probably rather they had a trial of endocrine 
treatment just to see whether or not they got a 
response. Rather than potentially twisting their 
arm to have an operation, in case anything 
happened. 
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N06 
Female 
Low 
PET 
No comments. Bombard pts with a bit too much info. Standard 
written info about all the Rxs, even if not 
relevant: opens their eyes to what the other 
options are. May seek further info to help DM. 
BCN gives extra info if feels something has been 
missed: there’s times where we might say “well 
actually, I might have thought about that”. 
Some pts just don't want to read it, they're a bit 
panicked. 
Pts may challenge Rx recommendation of MDT. 
Pts may seek for more info on options & DM 
based on written information given. They don't 
want to know… they just go based on what we 
tell them - passive DMers because they're 
frightened?  
No comments. 
N27 
Female 
Low 
PET 
No comments. Standard pack of written info. Ask if like to 
have lots of info. If there’s younger women you 
would look at sexuality, in older women you 
would try and give them the menopausal 
things. It is about informed consent, it is about 
giving them info. 
They want to actually put the onus back on us 
to make the decision for them. They listen 
actually and they’re much more compliant 
sometimes than our younger ladies.  
They want to actually put the onus back on us 
to make the decision for them. 
We actually say ‘no, the onus isn’t with us, we 
can give you the info but we come to a decision 
as a joint between you and us or the team’. No, 
it’s pt choice we can’t have somebody coming 
back and saying ‘You told me’ or ‘you said I 
should’.  
N30 
Female 
Low 
PET 
Large proportion of pts that come with 
predetermined ideas. ‘I would like to have this, 
my GP says I can have tablets’. A lot of people 
say ‘but I am 86’ or ‘I am so-and-so’ as though 
that’s a barrier to them having Rx.  
Enough info, the right info, and time to 
consider that info. Standard pack of written 
info + verbal. It’s exploring what’s right for the 
individual isn’t it... sufficient info so that they 
can, in their own time when the shock lessens, 
consider things and perhaps then come back 
and say ‘I’ve read this but what about for me?' 
because they can't all take it in at that time. 
Some people have defined or definite ideas on 
what’s right for them. Pts come with 
predetermined ideas. If they know there is a 
choice, they come and say ‘I would like to have 
this, my GP says I can have tablets’. 
They’re given the pros and cons of both aspects 
and I think it’s true to be said, if someone is 
struggling to make a decision then they’re 
encouraged more so to do what feels right for 
them. Generally speaking, most people are 
guided but they’re not told what to do. 
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Appendix 16: Sample interview transcripts 
Interview S01, on 29th January 2013. 
Jenna 
Morgan 
(J) 
I guess the first thing I should ask you is what treatment options you’d normally consider 
for a woman that presents over 70 with operable breast cancer – what would you, what 
would the options be for treatment? 
S01 OK, well firstly I think one has to try and treat them as well as you would treat a woman of 
any age. And make sure the treatment is adequate to deal with her cancer but also takes 
in to consideration her ability to tolerate the treatment. And that can sometimes be very 
straightforward because a woman of 70 may be as fit as a fiddle and need normal 
treatment as per the protocol for a woman of any age. It obviously has to take in to 
account her fitness for surgery, not necessarily surgery under general anaesthesia, fitness 
for chemotherapy, Herceptin and radiotherapy, and the appropriateness of those 
treatments…. It also has to take into account her preferences, which you know, she might 
be completely happy to have standard treatment but she may have things that she’s not 
prepared to consider. So I think, you would ideally like to treat every woman in the most 
aggressive way that you possibly can, that she can tolerate. But you also have to recognise 
that for someone who is very frail, that treating her with, you know, full mastectomy, 
axillary node clearance, chemotherapy, etc, etc, may be more treatment than she actually 
needs. And if she’s going to die in the very near future from her pre-existing lung cancer, 
or you know, the fact that she’s got COPD and is forever in and out of hospital with 
pneumonia then you’re not doing her any favours by treating her with that degree of 
aggression. So, unfortunately there are no hard and fast rules; there is no manual that 
says “if a person has this, then you shouldn’t offer her chemotherapy”. It’s very much left 
in the domain of the physician’s assessment of likely outcomes, and it’s a very 
heterogeneous population, and very much where the art of surgery comes in to play. The 
art of medicine, rather than the protocol-driven, “this is the best research-driven, level 
one quality evidence”, “This is what you do when you’ve got this”. 
J So going on from that, we’ve talked about the normal what you would like to treat 
women under 70. Would you consider primary endocrine therapy for any patients or all 
patients? Is it something you would consider for everyone in this age group? 
S01 Primary endocrine therapy obviously is only appropriate for someone who has got an 
oestrogen-sensitive tumour, so that automatically rules out about 15 or 20% of the 
population in this age group. I think it’s something that should be reserved for people 
who will struggle to get through standard treatment. 
J Right. 
S01 So if you’ve got someone who is clearly fit enough to have an operation then you should 
offer them an operation, and that doesn’t necessarily just mean an operation under 
general anaesthetic. We know that primary endocrine therapy will control breast cancer 
for an average of 2-3 years. Some women that will be 10 years, some women it will be a 
year. And if that woman goes on to live for more years than that then you’ve got to 
change management. So I think, yes, I do consider it for women in this age group, but I try 
to base that decision on whether or not they will tolerate an operation, and also whether 
they want an operation. So there will be a group of women where, yes, they might 
tolerate the operation, they might have major problems or complications and the risks of 
surgery may be higher than they would be on average – and for those women you may 
want to offer them a choice of treatments. And then there will be other women who are 
clearly not fit for a haircut in whom you just say “I’m sorry, I don’t think you’ll get through 
an operation and I think we just need to treat you with tablets”. So if you like, there are 
three categories, there’s women who you are not even going to talk about PET to because 
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clearly they need an operation, it’s the best thing for them, and you shouldn’t really be 
messing around with anything less than that. Women who are borderline could be offered 
a choice and women who are clearly not fit for any form surgery who you should just offer 
primary endocrine therapy. 
J Are there any other factors that you would think about that influence your decision. So 
we’ve talked about their level of fitness and their preference, and the ER status. Is there 
any other patient or relative factors maybe? 
S01 I think patient views obviously have the primacy. Relative views become important if 
you’ve got a patient who’s perhaps either not willing or not able to make the decision 
herself. So some women really don’t want to make that decision, they think it’s the sort of 
thing that a doctor should do, or they want to defer the decision to their relatives, carers, 
whatever, and they‘re quite passive and don’t really want to get involved in thinking 
about things. Other women aren’t capable of making the decision because they don’t 
have the cognitive capacity to retain enough information to be able to make an informed 
decision. They may have a preference, even though they can’t balance or weigh up the 
pros and cons, and you have to respect that. So you might get someone who, perhaps has 
got not such a good memory and can’t really weigh things up but who says “oh, I don’t 
want an operation” and again you can’t ignore those views, even if you think that that’s 
perhaps not the right thing for them. Other things would be, say, the Herceptin receptor 
status. We know that Herceptin sensitive cancers are less likely to have a durable and 
good quality response to anti-oestrogens, although some of them do. The type of tumour, 
mucinous tumours, whilst they are generally quite indolent and usually oestrogen-
sensitive, don’t usually get smaller on anti-oestrogens because it doesn’t get rid of the 
mucin and they just sit there and are static response and so people sometimes feel or 
perceive that they haven’t responded as well even though they have been inactivated 
they may not disappear which for some women might freak them out a little bit. 
Then you may have tumours where, say for example, they’re locally advanced, and an 
operation might ulcerate and be painful and if they are on board that might be a better 
way of getting symptomatic control. And for some ladies surgery may be, if it’s the sort of 
surgery where they need a mastectomy rather than a lumpectomy, you might be inclined 
to say well she’d probably be able to cope with a wide local for a small tumour under local 
but you wouldn’t be able to do a mastectomy under local, or doing a mastectomy - I don’t 
know if you’ve ever done any – trying to do a mastectomy under local on a large breasted 
woman is not a nice thing to do to someone. 
J No I can imagine. 
S01 The other thing is your anaesthetist because some anaesthetists are happy to put in 
epidurals and intra-pleural blocks and those kind of regional techniques which will permit 
you to do full surgery in an awake patient. Another anaesthetist not familiar with that 
won’t do that sort of thing or aren’t very good at doing it and also different anaesthetist 
have different thresholds for who’s fit for a GA, some of them will anaesthetise anything 
that’s breathing whereas others will send the patient home because they’ve got some 
minor problem with their blood pressure and “ooh no, not fit for surgery!”. So, I mean 
usually most surgeons, I think, will be used to working with their anaesthetist and will 
know where their thresholds sort of lie. But obviously it’s very much a team effort. 
The other thing would be breast care nursing, sometimes breast care nurses can be a little 
bit protective and maybe do have an influence on what women want and that may not be 
something that’s said when the surgeon is there but when the surgeon goes out of the 
room the decision-making happens in consultation with the relatives and the breast care 
nurses and the patient. And the BCN may impose their views somewhat and maybe “do 
you really want an operation” or the reverse “you should really have an operation”. So I 
think they do have a very important role to play and if they have a particular view what 
might be best for that particular woman then that can have an influence. 
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J What are your feelings on formalised assessments; so anaesthetic assessments or these 
Geriatric Comorbidity Scores? 
S01 If I’ve got someone where I’m not sure about the risks of surgery for them, and these 
would be a lot of the people who would be in the borderline group, then I think having a 
formalised anaesthetic assess is very useful. Not necessarily using geriatricians to get 
involved but if they’ve got a treatable co-morbidity, for example if they’ve got 
uncontrolled hypertension then going along and seeing a physician to get that under 
control. If they’ve got badly controlled cardiac problems, say AF or something like that, 
then again that could be improved which could make surgery safer. We have a system 
here where they go pre-op assess and an anaesthetist will review them and flag up any 
issues and then refer them on for medical management and optimisation. And I think 
sometimes it’s clear, you know, if you’ve got a very frail lady who’s in a nursing home 
who’s slightly demented, it’s going to be fairly obvious, I think that that sort of person is 
probably better off with tablets. If you’ve got someone, who say, gets a bit of 
breathlessness going up stairs, gets chest pains doing certain activities you might want to 
have an anaesthetic assessment: “what is the risk” – let’s put the actual risk of an 
anaesthetic into the mix. 
J Before you make that decision? 
S01 Yes. And so you have several consultations with them “OK, the anaesthetist says your risk 
of surviving an anaesthetic or not surviving the anaesthetic is 10%, your risk of surviving 
going on tablets is 100% but it may not work for very many years. So you’ve got to 
balance the immediate risks of an operation with the long to medium term risks of 
primary endocrine therapy not working for you”, and you then have another discussion 
about it. 
J So it’s sort of about providing all the information to make a balanced decision between 
you and the patient. 
S01 And sometimes going down that route. They may not want to go down that route 
because they may say “well actually I’d rather just try the tablets” and that’s the other 
thing, there’s no harm in most of them in starting them on the tablets and giving them 
some time to think. And see whether the tablets work, how they feel with the fact that 
they may have a tumour that’s still palpable. Some women might find that a little 
disturbing, although from previous studies that we’ve done most women actually if the 
tumour is shrinking, found that very reassuring because they knew that the tablets were 
continuing to work. So you give them a trial of endocrine therapy and if it’s not really 
working very well, say bring them back in 3-6 months and reassess, and then go down the 
road of anaesthetic assessment at that point. So, lots of different ways of doing it. 
J Specifically to surgery and PET, what do you feel are the risks and benefits balanced up 
against each other? 
S01 Well the risks of surgery are all the risks of surgery; the anaesthetic risks, pain, discomfort, 
hospitalisation – the fact that a woman who is brought into hospital out of their normal 
environment, which can result sometimes in a loss of function, which can last for quite 
some time. They often drop a level of functionality after an anaesthetic because it kills a 
few neurons. And there’s a recognised thing that happens in older people where they can 
have a long term period of being knocked off after an anaesthetic, I’ve forgotten what it’s 
called now, but they will often lose functionality after a hospital stay, they can become 
confused.  The risks of surgery in terms of pain, disfigurement, lymphoedema, mutilation, 
haematoma, bleeding, blah-blah – the list goes on. Balanced against that, it’s very good 
for treating the cancer in terms of local control. You have to also remember that the 
metastatic disease control is the same in both groups because they’ll both be getting anti-
oestrogens. 
J Yes. 
S01 So really what the surgery gives you is enhanced local control. The studies that have been 
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done, the RCTs that have been done, they show that local control is inferior with PET but 
metastatic control is the same because they’ve had the same level and so long as you’re 
following the PET patients up and as soon as the disease starts to progress, you cut-and-
run type of thing, then there shouldn’t be any difference in mortality and if there is it’s 
probably, I think with the RCTs that they did the difference in mortality was probably the 
patients who had ER negative tumours who’d been included inappropriately because they 
didn’t test in most of the RCTs – so they were effectively a delayed treatment arm and 
nothing else because they were effectively going on placebo… 
J Not getting treated… 
S01 So it’s very difficult because you can’t go back and re-test those patients in the trials to 
take out the ER negative group. But the percentage difference in mortality was such that 
it could have been completely accounted for by the ER negatives included in the 
endocrine arm and so in terms of if you had a properly selected cohort, then I suspect the 
mortality between the groups would be identical and its purely an issue of local control. 
So you’ve got the upfront risks of the surgical route, side effects of surgery, pain, 
disfigurement, blah-blah and the certainty of local control. On the PET arm you’ve got 
none of that but you’ve got the uncertainty of local control and you know that about 1/3 
of them will need a change of management and that’s in the trails, but they weren’t very 
well selected. So I suspect if you selected them better for a frailer cohort than was 
included in the trials you would have potentially a much higher local control rate, much 
more similar to the surgical arm. Bearing in mind that in the surgical arm, even if you do a 
mastectomy, you would have a 10% recurrence rate at 20 years – 10% at 20 years 
following mastectomy – so if you’ve got a 30% failure of local control in the PET arm but 
10-15% of them had ER negative tumours and therefore were on no treatment it’s not 
much different in local control really. 
J So by that logic then, just out of interest, had they selected better for the ER positive 
patients particularly in the PET arm, do you not think that actually the overall survival 
might have be higher in the PET arm because you’ve got the complications of surgery. 
S01 Might have been because some of them might have died as a result of surgery, but I don’t 
think that any of the studies actually had any immediate deaths. Breast surgery is very 
safe and I think the reported mortality overall from the national mastectomy and 
reconstruction audit is something like 1 in 1000. 
J So very low. 
S01 Very, very low with modern anaesthetics and I think if you look at older studies doing 
mastectomies and clearances it was sort of 1%. So it’s a very low mortality but it may be 
higher if you look at a subgroup who are elderly and frail but don’t think we have that 
data but I did a review of surgical studies from a few years ago in older women and even 
in older women it was low. But it’s not so much about the mortality of surgery it’s the 
morbidity of surgery. 
J Just a quick question, do things like cost and targets influence your choice of management 
at all…? 
S01 No. 
J Not at all? 
S01 No. I don’t think they do for many clinicians, or any clinicians to be honest. I think you try 
to do what’s best for the patient. Targets will influence us in terms of the quickness of 
getting them in… 
J But not that actual treatment they receive… 
S01 But not the actual treatment decision. Costs again, never… it never enters my head to 
think about the costs. 
J Ok. 
S01 Other than a sly smile to think “this is expensive, snigger, snigger”. Sorry. 
J What sort of factors influence your strategy or have evolved your strategy – is it a mixture 
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of things like evidence base or personal experience, or – what sort have factors have 
culminated? 
S01 Well in my case it’s evidence based because I’ve read most of the papers on this subject… 
J Indeed. Written some of them too… 
S01 Yes. But I think it is partly experience as well and I think – the whole reason I got 
interested in this was because one of my colleagues used to put everyone on PET if they 
were over 70 and I just used to get fed up with seeing them come back with failed local 
control and then having to go for an operation, you know, several years down the line. 
J And then of course they’re much older and frailer at that point… 
S01 When they’re older and frailer. And that made me aware of the fact that this over 70s 
policy that was prevalent around 20 years ago was just rubbish. You know, it’s just not a 
good way of doing it. Because it makes the surgery more difficult technical and less 
pleasant if they have to have a local anaesthetic operation when five years earlier they 
could have had a GA operation. And so that personal experience of seeing how it can be 
inappropriately employed was quite influential for me. And I guess you have a few 
patients where you see an old lady who is frail who is inappropriately had a major 
complication – I had one lady who had a stroke following breast surgery. She’d not been 
one that we’d considered for primary endocrine therapy and there were no risk factors or 
red flags but you suddenly realise that actually this kind of surgery can have major 
complications. I’ve also had a lady who had surgery as her choice and ended up having a 
significant hypotensive episode because she had post-operative bleed. She didn’t die, but 
she might have done. 
J Yes. 
S01 So you realise that surgery has risks that can potentially be sometimes better avoided, 
and you realise that PET when inappropriately used can just delay problems. And I’ve had 
one or two patients where there has been failure of local control because they’ve been 
pretty frail and rubbish and you think they’d never get through an operation in a million 
years. And so you put them on PET and then they don’t die of something else. 
J They don’t act the way you expect them to. 
S01 You think “How can they possibly be alive?” And they keep coming back and then you’re 
into palliative radiotherapy and all the hassle that that has because you’ve run out of 
endocrine therapies. So I suppose I’ve been around for long enough now that I’ve seen a 
few where we have lost local control and I’ve seen a few where we’ve had some major 
complications of surgery and so you see both ends of the inappropriate spectrum. 
J What about the amount of information you would give to a patient or relative – would 
that again be based on the patient or. 
S01 Yeah, I think the right answer there is as much as they want. And if that means you sitting 
down and talking to them several times over several hours and talking to the relatives and 
going over it all again when they’ve had a chance to think about it then that’s what you 
give them. And if they just want “no doctor, you decide what’s best for me, I don’t know, 
I’m not the expert” I mean I’ve had that said to me many times. And in that situation you 
say “Well I’ll tell you a little bit and let you have a little think about it and then if you want 
me to decide then I’ll decide for you.”  So you try to give them information but you 
obviously have to be guided by them. 
J And what do you think the patients sort of feel about either treatment, what do you think 
their main concerns tend to be? 
S01 I think by and large, they both tend to be very well tolerated. Most of them are pleasantly 
surprised by breast surgery because usually it’s better than they thought it was going to 
be. You’ll have a few who have significant side effects who struggle with them – so I’ve 
had one lady who had lymphoedema after surgery and said “well if I’d known this was 
going to happen I wouldn’t have let you do the operation” 
J Sure, and hindsight being a wonderful thing. 
 568 
 
 
 
 
 
S01 Hindsight being a wonderful thing. And they all think that PET is great because it’s the no 
risk scenario in some respects, certainly to start with. And you know, we’ve done some 
research on it and the opinion is that both of them are good options for those where it 
goes well. 
J Yes, right. The appropriately selected patients. 
S01 Yes, that’s right. 
J Good. Well I’ve asked my main questions. Are they any sort of bits and pieces that you’d 
like to put forward about either treatments or treatment in general of older ladies with 
operable breast cancer? 
S01 No. I think older ladies are changing though. I mean, when I was a newly qualified doctor, 
there was generally the view that anyone over 70 was too old to have anything. And I 
remember women of 70 coming in and having palliative treatments for cancers, like 
ethanol injections – rectal cancers, not breast cancer. And that was normal, you just 
wouldn’t consider them unless it was, well desperation I suppose. But you know, 
nowadays 70 is not regarded as old. 
J So the definition of old is changing, and broadening perhaps? 
S01 I think the definition of old is changing. Yes, and so I think what used to be “70 is old” is 
now become “80 is old” and things have by-and-large moved with that. I mean my step-
mother is 71 and she lives a completely full and active life, drives a car, drives to see 
friends down in Cornwall, you know, just does all the things a normal woman would. And 
you wouldn’t think she was 70 and I would be horrified to think that anyone wouldn’t 
treat her properly for cancer if she got it because she’s as fit as a fiddle. And then I’ve got 
my husband’s father who’s in his mid-80s and is frankly, I wouldn’t touch him with a 
bargepole for anything because he’s so unfit. So I think things have changed – they’ve 
moved up by about 10 years in the 20 years I’ve been practicing and I suspect they’ll 
continue to shift and we’ve got to keep moving the goalposts to match up with it. 
J So do you think that this research that we do now will be still relevant in a few years’ 
time. 
S01 No, it will probably need to be continually revised every 10 years just to see where the 
cut-offs are. Although I think in terms of age they need to be modified but if we look at 
things in terms of the biology and fitness, and study that properly we won’t need to take 
age into account. Then we can just base it on somebody’s biological fitness rather than 
their chronological age, which is what we should be doing now. 
J Do you think it would be useful to have a protocol, if you like, or a tool that would allow 
you to put these things in to help you to decide? 
S01 I think it would, I think it would give useful guidance because I think everyone’s got 
different thresholds for what is and isn’t appropriate at different ages. So I think having a 
bit more formal guidance and maybe some screening tests that are fairly easy to use – 
that give you a good- and I think the things that come out will be the functional 
assessments, rather than disease-related, it will be “are you living independently”, “can 
you wash”, “can you dress”, you know, something like the IDL and the ADL and I think you 
could do a very rapid screen on that and if you can live independently you should 
probably be having normal treatment and if you are not living independently then you 
should be considered for something else. And they’re fairly quick assessments because 
they’re only about 7 or 8 questions, very, very quick to do and I think that’s probably one 
of the key things that will come out of this is to whether or not they’re robust enough to 
use in normal practice, sensitive enough to make the right decision most of the time. 
J Do you think it’s important to try and standardise it or is it less about standardising and 
more about…? 
S01 I think in terms of standardisation of practice, the patients are the variable, the clinicians 
should be doing what’s best for the patient – and that should vary between surgeons. So 
yes, there should be a tool that’s based on the characteristics of the patient not the 
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preference of the surgeon, and at the moment everything’s based on the preference or 
the opinion of the surgeon as to their fitness and there’s no guidance and everyone’s got 
different thresholds and that means that people haven’t got a clue what they’re doing. 
J Well, that’s what we hope to investigate a little bit more here. 
S01 Yes. 
J Well I don’t think I’ve got any more questions. 
S01 No I think that’s fine. 
J Well thank you. 
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Interview N34, on 5th November 2013. 
Jenna 
Morgan 
(J) 
So this is Jenna Morgan interviewing N34 at “PLACE” on the 5
th
 of November. So, N34, if I 
could just get you to tell me a little bit about you, your role, how long you’ve been 
practicing and that sort of thing. 
N34 Right, well I’m one of the breast care nurses, so really our role is to support patients, as 
they need, both emotionally and physically through all of their treatment and we don’t 
disappear afterwards either, so it may be patient advocate, information giving, 
understanding the information they’ve been given, clarifying that maybe down the line 
they might come back and talk to us after they’ve seen the doctor. And ensuring they’ve 
got information they need they’re having surgery so they’re well prepared and supported 
them afterwards as well. I’ve been working 25 years probably about, I started as a ward 
nurse looking after breast patients among others and I worked my way up to being the 
ward sister so I’ve dealt with inpatient breast care for many years and I’ve done this role 
for about 5 or 6 years now. 
J Ok, and in this unit, how… what… let me just start by saying we’re talking about older 
women, so we’ve got a general cut-off of over 70 but appreciate that older patients vary 
greatly, and we’re talking about primary operable breast cancer. So when we have a 
patient presenting to this unit and they are elderly and they present with primary operable 
breast cancer, what treatment options are they usually offered here? 
N34 Well I would say, well what do you call as elderly really I suppose, I think any lady who’s fit 
for surgery is initially offered surgery in the fact we look at age more medically than 
actually years if that makes sense? But there are some ladies who perhaps have a problem 
with surgery and then they can be offered sometimes oestrogen tablets, you know, 
hormone-based treatment. But that’s very much for them to think about and they’re given 
all the information and for us it’s to make sure they’ve got that accurate information, to be 
able to make the decision that they need to. But I think also, often when you’re talking 
about surgery, what they’re perception of surgery is, is very different to how it actually is. 
They sort of perceive it as a big open wound that they’re going to be in for a week, and you 
know, just because someone’s 70-, I’ve got several 70 year olds that have had 
mastectomies as day cases because they’re more than fit for it and when you actually give 
them the information that they actually need and sometimes talk to someone else who’s 
had surgery they can view things very differently. So again it’s for us about seeing, they 
might be saying no I don’t want surgery but very much for us it’s about well, what are the 
issues about that, what’s right for you. So for me it’s about finding, giving that information 
to the patient to make the right decision for them and it could be sometimes we use the 
hormone treatment so they can go on it initially to give them time to maybe have an 
anaesthetic assessment, or time to find out the information they need to decide what they 
want to do. And so, you know it’s even though they might go on one treatment, it’s not the 
be all and end all. So yes, they can be offered a variety but generally if they’re fit for 
surgery, that’s what they’re offered. 
J Ok, are they offered a choice as well? Is primary endocrine therapy presented as an 
alternative? 
N34 Right then primary endocrine? Yes, as rule I mean basically, well yes because what we’d do, 
I think what – we tend to explain the difference. If having a cure, a potential cure is what 
they want then that’s potentially what surgery will give them. But if they have the hormone 
treatment, it will never take it away but it could keep it under control for as long as they 
need. But they need to realise it’s a cyclic treatment, and then the options could be that if 
they don’t get a good response, then we might be saying “well, our best option now is 
surgery but you could be a lot older”. So, yes, they’re often given, I mean if someone’s very 
keen for surgery, I mean ladies will often come in, know what they want so if they’re keen 
for surgery then that’s what they would have as a rule. 
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J Yes, ok. What sort of factors, like patient factors, or you know, might prevent or might 
mean that they don’t get offered surgery as sort of the first choice? 
N34 Medical fitness, fitness for surgery at the end of the day. If they’re not well enough, you’re 
going to kill them on the table, then there’s no benefit giving them surgery. I think that 
would be the single most important thing. But if a patient really doesn’t want it then 
another option, and you know, you might think just because someone’s 75, the thought of 
having a mastectomy doesn’t bother them but there’s some ladies where having the 
cancer isn’t the issue, it’s having a mastectomy because there’s some very glamorous 75 
year olds. 
J There are. 
N34 And you know, if they really, really don’t want it and they’re saying “I really don’t want this 
surgery” there’s another option. But as long as they realise, you know, the restrictions of 
each then that might be another option to do it. 
J What about things like dementia, does that come into it? 
N34 It does, but then again, I’ve had the situation with a GP where we can’t even get her to 
clinic. 
J Right. 
N34 And I’ve just had to advise her, I’ve gone through the consultant today and I’ve just rung 
them back and said, you know, she’s going to start her on Letrozole as an option because 
she will comply to that. As she’ll know, with a breast lump at 87, she’s probably going to 
have an ER sensitive tumour. 
J Yes the likelihood is. 
N34 So they’re going to treat her as opposed to doing nothing. And then I have had problems 
with dementia patients that won’t even comply for having the biopsy and then I can think 
of one patient off the top of my head this year I think, or maybe the end of last year, where 
because she wouldn’t have a biopsy, I mean it would have been difficult, it would have 
been dangerous to do the biopsy, she would have fought, we couldn’t have got informed 
consent, that we took the risk and we started her on a tablet and she’s still tolerating that 
really well. 
J Good. 
N34 So it gives you another option when they can’t always comply or understand but on the 
other hand I have had ladies who had mastectomies and actually have come with 
daughters who have very fixed ideas about what they should be having, but actually can 
take that information in and the daughters saying, “look she demented she can’t have any 
surgery” but then when we spoke to her she said “I actually do want to get rid of this, I 
need to get rid of it” and we brought her back again, I think a week later, and she could still 
remember the conversation and so she’s had surgery. 
J Very mild dementia. 
N34 I think the daughter was quite miffed, but actually it was right for her and at the end of the 
day I’m here for patients to advocate, to make sure they get the right decision for them 
and they understand that and make sure it’s a safe decision. 
J Yes. Ok. What do you think are the risks and benefits of surgery in this sort of, let’s talk 
about the older, less fit patients? 
N34 Well, I guess it depends if they’ve have a breast cancer that’s quite under the skin that 
potentially they don’t have surgery or hormone tablets don’t actually control it, they could 
end up with an ulcerated, quite unpleasant malodorous wound, which actually can be quite 
unpleasant for someone to have to manage. So it could be that actually for them the 
option that is the mastectomy is a far better option. Obviously the side effects and 
potential effects of anaesthetic but these days you’d hope generally if they’ve had a good 
anaesthetic assessment they’re fit for it but there’s always a risk with anaesthetic but 
ultimately I think the fact that women have choice is very significant because there’s a lot 
of evidence now that women are involved in the choice of their treatment they will cope 
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and live with it better. And I think it comes down to at the end of the day if it’s important 
for them to get rid of that cancer, and for some ladies it’s very important that actually 
they’re rid of it. Just because they’re eighty something doesn’t mean they feel any different 
to people who are younger and so it’s about making sure that patient’s able to give an 
informed choice and they are able to live with a choice that they feel is livable with. So 
there could be emotional impacts if you’re not going to give treatment and I’ve got ladies 
that can’t have treatment and have not been able to and are really struggling because they 
can’t have surgery because they can’t trust in the tablets. And that can be a lot of support 
that we need to give for these ladies. So yes, there’s obviously a risk of not being able as 
well as they were before but I think in a majority of cases ladies have surgery because 
they’re picked very carefully and then they are monitored very carefully so if they’re fit for 
surgery they cope very well and most of our ladies are very surprised by how well they do 
cope. And we even have 70 year olds who have reconstruction believe it or not. 
J Yes, I think that’s happening more and more now. Still, it’s in the minority but they’re being 
offered it. Ok, how often do you think primary endocrine therapy is used here in the over 
70s? 
N34 I wouldn’t know the proportions to be honest. I mean I’ve got a number of patients that 
are on it but I couldn’t give you the actual statistics for that. I mean we have over 700 
cancers a year so off the top of my head, I have a case load of about 200 a year, and they 
range from like 24 to 93 I think, so off the top of my head, I would say it’s the minority 
because the majority are probably offered surgery because that is seen as being the best 
care, you know, the optimum care as it were so I couldn’t give you, off the top of my head I 
couldn’t tell you I’m afraid. 
J Ok, those patients that are treated with it, how long do you think often it maintains control 
for, sort of on average? 
N34 Well again that varies, I’ve got one lady who’s actually come off it after 20 years and had 
surgery. 
J Wow. 
N34 Because she got so fed up of taking it. She’d been on Arimidex for 20 years. 
J That’s incredible. 
N34 That’s a huge thing for her to say, actually I tell a lie, she was actually on – she wasn’t on 
Arimidex, she was on the injection -  
J Faslodex. 
N34 Faslodex injections and she’d been taking them for 20 years and she said “I’m getting fed 
up with this really” so we said “well, you can have surgery” so you know, it’s difficult to tell 
isn’t it really? 
J Yes. 
N34 I mean and that’s what you say to ladies it could well be that it’s going to last you for life, 
it’s true I’ve got ladies that have been on it for 10 years but realistically you’re looking at 
maybe 3 to 5 years before you need to change it but certainly, the chances are if you get a 
good response to one, you’ll get a lesser but a good response to another, and vice versa 
obviously. 
J And what do you think patients that are treated with primary endocrine therapy feel about 
the treatment – do you think they like it? 
N34 I think generally most of our older ladies get on with it pretty well actually and I mean if 
they don’t you hear about it because they ring us. And they’re also good at self-monitoring, 
if they’re worried about anything, you know we obviously give them the information that if 
you’re worried it’s getting bigger or it’s harder or you’re worried you ring us and we’ll bring 
you back quicker and they will ring, without question. But most ladies get on pretty well. I 
mean I’ve got a lot of ladies 75, I mean if it’s a flush or something I’ve never stopped 
getting flushes since I was 50 which is a bit worrying for those of us that have not had them 
yet. So I’d say it’s tolerated pretty well to be honest and I think maybe they’ve perhaps got 
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a little bit of arthritic pain anyway so because they’re lifestyle is slightly slower it perhaps 
has less impact for the majority of ladies than perhaps someone who’s a bit younger who 
then gets the you know, side effects, bit of joint stiffness because it’s something they’ve 
been coping with for years probably. 
J And what about in terms of having the lump still there, do you think women are worried by 
that, bothered by that? 
N34 I think there are some that are in which case they would probably opt to have surgery and 
that certainly is one of the issues for ladies, especially, I’ve got one lady at the minute, she 
wasn’t actually fit for surgery but she had to go and get fitter, get her chest sorted out and 
things and she’s had the best part of a year almost on hormone treatments, but it’s not 
something we can feel so she couldn’t see it, so we had to arrange for her to come back 
and have it scanned every time she came regularly. And although she couldn’t feel the 
lump, the fact this was here was really bothering her so to see the scans and see it was 
actually shrinking, still needed a lot of reassurance for that but for her, surgery was always 
going to happen because that’s right for her but at least she did it safely. And I think if 
ladies really are bothered by the lump then they opt for surgery if they can do but some 
ladies are on the other side of the coin, having the lump and seeing it respond to the tablet 
is also quite reassuring for ladies so, somebody says, “oh, it’s gone and I can’t feel it” and 
they feel quite comfortable with that. So it’s each to their own really. 
J What about the follow-up, do you think women are bothered by the intensity of having to 
come back? 
N34 Well, I’m going to say yes and no to that one I suppose because we don’t do as much 
follow-up now because we tend to follow them up initially, which obviously they’re very 
relieved and again maybe at six months and then it could be that after a year we discharge 
to the GP, now some ladies have a real problem with that actually “how are my GPs going 
to know?” and “I’m not happy with it” and some ladies are quite happy to do that so I 
guess that’s going to be different for everybody. I mean it is an afternoon clinic, with idea 
it’s slightly easier for some ladies to get in if they’re a bit slow getting up in the morning. 
But I think the issues more sometimes with relatives than it is with patients, particularly the 
old clinics of old when we first started were huge because we followed up everybody, 
there were horrendous waits, but now we’ve streamlined those now, they’re in and out 
pretty quickly actually and I don’t think a major… it’s a bit of reassurance sometimes 
coming for clinic. So I haven’t heard anybody really complain like they used to many years 
ago. And if they were finding it difficult then that might be something as a breast care 
nurse we’d be saying “can we get the Gp to do it” so there’s flexibility within that. 
J Yes. Ok. What about those patients then that say “I’d rather not have surgery” – what do 
you think some of the reasons are for patients refusing surgery or standard treatment?  
N34 A lot of it can be fear, because they don’t know, not enough information is often the case. 
Or they’re fear of dying on the table. They might have a relative who’s had surgery and had 
some adverse response to it. They think it’s too big a thing to have done for them, usually. 
Or they just think they’re that old they’re not bothered about treating it at all sometimes 
they say “I’m too old for that to bother me” and feel too frail for it, the thought of having 
an operation and being put to sleep for anybody of that age is quite an enormity, you 
know. Well, I suppose not anybody, I’ve got 80 year olds that wouldn’t think twice about it 
who are playing golf four times a week. So I think it’s the enormity of surgery and their 
perception of that surgery. Could be fear of lying flat, I’ve got lots of ladies who will not 
have a mastectomy, and the thought of a mastectomy it is just not something that they will 
even entertain. So it could be the nature of the surgery, it could be the fact that a general 
anaesthetic seems like a huge thing to have and it’s funny isn’t it, I’ve had a lady quite 
recently, I think she’s about 85, quite recently had major bowel surgery, had basically half 
her insides removed and yet was really worried about having a mastectomy and I was 
saying “in comparison, what you had nine months ago” and again you see it’s the 
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anaesthetic, their perception of it, the mastectomy has a huge stigma in women of that age 
as well and her perception was that she would have a huge open wound. They can’t see 
how it’s going to close and she thought she’d have a huge open gaping wound on her chest 
and they can’t envisage that. And that’s quite common actually for people to think like 
that. 
J Of course. I see. 
N34 And when you actually talk through the surgery and talk about the recovery and you show 
them the picture of a mastectomy, or a photograph, they’re actually quite surprised and 
think “actually, that’s not that bad, I could cope with that”. A lot of it is lack of information I 
think and fear of the unknown, although it may be a very definite “I don’t want to have a 
mastectomy” and that’s fine. 
J Ok. And in those patients, particularly the younger, fitter end of the spectrum, where they 
sort of say “oh, I don’t really want surgery” how is that approached, do you, obviously not 
try and change their mind, but do you try and you know… 
N34 I’m not here to change anybody’s mind. 
J No, that’s what… 
N34 I think as a breast care nurse, that’s what’s pivotal to what I do. And sometimes you’ll sit 
there thinking, you know, I guess we’re all going to be prejudiced to some degree. 
J Of course, yes. 
N34 A patients will regularly ask me what I would do and I quite honestly say I don’t know what 
I’d do until I was sat in that chair, what I think I might do and what I would really do might 
be completely different and so, you know, it’s about laying out the facts, laying out you 
know, this is the pathway of this option, this is the pathway of that way. And some ladies 
say “well if I do nothing what’s going to happen?” and these are the pathways and we will 
support you to do whatever one’s right for you, but for us it’s sometimes looking at “what 
is it that’s making you think about that?” So, for us it’s much more about the nice, the 
emotional aspects behind that. So it could be that someone’s had a mother who’s died 
gruesomely of breast cancer or someone who’s had surgery and that didn’t go well. So, for 
me it’s about looking about “tell me what the issue is for you here, what is it you’re feeling, 
what is it your concerned about?” Often if you ask ladies why their crying when they’ve 
been given the diagnosis. Well you might say, “well of course you know why they’re crying” 
but often actually I will say “I can understand this is really distressful for you, it would be 
for anyone, but tell me what is it that’s making you cry at the moment?” and it’s hardly 
ever the cancer. It’ll be something else that’s happened. 
J Oh really? 
N34 Like my sister’s died of breast cancer or I looked after my mother when she had breast 
cancer or how am I going to tell my children or you know, so it’s very rarely about the 
cancer because probably they knew that was coming to be honest. And it will be some 
other, and basically people make decisions on their past experiences often, so for me it’s 
very much about finding out what the underlying things are and that doesn’t have to be 
done on that day, you know, we’ll probably bring them back another day and discuss that. 
And sometimes when you look at those issues and you discuss them then things are not so 
frightening and they can make different decisions but if they want to make that same 
decision, then I’m part of an advocate, I’m here to help them do that, make that decision. 
J What about the patients, so the opposite, and you briefly mentioned it, those patient’s 
where they’re offered a choice of the two treatments and they go “I don’t know doctor, 
you decide” and they try and make the doctor decide, they try and make you decide… 
N34 That happens quite commonly actually. 
J How is that approached, both by your surgeons and by yourself? 
N34 The surgeons tend to say “well you need to talk it through with the breast care nurse” but 
it’s important that you make the decision for you. 
J Yes. 
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N34 And again, a lot of the things, again I think when you’re given choices, people have the 
perception that there’s a lesser choice. 
J Well there’s a right and a wrong answer, yes. 
N34 Yes and it’s very much for us to explain the rationale behind that choice and actually you’ve 
got two very good options depending on what you want out of it. So forget the options, tell 
me what you want out of this treatment. You know, if you come in, where do you want to 
be in two years’ time sort of thing regarding your breast cancer? And they may say “well I 
want to keep my breast and I don’t want to have gone through surgery”, well, “then let’s 
look at the two options again and you’ll probably find that one of those will fit very well”. 
And other ladies say “well actually I want to be alive as long as I can” although we can 
guarantee that of course, but you know, “I want to be rid of this, I don’t want to have 
anything there”. You know, it’s about what do you want out of this because one of these 
options will fit that very nicely. 
J That’s a really nice way of thinking about it. 
N34 So you almost take the complexity out of it. 
J Yes, nobody’s ever said it like that before. That’s a really nice way of thinking about it. 
N34 Well we do this with every choice because everyone gets choice in breast cancer. 
J Of course. 
N34 It’s like well actually you’ve got two right choices – you’ve got to be careful not to do that 
(Participant was gesticulating) – you’ve got too right choices, the right one can only be… 
J Why not that (copies participant)? 
N34 Because it’s balancing breasts 
J Oh balancing breasts, ok! 
N34 So you’ve got two right choices 
J Right ok. 
N34 So, but it’s very much about that and ultimately it is a lonely place to make that decision 
because the evidence says if you are involved in that decision, you’ll live with it better but 
actually it’s you that’s got to live with it. 
J Yes. 
N34 And the other thing is you often have a lot of other people’s opinions, particularly with the 
older patients and you have to cut them a bit and say at the end of the day, people ask me 
what I might do and I would say I don’t know until I’m in that situation and lots of people 
have opinions about what people should do but if they were in that position and I’ve had 
people who have been in that position and made a very different decision because at the 
end of the day you live in your body not anybody else and it’s you that has to be there in a 
years’ time living with your decisions so it is something that you have to do but you’re not 
going to make a wrong choice. It’s a lifestyle choice at the end of the day it’s not a medical 
choice. We’ve done the medical choice, you’ve got to work out what’s right for you, your 
personality and it’s a lifestyle choice so we sort of take the medial bit out of it to help them 
choose really. 
J Ok. What about, what affects the amount of information that you give to patients after a 
new diagnosis of breast cancer? 
N34 Well I think they all have a deal of information but sometimes we will stagger that or it will 
be followed up. Interestingly actually, quite interesting, we have a woman recently who 
seemed absolutely lucid. Came on her own, kept her son outside the office and there was 
just something that I wasn’t sure about this woman. She was going to go on tablets, she 
definitely didn’t want surgery and I don’t know whether you just get an instinct but she 
seemed to take it all in, she took the information in, she took the leaflets, she took 
everything, including my contact number and I rang her up at the end of the week and she 
had no recollection of who I was. Claimed she’d never had any conversation and been told 
she’d got breast cancer and knew nothing and hadn’t got in contact with her GP, and had 
no paperwork. So I said “just do me a favour, just go and look in your bag and see what you 
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can find” and she suddenly found these leaflets and then remembered everything, 
absolutely everything, and I said “I’m Claire the breast care nurse” and she said “oh yes, I 
did meet a nurse and she was called Claire” so then what I did then was to ring the GP – 
I’ve forgot what the question was now. 
J About information giving. 
N34 Yes, so I actually rang the GP, had a long chat with the GP. She called her in, sorted her out 
her tablets and said “I’ve obviously got some concerns whether you’ll take it” and I’ve just 
followed up with calls and she’s been absolutely fine since. So whether it was shock or 
stress or some degree of both and I’ve got a feeling that the shock maybe has exposed a 
very early stage of perhaps something 
J Yes, gosh. 
N34 But then I would follow that up with a phone call which obviously, and I think instinctively 
sometimes you know, or sometimes patients will come back to see me. Often we see a 
patient maybe even after surgery when they’ve had results or even at diagnosis, it’s too 
much to do it on the day, they’re too upset or they’re too – it’s just too much – so we 
would bring them back and they have what we call a nurse appointment where we have an 
hour aside with time in the counselling room. So it’s just that hour for them and it’s their 
time to fire at everything and maybe I’m giving information or filtering the information that 
they need from the conversation. It’s titrated to them. 
J So it sort of varies on what they need. 
N34 Certainly, obviously they need information about the tablets they’re having and basic stuff 
but if there’s other issues for them some of them will need some counselling to sort out, 
some of them might need a bit of information or red cross or we’ve got boots macmillan 
support that we can tap into as well which is really useful. 
J What about sort of information needs of family and things like that, does that sort of 
impact on…? 
N34 Well we treat everybody. I mean if a patient wants us to, I wouldn’t talk to anybody 
without that but I’ve got several patients where I’ve got daughters all over the place and 
it’s all written in my notes, please speak to daughter who rings up and she had a choice to 
make for her surgery, because sometimes they’ve not only got a choice of hormone tablets 
but they’ve got a choice of surgery too. 
J Which surgery to do, yes. 
N34 And a real mess, so yes, I’m talking to daughters all around the country so, because she 
was saying “I’m not having this because there’s no one to take me for radiotherapy” but 
the family are saying “of course we’ll take you, it’s no issue at all”. So we got them all in a 
room together and said “right then” and she made a decision, they made it as a family, I 
think for her it was important. Yes, and often family come and it’s very important that 
they’ve got somebody who’s perhaps, we always encourage them to bring somebody 
because they need that support anyway, another pair of ears. 
J Yes. 
N34 But that can sometimes, they can have very strong opinions, you know, about what that 
person should do and that’s very difficult sometimes but on the other hand, family are 
family and they’re going to support that patient so they’re key. And I’ve had twelve people 
in a room before now, a whole family. 
J And in terms of making these sorts of decisions, is things like life expectancy, is that sort of 
discussed? 
N34 Well I think it always is when you’re talking of potentially of… 
J Outcomes? 
N34 Yes, if someone’s medically fit for surgery then you’re saying, you know, you’re life 
expectancy is relatively good and I think when you’re talking about what the evidence is 
with hormone tablets, in many cases these tablets will last as long as they need to but you 
don’t know that for sure, and I guess now people are living longer and longer, what was 70 
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ten years ago may not be quite what 70 is now. 
J Yes. 
N34 And so, yes, you’re obviously looking at life and ladies will often raise that on their own and 
will get it and say “well, I’ve only got five, I haven’t got much longer to live anyway” so of 
course the tablet will be fine, I’ll not be here, you know, whatever and you suggest to these 
ladies that they might live to 100 “oh, no I don’t want to ever be that old” you know, so I 
think a lot of these age group have looked at that themselves and might volunteer it to 
some degree. 
J Yes, ok. And what about things like decision making tools, or aids, do you think they can be 
helpful when making this sort of decision? 
N34 Yes, I mean, often, sometimes it depends, sometimes you get to know your patient and 
sometimes just writing things down, you sort of say “just get a list put your pros and cons, 
pros and cons and you’ll find that all of a sudden one of those columns becomes…” 
J Really long. 
N34 And to actually see it on a piece of paper, becomes visually “well of course that’s what I 
want to do”, you know so yes, and we can, we will pull in some of those if we feel it’s 
necessary. Having said that, you know what, these ladies have been making decisions all 
their lives and actually their decision-making skills are actually pretty good and you give the 
information and time and take the crisis element out of it and actually they’re very good at 
making decisions because they know what they want at the end of the day. These ladies 
have gone through big things in their lives and often have got their lives very much in 
proportion and I think you learn a lot from these ladies actually.  
J Do you think it’s more the younger ladies that struggle in comparison? 
N34 Perhaps. It can be, sometimes. I think it comes down to the individual, greatly so. But 
they’ve got a lot of, you know, when you get older, they’ve got a lot of living experience to 
fall back on, they might have lost a spouse and in the greater picture, having breast cancer 
is not the biggest thing in their life and that might sound silly. 
J No it doesn’t. 
N34 But they’ve developed skills, you know, they’re pretty savvy these ladies actually. I take my 
hat off to them, they’re a fabulous group of patients actually, so yes. 
J I think one of the reasons that we’re doing this is because of the amount of variation across 
the country so if you look at say, London and Oxford, 90% of women over 70 get operated 
on but in comparison to our units like Sheffield and Derby, where only about 60% of over 
70s get operated on – what do you think might cause a variation like that in the way older 
women are treated? 
N34 Choice? I mean ultimately I would say it comes down to choice, where it’s suitable, and 
obviously you get women who aren’t fit for surgery, and I guess it depends how many of 
those ladies are coming for screening, because some will pick up from screening. And if 
your uptake for screening at that age is not as good then you’re not going to pick up so 
many ladies maybe. And again it depends what level you’re picking up, perhaps the bigger 
lumps are not so operable, I don’t know. But certainly I think we treat our ladies like 
anybody else, it’s about choice and it’s not about – perhaps ladies are not given the choice 
I would have to argue. Or it’s not given in a way, in a non-biased way possibly. And that’s 
something we all, you know, sometimes you sit there and I’ll say “I’m not telling you that 
one’s better than the other” because you think you’ve perhaps done that and so I say “I’m 
telling you now there’s no right or wrong here, I’m here to give you the facts, ultimately it’s 
what you feel’s best for you” and I sometimes hear myself saying that and think “am I 
sounding a bit biased to one or the other” and ultimately it is, I think, we treat our ladies 
with autonomy and their given the choices that they want and I think we give them 
information to make a choice. They’ve got the information and I guess the information is 
given differently or whether it’s a cultural thing, I don’t know. 
J Because that’s my next question is about how much impact you think we as clinicians and 
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you are breast care nurse have on the decisions that these patients have to make? 
N34 I think massive in that group, I think they’re very much in awe of medical staff still, and we 
tell them not to be! 
J Yes! 
N34 And I make it clear, I tend to say “I know I wear uniform but at the end of the day, have no 
doubt about the side of the fence that I sit on, it’s very firmly on your side”. And I try to de-
medicalise everything, but there’s very much in, you’re talking about a generation still that 
think basically they come in they’ll be told what to do and treat doctors in an ivory tower. I 
think in 20 years’ time that’s going to be extremely different. 
J I was going to say, I think that will have gone. 
N34 It will do yes, I think the nature of that epidemiology will be very, very different. But at the 
minute I think you’re still looking at a generation that think the doctors know best and 
sometimes that’s a real struggle when you’re talking about a choice – “actually do you 
know what? You know best because it’s your body” 
J Particularly if you’ve got a doctor who says “I will not make a choice for you, it’s your 
decision” that can be hard for them as well. 
N34 They think that they’re making them make a medical choice and the minute you say “no, 
actually, we’ve made the medical choice, we’re never going to offer you a lesser choice, 
the route you get there might be slightly different but actually those choices are just as 
safe” and we’re saying “we’re experts in that, we can offer you this, but actually the expert 
about you is you” so, you know, I think once you actually clear that it’s, you know, but it’s a 
complete turning about of how they view the medical profession and everything, so yes, I 
do think that does impact greatly on this generation still. Lesser so, but still quite greatly 
so. And I think there is an element about some ladies will do what their husbands want 
them to do still. 
J Really? 
N34 On the other hand, you know, on the other hand not the case, most of my ladies are having 
very active sexual lives and it’s a very important part to them. 
J Yes. Right, I’ve not really looked at my paper so I’m just going to have a quick squidge to 
make sure I haven’t missed anything. 
N34 The term I guess I haven’t used and I guess I ought to put in somewhere, for me it’s all 
about quality of life really. And when I talk about quality of life, it’s not just about physical 
state, it’s about a mental and emotional state. 
J Right. 
N34 So that’s really what we’re looking at when we’re offering surgery and making sure they’re 
making the decision that’s right for them. 
J Ok. What sort of factors have influenced your personal strategy for dealing with these sort 
of patients, you know, giving the advice you give. Is it the literature that you’ve read, your 
past experience, the unit’s policy, what sort of? 
N34 All of the above I suppose. 
J Anything else? 
N34 Yes, I mean my mother had breast cancer but very differently so I guess from my 
experience talking to women and what they, and I’ve been a ward sister for many years 
you see, so I sit at the back and see what women actually worry about and so I guess I use 
all the above to actually focus on that one patient, or person should I say. And we’re very 
much see women as people and not as patients,  I think that’s the beauty of this job 
actually, as being on the ward, to make the decision that’s right for them. And I’m still 
learning now. 
J Yes. I think that might be all of my questions. Have you got anything else that you’d like to 
add that I have talked about, either about this group of patients, or women, or about the 
two treatments that we’ve talked about? 
N34 I don’t think so actually, not that I can think of off the top of my head. I didn’t have much 
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time to focus before I came in, because it was just in the middle of clinic will you do this, 
yes, ok, you know, whatever it is I’ll do it. 
J I know thank you so much. 
N34 I don’t know if it’s been useful 
J No very useful. 
N34 It’s a pleasure. 
J Thank you and thank you for taking the time to speak to me, I really appreciate it and I shall 
stop this. 
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Appendix 17: Letter to participant in questionnaire study 
 
 
 
 
 
 
 
 
 Miss Lynda Wyld 
Senior Lecturer 
Academic  Surgical Oncology Unit 
Room EU32, Royal Hallamshire Hospital 
Glossop Road, Sheffield, S10 2JF 
 
  
 
 
 Telephone: +44 (0) 114 271 2510 
Email: l.wyld@sheffield.ac.uk 
24
th
 October, 2012 
Dear Colleague, 
Clinician Preferences for the Treatment of Older Women with Operable Breast Cancer. 
We would like to invite you to participate in the above research study that has been funded by the 
National Institute for Health Research and is being undertaken by researchers from The University 
of Sheffield, Sheffield Hallam University and the University of Leicester.   
There is wide variation in UK practice relating to the treatment of older women with breast cancer, 
with some areas demonstrating much higher rates of Primary Endocrine Therapy (PET) compared 
with others. Studies have shown that primary endocrine therapy is an effective treatment for breast 
cancer in older women but there is uncertainty about the age, fitness level, disease biology and 
stage for which it is indicated.  The 4 fold variance in UK practice is testament to this lack of 
guidance.  This research project is part of a larger study to try and define best practice for this age 
group of women by helping to define the characteristics of older women that suggest they may 
benefit from either surgery or PET.  We want to establish the views of health care professionals 
across the UK about their own criteria for each treatment. 
We are writing to you because you are a specialist health professional to ask you to consider taking 
part in this study by completing the attached questionnaire. We anticipate that it should take you 
about 15 minutes to complete. Taking part is completely voluntary. If you wish to take part in the 
study, then please complete the attached questionnaire and return it to the researchers in the 
FREEPOST envelope provided.  
If you would like to find out more about the study before deciding whether or not to take part 
please contact myself, Lynda Wyld, Senior Lecturer and Consultant Breast Surgeon, at the Royal 
Hallamshire Hospital, via e-mail, l.wyld@sheffield.ac.uk, or Miss Jenna Morgan, a researcher on the 
project, at the Royal Hallamshire Hospital. Telephone 0114 2620174 ext 13611 or email 
j.morgan@sheffield.ac.uk  
Many thanks for considering taking part. 
Yours faithfully, 
Lynda Wyld, Senior Lecturer and Consultant Surgeon 
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Appendix 18: Final questionnaire 
 
 
 Variation in Clinician Preferences for Treatment 
of Older Women with Operable Breast Cancer 
 
 
Health Care Professional Questionnaire 
 
All information that you provide will remain strictly 
confidential 
 
When you have finished please post the questionnaire back 
in the FREEPOST envelope provided. You do not need a 
stamp. 
 
  
 
If you have any queries about this questionnaire or the study, 
please contact Lynda Wyld (Senior Lecturer and Consultant 
Breast Surgeon), EU36, University of Sheffield Medical 
School, Beech Hill Road, Sheffield. Telephone 0114 2268640. 
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This sheet is intentionally blank. 
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Section One 
This section requires you to give brief information about your professional 
background 
 
   1. What is your age in years?   …     
 
 
  2. What is your gender? (please tick appropriate box) 

 Male  Female
 
 
3. What is your profession or speciality?  (please tick appropriate box) 
 

Breast Surgeon 
 
 Oncologist 
 
 
 
 
 
 
Breast Care Nurse Specialist 
 
 Other (specify)………… 
 

 
 
4. Which area do you currently work in? (please tick appropriate box) 
Eastern 
 
 North West 
 
 
 
 
 
 
Northern & Yorkshire 
 
 Northern Ireland 
 

Oxford 
 
 Scotland 
  

South West  Thames 
Trent 
 
 Wales 
West Midlands  Other (specify)………… 
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Section Two 
The table below contains factors that may be considered when discussing treatment 
options with an older patient with operable breast cancer.  Please rate the 
importance of each of these factors in shaping your advice regarding treatment 
options in an older woman (≥70) in whom you are considering the choice between 
surgery and primary endocrine therapy. 
   
For each factor place your tick in the relevant box that best describes how 
important you think each factor is. Please only tick one box per question. 
 
Patient Characteristic Very important Important 
Some 
impor
tance 
Not 
important 
Patient age 1 2 3 4 
Breast cancer ER positivity 1 2 3 4 
Breast cancer Her 2 receptor status 1 2 3 4 
Size of tumour (e.g. suitability for 
WLE) 
1 2 3 4 
Presence of axillary nodal disease 1 2 3 4 
Suitability for surgery under local or 
regional anaesthesia in a frail patient 
1 2 3 4
Estimated life expectancy of the 
patient 
1 2 3 4 
Patient’s preference for operation or 
PET 
1 2 3 4 
Functional status (level of 
independence, ability to perform 
activities of daily living) 
1 2 3 4 
Cognitive function (dementia) 1 2 3 4 
Co-morbidity (are they fit and well or 
do they have multiple health 
problems?) 
1 2 3 4 
Patient’s anxiety level about breast 
cancer 
1 2 3 4 
Patient’s anxiety levels about an 
operation 
 
1 2 3 4 
Family member/carer preference for 
operation of PET 
1 2 3 4 
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Section Three 
The following questions relate to your views about the choice between surgery and 
primary endocrine therapy.  
 
For each of the statements below please circle one box to indicate yours views 
about the validity and accuracy of the statement: 
 
1)  All women ≥70 with operable breast cancer should be offered an operation, 
regardless of age. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
2) All women ≥70 with operable ER+ve breast cancer, who have multiple co-
morbidities such that anaesthesia may carry an increased risk of morbidity and 
mortality, should be treated with PET. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
3) All women ≥70 with operable ER +ve breast cancer, who have significant 
dementia, (unable to give informed consent) should be treated with PET. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
4) Primary endocrine therapy may be offered to any woman ≥70 with ER+ve 
disease as there is no proven survival disadvantage. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
5) Surgery is almost always possible for older women ≥70 with operable breast 
cancer under local or regional anaesthesia. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
6) Most older women ≥70, if given a choice of treatment would prefer to have non-
surgical treatment for their breast cancer. 
STRONGLY 
DISAGREE 
DISAGREE AGREE STRONGLY 
AGREE 
 586 
 
 
 
 
 
Section Four 
The following questions relate to your experiences with treating older women ≥70 
with operable breast cancer. For each of the questions below please tick the box of 
the answer that is most similar to your experiences. 
1) What percentage of women ≥70 receive PET in your unit? 
Less than 10% 
 
 10 to 20% 
 
 
 
 
 
 
20 to 30%  30 to 40% 
More than 40%   
2) In your experience, how long on average does PET maintain local control? 
6 months 
 
 12 months 
 
 
 
 
 
 
18 months  24 months 
3 years  5 years 
3) What action would you take if your first line anti-oestrogen failed to achieve a 
response in a patient being treated with PET? 
Start second line anti-oestrogen  Advise operative 
management 
 
 
Advise radiotherapy Other (specify)……………….. 
4) In your experience, are anaesthetists in your unit happy to perform regional 
blocks to allow you to undertake surgical excision in women ≥70 who have multiple 
co-morbidities where a general anaesthetic may carry increased risk or morbidity 
and mortality? 
Never perform regional blocks in this 
group 
 Rarely perform regional 
blocks in this group 
 
 
 
 
 
Regularly perform regional blocks in 
this group 
 
5) In your experience, is surgery under general anaesthesia well-tolerated in women 
≥70 with operable breast cancer? 
Yes  No  Not sure  
6) In your experience, is surgery under local anaesthesia well-tolerated in women 
≥70 with operable breast cancer? 
Yes  No  Not sure  
7) In your experience, is PET well-tolerated in women ≥70 with operable breast 
cancer? 
Yes  No  Not sure  
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Section Five: Introduction 
This section comprises a series of 20 clinical scenarios on which you are asked to make a 
hypothetical decision. They are concerned with the importance that you place on various 
factors influencing your preferred option for surgery or PET in individual women ≥70 with 
operable breast cancer. PLEASE NOTE: the option for surgery may include operations 
under General, Regional or Local anaesthetic if this is how you would treat the patient. 
Please tear out this double-sided sheet to use as a reference when working through the 
scenarios 
 
1.  Patient age (years) Divided into the following age bands: 
70 – 74   75 – 79 
80 – 84   85 and over 
2.  Co-morbidity            Divided into the following: 
5) No co-morbidity 
6) Mild co-morbidity, e.g. arthritis, hypertension 
7) Moderate/well-controlled co-morbidity, e.g. diabetes, 
coronary heart disease, moderate COPD 
8) Severe co-morbidity, e.g. disabling stroke, congestive 
cardiac failure, severe COPD 
3. Cancer Stage                    Divided into the following: 
5) Small tumour, no nodal involvement 
6) Small tumour, nodal involvement 
7) Large tumour, no nodal involvement 
8) Large tumour, nodal involvement 
4. Cancer Biology      Divided into the following: 
4) ER++/HER2- (ER strongly positive, HER2 negative) 
5) ER+/HER2- (ER moderately positive, HER2 negative) 
6) ER+/HER2- (ER moderately positive, HER2 positive) 
5. Functional Status      Divided into the following: 
5) Fully independent 
6) Mild dependence; requires weekly help for domestic 
activities, e.g. shopping 
7) Moderate dependence; requires daily help with 
washing, dressing, continence management, etc. 
8) Severe dependence; requires 24 hour care, e.g. resides 
in a residential or nursing home 
6. Cognitive Function  Divided into the following: 
5) Normal cognitive function 
6) Mild cognitive impairment; functions normally in society 
7) Moderate cognitive impairment; unable to cope without 
help 
8) Severe cognitive impairment; requires daily social 
services input or lives in residential or nursing home 
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Section Five: Patient Scenarios 
For each of the 20 scenarios below, based on the information provided, 
please indicate your preferred choice of recommendation for treatment (i.e. in 
favour of operative treatment or primary endocrine therapy (PET), by placing a 
tick () in the relevant box below the scenario description.  If you prefer both 
options equally, please tick both boxes. Please assume that each hypothetical 
patient has asked you to advise them on what treatment option they should 
choose. 
Scenario 1 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 2 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
SEVERE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 3 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 4 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
MODERATE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 5 
PATIENT AGE (YEARS) 75-80 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 6 
PATIENT AGE (YEARS) 75-80 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 7 
PATIENT AGE (YEARS) 80-85 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 8 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 9 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
SEVERE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 10 
PATIENT AGE (YEARS) 75-80 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 11 
PATIENT AGE (YEARS) 80-85 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
MODERATE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 12 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 13 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 14 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
SEVERE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 15 
PATIENT AGE (YEARS) 80-85 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 16 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER+ / HER2+ 
FUNCTIONAL STATUS INDEPENDENT 
COGNITIVE FUNCTION 
NORMAL 
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 17 
PATIENT AGE (YEARS) 80-85 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
SMALL TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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Scenario 18 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
MILD 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
MILD IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 19 
PATIENT AGE (YEARS) 70-75 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER+ / HER2- 
FUNCTIONAL STATUS SEVERE DEPENDENCE  
COGNITIVE FUNCTION 
SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Scenario 20 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
MODERATE 
LARGE TUMOUR, NODE NEGATIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MILD DEPENDENCE  
COGNITIVE FUNCTION 
MODERATE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
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If you have any additional comments, please write them on this page.   
Use additional sheets if necessary. 
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If you would like to receive a summary of the research findings please provide 
your name, position and either a contact telephone number, address or e mail 
address so that we can contact you to arrange for this to be sent to you.  The 
results may take up to a year to be produced.   
 
If you wish to remain anonymous, please leave this blank: the results may still 
be available to you via publication in peer reviewed journals.   
 
If you would like to have your results sent back to you with a comparison of 
your answers to the rest of the sampled population please tick the ‘Feedback’ 
box. 
 
 
Name: .................................................................................................................... 
 
 
Profession: ........................................................................................................... 
 
 
Contact telephone number: ................................................................................ 
 
E mail 
Address: ................................................................................ 
 
 
 
I would like to receive Individualised Feedback please:  
 
 
 
 
Thank you for completing this questionnaire and for taking part in the study. 
 
Please return the completed questionnaire in the FREEPOST envelope 
provided. 
 
 
Miss Jenna Morgan, EU25, University of Sheffield Medical School, Beech Hill 
Road, Sheffield.  
 
Email: j.morgan@sheffield.ac.uk 
 
